



US 20120115746A1

(19) **United States**(12) **Patent Application Publication**
Pasricha et al.(10) **Pub. No.: US 2012/0115746 A1**(43) **Pub. Date: May 10, 2012**(54) **COMPOSITIONS AND METHODS FOR
TREATING AND DIAGNOSING IRRITABLE
BOWEL SYNDROME****Publication Classification**(75) Inventors: **Pankaj Pasricha**, Houston, TX
(US); **Mohan Shenoy**, Galveston,
TX (US); **John Winston**, League
City, TX (US)(51) **Int. Cl.**
C40B 30/04 (2006.01)
C12Q 1/68 (2006.01)
G01N 33/566 (2006.01)
C07K 14/435 (2006.01)
C07H 21/04 (2006.01)(73) Assignee: **THE BOARD OF REGENTS OF
THE UNIVERSITY OF TEXAS
SYSTEM**, AUSTIN, TX (US)(52) **U.S. Cl. 506/9; 530/350; 536/24.31; 436/501;
435/6.12**(21) Appl. No.: **13/311,492**(22) Filed: **Dec. 5, 2011**(57) **ABSTRACT****Related U.S. Application Data**(62) Division of application No. 10/923,035, filed on Aug.
23, 2004, now Pat. No. 8,071,652.(60) Provisional application No. 60/496,716, filed on Aug.
21, 2003.

Compositions and methods for diagnosing and treating CVH and CVH-associated disorders are disclosed. Genes differentially expressed in CVH tissues relative to normal tissues are identified. The genes and the gene products (i.e., the polynucleotides transcribed from and polypeptides encoded by the genes) can be used as markers of CVH. The genes and the gene products can also be used to screen agents that modulate the gene expression or the activities of the gene products.




FIG. 1






FIG. 2

HISTOLOGY: NO OVERT INFLAMMATION



A: Control, CNI-1493

B: Sensitized, vehicle



C: Control, vehicle

D: Sensitized, CNI-1493

E: MPO activity




FIG. 3

COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING IRRITABLE BOWEL SYNDROME

[0001] This application claims priority from U.S. Provisional Application Ser. No. 60/496,716 filed Aug. 21, 2003. The entirety of that provisional application is incorporated herein by reference.

TECHNICAL FIELD

[0002] The present invention relates generally to the diagnosis and treatment of disorders associated with chronic visceral hypersensitivity (CVH), and in particular irritable bowel syndrome (IBS). The invention also relates to genes associated with CVH, polynucleotides transcribed from these genes and polypeptides encoded by these genes. Such polynucleotides and polypeptides can be used for the diagnosis and treatment of CVH.

BACKGROUND OF THE INVENTION

[0003] Irritable Bowel Syndrome (IBS) is a functional bowel disorder of unknown etiology. A functional disorder refers to a disorder or disease where the primary abnormality is an altered physiological function, rather than an identifiable structural or biochemical cause. IBS is characterized by a group of symptoms including intermittent abdominal pain and discomfort and alterations in bowel habits, such as loose or more frequent bowel movements, diarrhea, and/or constipation that occur in the absence of detectable ongoing organic disease.

[0004] IBS affects approximately 10-20% of the general population. It is the most common disease diagnosed by gastroenterologists and one of the most common disorders seen by primary care physicians. IBS is understood as a multi-faceted disorder. In people with IBS, symptoms result from what appears to be a disturbance in the interaction between the gut or intestines, the brain, and the autonomic nervous system that alters regulation of bowel motility (motor function) or sensory function.

[0005] Human studies demonstrate that IBS is associated with a state of chronic visceral hypersensitivity (CVH) suggesting that processing of visceral sensory information is altered. However, little is known about how the afferent nervous system is changed in this syndrome. A hallmark of IBS is increased visceral hypersensitivity, but the molecular changes underlying the development and maintenance of chronic visceral hypersensitivity in IBS are not known. Current medical treatments for IBS primarily target peripheral symptoms rather than the underlying causes, and therapeutic gains from drug treatments are usually modest and the placebo responses are high (Mertz et al., *Gastroenterology*, 109: 40-52, 1995). Defining the underlying neurological and molecular defects is therefore important to the design of more successful therapeutic strategies. Moreover, there is a need in the art for improved methods for screening, diagnosing, and treating MS and other CVH-related disorders.

[0006] CNI-1493 is a MAPK and TNF inhibitor with anti-inflammatory and possible analgesic actions. CNI-1493 inhibits signal transduction pathways by preventing phosphorylation of p38 MAP kinase and JNK, and inhibits production of the proinflammatory cytokines such as TNF-alpha, IL-1, MIP-1 alpha, and MIP-1 beta. In animal models, CNI-1493

has shown protective activity against a wide variety of conditions, ranging from stroke to inflammatory bowel disease. However, CNI-1493 has never been tested for its anti-nociceptive activity in the absence of inflammation. Recently, an animal model of chronic visceral hypersensitivity was created using mechanical and chemical irritation of the colon of neonatal rats (Al-Chaer et al., *Gastroenterology*, 119:1276-1285, 2000). The animal model provides an ideal platform for studying IBS, validating the neurogenic components of functional abdominal pain, and testing agents that may reduce visceral hypersensitivity.

SUMMARY OF THE INVENTION

[0007] One aspect of the present invention relates to the treatment for disorders associated with CVH using guanylhydrazine. In one embodiment, the present invention provides a treatment for IBS using CNI1493.

[0008] Another aspect of the present invention relates to CVH-related genes (CVHGs) and the gene products, which include the polynucleotides transcribed from the CVHGs (CHVPNs) and the polypeptides encoded by the CVHGs (CHVPPs).

[0009] In one embodiment, the present invention provides methods for diagnosing and monitoring CVH and CVH-related disorders by comparing the expression levels of one or more CVHGs at the nucleotide or protein level in biological samples from a subject to control samples.

[0010] In another embodiment, the present invention provides pharmaceutical compositions for the treatment of CVH and CVH-related disorders. The pharmaceutical compositions comprise a pharmaceutically acceptable carrier and at least one of the following: (1) a CVHG product; (2) an agent that modulates an activity of a CVHG product; and (3) an agent that modulates the expression of a CVHG.

[0011] In another embodiment, the present invention provides methods for treating CVH and CVH-related disorders in a patient with the pharmaceutical compositions described above. The patient may be afflicted with CVH, in which case the methods provide treatment for the disease. The patient may also be considered at risk for CVH, in which case the methods provide prevention for disease development.

[0012] In another embodiment, the present invention provides methods for screening anti-CVH agents based on the agents' interaction with CVHPPs, or the agents' effect on the activity or expression of CVHPPs.

[0013] In another embodiment, the present invention provides biochips for diagnosing CVH and CVH-related disorders, and for screening agents that inhibit CVH. The biochips comprise at least one of the following (1) a CVHPP or its variant, (2) a portion of a CVHPP or its variant (3) a CVHPN or its variant, and (4) a portion of a CVHPN or its variant.

[0014] In another embodiment, the present invention provides a kit for diagnosing CVH and CVH-related disorders. The kit comprises at least one of the following (1) polynucleotide probe that specifically hybridizes to a CVHPN, and (2) an antibody capable of specific binding to a CVHPP.

BRIEF DESCRIPTION OF FIGURES

[0015] FIG. 1. Increased sensitivity to CRD in adult rats treated with acetic acid on P10 (n=8). Data was analyzed by two-way repeated measures ANOVA with distention pressure as the repeated factor and P10 treatment as a between group factor. There was a significant effect of P10 treatment (F 1,

12.98) $p < 0.003$, of distention pressure (F 7, 89.9) $p < 0.001$, and there was a significant interaction between distention pressure and P10 treatment (F 7, 4.04) $p < 0.001$. Means were compared with a Tukey test. Significant differences between acetic acid treated and controls were found at distention pressures of 30 ($p = 0.004$), 40 ($p < 0.001$), 50 ($p < 0.001$), 60 ($p = 0.001$) and 70 ($p = 0.035$) mm Hg.

[0016] FIG. 2. Effect of CNI-1493 on the response of sensitized rats to graded CRD ($n = 8$). Data was analyzed by two-way repeated measures ANOVA with distention pressure as the repeated factor and drug treatment as a between group factor. There was a significant effect of CNI1493 treatment (F 1, 16.96) $p = 0.001$, of distention pressure (F 7, 28.55) $p < 0.001$, but there was no significant interaction between distention pressure and CNI1493 treatment (F 7, 1.94) $p = 0.071$. Means were compared with a Tukey test. Significant differences between CNI-1493 treated and controls were found at distention pressures of 20 ($P = 0.001$), 30 ($p = 0.003$), 40 ($p < 0.001$), 50 ($p = 0.001$), 60 ($p < 0.001$) and 70 ($p = 0.015$) and 80 ($p = 0.007$) mm Hg.

[0017] FIG. 3. Colon histology and MPO activity. H&E stained colon sections from control, vehicle (A); control, cni-1493 (B); sensitized, vehicle (C); and sensitized, CNI1493 (D). Histogram showing MPO activity in colons (E).

DETAILED DESCRIPTION OF THE INVENTION

[0018] The preferred embodiments of the invention are described below. Unless specifically noted, it is intended that the words and phrases in the specification and claims be given the ordinary and accustomed meaning to those of ordinary skill in the applicable art or arts. If any other meaning is intended, the specification will specifically state that a special meaning is being applied to a word or phrase.

[0019] It is further intended that the inventions not be limited only to the specific structure, material or acts that are described in the preferred embodiments, but in addition, include any and all structures, materials or acts that perform the claimed function, along with any and all known or later-developed equivalent structures, materials or acts for performing the claimed function.

[0020] Further examples exist throughout the disclosure, and it is not applicant's intention to exclude from the scope of his invention the use of structures, materials, methods, or acts that are not expressly identified in the specification, but nonetheless are capable of performing a claimed function.

[0021] The present invention is generally directed to compositions and methods for the diagnosis, treatment, and prevention of CVH and CVH-related disorders; and to the identification of novel therapeutic agents for CVH and CVH-related disorders. The present invention is based on the finding that guanylylhydrazide is capable of ameliorating CVH in a rat model of IBS and the discovery of transcribed polynucleotides that are differentially expressed in the colon tissue of rats with chemically induced CVH relative to control animals.

DEFINITIONS AND TERMS

[0022] To facilitate an understanding of the present invention, a number of terms and phrases are defined below:

[0023] As used herein, the terms "a differentially expressed gene" refer to a gene that meets all of the following criteria during an Affymetrix microarray analysis: (1) the average

expression of the gene shows a fold change of two or greater compared with controls and (2) significant changes in gene expression were detected by analyzing signal intensity values by two-way ANOVA with 99% confidence. The differentially expressed genes identified in the colon tissue samples of CVH and CNI1493-treated rats are designated as CVH-related genes (CVHGs). CVHGs generally refer to the genes listed in Tables 3-8.

[0024] As used herein, the terms "CVH-related polynucleotide (CVHPN)" and "CVHG polynucleotide" are used interchangeably. The terms include a transcribed polynucleotide (e.g., DNA, cDNA or mRNA) that comprises one of the CVHG sequences or a portion thereof.

[0025] As used herein, the terms "CVH-related polypeptide (CVHPP)" and "CVHG protein" are used interchangeably. The terms include polypeptides encoded by an CVHG, an CVHPN, or a portion of an CVHG or CVHPN.

[0026] As used herein, a "CVHG product" includes a nucleic acid sequence and an amino acid sequence (e.g., a polynucleotide or polypeptide) generated when an CVHG is transcribed and/or translated. Specifically, CVHG products include CVHPNs and CVHPPs.

[0027] As used herein, a "variant of a polynucleotide" includes a polynucleotide that differs from the original polynucleotide by one or more substitutions, additions, deletions and/or insertions such that the activity of the encoded polypeptide is not substantially changed (e.g., the activity may be diminished or enhanced, by less than 50%, and preferably less than 20%) relative to the polypeptide encoded by the original polynucleotide.

[0028] A variant of a polynucleotide also includes polynucleotides that are capable of hybridizing under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions to the original polynucleotide (or a complementary sequence). Examples of conditions of different stringency are listed in Table 2.

[0029] It will be appreciated by those of ordinary skill in the art that, as a result of the degeneracy of the genetic code, there are many nucleotide sequences that encode a polypeptide as described herein. Some of these polynucleotides bear minimal homology to the nucleotide sequence of any native gene. Nonetheless, polynucleotides that vary due to differences in codon usage are specifically contemplated by the present invention.

[0030] As used herein, a "variant of a polypeptide" is a polypeptide that differs from a native polypeptide in one or more substitutions, deletions, additions and/or insertions, such that the bioactivity or immunogenicity of the native polypeptide is not substantially diminished. In other words, the bioactivity of a variant polypeptide or the ability of a variant polypeptide to react with antigen-specific antisera may be enhanced or diminished by less than 50%, and preferably less than 20%, relative to the native polypeptide. Variant polypeptides include those in which one or more portions, such as an N-terminal leader sequence or transmembrane domain, have been removed. Other preferred variants include variants in which a small portion (e.g., 1-30 amino acids, preferably 5-15 amino acids) has been removed from the N- and/or C-terminal of the mature protein.

[0031] Modifications and changes can be made in the structure of a polypeptide of the present invention and still obtain a molecule having biological activity and/or immunogenic properties. Because it is the interactive capacity and nature of

a polypeptide that defines that polypeptide's biological activity, certain amino acid sequence substitutions can be made in a polypeptide sequence (or, of course, its underlying DNA coding sequence) and nevertheless obtain a polypeptide with like properties.

[0032] In making such changes, the hydropathic index of amino acids can be considered. The importance of the hydropathic amino acid index in conferring interactive biologic function on a polypeptide is generally understood in the art. It is believed that the relative hydropathic character of the amino acid residue determines the secondary and tertiary structure of the resultant polypeptide, which in turn defines the interaction of the polypeptide with other molecules, such as enzymes, substrates, receptors, antibodies, antigens, and the like. It is known in the art that an amino acid can be substituted by another amino acid having a similar hydropathic index and still obtain a functionally equivalent polypeptide. In such changes, the substitution of amino acids whose hydropathic indices are within ± 2 is preferred, those that are within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

[0033] Substitution of like amino acids can also be made on the basis of hydrophilicity, particularly where the biological functional equivalent polypeptide or polypeptide fragment, is intended for use in immunological embodiments. U.S. Pat. No. 4,554,101, incorporated hereinafter by reference, states that the greatest local average hydrophilicity of a polypeptide, as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity and antigenicity, i.e. with a biological property of the polypeptide.

[0034] As detailed in U.S. Pat. No. 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0 $\pm$ 1); glutamate (+3.0 $\pm$ 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); proline (−0.5 $\pm$ 1); threonine (−0.4); alanine (−0.5); histidine (−0.5); cysteine (−1.0); methionine (−1.3); valine (−1.5); leucine (−1.8); isoleucine (−1.8); tyrosine (−2.3); phenylalanine (−2.5); tryptophan (−3.4). It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular, an immunologically equivalent polypeptide. In such changes, the substitution of amino acids whose hydrophilicity values are within ± 2 is preferred, those that are within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

[0035] As outlined above, amino acid substitutions are generally therefore based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions which take various of the foregoing characteristics into consideration are well known to those of skill in the art and include: arginine and lysine; glutamate and aspartate; serine and threonine; glutamine and asparagine; and valine, leucine and isoleucine (See Table 1, below). The present invention thus contemplates functional or biological equivalents of an CVHPP as set forth above.

TABLE 1

Amino Acid Substitutions	
Original Residue	Exemplary Residue Substitution
Ala	Gly; Ser
Arg	Lys
Asn	Gln; His

TABLE 1-continued

Amino Acid Substitutions	
Original Residue	Exemplary Residue Substitution
Asp	Glu
Cys	Ser
Gln	Asn
Glu	Asp
Gly	Ala
His	Asn; Gln
Ile	Leu; Val
Leu	Ile; Val
Lys	Arg
Met	Leu; Tyr
Ser	Thr
Thr	Ser
Trp	Tyr
Tyr	Trp; Phe
Val	Ile; Leu

[0036] A variant may also, or alternatively, contain nonconservative changes. In a preferred embodiment, variant polypeptides differ from a native sequence by substitution, deletion or addition of five amino acids or fewer. Variants may also (or alternatively) be modified by, for example, the deletion or addition of amino acids that have minimal influence on the immunogenicity, secondary structure, tertiary structure, and hydropathic nature of the polypeptide.

[0037] Polypeptide variants preferably exhibit at least about 70%, more preferably at least about 90% and most preferably at least about 95% sequence homology to the original polypeptide.

[0038] A polypeptide variant also includes a polypeptide that is modified from the original polypeptide by either natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a fluorophore or a chromophore, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

[0039] As used herein, a "biologically active portion" of a CVHPP includes a fragment of a CVHPP comprising amino

acid sequences sufficiently homologous to or derived from the amino acid sequence of the CVHPP, which includes fewer amino acids than the full length CVHPP, and exhibits at least one activity of the CVHPP. Typically, a biologically active portion of a CVHPP comprises a domain or motif with at least one activity of the CVHPP. A biologically active portion of a CVHPP can be a polypeptide which is, for example, 10, 25, 50, 100, 200 or more amino acids in length. Biologically active portions of a CVHPP can be used as targets for developing agents which modulate a CVHPP-mediated activity.

[0040] As used herein, an “immunogenic portion,” an “antigen,” an “immunogen,” or an “epitope” of a CVHPP includes a fragment of a CVHPP comprising an amino acid sequence sufficiently homologous to, or derived from, the amino acid sequence of the CVHPP, which includes fewer amino acids than the full length CVHPP and can be used to induce an anti-CVHPP humoral and/or cellular immune response.

[0041] As used herein, the term “modulation” includes, in its various grammatical forms (e.g., “modulated”, “modulation”, “modulating”, etc.), up-regulation, induction, stimulation, potentiation, and/or relief of inhibition, as well as inhibition and/or down-regulation or suppression.

[0042] As used herein, the term “control sequences” or “regulatory sequences” refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The term “control/regulatory sequence” is intended to include promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Control/regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cells and those which direct expression of

the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences).

[0043] A nucleic acid sequence is “operably linked” to another nucleic acid sequence when the former is placed into a functional relationship with the latter. For example, a DNA for a presequence or secretory leader peptide is operably linked to DNA for a polypeptide if it is expressed as a pre-protein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, “operably linked” means that the DNA sequences being linked are contiguous and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

[0044] As used herein, the “stringency” of a hybridization reaction refers to the difficulty with which any two nucleic acid molecules will hybridize to one another. The present invention also includes polynucleotides capable of hybridizing under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in Table 2 below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

TABLE 2

Stringency Condition				
Stringency Condition	Poly-nucleotide Hybrid	Hybrid Length (bp) ¹	Hybridization Temperature and Buffer ²	Wash Temp. and Buffer ²
A	DNA:DNA	>50	65° C.; 1xSSC -or- 42° C.; 1xSSC, 50% formamide	65° C.; 0.3xSSC
B	DNA:DNA	<50	T _B *; 1xSSC	T _B *; 1xSSC
C	DNA:RNA	>50	67° C.; 1xSSC -or- 45° C.; 1xSSC, 50% formamide	67° C.; 0.3xSSC
D	DNA:RNA	<50	T _D *; 1xSSC	T _D *; 1xSSC
E	RNA:RNA	>50	70° C.; 1xSSC -or- 50° C.; 1xSSC, 50% formamide	70° C.; 0.3xSSC
F	RNA:RNA	<50	T _F *; 1xSSC	T _F *; 1xSSC
G	DNA:DNA	>50	65° C.; 4xSSC -or- 42° C.; 4xSSC, 50% formamide	65° C.; 1xSSC
H	DNA:DNA	<50	T _H *; 4xSSC	TH*; 4xSSC
I	DNA:RNA	>50	67° C.; 4xSSC -or- 45° C.; 4xSSC, 50% formamide	67° C.; 1xSSC
J	DNA:RNA	<50	T _J *; 4xSSC	T _J *; 4xSSC
K	RNA:RNA	>50	70° C.; 4xSSC -or- 50° C.; 4xSSC, 50% formamide	67° C.; 1xSSC
L	RNA:RNA	<50	T _L *; 2xSSC	T _L *; 2xSSC
M	DNA:DNA	>50	50° C.; 4xSSC -or- 40° C.; 6xSSC, 50% formamide	50° C.; 2xSSC
N	DNA:DNA	<50	T _N *; 6xSSC	T _N *; 6xSSC
O	DNA:RNA	>50	55° C.; 4xSSC -or- 42° C.; 6xSSC, 50% formamide	55° C.; 2xSSC
P	DNA:RNA	<50	T _P *; 6xSSC	T _P *; 6xSSC

TABLE 2-continued

Stringency Condition				
Stringency Condition	Poly-nucleotide Hybrid	Hybrid Length (bp) ¹	Hybridization Temperature and Buffer ^{2f}	Wash Temp. and Buffer ^{2f}
Q	RNA:RNA	>50	60° C.; 4xSSC -or- 45° C.; 6xSSC, 50% formamide	60° C.; 2xSSC
R	RNA:RNA	<50	T _R *; 4xSSC	T _R *; 4xSSC

¹The hybrid length is that anticipated for the hybridized region(s) of the hybridizing polynucleotides. When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that of the hybridizing polynucleotide. When polynucleotides of known sequence are hybridized, the hybrid length can be determined by aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarity.

^{2f}SSPE (1xSSPE is 0.15M NaCl, 10 mM NaH₂PO₄, and 1.25 mM EDTA, pH 7.4) can be substituted for SSC (1xSSC is 0.15M NaCl and 15 mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes after hybridization is complete.

T_R* - T_R*: The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10° C. less than the melting temperature (T_m) of the hybrid, where T_m is determined according to the following equations.

For hybrids less than 18 base pairs in length, T_m(° C.) = 2(# of A + T bases) + 4(# of G + C bases).

For hybrids between 18 and 49 base pairs in length, T_m(° C.) = 81.5 + 16.6(log₁₀Na⁺) + 0.41(% G+C) - (600/N), where N is the number of bases in the hybrid, and Na⁺ is the concentration of sodium ions in the hybridization buffer (Na⁺ for 1xSSC = 0.165M).

[0045] As used herein, the terms “immunospecific binding” and “specifically bind to” refer to antibodies that bind to an antigen with a binding affinity of 10⁵ Moles taken either from pre-CVH or from a subject who has not suffered CVH, or from a cell, tissue or sample that is not affected by CVH. Control samples of the present invention are taken from normal samples.

[0046] As used herein, the term “expression pattern” includes expression of a group of genes at RNA or protein level, the quantity or activity of each member of which is correlated with the incidence or risk of incidence of CVH and CVH associated diseases. An expression pattern comprises expression level of 2 or more CVHGs. An expression pattern may also comprise expression level of 2-5, 5-15, 15-35, 35-50, or more than 50 CVHGs.

[0047] As used herein, the terms “treating,” “treatment,” and “therapy” refer to curative therapy, prophylactic therapy, and preventative therapy.

[0048] Various aspects of the invention are described in further detail in the following subsections. The subsections below describe in more detail the present invention. The use of subsections is not meant to limit the invention; subsections may apply to any aspect of the invention.

[0049] One aspect of the present invention relates to a method for treating CVH and CVH-related disorders with compositions comprising a guanyldiazide compound. In one embodiment, the CVH-related disorder is IBS and the guanyldiazide compound is CNI1493.

[0050] Another aspect of the present invention relates to CVH-related genes. Briefly, new born rats were sensitized by infusion of acetic acid into the colon at P10. Control rats received saline. At eight weeks, the animals were divided into four groups: control+vehicle; control+CNI1493; sensitized+

vehicle; and sensitized+CNI1493. Colon samples were obtained after CNI1493 treatment (5 mg/kg for four days, the vehicle group received vehicle only). Gene expression patterns in the colon tissue samples and S1 dorsal root ganglia (S1 DRG) were analyzed using Affymetrix rat genome 230A chips (Affymetrix, Santa Clara, Calif.). Single array analysis for each chip was performed by Affymetrix Microarray Suite (MAS) software to produce a detection call, present, absent or marginal and a signal intensity value for each gene that is a relative measure of abundance of the transcript. For comparison of signal intensity values between chips, all chips will be scaled to an average intensity of 500. Genes called “Absent” across all chips and genes without a Fold-change ≥ 2.0 in at least one of the pairwise comparisons of chips from different treatment groups are excluded. The probe sets with absolute call “Absent” across all chips and Fold-change <2.0 in all of the possible pairwise comparisons, are filtered out. ANOVA was then performed on the filtered data set. Significant changes in gene expression were detected by analyzing signal intensity values by two-way ANOVA with 99% confidence limits. The differentially regulated genes were subjected to cluster analysis to identify genes associated with sensitization and treatment.

[0051] Tables 3 and 4 provides a list of the genes that are differentially expressed in the colon and S1 DRG, respectively, of the sensitized animals, i.e., animals suffering from CVH. Tables 5 and 6 provide a list of the genes that are differentially expressed in the colon and S1 DRG, respectively, in CNI1493-treated animals. Since CNI1493 treatment ameliorates CVH in the sensitized animals, genes differentially regulated by CNI1493 may also be related to the etiology of CVH. Accordingly, genes listed in Tables 3-6 are designated as CVH-related genes (CVHGs).

TABLE 3

Genes differentially expressed in sensitized colon						
No.	Acce. No.	Symbol	CTRL-VHL	CTRL-CNI	IBS-VHL	IBS-CNI
73	NM_021769	Sult-n	1.00	0.85	2.98	1.85
57	NM_022531	Des	1.00	1.03	2.55	1.31
14	BF389682	zzN/A	1.00	1.53	2.49	2.04

TABLE 3-continued

Genes differentially expressed in sensitized colon						
No.	Acce. No.	Symbol	CTRL-VHL	CTRL-CNI	IBS-VHL	IBS-CNI
16	BF419200	Cebpd	1.00	1.03	2.44	2.28
26	BI296437	zzN/A	1.00	1.14	2.43	1.21
25	NM_013002	Pcp4	1.00	0.88	2.29	1.14
55	NM_013122	Igfbp2	1.00	0.75	2.19	0.94
74	NM_024400	Adams1	1.00	0.90	2.11	1.14
65	AI229029	Tubb3	1.00	0.93	2.05	1.53
43	BI282702	Acta2	1.00	0.95	2.03	0.99
44	BF399310	zzN/A	1.00	0.64	2.01	0.78
64	NM_031970	Hspb1	1.00	1.14	1.90	1.40
12	ILGFBP4	BC019836	1.00	1.41	1.88	2.00
58	BF290193	zzN/A	1.00	0.65	1.84	0.90
36	AA012755		1.00	0.72	1.83	0.79
45	AI103600	zzN/A	1.00	0.57	1.81	0.58
63	AA851939	Fxyd6	1.00	0.95	1.81	1.26
56	AA799832	zzN/A	1.00	0.78	1.80	0.95
50	NM_019904	Lgals1	1.00	0.74	1.79	0.96
37	NM_017148	Csrp1	1.00	0.63	1.72	0.71
35	BI283060	zzN/A	1.00	0.63	1.71	0.69
39	AA800892	zzN/A	1.00	0.57	1.71	0.68
29	BG373779	LOC308709	1.00	0.48	1.68	0.59
2	BI285494	Ifitm31	1.00	3.86	1.66	4.90
47	NM_053770	Argbp2	1.00	0.79	1.66	0.77
34	NM_012893	Actg2	1.00	0.48	1.66	0.56
46	NM_130403	Ppp1r14a	1.00	0.91	1.65	0.99
15	BG663107	zzN/A	1.00	1.06	1.65	1.23
30	D29960	Loc192245	1.00	0.51	1.64	0.54
48	BM386598	zzN/A	1.00	0.90	1.60	0.95
71	AA818342	zzN/A	1.00	0.88	1.58	1.25
5	AW523747	Amigo2	1.00	0.88	1.57	2.10
40	AA817802	zzN/A	1.00	0.55	1.57	0.69
75	BE112887	zzN/A	1.00	1.06	1.55	1.05
33	M23764	Tpm1	1.00	0.60	1.54	0.68
59	AW522471	Exo70	1.00	0.65	1.54	1.00
8	EST		1.00	0.93	1.52	2.14
31	AI044427	zzN/A	1.00	0.59	1.52	0.69
41	BI279044	zzN/A	1.00	0.49	1.51	0.52
9	EST		1.00	1.48	1.51	2.10
28	BI291848	zzN/A	1.00	0.62	1.51	0.81
24	AI411809	zzN/A	1.00	0.89	1.51	1.06
67	NM_053440	Stmn2	1.00	0.79	1.49	1.06
54	BI285456	zzN/A	1.00	0.83	1.49	1.06
32	NM_031549	Tagln	1.00	0.54	1.47	0.64
38	AI177055	zzN/A	1.00	0.79	1.47	0.82
52	BI279661	Wfdc1	1.00	0.66	1.46	0.94
20	AI229240	zzN/A	1.00	0.68	1.46	1.69
1	BI285346	Ppp4r1	1.00	1.34	1.46	1.51
53	NM_134449	Prkcdbp	1.00	0.87	1.45	1.01
49	BF555956	zzN/A	1.00	0.85	1.45	0.91
42	X16262	Myh11	1.00	0.54	1.44	0.60
51	BG666999	Slc25a4	1.00	0.79	1.44	0.94
70	AI177366	Itgb1	1.00	1.00	1.42	1.24
61	AA686007	Parva	1.00	0.80	1.41	0.99
68	BM389644	zzN/A	1.00	0.88	1.41	1.07
18	BG378721	zzN/A	1.00	0.95	1.40	1.21
60	AA893484	Fn1	1.00	0.51	1.40	0.88
27	NM_019304	Dgkb	1.00	0.67	1.31	0.86
7	EST		1.00	1.09	1.31	1.51
19	NM_017131	Casq2	1.00	0.71	1.30	1.19
6	U06434	Scya4	1.00	1.18	1.30	1.76
10	AB043636	Kcnj8	1.00	1.22	1.29	1.65
11	EST		1.00	0.82	1.29	1.55
66	AF081582	Evt1	1.00	0.85	1.29	1.03
3	NM_024145	Fgr	1.00	1.03	1.26	1.70
72	BI296312	zzN/A	1.00	0.80	1.26	1.04
13	AA859496	Gch	1.00	0.93	1.24	1.34
22	BF394235	zzN/A	1.00	0.55	1.23	0.99
69	BF551377	zzN/A	1.00	0.81	1.21	0.99
62	AI179984	Dmrs91	1.00	0.49	1.21	0.70
21	NM_133605	Camk2g	1.00	0.77	1.18	1.01
17	U27518	LOC286989	1.00	0.50	1.11	1.19
4	NM_022688	Porfl	1.00	0.80	1.08	1.42
23	AW254190		1.00	0.66	1.05	1.03

TABLE 3-continued

Genes differentially expressed in sensitized colon						
No.	Acce. No.	Symbol	CTRL-VHL	CTRL-CNI	IBS-VHL	IBS-CNI
87	BM386844	zzN/A	1.00	1.40	1.00	0.84
94	BF390024	Ncor1	1.00	1.34	0.93	0.89
92	BE098713	zzN/A	1.00	1.11	0.87	0.82
86	BF404414	zzN/A	1.00	1.19	0.85	0.80
82	AA945828	zzN/A	1.00	1.54	0.84	1.07
88	AA849756	zzN/A	1.00	0.86	0.84	0.66
83	BM392373	Ceacam1	1.00	1.38	0.82	0.87
78	BM385170	zzN/A	1.00	1.30	0.81	1.11
77	BF411331	zzN/A	1.00	1.22	0.80	1.04
104	AI177513	zzN/A	1.00	0.90	0.80	0.70
107	AA964600	zzN/A	1.00	0.83	0.79	0.68
85	BI295141	zzN/A	1.00	1.07	0.78	0.82
108	AI227627	Cd9	1.00	0.74	0.77	0.61
90	NM_031762	Cdkn1b	1.00	1.02	0.74	0.45
89	AI180286	zzN/A	1.00	0.90	0.74	0.70
91	AI105205	Ctl1	1.00	0.93	0.73	0.57
103	BG380281	zzN/A	1.00	0.72	0.72	0.64
101	BI301490	zzN/A	1.00	0.68	0.69	0.66
113	BM384203	zzN/A	1.00	0.90	0.69	0.66
114	BG373555	zzN/A	1.00	0.98	0.68	0.74
105	BI288816	zzN/A	1.00	0.65	0.68	0.48
109	AA894262	zzN/A	1.00	1.07	0.68	0.59
106	AI228548	zzN/A	1.00	0.62	0.67	0.30
76	AW433971	Mvk	1.00	1.12	0.67	0.98
80	AA800750	zzN/A	1.00	1.13	0.65	0.92
84	AI171229	zzN/A	1.00	1.23	0.65	0.78
112	AI407835	Add3	1.00	0.74	0.65	0.65
97	NM_023989	LOC78973	1.00	0.84	0.65	0.70
81	AA893602	zzN/A	1.00	1.13	0.65	0.93
98	AA943165	zzN/A	1.00	0.71	0.64	0.52
93	NM_031347	Ppargc1	1.00	1.17	0.62	0.52
79	BE102350	zzN/A	1.00	1.64	0.61	1.18
110	AI408598	zzN/A	1.00	0.85	0.61	0.53
111	AI175820	zzN/A	1.00	0.64	0.61	0.57
99	AI179665	zzN/A	1.00	0.77	0.59	0.64
100	BI296591	zzN/A	1.00	0.53	0.54	0.55
102	AF189724	Cxcl12	1.00	0.73	0.50	0.61
96	BF417032	zzN/A	1.00	0.87	0.49	0.57
95	M58040	Tfrc	1.00	0.63	0.45	0.42

TABLE 4

Genes differentially expressed in sensitized S1 DRG						
No.	Identifier	Acce. No.	CTRL-VHL	CTRL-CNI	IBS-VHL	IBS-CNI
11	1376554_at	BE121079	1	1.74	2.23	2.01
23	1369233_at	AF196965	1	1.45	2.09	1.71
4	1374620_at	BM392373	1	1.43	1.87	2.41
6	1390403_at	BE108405	1	1.39	1.83	1.86
8	1379272_at	AA963084	1	1.08	1.83	1.70
24	1369157_at	NM_017229	1	1.05	1.78	1.09
19	1382915_at	AI237079	1	1.26	1.76	1.38
25	1374802_at	AI010721	1	0.90	1.72	0.96
5	1389222_at	BI282847	1	1.30	1.69	1.66
22	1368379_at	NM_054001	1	1.31	1.68	1.66
7	1368678_at	X67108	1	1.38	1.66	1.72
10	1386218_at	AI639301	1	1.35	1.65	1.58
26	1370301_at	U65656	1	1.17	1.64	1.02
17	1389099_at	AI600184	1	1.50	1.64	1.50
18	1383159_at	AW434445	1	1.40	1.64	1.58
13	1384217_at	BI276341	1	1.24	1.59	1.67
21	1389713_at	AI602851	1	1.17	1.58	1.45
12	1372620_at	AI008642	1	1.32	1.57	1.94
78	1385386_at	BI302745	1	0.79	0.09	0.31
28	1387658_at	U93849	1	1.60	0.43	0.82
47	1368703_at	NM_053326	1	0.65	0.44	0.70
62	1377606_at	AI500913	1	0.49	0.44	0.36
50	1375606_at	AI235906	1	0.75	0.46	0.43

TABLE 4-continued

Genes differentially expressed in sensitized S1 DRG						
No.	Identifier	Acce. No.	CTRL-VHL	CTRL-CNI	IBS-VHL	IBS-CNI
49	1369255_at	NM_013123	1	0.80	0.46	0.58
40	1386999_at	BG380730	1	0.78	0.47	0.68
42	1388589_at	BG381046	1	0.74	0.47	0.61
41	1370666_at	AF201839	1	0.66	0.49	0.44
52	1389864_at	BF405086	1	0.69	0.50	0.58
72	1374283_at	BF419505	1	0.82	0.51	0.59
34	1375469_at	BE111847	1	0.67	0.52	0.67
38	1374002_at	AI045904	1	0.71	0.55	0.79
65	1394114_at	AA799434	1	0.67	0.56	0.63
67	1388101_at	AF389425	1	0.73	0.56	0.71
57	1368279_at	NM_053718	1	0.78	0.56	0.39
45	1376350_at	BF396151	1	0.90	0.57	0.75
74	1376122_at	BF401577	1	0.77	0.57	0.44
36	1369036_at	NM_019309	1	0.72	0.58	0.65
66	1367814_at	M14137	1	0.67	0.59	0.67
71	1372177_at	AI180033	1	0.63	0.60	0.61
70	1373981_at	BI299720	1	0.62	0.60	0.55
35	1383468_at	BM958512	1	0.66	0.62	0.67
46	1376931_at	BG380736	1	0.73	0.62	0.75
75	1371281_at	M37568	1	0.97	0.63	0.39
44	1387818_at	NM_053736	1	0.87	0.63	0.75
51	1369048_at	NM_017289	1	0.71	0.64	0.56
37	1374084_at	BE119993	1	0.68	0.64	0.59
30	1387327_at	NM_133318	1	1.25	0.65	0.66
39	1373031_at	BI275757	1	0.83	0.65	0.77
32	1375448_at	BM391628	1	0.90	0.65	0.74
88	1369884_at	NM_022182	1	0.90	0.66	0.54
59	1375294_at	BF415950	1	0.75	0.66	0.42
90	1387404_at	NM_078620	1	1.02	0.66	0.50
69	1386907_at	NM_012949	1	0.75	0.67	0.67
63	1392500_at	AA957990	1	0.59	0.67	0.58
68	1369000_at	NM_021589	1	0.75	0.67	0.67

TABLE 5

Genes differentially expressed in CNI1493-treated colon			
No.	Identifier	Acce. No.	Description
1	1370531_at	U69550	phospholipase D gene 1
2	1369708_at	NM_031017	cAMP response element binding protein 1
3	1368889_at	NM_023101	SNARE Vti1a-beta protein
4	1387046_at	NM_053792	selective LIM binding factor
5	1371192_at	BF566236	neurofibromatosis 2
6	1369195_at	NM_013068	Fatty acid binding protein 2
7	1398540_at	BM386789	<i>Rattus norvegicus</i> transcribed sequences
8	1375464_at	BI290815	<i>Rattus norvegicus</i> transcribed sequences
9	1387119_at	AW433971	mevalonate kinase
10	1374034_at	BG379410	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein sp: P49589 (<i>H. sapiens</i>) SYC_HUMAN CYSTEINYL-TRNA SYNTHETASE (CYSTEINE--TRNA LIGASE) (CYSRS)
11	1392633_at	AI045724	<i>Rattus norvegicus</i> transcribed sequences
12	1371027_at	BF556820	Cas-Br-M (murine) ectropic retroviral transforming sequence b
13	1376708_at	BM385170	<i>Rattus norvegicus</i> transcribed sequences
14	1387220_at	NM_019323	mast cell protease 9
15	1377034_at	BF411331	" <i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein ref: NP_109591.1 (<i>H. sapiens</i>) serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 1; protease inhibitor 2 (anti-elastase), monocyte/neutrophil; protease inhibitor
16	1374324_at	AA945828	<i>Rattus norvegicus</i> transcribed sequences
17	1370510_a_at	AB012600	aryl hydrocarbon receptor nuclear translocator-like
18	1387130_at	NM_133315	"solute carrier family 39 (iron-regulated transporter), member 1"
19	1390562_s_at	BE102350	<i>Rattus norvegicus</i> transcribed sequences
20	1390960_at	AA893602	<i>Rattus norvegicus</i> transcribed sequences

TABLE 5-continued

Genes differentially expressed in CNI1493-treated colon			
No.	Identifier	Acce. No.	Description
21	1371925_at	AA893621	<i>Rattus norvegicus</i> clone C201 intestinal epithelium proliferating cell-associated mRNA sequence
22	1370693_a_at	M18630	cyclic nucleotide phosphodiesterase 1
23	1377036_at	BE102350	<i>Rattus norvegicus</i> transcribed sequences
24	1392794_at	AA893579	<i>Rattus norvegicus</i> transcribed sequences
25	1388694_at	AI233121	MHC class I RT1.O type 149 processed pseudogene
26	1388754_at	AI176839	<i>Rattus norvegicus</i> transcribed sequences
27	1368233_at	NM_031042	"general transcription factor IIF, polypeptide 2 (30 kD subunit)"
28	1368679_a_at	L14782	lyn protein non-receptor kinase
29	1372177_at	AI180033	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein ref: NP_004522.1 (<i>H. sapiens</i>) molybdenum cofactor synthesis 2 [<i>Homo sapiens</i>]
30	1372868_at	BF284295	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein sp: O14657 (<i>H. sapiens</i>) TO1B_HUMAN Torsin B precursor
31	1380472_at	AI639486	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_003860.1 (<i>H. sapiens</i>) carboxylesterase 2; intestinal carboxylesterase; liver carboxylesterase-2 [<i>Homo sapiens</i>]
32	1387994_at	U89280	oxidative 17 beta hydroxysteroid dehydrogenase type 6
33	1390531_at	BE098021	<i>Rattus norvegicus</i> transcribed sequences
34	1388055_at	U39207	cytochrome P450 4F5
35	1368379_at	NM_054001	"CD36 antigen (collagen type I receptor, thrombospondin receptor)-like 2"
36	1368101_at	NM_012518	calmodulin 3
37	1389302_at	BI289482	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein pir: S30833 (<i>S. cerevisiae</i>) S30833 hypothetical protein YEL044w - yeast (<i>Saccharomyces cerevisiae</i>)
38	1389378_at	AI599324	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein pir: A42973 (<i>H. sapiens</i>) A42973 serum protein MSE55 - human
39	1387444_at	NM_133592	brain-enriched membrane-associated protein tyrosine BEM-2
40	1374284_at	AI227769	<i>Rattus norvegicus</i> transcribed sequences
41	1371239_s_at	AF053361	"tropomyosin 3, gamma"
42	1387596_at	NM_053897	"Proteinase-activated receptor-2, G protein-coupled receptor 11"
43	1389873_at	BI282953	apoptosis-associated speck-like protein containing a CARD
44	1369773_at	NM_017105	Bone morphogenetic protein 3
45	1374119_at	BI279615	" <i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein ref: NP_004424.1 (<i>H. sapiens</i>) E74-like factor 3 (ets domain transcription factor, epithelial-specific); E74-like factor 3 (ets domain transcription factor); ets domain transcription
46	1368128_at	NM_031598	"phospholipase A2, group IIA (platelets, synovial fluid)"
47	1368270_at	NM_012907	Apolipoprotein B editing protein
48	1367960_at	NM_019186	ADP-ribosylation-like 4
49	1367942_at	NM_019144	acid phosphatase 5
50	1392694_at	AW526101	<i>Rattus norvegicus</i> transcribed sequences
51	1374452_at	BF399743	phosphodiesterase 9A
52	1368727_at	NM_053929	"solute carrier family 7 (cationic amino acid transporter, y+ system), member 9"
53	1376625_at	BI296015	<i>Rattus norvegicus</i> transcribed sequences
54	1367768_at	NM_031655	latexin
55	1369193_at	AF474979	cyclin dependent kinase inhibitor 2B
56	1382714_at	AA875186	<i>Rattus norvegicus</i> transcribed sequences
57	1376359_at	BG375355	" <i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_113645.1 (<i>H. sapiens</i>) membrane-spanning 4-domains, subfamily A, member 8B [<i>Homo sapiens</i>]"
58	1372064_at	BI296385	<i>Rattus norvegicus</i> CDK104 mRNA
59	1388396_at	BI275932	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein sp: O00506 (<i>H. sapiens</i>) ST25_HUMAN Serine/threonine protein kinase 25 (Sterile 20/oxidant stress-response kinase 1) (Ste20/oxidant stress response kinase-1) (SOK-1) (Ste20-like kinase)
60	1384191_at	BF387765	<i>Rattus norvegicus</i> transcribed sequences

TABLE 5-continued

Genes differentially expressed in CNI1493-treated colon			
No.	Identifier	Acce. No.	Description
61	1372255_at	BF283284	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein sp: P54136 (<i>H. sapiens</i>) SYR_HUMAN ARGINYL-TRNA SYNTHETASE (ARGININE--TRNA LIGASE) (ARGRS)
62	1369262_at	NM_022277	caspase-8
63	1376117_at	BI289103	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein ref: NP_079533.1 (<i>H. sapiens</i>) NG22 protein; choline transporter-like protein 4 [<i>Homo sapiens</i>]
64	1380262_at	AA893436	<i>Rattus norvegicus</i> transcribed sequences
65	1370113_at	NM_023987	inhibitor of apoptosis protein 1
66	1368437_at	NM_019174	carbonic anhydrase 4
67	1390455_at	AI013474	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein sp: P08910 (<i>H. sapiens</i>) HPS1 HUMAN Protein PHS1-2
68	1378658_at	BI292185	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_036260.1 (<i>H. sapiens</i>) calcium activated chloride channel 4 [<i>Homo sapiens</i>]
69	1376976_at	AI009823	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_002995.1 (<i>H. sapiens</i>) secreted and transmembrane 1 precursor; K12 protein precursor; type 1a transmembrane protein [<i>Homo sapiens</i>]
70	1370706_a_at	U39943	cytochrome P450 monooxygenase
71	1372997_at	AI105243	<i>Rattus norvegicus</i> transcribed sequences
72	1369183_at	NM_019231	mitogen activated protein kinase 13
73	1386917_at	NM_012744	Pyruvate carboxylase
74	1390678_at	AA955527	<i>Rattus norvegicus</i> transcribed sequences
75	1398847_at	BG376935	diphosphoinositol polyphosphate phosphohydrolase type II
76	1368073_at	NM_012591	Interferon regulatory factor 1
77	1371394_x_at	BG664827	" <i>Rattus norvegicus</i> endogenous retrovirus mRNA, partial sequence"
78	1370422_at	AF036537	homocysteine respondent protein HCYP2
79	1375230_at	AA800192	" <i>Rattus norvegicus</i> endogenous retrovirus mRNA, partial sequence"
80	1368007_at	NM_022849	deleted in malignant brain tumors 1
81	1372671_at	BI284293	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein ref: NP_060809.1 (<i>H. sapiens</i>) hypothetical protein FLJ11149 [<i>Homo sapiens</i>]
82	1368219_at	NM_017137	chloride channel 2
83	1367760_at	D13341	mitogen activated protein kinase kinase 1
84	1388006_at	U89744	putative cell surface antigen
85	1367925_at	NM_022715	major vault protein
86	1390128_at	BF557618	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein ref: NP_065145.1 (<i>H. sapiens</i>) CHMP1.5 protein [<i>Homo sapiens</i>]
87	1388745_at	AI228417	" <i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein pdb: 1BGM (<i>E. coli</i>) O Chain O, Beta-Galactosidase (Chains I-P)"
88	1369940_at	NM_031811	transaldolase 1
89	1370400_at	L23128	" <i>Rattus norvegicus</i> MHC class I mRNA, complete cds"
90	1371970_at	AA799328	<i>Rattus norvegicus</i> transcribed sequences
91	1386933_at	NM_134418	secretory (zymogen) granule membrane glycoprotein GP2
92	1369100_at	NM_134375	angiotensin/vasopressin receptor
93	1372619_at	AI172185	" <i>Rattus norvegicus</i> Aa2-277 mRNA, complete cds"
94	1380129_at	AA818937	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein sp: P10266 (<i>H. sapiens</i>) POL1_HUMAN Endogenous retrovirus HERV-K10 putative pol polyprotein [Includes: Reverse transcriptase; Endonuclease]
95	1371078_at	AI500830	RT1 class Ib gene
96	1367586_at	NM_017025	lactate dehydrogenase A
97	1374033_at	BG373505	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pir: I38135 (<i>H. sapiens</i>) I38135 multicatalytic endopeptidase complex (EC 3.4.99.46) beta chain MECL-1 - human
98	1373913_at	BF282271	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein pir: T50626 (<i>H. sapiens</i>) T50626 hypothetical protein DKFZp762K1914.1 - human (fragment)
99	1372665_at	AI230228	" <i>Rattus norvegicus</i> phosphoserine aminotransferase mRNA, complete cds"

TABLE 5-continued

Genes differentially expressed in CNI1493-treated colon			
No.	Identifier	Acce. No.	Description
100	1376056_at	BF291214	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein ref: NP_116178.1 (<i>H. sapiens</i>) hypothetical protein FLJ14464 [<i>Homo sapiens</i>]
101	1368066_at	NM_053812	BCL2-antagonist/killer 1
102	1374838_at	BI293504	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein sp: Q13342 (<i>H. sapiens</i>) LY10_HUMAN LYSP100 protein (Lymphoid-restricted homolog of Sp100) (Nuclear autoantigen Sp-140) (Speckled 140 kDa) (Nuclear body protein Sp140)
103	1372816_at	BE107319	<i>Rattus norvegicus</i> transcribed sequences
104	1388236_x_at	M24026	RT1 class Ib gene
105	1371210_s_at	AJ276126	RT1 class Ib gene
106	1390325_at	BI289418	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_083693.1 (<i>M. musculus</i>) RIKEN cDNA 9030605E16 [<i>Mus musculus</i>]
107	1369279_at	NM_130819	retinol dehydrogenase homolog
108	1390021_at	BM391206	histone 2b
109	1368317_at	NM_019157	aquaporin 7
110	1387100_at	NM_031703	aquaporin 3
111	1368975_at	NM_013127	CD38 antigen
112	1386908_at	NM_022278	glutaredoxin 1 (thioltransferase)
113	1369427_at	NM_022617	macrophage expressed gene 1
114	1369110_x_at	NM_012645	RT1 class Ib gene
115	1369957_at	NM_019341	regulator of G-protein signaling 5
116	1398985_at	AI716480	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein ref: NP_004277.1 (<i>H. sapiens</i>) GTP binding protein 1 [<i>Homo sapiens</i>]
117	1368413_at	NM_022935	Amiloride binding protein 1
118	1370960_at	BE104060	insulin-like growth factor-binding protein 5
119	1368505_at	NM_017214	regulator of G-protein signaling 4
120	1373386_at	AI179953	<i>Rattus norvegicus</i> transcribed sequences
121	1387348_at	BE113270	insulin-like growth factor-binding protein 5
122	1370638_at	AF069525	ankyrin 3 (G)
123	1377112_at	AA859352	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein ref: NP_001776.1 (<i>H. sapiens</i>) cytidine deaminase [<i>Homo sapiens</i>]
124	1389611_at	AA849857	Very low density lipoprotein receptor
125	1369098_at	NM_013155	Very low density lipoprotein receptor
126	1368294_at	NM_053907	deoxyribonuclease I-like 3
127	1368342_at	NM_031544	Adenosine monophosphate deaminase 3
128	1368965_at	NM_030834	monocarboxylate transporter
129	1392819_at	AW921478	" <i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_071744.1 (<i>H. sapiens</i>) CD20-like precursor; membrane-spanning 4-domains, subfamily A, member 6 [<i>Homo sapiens</i>]"
130	1367774_at	NM_031509	"glutathione S-transferase, alpha 1"
131	1387687_at	NM_133542	"immunoglobulin superfamily, member 6"
132	1369173_at	NM_032060	complement component 3a receptor 1
133	1372013_at	BG380285	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_006426.1 (<i>H. sapiens</i>) interferon induced transmembrane protein 2 (1-8D); interferon-inducible [<i>Homo sapiens</i>]
134	1373025_at	AI411618	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pir: C1HUQC (<i>H. sapiens</i>) C1HUQC complement subcomponent C1q chain C precursor - human
135	1376652_at	BF418957	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pir: C1HUQA (<i>H. sapiens</i>) C1HUQA complement subcomponent C1q chain A precursor - human
136	1368420_at	NM_012532	ceruloplasmin
137	1373932_at	BE098739	<i>Rattus norvegicus</i> transcribed sequences
138	1387893_at	D88250	"complement component 1, s subcomponent"
139	1388557_at	BF284922	<i>Rattus norvegicus</i> transcribed sequences
140	1374730_at	AI102519	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_003323.1 (<i>H. sapiens</i>) TYRO protein tyrosine kinase binding protein; polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy [<i>Homo sapiens</i>]
141	1368000_at	NM_016994	Complement component 3
142	1368558_s_at	NM_017196	allograft inflammatory factor 1

TABLE 5-continued

Genes differentially expressed in CNI1493-treated colon		
No.	Identifier	Acce. No. Description
143	1373523_at	AI011757 <i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein sp: P08637 (<i>H. sapiens</i>) FC3A_HUMAN Low affinity immunoglobulin gamma FC region receptor III-A precursor (IGG FC receptor III-2) (FC-gamma RIII-alpha) (FC-gamma RIIIA) (FCRIIA) (FC-gamm
144	1387011_at	NM_130741 lipocalin 2
145	1370885_at	AA849399 cathepsin Y
146	1389470_at	AI639117 Complement component 2
147	1368430_at	AF154349 "protease, cysteine, 1 (legumain)"
148	1375010_at	AI177761 <i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_001242.1 (<i>H. sapiens</i>) CD68 antigen; Macrophage antigen CD68 (microsialin) [<i>Homo sapiens</i>]
149	1389006_at	AI170394 <i>Rattus norvegicus</i> transcribed sequences
150	1373575_at	BE111722 <i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pir: A35241 (<i>H. sapiens</i>) A35241 IgE Fc receptor gamma chain precursor - human
151	1390510_at	BI294706 " <i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_071744.1 (<i>H. sapiens</i>) CD20-like precursor; membrane-spanning 4-domains, subfamily A, member 6 [<i>Homo sapiens</i>]"
152	1376390_at	BF395317 " <i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_071744.1 (<i>H. sapiens</i>) CD20-like precursor; membrane-spanning 4-domains, subfamily A, member 6 [<i>Homo sapiens</i>]"
153	1368187_at	NM_133298 glycoprotein (transmembrane) nmb
154	1389553_at	BF393825 " <i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_057268.1 (<i>H. sapiens</i>) C-type (calcium dependent, carbohydrate-recognition domain) lectin, superfamily member 6; dendritic cell immunoreceptor; C-type lectin [<i>Homo sapiens</i>]"
155	1367568_a_at	NM_012862 matrix Gla protein
156	1370628_at	M34097 granzyme B
157	1379604_at	BF284937 " <i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_085146.1 (<i>H. sapiens</i>) apolipoprotein L, 4 [<i>Homo sapiens</i>]"
158	1368464_at	NM_022393 macrophage galactose N-acetyl-galactosamine specific lectin
159	1379766_at	AI500952 <i>Rattus norvegicus</i> transcribed sequences
160	1370516_at	AB026665 peptide/histidine transporter PHT2
161	1373071_at	AI103101 <i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein pir: T00702 (<i>H. sapiens</i>) T00702 hypothetical protein F25965 1 - human (fragment)
162	1393224_at	AW529774 <i>Rattus norvegicus</i> transcribed sequences
163	1390312_at	BG670441 <i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_060124.1 (<i>H. sapiens</i>) hypothetical protein FLJ20073 [<i>Homo sapiens</i>]
164	1377412_at	AI146237 <i>Rattus norvegicus</i> transcribed sequences
165	1399125_at	BI275516 <i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein sp: P49441 (<i>H. sapiens</i>) INPP_HUMAN Inositol polyphosphate 1-phosphatase (IPase) (IPP)
166	1386986_at	NM_053340 opioid growth factor receptor
167	1374731_at	BI275929 " <i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pdb: 1LBG (<i>E. coli</i>) B Chain B, Lactose Operon Repressor Bound To 21-Base Pair Symmetric Operator Dna, Alpha Carbons Only"
168	1388880_at	BI278962 Lysosomal associated membrane protein 1 (120 kDa)
169	1376075_at	BM385544 <i>Rattus norvegicus</i> transcribed sequences
170	1369559_a_at	NM_019195 integrin-associated protein
171	1376972_at	AI407028 "solute carrier family 39 (iron-regulated transporter), member 1"
172	1388776_at	AI169176 <i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_057563.1 (<i>H. sapiens</i>) hypothetical protein LOC51246 [<i>Homo sapiens</i>]
173	1376029_at	BI295991 <i>Rattus norvegicus</i> transcribed sequences
174	1388164_at	AF029241 "Rat MHC class I RT1.C/E mRNA, 3' end"
175	1389734_x_at	BI282965 RT1 class Ib gene
176	1370429_at	L40362 RT1 class Ib gene
177	1388900_at	BG381414 <i>Rattus norvegicus</i> transcribed sequences
178	1375955_at	BI289415 <i>Rattus norvegicus</i> transcribed sequences

TABLE 5-continued

Genes differentially expressed in CNI1493-treated colon			
No.	Identifier	Acce. No.	Description
179	1389011_at	BG374333	<i>Rattus norvegicus</i> transcribed sequences
180	1389387_at	BF561377	hydroxyindole-O-methyltransferase
181	1387206_at	NM_031740	"UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 6"
182	1388071_x_at	M24024	RT1 class Ib gene
183	1398925_at	BI274664	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_060818.1 (<i>H. sapiens</i>) hypothetical protein FLJ11171 [<i>Homo sapiens</i>]
184	1368224_at	NM_031531	Serine protease inhibitor
185	1374718_at	AA945915	<i>Rattus norvegicus</i> transcribed sequences
186	1394340_at	BF523172	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein sp: P49441 (<i>H. sapiens</i>) INPP_HUMAN Inositol polyphosphate 1-phosphatase (IPase) (IPP)
187	1376022_at	BI292196	<i>Rattus norvegicus</i> transcribed sequences
188	1368732_at	NM_032056	"transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)"
189	1367710_at	NM_017257	"protease (prosome, macropain) 28 subunit, beta"
190	1367786_at	NM_080767	"proteasome (prosome, macropain) subunit, beta type, 8 (low molecular mass polypeptide 7)"
191	1389170_at	BF283754	<i>Rattus norvegicus</i> transcribed sequences
192	1375853_at	BF284358	<i>Rattus norvegicus</i> transcribed sequences
193	1373757_at	AW529298	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein ref: NP_006691.1 (<i>H. sapiens</i>) FLN29 gene product [<i>Homo sapiens</i>]
194	1388149_at	X57523	"transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)"
195	1372604_at	BI289459	" <i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_055164.1 (<i>H. sapiens</i>) apolipoprotein L, 3; TNF-inducible protein CG12-1 [<i>Homo sapiens</i>]"
196	1387027_a_at	U72741	"Lectin, galactose binding, soluble 9 (Galectin-9)"
197	1372034_at	BF284106	<i>Rattus norvegicus</i> transcribed sequences
198	1370186_at	AI599350	"proteasome (prosome, macropain) subunit, beta type 9 (large multifunctional protease 2)"
199	1388212_a_at	AJ243974	"Rat MHC class I RT1.C/E mRNA, 3' end"
200	1388213_a_at	AJ243973	"Rat MHC class I RT1.C/E mRNA, 3' end"
201	1371123_x_at	AJ243973	"Rat MHC class I RT1.C/E mRNA, 3' end"
202	1371152_a_at	Z18877	25 oligoadenylate synthetase
203	1372930_at	AI411381	" <i>Rattus norvegicus</i> cDNA, clone: aC10, differentially expressed in pylorus"
204	1388791_at	BI275911	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pir: T14738 (<i>H. sapiens</i>) T14738 hypothetical protein DKFZp564A2416.1 - human (fragment)
205	1369716_s_at	NM_012976	"Lectin, galactose binding, soluble 5 (Galectin-5)"
206	1376496_at	AI717736	" <i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_112092.1 (<i>H. sapiens</i>) apolipoprotein L, 2 [<i>Homo sapiens</i>]"
207	1374337_at	AI408954	" <i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pdb: 1LBG (<i>E. coli</i>) B Chain B, Lactose Operon Repressor Bound To 21-Base Pair Symmetric Operator Dna, Alpha Carbons Only"
208	1387242_at	NM_019335	"Protein kinase, interferon-inducible double stranded RNA dependent"
209	1376144_at	AA819679	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_113646.1 (<i>H. sapiens</i>) B aggressive lymphoma gene [<i>Homo sapiens</i>]
210	1368835_at	AW434718	signal transducer and activator of transcription 1
211	1387946_at	AF065438	peptidylprolyl isomerase C-associated protein
212	1383564_at	BF411036	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein ref: NP_004022.1 (<i>H. sapiens</i>) interferon regulatory factor 7 isoform d [<i>Homo sapiens</i>]
213	1389034_at	BI295179	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein sp: Q9UMW8 (<i>H. sapiens</i>) UBPL_HUMAN Ubiquitin carboxyl-terminal hydrolase 18 (Ubiquitin thiolesterase 18) (Ubiquitin-specific processing protease 18) (Deubiquitinating enzyme 18) (Ubiqui

TABLE 5-continued

Genes differentially expressed in CNI1493-treated colon			
No.	Identifier	Acce. No.	Description
214	1388347_at	AI233210	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein sp: Q16553 (<i>H. sapiens</i>) LY6E_HUMAN Lymphocyte antigen Ly-6E precursor (Retinoic acid-induced gene E protein) (RIG-E) (Thymic shared antigen-1) (TSA-1) (Stem cell antigen 2) (SCA-2)
215	1376845_at	AA819034	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein ref: NP_114425.1 (<i>H. sapiens</i>) TLH29 protein precursor [<i>Homo sapiens</i>]
216	1376693_at	AA998964	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein ref: NP_060124.1 (<i>H. sapiens</i>) hypothetical protein FLJ20073 [<i>Homo sapiens</i>]
217	1387770_at	NM_130743	"interferon, alpha-inducible protein 27-like"
218	1376920_at	BF408536	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_060124.1 (<i>H. sapiens</i>) hypothetical protein FLJ20073 [<i>Homo sapiens</i>]
219	1387354_at	NM_032612	signal transducer and activator of transcription 1
220	1373037_at	BI279216	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein ref: NP_004214.1 (<i>H. sapiens</i>) ubiquitin-conjugating enzyme E2L 6 [<i>Homo sapiens</i>]
221	1387995_a_at	BI285494	interferon induced transmembrane protein 3-like
222	1377497_at	BF419319	" <i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pir: I60307 (<i>E. coli</i>) I60307 beta-galactosidase, alpha peptide - <i>Escherichia coli</i> "
223	1368227_at	NM_031664	"solute carrier family 28, member 2"
224	1390507_at	BI296097	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein ref: NP_002192.2 (<i>H. sapiens</i>) interferon stimulated gene (20 kD) [<i>Homo sapiens</i>]
225	1371440_at	AW916647	Prostaglandin F receptor
226	1369590_a_at	NM_024134	DNA-damage inducible transcript 3
227	1369202_at	NM_017028	myxovirus (influenza virus) resistance 2
228	1374627_at	BF283727	<i>Rattus norvegicus</i> transcribed sequences
229	1374551_at	BM388891	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein pir: JC5262 (<i>H. sapiens</i>) JC5262 leucine zipper protein IFP35 - human
230	1387134_at	NM_053687	schlafen 4
231	1373514_at	AA899109	<i>Rattus norvegicus</i> transcribed sequences
232	1372585_at	BM388445	<i>Rattus norvegicus</i> transcribed sequences
233	1369031_at	NM_053374	interferon gamma inducing factor binding protein
234	1371070_at	AJ302054	tumor stroma and activated macrophage protein DLM-1
235	1367595_s_at	NM_012512	Beta-2-microglobulin
236	1367663_at	NM_017264	"protease (prosome, macropain) 28 subunit, alpha"
237	1390042_at	AI071166	<i>Rattus norvegicus</i> transcribed sequences
238	1369186_at	D85899	caspase 1
239	1389571_at	BG666368	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein sp: P52630 (<i>H. sapiens</i>) STA2_HUMAN Signal transducer and activator of transcription 2 (p113)
240	1370913_at	AI409634	Best5 protein
241	1387969_at	U22520	chemokine (C-X-C motif) ligand 10
242	1376908_at	AW531805	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein sp: O14879 (<i>H. sapiens</i>) IFT4_HUMAN Interferon-induced protein with tetratricopeptide repeats 4 (IFT4) (Interferon-induced 60 kDa protein) (IFI-60K) (ISG-60) (CIG49) (Retinoic acid-ind
243	1369973_at	NM_017154	xanthine dehydrogenase
244	1368332_at	NM_133624	"guanylate binding protein 2, interferon-inducible"
245	1372254_at	AW915763	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein sp: P05155 (<i>H. sapiens</i>) IC1_HUMAN Plasma protease C1 inhibitor precursor (C1 Inh) (C1Inh)
246	1373197_at	AI578263	<i>Rattus norvegicus</i> transcribed sequences
247	1370892_at	BI285347	complement component 4a
248	1372757_at	BM386875	signal transducer and activator of transcription 1
249	1376151_a_at	AI407953	<i>Rattus norvegicus</i> transcribed sequences
250	1387283_at	NM_134350	myxovirus (influenza virus) resistance 2
251	1371015_at	X52711	myxovirus (influenza virus) resistance
252	1373992_at	AI408440	" <i>Rattus norvegicus</i> cDNA, clone: ad9, differentially expressed in pylorus"
253	1390738_at	BM385476	<i>Rattus norvegicus</i> mRNA for DAMP-1 protein
254	1388056_at	AF068268	2'5' oligoadenylate synthetase-2
255	1389365_at	AI228291	<i>Rattus norvegicus</i> transcribed sequences
256	1369726_at	NM_033098	TAP binding protein

TABLE 5-continued

Genes differentially expressed in CNI1493-treated colon			
No.	Identifier	Acce. No.	Description
257	1370172_at	AA892254	superoxide dismutase 2
258	1386893_at	NM_017113	granulin
259	1375796_at	BI300770	" <i>Rattus norvegicus</i> Ac2-233 mRNA, complete cds"
260	1389014_at	BI297612	pre-B-cell colony-enhancing factor
261	1371209_at	AJ243338	RT1 class Ib gene
262	1388255_x_at	AJ243338	RT1 class Ib gene
263	1373406_at	BM384991	<i>Rattus norvegicus</i> transcribed sequences
264	1375006_at	BE121050	<i>Rattus norvegicus</i> transcribed sequences
265	1387897_at	L16532	cyclic nucleotide phosphodiesterase 1
266	1369456_at	NM_017250	5-hydroxytryptamine (serotonin) receptor 2B
267	1374141_at	BG372419	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein ref: NP_071387.1 (<i>H. sapiens</i>) chromosome 20 open reading frame 67 [<i>Homo sapiens</i>]
268	1374678_at	BE109578	<i>Rattus norvegicus</i> transcribed sequences
269	1372968_at	BM385950	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein pir: S37032 (<i>R. norvegicus</i>) S37032 gene LL5 protein - rat
270	1371832_at	AW526333	<i>Rattus norvegicus</i> transcribed sequences
271	1390117_at	BG372455	<i>Rattus norvegicus</i> transcribed sequences
272	1369381_a_at	D50306	"solute carrier family 15 (oligopeptide transporter), member 1"
273	1388103_at	AF361355	voltage-dependent calcium channel gamma subunit-like protein
274	1386943_at	NM_022533	plasmolipin
275	1373060_at	AI406281	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein pir: T12468 (<i>H. sapiens</i>) T12468 hypothetical protein DKFZp564O123.1 - human
276	1375911_at	AI171772	" <i>Rattus norvegicus</i> hypothetical protein LK44 mRNA, complete cds"
277	1370071_at	NM_130399	Adenosine deaminase
278	1368762_at	NM_053299	ubiquitin D
279	1369712_at	NM_031735	serine/threonine kinase 3
280	1368419_at	AF202115	ceruloplasmin
281	1369029_at	NM_057194	phospholipid scramblase 1
282	1369888_at	NM_012707	glucagon
283	1398879_at	BE329031	arrestin-E
284	1369942_at	NM_031675	actinin alpha 4
285	1370807_at	AF411216	vacuole Membrane Protein 1
286	1377124_at	AA964824	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein pir: S48059 (<i>H. sapiens</i>) S48059 metal-regulatory transcription factor - human
287	1390221_at	BM385216	<i>Rattus norvegicus</i> transcribed sequences
288	1390604_s_at	BM387863	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_055103.1 (<i>H. sapiens</i>) integrin beta 3 binding protein (beta3-endonexin); beta 3 endonexin [<i>Homo sapiens</i>]
289	1398916_at	AI104388	heat shock 27 kDa protein 1
290	1374600_at	BM986536	germinal histone H4 gene
291	1370307_at	M64780	Agrin
292	1371888_at	AA892843	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein ref: NP_078816.1 (<i>H. sapiens</i>) hypothetical protein FLJ20917 [<i>Homo sapiens</i>]
293	1373603_at	BG673166	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pir: T45061 (<i>H. sapiens</i>) T45061 hypothetical protein c316G12.2 [imported]- human
294	1388408_at	AA800199	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein pir: T34520 (<i>H. sapiens</i>) T34520 hypothetical protein DKFZp564J157.1 - human (fragment)
295	1368471_at	NM_013118	guanylate cyclase activator 2A
296	1374401_at	AI549249	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein sp: O60749 (<i>H. sapiens</i>) SNX2_HUMAN Sorting nexin 2
297	1371267_at	M64795	zzN/A
298	1370832_at	U06434	small inducible cytokine A4
299	1383241_at	BI292425	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein sp: P00736 (<i>H. sapiens</i>) C1R_HUMAN Complement C1r component precursor
300	1387922_at	AF109674	late gestation lung protein 1

TABLE 5-continued

Genes differentially expressed in CNI1493-treated colon			
No.	Identifier	Acce. No.	Description
301	1376447_at	AI706850	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein sp: P10163 (<i>H. sapiens</i>) PRB4_HUMAN Salivary proline-rich protein PO precursor (Allele S)
302	1367740_at	M14400	"creatine kinase, brain"
303	1387036_at	NM_024360	hairy and enhancer of split 1 (<i>Drosophila</i>)
304	1370360_at	AF146738	testis specific protein
305	1389111_at	BF396316	<i>Rattus norvegicus</i> transcribed sequences
306	1374454_at	BM388557	<i>Rattus norvegicus</i> transcribed sequences
307	1367764_at	NM_012923	Cyclin G1
308	1368038_at	AF260258	synaptojanin 2 binding protein
309	1372635_at	BF282163	<i>Rattus norvegicus</i> transcribed sequences
310	1373571_at	AI170276	<i>Rattus norvegicus</i> transcribed sequences
311	1375872_at	AI144944	<i>Rattus norvegicus</i> transcribed sequences
312	1383767_at	AW524430	<i>Rattus norvegicus</i> transcribed sequences
313	1376325_at	BM388975	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein pir: S52863 (<i>H. sapiens</i>) S52863 DNA-binding protein R kappa B - human
314	1388485_at	BG380414	<i>Rattus norvegicus</i> transcribed sequences
315	1368782_at	NM_019348	somatostatin receptor 2
316	1375867_at	AW524493	<i>Rattus norvegicus</i> transcribed sequences
317	1375138_at	AA893169	Tissue inhibitor of metalloproteinase 3
318	1390112_at	BF284634	" <i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein ref: NP_004096.2 (<i>H. sapiens</i>) EGF-containing fibulin-like extracellular matrix protein 1 precursor, isoform a precursor; fibrillin-like [<i>Homo sapiens</i>]"
319	1372935_at	AI598550	<i>Rattus norvegicus</i> transcribed sequences
320	1368322_at	NM_012880	superoxide dismutase 3
321	1372104_at	BF289002	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_003106.1 (<i>H. sapiens</i>) UDP-N-acetylglucosamine pyrophosphorylase 1; AgX; sperm associated antigen 2; UDP-N-acetylglucosamine pyrophosphorylase 1; Sperm associated antigen 2 [Homo sapiens]
322	1367687_a_at	M25719	Peptidylglycine alpha-amidating monooxygenase
323	1372455_at	AI410264	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein sp: O95859 (<i>H. sapiens</i>) TNE2_HUMAN Tetraspan NET-2
324	1372940_at	BM389329	<i>Rattus norvegicus</i> transcribed sequences
325	1367631_at	NM_022266	connective tissue growth factor
326	1376344_at	AI010267	<i>Rattus norvegicus</i> transcribed sequences
327	1370408_at	AF313411	putative small membrane protein NID67
328	1390283_at	BI274636	<i>Rattus norvegicus</i> transcribed sequences
329	1372327_at	BF552877	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein ref: NP_057216.1 (<i>H. sapiens</i>) myelin gene expression factor 2 [<i>Homo sapiens</i>]
330	1376175_at	BF283433	<i>Rattus norvegicus</i> transcribed sequences
331	1373966_at	BF406242	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pir: T43490 (<i>H. sapiens</i>) T43490 hypothetical protein DKFZp434A139.1 - human (fragments)
332	1376749_at	AA945955	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pir: B35272 (<i>H. sapiens</i>) B35272 osteoinductive factor - human
333	1367604_at	NM_022501	cysteine-rich protein 2
334	1398345_at	BM389225	angiopoietin-like 2
335	1389836_a_at	AI599265	Tissue inhibitor of metalloproteinase 3
336	1389256_at	BG381256	<i>Rattus norvegicus</i> transcribed sequences
337	1371500_at	BG375362	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein ref: NP_003564.1 (<i>H. sapiens</i>) latent transforming growth factor beta binding protein 4 [<i>Homo sapiens</i>]
338	1371629_at	AI105444	" <i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pir: I60307 (<i>E. coli</i>) I60307 beta-galactosidase, alpha peptide - <i>Escherichia coli</i> "
339	1387707_at	NM_017102	"solute carrier family 2, member 2"
340	1387505_at	NM_013145	"Guanine nucleotide binding protein, alpha inhibiting 1"
341	1388890_at	BM390316	<i>Rattus norvegicus</i> transcribed sequences
342	1373506_at	AA944568	<i>Rattus norvegicus</i> transcribed sequences
343	1369415_at	NM_053328	"basic helix-loop-helix domain containing, class B2"

TABLE 5-continued

Genes differentially expressed in CNI1493-treated colon			
No.	Identifier	Acce. No.	Description
344	1372264_at	BI277460	" <i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein sp: P35558 (<i>H. sapiens</i>) PPCC_HUMAN Phosphoenolpyruvate carboxykinase, cytosolic [GTP] (Phosphoenolpyruvate carboxylase) (PEPCK-C)"
345	1374105_at	H31665	<i>Rattus norvegicus</i> transcribed sequences
346	1387156_at	NM_024391	17-beta hydroxysteroid dehydrogenase type 2
347	1376569_at	BM385790	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein sp: Q9Y5W3 (<i>H. sapiens</i>) KLF2_HUMAN Kruppel-like factor 2 (Lung kruppel-like factor)
348	1387028_a_at	M86708	"Inhibitor of DNA binding 1, helix-loop-helix protein (splice variation)"
349	1376661_at	AI556122	<i>Rattus norvegicus</i> transcribed sequences
350	1377287_at	AA957673	<i>Rattus norvegicus</i> transcribed sequences
351	1375910_at	AA874943	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pir: T46465 (<i>H. sapiens</i>) T46465 hypothetical protein DKFZp434A0530.1 - human
352	1388447_at	AA800701	<i>Rattus norvegicus</i> transcribed sequences
353	1370912_at	BI278231	<i>R. norvegicus</i> hsp70.2 mRNA for heat shock protein 70
354	1368883_at	NM_030868	NOV protein
355	1388945_at	BM385779	" <i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pir: I60307 (<i>E. coli</i>) I60307 beta-galactosidase, alpha peptide - <i>Escherichia coli</i> "
356	1389514_at	AI711152	<i>Rattus norvegicus</i> transcribed sequences
357	1377086_at	AI233530	<i>Rattus norvegicus</i> transcribed sequences
358	1373947_at	BI278545	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein pir: A47220 (<i>H. sapiens</i>) A47220 dermatopontin precursor - human
359	1374171_at	AI170507	"ATP-binding cassette, sub-family C (CFTR/MRP), member 9"
360	1372490_at	BF283759	<i>Rattus norvegicus</i> transcribed sequences
361	1390257_at	BG376956	<i>Rattus norvegicus</i> transcribed sequences
362	1369651_at	NM_012673	Thymus cell surface antigen
363	1388866_at	AA799392	" <i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pdb: 1LBG (<i>E. coli</i>) B Chain B, Lactose Operon Repressor Bound To 21-Base Pair Symmetric Operator Dna, Alpha Carbons Only"
364	1368303_at	NM_031678	period homolog 2
365	1370399_at	M29853	"cytochrome P450, subfamily 4B, polypeptide 1"
366	1385606_at	BF559626	<i>Rattus norvegicus</i> transcribed sequences
367	1376170_at	BI290821	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pir: S46657 (<i>H. sapiens</i>) S46657 collagen alpha 1(XIV) chain - human (fragments)
368	1376832_at	AA800763	<i>Rattus norvegicus</i> transcribed sequences
369	1376049_at	AA925805	<i>Rattus norvegicus</i> transcribed sequences
370	1398365_at	AI171466	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein ref: NP_057048.1 (<i>H. sapiens</i>) CGI-38 protein [<i>Homo sapiens</i>]
371	1372847_at	AW524458	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein ref: NP_064571.1 (<i>H. sapiens</i>) DC11 protein [<i>Homo sapiens</i>]
372	1372872_at	BI291271	<i>Rattus norvegicus</i> transcribed sequences
373	1376177_at	AI179609	<i>Rattus norvegicus</i> transcribed sequences
374	1387039_at	NM_030828	glypican 1
375	1372208_at	AA942959	"protein phosphatase 1, regulatory (inhibitor) subunit 1B"
376	1376933_at	AI170377	<i>Rattus norvegicus</i> transcribed sequences
377	1388034_at	AB070355	kinesin family member 1B
378	1371794_at	BM391449	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pir: T14273 (<i>M. musculus</i>) T14273 zinc finger protein 106 - mouse
379	1393464_at	BM383378	<i>Rattus norvegicus</i> transcribed sequences
380	1389007_at	AI231799	<i>Rattus norvegicus</i> transcribed sequences
381	1371508_at	AI412098	"protein tyrosine phosphatase type IVA, member 2"
382	1374694_at	BF284602	<i>Rattus norvegicus</i> transcribed sequences
383	1374558_at	AI010316	<i>Rattus norvegicus</i> transcribed sequences
384	1399028_at	AI171954	<i>Rattus norvegicus</i> transcribed sequences
385	1368550_at	NM_022858	HNF-3/forkhead homolog-1
386	1370211_at	BE106940	neurogranin
387	1387090_a_at	NM_024135	LIM motif-containing protein kinase 2
388	1370072_at	NM_012608	membrane metallo endopeptidase

TABLE 5-continued

Genes differentially expressed in CNI1493-treated colon			
No.	Identifier	Acce. No.	Description
389	1371703_at	AI407114	Complement component 3
390	1390319_at	BG378301	<i>Rattus norvegicus</i> transcribed sequence
391	1387008_at	NM_022948	tricarboxylate carrier-like protein
392	1389561_at	BE110624	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein ref: NP_079740.1 (<i>M. musculus</i>) RIKEN cDNA 1810021J13 [<i>Mus musculus</i>]
393	1376023_at	BM386555	<i>Rattus norvegicus</i> transcribed sequences
394	1386979_at	NM_133395	developmentally regulated protein TPO1
395	1368163_at	J02997	Dipeptidyl peptidase 4
396	1374935_at	AI412099	" <i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pir: I60307 (<i>E. coli</i>) I60307 beta-galactosidase, alpha peptide - <i>Escherichia coli</i> "
397	1387084_at	NM_012789	Dipeptidyl peptidase 4
398	1369770_at	NM_012719	somatostatin receptor 1
399	1389601_at	BI293610	" <i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pir: I60307 (<i>E. coli</i>) I60307 beta-galactosidase, alpha peptide - <i>Escherichia coli</i> "
400	1368295_at	NM_080786	"solute carrier family 21 (organic anion transporter), member 9"
401	1376242_at	BF402365	<i>Rattus norvegicus</i> transcribed sequences
402	1387059_at	NM_019362	"serine threonine kinase 39 (STE20/SPS1 homolog, yeast)"
403	1389310_at	BF400694	<i>Rattus norvegicus</i> transcribed sequences
404	1387169_at	NM_053400	"transducin-like enhancer of split 3, homolog of <i>Drosophila</i> "
405	1387023_at	NM_031154	"glutathione S-transferase, mu type 3 (Yb3)"
406	1398430_at	AW524711	<i>Rattus norvegicus</i> transcribed sequences
407	1369249_at	NM_053714	progressive ankylosis
408	1387913_at	U48220	cytochrome P450 2D18
409	1370320_at	AY083160	MAWD binding protein
410	1376047_at	BI285321	<i>Rattus norvegicus</i> transcribed sequences
411	1387315_at	NM_012878	"surfactant, pulmonary-associated protein D"
412	1387239_a_at	AB008803	"peptidyl arginine deiminase, type 4"
413	1371477_at	BG380735	<i>Rattus norvegicus</i> transcribed sequences
414	1386974_at	NM_134397	LL5 protein
415	1370930_at	BF417285	kinesin 1C
416	1371689_at	BE107334	eukaryotic translation elongation factor 1 alpha 1
417	1389040_at	AI170825	<i>Rattus norvegicus</i> transcribed sequences
418	1390710_x_at	AA850618	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein ref: NP_003096.1 (<i>H. sapiens</i>) sortilin-related receptor containing LDLR class A repeats preproprotein; sorting protein-related receptor containing LDLR class A repeats; low-density li
419	1367700_at	NM_080698	fibromodulin
420	1388317_at	BE110655	<i>Rattus norvegicus</i> transcribed sequences
421	1387184_at	NM_024355	axin 2
422	1390399_at	BE102391	<i>Rattus norvegicus</i> transcribed sequences
423	1375590_at	AA894335	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pir: T00368 (<i>H. sapiens</i>) T00368 hypothetical protein KIAA0663 - human
424	1387901_at	L19180	"protein tyrosine phosphatase, receptor type, D"
425	1388768_at	BI285601	<i>Rattus norvegicus</i> transcribed sequences
426	1373434_at	AA944179	<i>Rattus norvegicus</i> transcribed sequences
427	1376784_at	BI274481	<i>Rattus norvegicus</i> transcribed sequences
428	1390311_at	AW528602	<i>Rattus norvegicus</i> transcribed sequences
429	1389150_at	AW524559	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein ref: NP_076933.1 (<i>H. sapiens</i>) hypothetical protein MGC3265 [<i>Homo sapiens</i>]
430	1372728_at	BE103745	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein sp: Q99523 (<i>H. sapiens</i>) SORT_HUMAN Sortilin precursor (Glycoprotein 95) (Gp95) (Neurotensin receptor 3) (NT3) (100 kDa NT receptor)
431	1377325_a_at	AW531278	<i>Rattus norvegicus</i> transcribed sequences
432	1389288_at	BI279838	" <i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein ref: NP_002479.1 (<i>H. sapiens</i>) NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2 (8 kD, B8) [<i>Homo sapiens</i>]"
433	1375951_at	AA818521	thrombomodulin
434	1367880_at	NM_012974	Laminin chain beta 2
435	1399109_at	BI281673	<i>Rattus norvegicus</i> transcribed sequences
436	1369926_at	NM_022525	glutathione peroxidase 3

TABLE 5-continued

Genes differentially expressed in CNI1493-treated colon			
No.	Identifier	Acce. No.	Description
437	1388145_at	BM390128	Tenascin X
438	1398973_at	BI296499	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein sp: Q9HD45 (<i>H. sapiens</i>) T9S3_HUMAN Transmembrane 9 superfamily protein member 3 precursor (SM-11044 binding protein) (EP70-P-iso)
439	1398990_at	BI281754	<i>Rattus norvegicus</i> transcribed sequences
440	1371245_a_at	BI287300	hemoglobin beta chain complex
441	1392890_at	BG663460	<i>Rattus norvegicus</i> transcribed sequences
442	1371102_x_at	X05080	hemoglobin beta chain complex
443	1370240_x_at	AI179404	"hemoglobin, alpha 1"
444	1367553_x_at	NM_033234	hemoglobin beta chain complex
445	1370239_at	AI179404	"hemoglobin, alpha 1"
446	1388608_x_at	AI577319	"hemoglobin, alpha 1"
447	1388848_at	AA891760	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein ref: NP_071934.1 (<i>H. sapiens</i>) hypothetical protein FLJ22056 [<i>Homo sapiens</i>]
448	1389186_at	AA944175	" <i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pir: I60307 (<i>E. coli</i>) I60307 beta-galactosidase, alpha peptide - <i>Escherichia coli</i> "
449	1371972_at	BM388888	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pir: T00371 (<i>H. sapiens</i>) T00371 hypothetical protein KIAA0668 - human (fragment)
450	1372640_at	BI277758	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein ref: NP_076223.1 (<i>M. musculus</i>) RIKEN cDNA 1200009H11 [<i>Mus musculus</i>]
451	1373162_at	AI600085	" <i>Rattus norvegicus</i> NYGGF3 mRNA, partial cds"
452	1387310_at	NM_134462	putative secretory pathway Ca-ATPase SPCA2
453	1388698_at	AI407838	extracellular matrix protein 1
454	1376105_at	AI599143	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pir: S46657 (<i>H. sapiens</i>) S46657 collagen alpha 1(XIV) chain - human (fragments)
455	1373674_at	BI283094	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein sp: Q13361 (<i>H. sapiens</i>) MGP2_HUMAN Microfibril-associated glycoprotein 2 precursor (MAGP-2) (MP25)
456	1373952_at	AI409841	<i>Rattus norvegicus</i> transcribed sequences
457	1387625_at	NM_013104	zzN/A
458	1374674_at	AW528792	<i>Rattus norvegicus</i> transcribed sequences
459	1375844_at	AI406370	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein ref: NP_067013.1 (<i>H. sapiens</i>) polypyrimidine tract binding protein 2; neural polypyrimidine tract binding protein; PTB-like protein [<i>Homo sapiens</i>]
460	1368407_at	NM_022605	heparanase
461	1377076_at	AI716131	<i>Rattus norvegicus</i> transcribed sequences
462	1375412_at	AI101331	<i>Rattus norvegicus</i> transcribed sequences
463	1376398_at	BF417784	<i>Rattus norvegicus</i> transcribed sequences
464	1399054_at	BG375798	<i>Rattus norvegicus</i> transcribed sequences
465	1374126_at	BG374261	<i>Rattus norvegicus</i> transcribed sequences
466	1368099_at	NM_053722	CLIP-associating protein 2
467	1387182_at	NM_057201	G protein-coupled receptor 37 (endothelin receptor type B-like)
468	1372814_at	BF283084	<i>Rattus norvegicus</i> transcribed sequences
469	1376115_at	AA964244	<i>Rattus norvegicus</i> transcribed sequences
470	1369373_at	NM_053429	fibroblast growth factor receptor 3
471	1376781_at	BI286116	<i>Rattus norvegicus</i> transcribed sequences
472	1369638_at	NM_012947	Eukaryotic elongation factor 2 kinase
473	1389003_at	BI282008	<i>Rattus norvegicus</i> transcribed sequences
474	1376089_at	BI294974	Low density lipoprotein receptor
475	1367932_at	NM_017268	3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1
476	1387809_at	NM_053703	mitogen-activated protein kinase kinase 6
477	1375549_at	AI407719	<i>Rattus norvegicus</i> transcribed sequences
478	1370209_at	BE101336	Kruppel-like factor 9
479	1389311_at	AW915161	<i>Rattus norvegicus</i> transcribed sequences
480	1390164_at	BE099850	<i>Rattus norvegicus</i> transcribed sequences
481	1376989_at	BE099568	<i>Rattus norvegicus</i> transcribed sequences
482	1368656_at	NM_053856	secretogranin III
483	1373415_at	AI407050	<i>Rattus norvegicus</i> transcribed sequences
484	1374819_at	AI599945	<i>Rattus norvegicus</i> transcribed sequences
485	1367594_at	NM_017087	biglycan
486	1372624_at	BF551377	<i>Rattus norvegicus</i> transcribed sequences

TABLE 5-continued

Genes differentially expressed in CNI1493-treated colon			
No.	Identifier	Acce. No.	Description
487	1376425_at	BF420705	"transforming growth factor, beta 2"
488	1389138_at	AA945574	<i>Rattus norvegicus</i> transcribed sequences
489	1367940_at	NM_053352	chemokine orphan receptor 1
490	1371747_at	AI406304	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein ref: NP_077275.1 (<i>H. sapiens</i>) chromosome 20 open reading frame 149 [<i>Homo sapiens</i>]
491	1372978_at	BI291218	<i>Rattus norvegicus</i> transcribed sequences
492	1387812_at	NM_012999	Subtilisin - like endoprotease
493	1389794_at	AI044984	<i>Rattus norvegicus</i> transcribed sequences
494	1388384_at	AI407618	<i>Rattus norvegicus</i> transcribed sequences
495	1374557_at	BF394235	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein ref: NP_079187.1 (<i>H. sapiens</i>) hypothetical protein FLJ23091 [<i>Homo sapiens</i>]
496	1370579_at	U53513	"glycine-, glutamate-, thienylcyclohexylpiperidine-binding protein"
497	1367918_at	NM_031066	protein kinase C-binding protein Zeta1
498	1368930_at	NM_023021	intermediate conductance calcium-activated potassium channel
499	1387654_at	NM_023092	unconventional myosin Myr2 I heavy chain
500	1367759_at	NM_012578	Histone H1-0
501	1386957_at	NM_053622	nuclear pore membrane glycoprotein 121 kD
502	1388709_at	BF284695	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein pir: A35804 (<i>H. sapiens</i>) A35804 nucleolin - human
503	1384371_at	AW921429	zzN/A
504	1371940_at	AW920000	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein sp: Q9UPN3 (<i>H. sapiens</i>) ACF7_HUMAN Actin cross-linking family protein 7 (Macrophin) (Trabeculin-alpha) (620 kDa actin-binding protein) (ABP620)
505	1370131_at	NM_031556	caveolin
506	1372825_at	BI290551	<i>Rattus norvegicus</i> transcribed sequences
507	1367989_at	NM_012751	"solute carrier family 2, member 4"
508	1376724_at	AI170671	<i>Rattus norvegicus</i> transcribed sequences
509	1372967_at	BI280323	<i>Rattus norvegicus</i> transcribed sequences
510	1370291_at	AF002281	actinin alpha 2 associated LIM protein
511	1377281_at	BM388545	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein ref: NP_065099.1 (<i>H. sapiens</i>) retinitis pigmentosa GTPase regulator interacting protein 1; RPGR-interacting protein [<i>Homo sapiens</i>]
512	1367930_at	NM_017195	growth associated protein 43
513	1367628_at	NM_019904	"lectin, galactose binding, soluble 1"
514	1388112_at	BG666999	solute carrier family 25 (mitochondrial adenine nucleotide translocator) member 4
515	1387873_at	BI279661	wap four-disulfide core domain 1
516	1389194_at	AI406491	<i>Rattus norvegicus</i> transcribed sequences
517	1388928_at	BF399310	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein ref: NP_068733.1 (<i>H. sapiens</i>) cofilin 2 (muscle) [<i>Homo sapiens</i>]
518	1370857_at	BI282702	smooth muscle alpha-actin
519	1387018_at	NM_053770	Arg/Abl-interacting protein ArgBP2
520	1398327_at	BM386598	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein pir: S69890 (<i>H. sapiens</i>) S69890 mitogen inducible gene mig-2 - human
521	1389189_at	BF555956	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein sp: Q9Z1P2 (<i>R. norvegicus</i>) AAC1_RAT Alpha-actinin 1 (Alpha-actinin cytoskeletal isoform) (Non-muscle alpha-actinin 1) (F-actin cross linking protein)
522	1371361_at	BI278826	tensin
523	1375349_at	BI295776	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein pir: T17257 (<i>H. sapiens</i>) T17257 hypothetical protein DKFZp586P1422.1 - human
524	1376572_a_at	AI045848	" <i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein ref: NP_068506.1 (<i>H. sapiens</i>) supervillin, isoform 2; membrane-associated F-actin binding protein p205; archvillin [<i>Homo sapiens</i>]"
525	1367813_at	NM_130403	"protein phosphatase 1, regulatory (inhibitor) subunit 14a"
526	1367648_at	NM_013122	Insulin-like growth factor binding protein 2
527	1374969_at	AA799832	<i>Rattus norvegicus</i> transcribed sequences
528	1371954_at	BF290193	<i>Rattus norvegicus</i> transcribed sequences

TABLE 5-continued

Genes differentially expressed in CNI1493-treated colon			
No.	Identifier	Acce. No.	Description
529	1370347_at	AF095585	enigma (LIM domain protein)
530	1388483_at	BI296011	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein ref: NP_068733.1 (<i>H. sapiens</i>) cofilin 2 (muscle) [<i>Homo sapiens</i>]
531	1375890_at	BI296994	<i>Rattus norvegicus</i> transcribed sequences
532	1368724_a_at	NM_019131	"tropomyosin 1, alpha"
533	1370288_a_at	AF372216	"tropomyosin 1, alpha"
534	1367785_at	NM_031747	Calponin 1
535	1388422_at	BI275904	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pir: JC2324 (<i>H. sapiens</i>) JC2324 LIM protein - human
536	1368988_at	AW520914	calsequestrin 2
537	1370585_a_at	X04440	"protein kinase C, beta 1"
538	1389187_at	BI286421	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_115950.1 (<i>H. sapiens</i>) EVG1 protein [<i>Homo sapiens</i>]
539	1389050_at	AI170797	<i>Rattus norvegicus</i> transcribed sequences
540	1372658_at	BG373779	desmuslin
541	1387898_at	D29960	heat shock 20-kDa protein
542	1373915_at	AI044427	" <i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pir: B49364 (<i>H. sapiens</i>) B49364 protein kinase (EC 2.7.1.37), myotonic dystrophy-associated - human"
543	1367570_at	NM_031549	Transgelin (Smooth muscle 22 protein)
544	1370287_a_at	M23764	"tropomyosin 1, alpha"
545	1386869_at	NM_012893	"actin, gamma 2"
546	1388842_at	BG380385	<i>Rattus norvegicus</i> transcribed sequences
547	1371382_at	BI283060	" <i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein pir: A37098 (<i>H. sapiens</i>) A37098 gelation factor ABP-280, long form - human"
548	1372219_at	AA012755	" <i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein sp: P06468 (<i>H. sapiens</i>) TPM2_HUMAN Tropomyosin beta chain, fibroblast and epithelial muscle-type (Tropomyosin 2, fibroblast and epithelial muscle-type) (TM36) (TME1) (TM1)"
549	1370057_at	NM_017148	cysteine rich protein 1
550	1371541_at	AI177055	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein ref: NP_444278.1 (<i>H. sapiens</i>) mitochondrial ribosomal protein L53 [<i>Homo sapiens</i>]
551	1388496_at	AI103600	" <i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein ref: NP_001449.1 (<i>H. sapiens</i>) gamma filamin; filamin C, gamma (actin-binding protein-280); filamin 2; actin-binding protein 280 [<i>Homo sapiens</i>]"
552	1370896_a_at	X16262	myosin heavy chain 11
553	1372015_at	AI008689	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein sp: O75410 (<i>H. sapiens</i>) TAC1_HUMAN Transforming acidic coiled-coil-containing protein 1
554	1372296_at	AA800892	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein sp: P55822 (<i>H. sapiens</i>) SH3B_HUMAN SH3 domain-binding glutamic acid-rich protein (SH3BGR protein) (21-glutamic acid-rich protein) (21-GARP)
555	1388451_at	AA817802	<i>Rattus norvegicus</i> transcribed sequences
556	1388298_at	BI279044	" <i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein pir: A32031 (<i>H. sapiens</i>) A32031 myosin regulatory light chain, smooth muscle - human"
557	1371677_at	BE113200	<i>Rattus norvegicus</i> transcribed sequences
558	1367691_at	NM_134449	PKC-delta binding protein
559	1372159_at	BI285456	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein ref: NP_067541.1 (<i>M. musculus</i>) junctophilin 2 [<i>Mus musculus</i>]
560	1371331_at	BG665037	<i>Rattus norvegicus</i> transcribed sequences
561	1370234_at	AA893484	Fibronectin 1
562	1372111_at	BI285449	caveolin
563	1399065_at	BM389543	<i>Rattus norvegicus</i> transcribed sequences
564	1371855_at	BM390254	<i>Rattus norvegicus</i> transcribed sequences
565	1389394_at	AI411809	<i>Rattus norvegicus</i> transcribed sequences
566	1368145_at	NM_013002	Neuron specific protein PEP-19 (Purkinje cell protein 4)

TABLE 5-continued

Genes differentially expressed in CNI1493-treated colon			
No.	Identifier	Acce. No.	Description
567	1371566_at	BI296437	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_116264.1 (<i>H. sapiens</i>) hypothetical protein MGC15482 [<i>Homo sapiens</i>]
568	1368105_at	AI228231	Tspan-2 protein
569	1372625_at	AA851663	<i>Rattus norvegicus</i> transcribed sequences
570	1372537_at	BI289642	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein sp: O00423 (<i>H. sapiens</i>) EML1_HUMAN Echinoderm microtubule-associated protein-like 1 (EMAP-1) (HuEMAP-1)
571	1390430_at	BF284190	"nuclear receptor subfamily 1, group D, member 2"
572	1371969_at	BI291848	<i>Rattus norvegicus</i> transcribed sequences
573	1386860_at	NM_012811	milk fat globule-EGF factor 8 protein
574	1371588_at	AA686007	"parvin, alpha"
575	1387224_at	NM_019304	"diacylglycerol kinase, beta"
576	1374237_at	BI286025	" <i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein sp: P29536 (<i>H. sapiens</i>) LMD1_HUMAN Leiomodrin 1 (Leiomodrin, muscle form) (64 kDa autoantigen D1) (64 kDa autoantigen 1D) (64 kDa autoantigen 1D3) (Thyroid-associated ophthalmopathy aut
577	1373911_at	BM389026	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pir: S36110 (<i>H. sapiens</i>) S36110 osteoblast-specific factor 2 - human
578	1371732_at	BI285485	<i>Rattus norvegicus</i> transcribed sequences
579	1371700_at	AI177059	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein sp: P55083 (<i>H. sapiens</i>) MFA4_HUMAN Microfibril-associated glycoprotein 4
580	1376099_at	AW254017	"collagen, type V, alpha 1"
581	1388935_at	AI231814	<i>Rattus norvegicus</i> transcribed sequences
582	1379936_at	AA875132	<i>Rattus norvegicus</i> transcribed sequences
583	1372342_at	AI176583	<i>Rattus norvegicus</i> transcribed sequences
584	1398370_at	AW522471	rexo70
585	1369652_at	AI145313	Thymus cell surface antigen
586	1376640_at	BF285466	<i>Rattus norvegicus</i> transcribed sequences
587	1369955_at	NM_134452	"collagen, type V, alpha 1"
588	1373858_at	BE109064	" <i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein pdb: 1LBG (<i>E. coli</i>) B Chain B, Lactose Operon Repressor Bound To 21-Base Pair Symmetric Operator Dna, Alpha Carbons Only"
589	1387854_at	BI282748	"procollagen, type I, alpha 2"
590	1386862_at	NM_013132	annexin 5
591	1388116_at	BI285575	"collagen, type 1, alpha 1"
592	1370959_at	BI275716	"collagen, type III, alpha 1"
593	1370155_at	BM388837	"procollagen, type I, alpha 2"
594	1388569_at	AI179984	alpha-2 antiplasmin
595	1373032_at	AW251450	fracture callus protein MUSTANG
596	1376265_at	AI411542	<i>Rattus norvegicus</i> transcribed sequences
597	1389367_at	AI409747	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein ref: NP_055390.1 (<i>H. sapiens</i>) schwannomin interacting protein 1 [<i>Homo sapiens</i>]
598	1373957_at	BF281544	Reelin
599	1370927_at	BE108345	"procollagen, type XII, alpha 1"
600	1372305_at	AA893634	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein ref: NP_057513.1 (<i>H. sapiens</i>) COPZ2 for nonclathrin coat protein zeta-COP [<i>Homo sapiens</i>]
601	1383822_at	AI029990	" <i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein ref: NP_001705.1 (<i>H. sapiens</i>) Bicaudal D homolog 1 (<i>Drosophila</i>); Bicaudal-D, <i>Drosophila</i> , homolog of, 1; Bicaudal D (<i>Drosophila</i>) homolog 1 [<i>Homo sapiens</i>]"
602	1374774_at	BF552241	<i>Rattus norvegicus</i> transcribed sequences
603	1388312_at	BI274487	tissue inhibitor of metalloproteinase 2
604	1376662_at	BF390141	<i>Rattus norvegicus</i> transcribed sequences
605	1374971_at	AA818954	<i>Rattus norvegicus</i> transcribed sequences
606	1389066_at	BI274408	<i>Rattus norvegicus</i> transcribed sequences
607	1373102_at	BI282750	<i>Rattus norvegicus</i> transcribed sequences
608	1388738_at	AI411227	<i>Rattus norvegicus</i> transcribed sequences
609	1368842_at	BG377130	<i>Rattus norvegicus</i> transcribed sequences
610	1390444_at	AI044433	<i>Rattus norvegicus</i> transcribed sequences
611	1377087_at	AA963029	<i>Rattus norvegicus</i> transcribed sequences
612	1387042_at	NM_012828	"calcium channel, voltage-dependent, beta 3 subunit"

TABLE 5-continued

Genes differentially expressed in CNI1493-treated colon			
No.	Identifier	Acce. No.	Description
613	1369974_at	NM_012663	vesicle-associated membrane protein 2
614	1374870_at	BF286402	<i>Rattus norvegicus</i> transcribed sequences
615	1374087_at	AI411088	<i>Rattus norvegicus</i> transcribed sequences
616	1374117_at	BI279562	brain-specific angiogenesis inhibitor 1-associated protein 2
617	1390016_at	BF415854	<i>Rattus norvegicus</i> transcribed sequences
618	1390341_at	BF396709	<i>Rattus norvegicus</i> transcribed sequences
619	1374709_at	AI406795	<i>Rattus norvegicus</i> transcribed sequences
620	1374726_at	AI411941	<i>Rattus norvegicus</i> transcribed sequences
621	1389511_s_at	BF403383	synaptogyrin 1
622	1390489_at	BE108860	<i>Rattus norvegicus</i> transcribed sequences
623	1388598_at	BI281230	<i>Rattus norvegicus</i> transcribed sequences
624	1370375_at	J05499	liver mitochondrial glutaminase
625	1388821_at	AI010430	<i>Rattus norvegicus</i> transcribed sequences
626	1368276_at	NM_012664	Synaptophysin
627	1375862_at	BM384701	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein sp: P07202 (<i>H. sapiens</i>) PERT_HUMAN Thyroid peroxidase precursor (TPO)
628	1377136_at	AW254190	<i>Rattus norvegicus</i> transcribed sequences
629	1392887_at	AI575082	<i>Rattus norvegicus</i> transcribed sequences
630	1389157_at	BI275583	<i>Rattus norvegicus</i> transcribed sequences
631	1377013_at	AI639108	<i>Rattus norvegicus</i> transcribed sequences
632	1371389_at	AI170668	<i>Rattus norvegicus</i> transcribed sequences
633	1370969_at	BE107303	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein sp: P03845 (<i>E. coli</i>) YPA1_ECOLI HYPOTHETICAL PROTEIN 1
634	1373438_at	BE329352	<i>Rattus norvegicus</i> transcribed sequence with weak similarity to protein pir: RGECDW (<i>E. coli</i>) RGECDW transcription activator of D-serine dehydratase - <i>Escherichia coli</i>
635	1388456_at	AI228548	" <i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein sp: P23297 (<i>H. sapiens</i>) S10A_HUMAN S-100 protein, alpha chain (S100 calcium-binding protein A1)"
636	1373427_at	BI288816	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein ref: NP_067067.1 (<i>H. sapiens</i>) Rag D protein; hypothetical GTP-binding protein DKFZp761H171 [<i>Homo sapiens</i>]
637	1368085_at	NM_133595	GTP cyclohydrolase I feedback regulatory protein
638	1369103_at	NM_012755	Fyn proto-oncogene
639	1389456_at	BI296591	<i>Rattus norvegicus</i> transcribed sequences
640	1370904_at	BI301490	<i>R. norvegicus</i> mRNA for RT1.Ma
641	1371499_at	AI227627	CD9 antigen (p24)
642	1371362_at	BI285402	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein sp: Q92841 (<i>H. sapiens</i>) DD17_HUMAN Probable RNA-dependent helicase p72 (DEAD-box protein p72) (DEAD-box protein 17)
643	1388920_at	AI230985	bone morphogenetic protein 6
644	1368851_at	NM_012555	v-ets erythroblastosis virus E26 oncogene homolog 1 (avian)
645	1373343_at	AI175820	<i>Rattus norvegicus</i> transcribed sequences
646	1374888_at	AI317837	<i>Rattus norvegicus</i> transcribed sequences
647	1376453_at	BF419074	<i>Rattus norvegicus</i> transcribed sequences
648	1376062_at	BG375315	syndecan 1
649	1371046_at	AW920849	" <i>Rattus norvegicus</i> beta II spectrin-short isoform mRNA, partial cds"
650	1368080_at	NM_054008	Rgc32 protein
651	1371931_at	BI274753	general transcription factor II I
652	1388463_at	AW252660	<i>Rattus norvegicus</i> transcribed sequence with moderate similarity to protein ref: NP_057010.1 (<i>H. sapiens</i>) putative secreted protein; similar to putative secreted protein (<i>H. sapiens</i>) [<i>Homo sapiens</i>]
653	1388639_at	BF284148	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein ref: NP_060149.1 (<i>H. sapiens</i>) hypothetical protein FLJ20128 [<i>Homo sapiens</i>]
654	1379685_at	AI502753	CTD-binding SR-like protein rA4
655	1389967_at	AA892386	" <i>Rattus norvegicus</i> ADP-ribosylation-like factor 6-interacting protein mRNA, complete cds"
656	1368941_at	NM_032076	prostaglandin E receptor 4 (subtype EP4)
657	1390457_at	BM385762	<i>Rattus norvegicus</i> transcribed sequences

TABLE 5-continued

Genes differentially expressed in CNI1493-treated colon			
No.	Identifier	Acce. No.	Description
658	1390458_at	BG666849	<i>Rattus norvegicus</i> transcribed sequences
659	1375254_at	BE103444	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein pir: JC5023 (<i>H. sapiens</i>) JC5023 CMP-sialic acid transporter - human
660	1375530_at	BG374612	<i>Rattus norvegicus</i> transcribed sequence with strong similarity to protein ref: NP_062298.1 (<i>M. musculus</i>) glucosamine-phosphate N-acetyltransferase 1; glucosamine-6-phosphate acetyltransferase; glucosamine-phosphate N-acetyltransferase [<i>Mus musculus</i>]

TABLE 6

Genes differentially expressed in CNI1493-treated S1 DRG						
No.	Identifier	Acce. No.	CTRL-VHL	CTRL-CNI	IBS-VHL	IBS-CNI Description
52	1373932_at	BE098739	1.00	4.46	1.91	6.75 ESTs
48	1370913_at	AI409634	1.00	1.70	0.98	3.44 Best5 protein
15	1369202_at	NM_017028	1.00	2.20	0.35	3.04 myxovirus (influenza virus) resistance 2
62	1371152_a_at	Z18877	1.00	1.49	0.48	2.48 25 oligoadenylate synthetase
53	1367850_at	NM_053843	1.00	1.66	1.01	2.32 "Fc receptor, IgG, low affinity III"
54	1389006_at	AI170394	1.00	1.53	1.03	2.28 ESTs
58	1383564_at	BF411036	1.00	1.34	0.52	2.26 "ESTs, Highly similar to IRF7 MOUSE Interferon regulatory factor 7 (IRF-7) [<i>M. musculus</i>]"
67	1389034_at	BI295179	1.00	1.49	0.59	2.24 "ESTs, Moderately similar to UBPI_MOUSE Ubiquitin carboxyl-terminal hydrolase 18 (Ubiquitin thiolesterase 18) (Ubiquitin-specific processing protease 18) (Deubiquitinating enzyme 18) (43 kDa ubiquitin-specific protease) [<i>M. musculus</i>]"
35	1386166_at	AA892881	1.00	1.59	1.43	2.18 EST
69	1388164_at	AF029241	1.00	1.52	0.97	2.09 " <i>Rattus norvegicus</i> partial mRNA for BM1k MHC class Ib antigen, strain SHR"
65	1370892_at	BI285347	1.00	1.66	0.69	2.05 Complement component 4
73	1369186_at	D85899	1.00	1.78	1.10	2.05 caspase 1
56	1372691_at	BI292558	1.00	1.34	0.94	2.02 "ESTs, Highly similar to A57501 uridine phosphorylase (EC 2.4.2.3) I - mouse [<i>M. musculus</i>]"
70	1371015_at	X52711	1.00	1.40	0.81	1.98 "Myxovirus (influenza) resistance, homolog of murine Mx (also interferon-inducible protein IFI78)"
74	1376151_a_at	AI407953	1.00	1.51	0.92	1.95 ESTs
51	1374730_at	AI102519	1.00	1.42	1.11	1.91 "ESTs, Highly similar to TYRO protein tyrosine kinase binding protein; killer cell activating receptor associated protein [<i>Mus musculus</i>] [<i>M. musculus</i>]"
30	1390730_at	BM383911	1.00	1.69	1.33	1.86 ESTs
36	1375346_at	BI290002	1.00	1.62	1.43	1.82 "ESTs, Weakly similar to hypothetical protein FLJ20010 [<i>Homo sapiens</i>] [<i>H. sapiens</i>]"
72	1390738_at	BM385476	1.00	1.66	1.20	1.74 ESTs
47	1370186_at	AI599350	1.00	1.32	1.05	1.74 "proteasome (prosome, macropain) subunit, beta type 9 (large multifunctional protease 2)"

TABLE 6-continued

Genes differentially expressed in CNI1493-treated S1 DRG							
No.	Identifier	Acce. No.	CTRL-VHL	CTRL-CNI	IBS-VHL	IBS-CNI	Description
80	1389553_at	BF393825	1.00	1.16	0.85	1.73	“ESTs, Weakly similar to RIKEN cDNA 1810046124 [<i>Mus musculus</i>] [<i>M. musculus</i>]”
77	1372930_at	AI411381	1.00	1.14	0.76	1.72	“ESTs, Weakly similar to DEAF-1 related transcriptional regulator (NUDR) [<i>Rattus norvegicus</i>] [<i>R. norvegicus</i>]”
59	1367786_at	NM_080767	1.00	1.23	0.73	1.66	“proteasome (prosome, macropain) subunit, beta type, 8 (low molecular mass polypeptide 7)”
49	1388071_x_at	M24024	1.00	1.28	1.05	1.66	RT1 class Ib gene
44	1380030_at	AW523520	1.00	1.49	0.96	1.65	“ESTs, Highly similar to RIKEN cDNA 3110024A21 [<i>Mus musculus</i>] [<i>M. musculus</i>]”
57	1390510_at	BI294706	1.00	1.21	0.83	1.65	“ESTs, Weakly similar to RIKEN cDNA 1810027D10 [<i>Mus musculus</i>] [<i>M. musculus</i>]”
42	1374944_at	BI275829	1.00	1.26	0.65	1.65	“ESTs, Moderately similar to hypothetical protein LOC51058 [<i>Homo sapiens</i>] [<i>H. sapiens</i>]”
23	1384446_at	BF402271	1.00	1.72	1.51	1.62	ESTs
34	1375988_at	AW914928	1.00	1.39	1.38	1.62	ESTs
27	1373403_at	AI230625	1.00	1.59	1.11	1.61	ESTs
66	1387995_a_at	BI285494	1.00	1.40	0.84	1.60	interferon-inducible protein variant 10
39	1387969_at	U22520	1.00	1.52	1.06	1.59	“small inducible cytokine B subfamily (Cys-X-Cys), member 10”
32	1384167_at	AW522260	1.00	1.70	1.38	1.59	ESTs
37	1387566_at	NM_133551	1.00	1.42	1.25	1.59	“phospholipase A2, group IVA (cytosolic, calcium-dependent)”
55	1372516_at	AI317842	1.00	1.24	1.06	1.58	“ESTs, Weakly similar to S62328 kinesin-like DNA binding protein KID - human [<i>H. sapiens</i>]”
43	1374277_at	BI289615	1.00	1.44	1.01	1.56	ESTs
28	1376264_at	AW526697	1.00	1.56	1.51	1.56	ESTs
33	1388872_at	BI290053	1.00	1.25	1.19	1.56	isopentenyl-diphosphate delta isomerase
14	1390312_at	BG670441	1.00	1.45	0.77	1.55	“ESTs, Weakly similar to hypothetical protein FLJ20073 [<i>Homo sapiens</i>] [<i>H. sapiens</i>]”
64	1388149_at	X57523	1.00	1.15	0.72	1.52	“Transporter 1, ABC (ATP binding cassette)”
71	1389571_at	BG666368	1.00	1.20	0.95	1.52	“ESTs, Weakly similar to signal transducer and activator of transcription 1 [<i>Rattus norvegicus</i>] [<i>R. norvegicus</i>]”
68	1368835_at	AW434718	1.00	1.33	0.87	1.51	signal transducer and activator of transcription 1
60	1388347_at	AI233210	1.00	1.11	0.93	1.51	“ESTs, Moderately similar to I49013 thymic shared antigen-1 - mouse [<i>M. musculus</i>]”
12	1376693_at	AA998964	1.00	1.27	0.60	1.49	“ESTs, Moderately similar to hypothetical protein FLJ20073 [<i>Homo sapiens</i>] [<i>H. sapiens</i>]”
50	1373043_at	BI275923	1.00	1.36	1.16	1.49	“ESTs, Highly similar to stromal cell-derived factor 2-like 1 [<i>Mus musculus</i>] [<i>M. musculus</i>]”
24	1374465_at	AI237098	1.00	1.48	1.04	1.49	“ESTs, Highly similar to ubiquitously expressed transcript [<i>Mus musculus</i>] [<i>M. musculus</i>]”
63	1373025_at	AI411618	1.00	1.15	0.61	1.47	“ESTs, Weakly similar to S49158 complement protein C1q beta chain precursor - rat [<i>R. norvegicus</i>]”

TABLE 6-continued

Genes differentially expressed in CNI1493-treated S1 DRG							
No.	Identifier	Acce. No.	CTRL-VHL	CTRL-CNI	IBS-VHL	IBS-CNI	Description
25	1369962_at	NM_031014	1.00	1.58	1.36	1.47	5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP
19	1377117_at	BF387780	1.00	1.88	0.94	1.45	ESTs
16	1388754_at	AI176839	1.00	1.49	0.88	1.45	ESTs
46	1376056_at	BF291214	1.00	1.33	1.07	1.43	"ESTs, Moderately similar to hypothetical protein FLJ14464 [<i>Homo sapiens</i>] [<i>H. sapiens</i>]"
29	1399056_at	AI716436	1.00	1.57	1.21	1.43	"ESTs, Moderately similar to candidate tumor suppressor protein [<i>Homo sapiens</i>] [<i>H. sapiens</i>]"
3	1376751_at	AI044250	1.00	1.74	1.16	1.41	"ESTs, Highly similar to ST19_MOUSE Serine/threonine-protein kinase 19 (RP1 protein) [<i>M. musculus</i>]"
11	1367846_at	NM_012618	1.00	1.59	0.95	1.41	S100 calcium-binding protein A4
45	1373504_at	BF287967	1.00	1.32	0.96	1.40	"ESTs, Weakly similar to JE0204 testicular protein Tpx-1 - rat [<i>R. norvegicus</i>]"
22	1372043_at	BI282363	1.00	1.52	1.16	1.37	"ESTs, Moderately similar to ribosomal protein P0-like protein; 60S acidic ribosomal protein PO [<i>Homo sapiens</i>] [<i>H. sapiens</i>]"
38	1370214_at	AI175539	1.00	1.18	0.84	1.34	Parvalbumin (calcium binding protein)
9	1390655_at	BF420653	1.00	1.47	0.54	1.34	"ESTs, Highly similar to T14155 zinc finger protein Peg3 - mouse [<i>M. musculus</i>]"
26	1375669_at	BI285619	1.00	1.39	1.03	1.32	"ESTs, Weakly similar to FK506 binding protein 2 (13 kDa) [<i>Rattus norvegicus</i>] [<i>R. norvegicus</i>]"
21	1398884_at	BM384924	1.00	1.71	1.10	1.32	"ESTs, Highly similar to prefoldin 5; EIG-1; c-myc binding protein MM-1; DNA segment, Chr 15, ERATO Doi 697, expressed [<i>Mus musculus</i>] [<i>M. musculus</i>]"
1	1368465_at	NM_012892	1.00	1.66	1.12	1.30	amiloride-sensitive cation channel 1
20	1371381_at	AI007981	1.00	1.46	0.99	1.29	"ESTs, Moderately similar to UCRX_HUMAN Ubiquinol-cytochrome C reductase complex 7.2 kDa protein (Cytochrome C1, nonheme 7 kDa protein) (Complex III subunit X) (7.2 kDa cytochrome c1-associated protein subunit) (HSPC119) [<i>H. sapiens</i>]"
4	1372815_at	BG673028	1.00	1.70	1.02	1.29	"ESTs, Highly similar to MGN_HUMAN Mago nashi protein homolog [<i>M. musculus</i>]"
41	1388628_at	BI284430	1.00	1.30	0.84	1.29	"ESTs, Weakly similar to PSD7_MOUSE 26S proteasome non-ATPase regulatory subunit 7 (26S proteasome regulatory subunit S12) (Proteasome subunit p40) (Mov34 protein) [<i>M. musculus</i>]"
61	1373037_at	BI279216	1.00	1.07	0.74	1.26	"ESTs, Weakly similar to ubiquitin-conjugating enzyme E2D 2 [<i>Rattus norvegicus</i>] [<i>R. norvegicus</i>]"
2	1374950_at	BF400611	1.00	1.52	0.89	1.23	ESTs
10	1386425_at	H33472	1.00	1.27	0.73	1.23	EST

TABLE 6-continued

Genes differentially expressed in CNI1493-treated S1 DRG							
No.	Identifier	Acce. No.	CTRL-VHL	CTRL-CNI	IBS-VHL	IBS-CNI	Description
31	1390065__at	BE096685	1.00	1.53	0.86	1.22	ESTs
17	1390389__at	BM385936	1.00	1.21	0.87	1.20	ESTs
7	1369970__at	NM_031827	1.00	1.45	0.89	1.18	vesicle-associated membrane protein 8 (endobrevin)
13	1390562__s_at	BE102350	1.00	1.09	0.68	1.15	ESTs
8	1390147__at	AI549079	1.00	1.26	0.75	1.12	"ESTs, Highly similar to T17232 hypothetical protein DKFZp434I116.1 - human (fragment) [<i>H. sapiens</i>]"
95	1369157__at	NM_017229	1.00	1.05	1.77	1.09	phosphodiesterase 3B
78	1387242__at	NM_019335	1.00	0.96	2.62	0.95	"Protein kinase, interferon-inducible double stranded RNA dependent"
79	1377225__at	BF400628	1.00	0.76	3.47	0.85	ESTs
18	1372137__at	BI279854	1.00	1.13	0.73	1.03	"ESTs, Highly similar to GC5L_MOUSE GCN5-LIKE PROTEIN 1 [<i>M. musculus</i>]"
75	1393280__at	AA874924	1.00	1.18	0.28	1.09	"ESTs, Moderately similar to lymphocyte antigen 86 [<i>Mus musculus</i>] [<i>M. musculus</i>]"
76	1372604__at	BI289459	1.00	1.55	0.08	1.29	"ESTs, Weakly similar to apolipoprotein L, 3; TNF-inducible protein CG12-1 [<i>Homo sapiens</i>] [<i>H. sapiens</i>]"
102	1374802__at	AI010721	1.00	0.90	1.72	0.96	"ESTs, Moderately similar to hypothetical protein FLJ20424 [<i>Homo sapiens</i>] [<i>H. sapiens</i>]"
40	1371171__at	M10094	1.00	0.76	6.16	0.89	RT1 class Ib gene
88	1371725__at	BM392410	1.00	0.56	1.01	0.95	ESTs
5	1368316__at	NM_019158	1.00	1.22	0.71	0.91	aquaporin 8
89	1375084__at	BF419780	1.00	0.64	1.12	0.90	ESTs
85	1398272__at	NM_022860	1.00	0.66	0.99	0.90	beta-4N-acetylglactosaminyltransferase
81	1374721__at	AI178647	1.00	0.74	1.15	0.89	ESTs
90	1374398__at	AI178787	1.00	0.68	1.10	0.86	"ESTs, Highly similar to suppressor of Ty 6 homolog (<i>S. cerevisiae</i>) [<i>Mus musculus</i>] [<i>M. musculus</i>]"
91	1369999__a_at	NM_053601	1.00	0.68	0.95	0.84	neuronatin
6	1387658__at	U93849	1.00	1.61	0.43	0.83	Eukaryotic elongation factor 2 kinase
129	1387349__at	NM_013028	1.00	0.56	0.76	0.81	Short stature homeobox 2
94	1390347__at	AW535909	1.00	0.72	1.02	0.80	ESTs
100	1376944__at	AI407163	1.00	0.94	1.34	0.79	ESTs
96	1369052__at	NM_133323	1.00	0.90	1.29	0.79	zinc finger protein 111
84	1376410__at	BI291814	1.00	0.66	0.93	0.76	ESTs
118	1389193__at	BM388083	1.00	0.60	0.83	0.76	ESTs
99	1376537__at	AW435010	1.00	0.81	1.06	0.75	ESTs
136	1374655__at	BG378095	1.00	0.57	0.90	0.75	ESTs
97	1375983__at	AI234287	1.00	0.77	1.21	0.74	ESTs
92	1392890__at	BG663460	1.00	0.59	1.24	0.74	ESTs
135	1369061__at	NM_053906	1.00	0.25	0.81	0.74	glutathione reductase
101	1376610__a_at	BE109163	1.00	0.77	1.60	0.74	"ESTs, Weakly similar to G02540 nucleobindin - human [<i>H. sapiens</i>]"
103	1377823__at	AW531363	1.00	1.04	1.60	0.74	ESTs
82	1388116__at	BI285575	1.00	0.56	1.13	0.73	"collagen, type 1, alpha 1"
121	1377070__at	BE098910	1.00	0.59	0.72	0.73	"ESTs, Moderately similar to S3B2__HUMAN Splicing factor 3B subunit 2 (Spliceosome associated protein 145) (SAP 145) (SF3b150) (Pre-mRNA splicing factor SF3b 145 kDa subunit) [<i>H. sapiens</i>]"
131	1369958__at	NM_022542	1.00	0.59	0.77	0.72	rhoB gene
130	1376288__at	AI408455	1.00	0.64	0.78	0.71	ESTs
132	1391078__at	BM391856	1.00	0.56	0.66	0.71	"ESTs, Moderately similar to A56284 differentiation-specific element binding protein - mouse [<i>M. musculus</i>]"

TABLE 6-continued

Genes differentially expressed in CNI1493-treated S1 DRG							
No.	Identifier	Acce. No.	CTRL-VHL	CTRL-CNI	IBS-VHL	IBS-CNI	Description
113	1374593__at	AA799421	1.00	0.66	0.74	0.70	“ESTs, Highly similar to KPCE__RAT PROTEIN KINASE C, EPSILON TYPE (NPKC-EPSILON) [<i>R. norvegicus</i>]”
112	1372158__at	BI295768	1.00	0.66	0.79	0.70	LRP16 protein
83	1370969__at	BE107303	1.00	0.58	1.05	0.69	homeo box A5
93	1370583__s__at	AY082609	1.00	0.73	0.98	0.69	P-glycoprotein/multidrug resistance 1
98	1370139__a__at	AB051214	1.00	0.87	1.16	0.68	zzN/A
87	1389919__at	BI296756	1.00	0.60	0.97	0.67	“ESTs, Weakly similar to actopaxin [<i>Rattus norvegicus</i>] [<i>R. norvegicus</i>]”
117	1368242__at	NM__013186	1.00	0.60	0.72	0.66	“Potassium voltage gated channel, Shab-related subfamily, member 1”
106	1379747__at	AA866443	1.00	0.83	0.97	0.66	ESTs
141	1390626__at	BF398788	1.00	0.66	1.04	0.66	ESTs
133	1369113__at	NM__019282	1.00	0.59	0.87	0.65	“cysteine knot superfamily 1, BMP antagonist 1”
137	1376320__at	BF393051	1.00	0.75	1.08	0.65	ESTs
86	1387588__at	NM__138890	1.00	0.47	1.13	0.65	zzN/A
148	1399138__at	BG672805	1.00	0.71	0.87	0.65	ESTs
105	1398311__a__at	AF313464	1.00	0.92	1.13	0.64	kinase D-interacting substance of 220 kDa
115	1375538__at	AI230737	1.00	0.66	0.82	0.63	ESTs
140	1376204__at	AW531412	1.00	0.71	0.94	0.63	ESTs
111	1390538__at	BF414192	1.00	0.64	0.80	0.63	ESTs
151	1374909__at	BI296626	1.00	0.69	0.90	0.62	“ESTs, Weakly similar to Gasz [<i>Rattus norvegicus</i>] [<i>R. norvegicus</i>]”
146	1368769__at	NM__031760	1.00	0.82	1.01	0.62	“ATP-binding cassette, subfamily B (MDR/TAP), member 11”
107	1387929__at	AB020504	1.00	0.76	0.82	0.61	PMF32 protein
149	1376464__at	BE102505	1.00	0.79	0.79	0.60	ESTs
110	1375705__at	AI103622	1.00	0.60	0.73	0.59	Guanine nucleotide-binding protein beta 1
128	1374084__at	BE119993	1.00	0.68	0.64	0.59	ESTs
123	1390722__at	AW531272	1.00	0.60	0.70	0.59	ESTs
122	1373008__x__at	BF386649	1.00	0.44	0.57	0.58	reticulon 4 receptor
139	1376939__at	BI284907	1.00	0.67	0.85	0.58	ESTs
119	1369059__at	NM__053705	1.00	0.55	0.78	0.58	“transient receptor potential-related protein, ChaK”
126	1392500__at	AA957990	1.00	0.59	0.67	0.58	ESTs
152	1369048__at	NM__017289	1.00	0.71	0.64	0.56	“gamma-aminobutyric acid A receptor, delta”
124	1375508__at	BE095963	1.00	0.50	0.61	0.56	“ESTs, Highly similar to KIF2__MOUSE KINESIN-LIKE PROTEIN KIF2 [<i>M. musculus</i>]”
142	1368429__at	NM__133615	1.00	0.60	0.81	0.56	“TAF9-like RNA polymerase II, TATA box binding protein (TBP)-associated factor, 31 kD”
144	1373981__at	BI299720	1.00	0.62	0.60	0.55	ESTs
114	1369285__at	NM__031082	1.00	0.74	0.76	0.55	geranylgeranyltransferase type I (GGTase-I)
108	1372804__at	AI175555	1.00	0.80	0.87	0.54	“ESTs, Highly similar to hypothetical brain protein similar to X96994 BR-1 protein (<i>Helix pomatia</i>) [<i>Mus musculus</i>] [<i>M. musculus</i>]”
134	1386299__at	AI639471	1.00	0.50	0.86	0.53	EST
138	1377362__at	BF390409	1.00	0.43	0.81	0.51	ESTs
125	1387131__at	AF193015	1.00	0.44	0.55	0.50	“serine (or cysteine) proteinase inhibitor, clade I (neuroserpin), member 1”
147	1373778__at	BE349670	1.00	0.83	0.92	0.46	ESTs
145	1377030__at	BF390550	1.00	0.59	0.82	0.45	ESTs
143	1389436__at	AI236615	1.00	0.75	0.77	0.45	ESTs
116	1386181__at	AI639056	1.00	0.51	0.85	0.44	EST

TABLE 6-continued

Genes differentially expressed in CNI1493-treated S1 DRG						
No.	Identifier	Acce. No.	CTRL-VHL	CTRL-CNI	IBS-VHL	IBS-CNI Description
150	1371042_at	BG664160	1.00	0.63	0.70	0.42 mitogen-activated protein kinase kinase kinase 3
109	1387453_at	NM_024489	1.00	0.49	0.83	0.39 zinc finger protein RIN ZF
127	1390368_at	AI716535	1.00	0.40	0.46	0.34 ESTs
104	1372640_at	BI277758	1.00	0.85	1.80	0.33 ESTs
120	1369054_at	NM_133518	1.00	0.48	0.60	0.25 rabphilin 3A

[0052] The human homologs of some of the rat CVHGs are provided in Table 7.

TABLE 7

Human homologs of rat CVHGs			
Gene	Locus ID	Nucleotide sequence	Amino acid sequence
desmin	1674	SEQ ID NO: 1	SEQ ID NO: 34
PEP-19	5121	SEQ ID NO: 2	SEQ ID NO: 35
IGFBP2	3485	SEQ ID NO: 3	SEQ ID NO: 36
ADAMTS1	9510	SEQ ID NO: 4	SEQ ID NO: 37
ARGBP2	8470	SEQ ID NO: 5	SEQ ID NO: 38
stathmin-like 2	11075	SEQ ID NO: 6	SEQ ID NO: 39
myxovirus resistance 2	4600	SEQ ID NO: 7	SEQ ID NO: 40
IRF7	3665	SEQ ID NO: 8	SEQ ID NO: 41
GBP2	2634	SEQ ID NO: 9	SEQ ID NO: 42
SLC28a2	9153	SEQ ID NO: 10	SEQ ID NO: 43
BDNF	627	SEQ ID NO: 11	SEQ ID NO: 44
phosphodiesterase 3B	5140	SEQ ID NO: 12	SEQ ID NO: 45
TREK2	54207	SEQ ID NO: 13	SEQ ID NO: 46
trkA	4914	SEQ ID NO: 14	SEQ ID NO: 47
IL1R1	3554	SEQ ID NO: 15	SEQ ID NO: 48
EEF2k	29904	SEQ ID NO: 16	SEQ ID NO: 49
actin, gamma 2	72	SEQ ID NO: 17	SEQ ID NO: 50
myosin heavy chain 11	4629	SEQ ID NO: 18	SEQ ID NO: 51
MRCL3	10627	SEQ ID NO: 19	SEQ ID NO: 52
MRCL2	103910	SEQ ID NO: 20	SEQ ID NO: 53
Rho family GTPase 1	27289	SEQ ID NO: 21	SEQ ID NO: 54
HSPB1	3315	SEQ ID NO: 22	SEQ ID NO: 55
RIPK4	54101	SEQ ID NO: 23	SEQ ID NO: 56
type I protein phosphatase inhibitor	80316	SEQ ID NO: 24	SEQ ID NO: 57
transgelin	6876	SEQ ID NO: 25	SEQ ID NO: 58
beta 1 integrin	3688	SEQ ID NO: 26	SEQ ID NO: 59
Desmuslin	23336	SEQ ID NO: 27	SEQ ID NO: 60
C/EBP delta	1052	SEQ ID NO: 28	SEQ ID NO: 61
FBXL22	283807	SEQ ID NO: 29	SEQ ID NO: 62
AF427491		SEQ ID NO: 30	SEQ ID NO: 63
cig5	91543	SEQ ID NO: 31	SEQ ID NO: 64
SAMD9	54809	SEQ ID NO: 32	SEQ ID NO: 65
IFI27	3429	SEQ ID NO: 33	SEQ ID NO: 66

CVHGs and CVHG Products as Markers for CVH and CVH-Related Disorders

[0053] In general, Table 3 and Table 5 provide CVHGs that are differentially expressed at in the CVH colon relative to controls. These genes may be a component in the disease mechanism and can be used as markers for diagnosing and monitoring CVH and CVH-related disorders. The CVHGs of Tables 3 and 5, as well as the corresponding CVHG products (CVHPN and CVHPP) may become novel therapeutic targets for the treatment and prevention of CVH and CVH-related disorders. Furthermore, the CVHG products themselves may be used for the treatment of CVH.

[0054] Accordingly, the present invention pertains to the use of the CVHGs listed in Tables 3 and 5, the transcribed polynucleotides (CVHPNs), and the encoded polypeptides (CVHPPs) as markers for CVH and CVH-related disorders. Moreover, the use of expression profiles of these genes can indicate the presence of or a risk of CVH and CVH-related disorders. These markers are further useful to correlate differences in levels of expression with a poor or favorable prognosis of CVH and CVH-related disorders. In particular, the present invention is directed to the use of CVHGs and panels of CVHGs set forth in Tables 3 and 5 or homologs thereof. For example, panels of the CVHGs can be conveniently arrayed on solid supports, i.e., biochips, such as the GeneChip®, for use in kits. The CVHGs can be used to assess the efficacy of a treatment or therapy of CVH and CVH-related disorders, or as a target for a treatment or therapeutic agent. The CVHGs can also be used to produce antibodies specific to CVHG products, and to construct gene therapy vectors that inhibit the development of CVH and CVH-related disorders. Therefore, without limitation as to mechanism, the invention is based in part on the principle that modulation of the expression of the CVHGs of the invention may ameliorate CVH and CVH-related disorders when they are expressed at levels similar or substantially similar to normal (non-diseased) tissue.

[0055] In one aspect, the invention provides CVHGs whose level of expression, which signifies their quantity or activity, is correlated with the presence of CVH and CVH-related disorders. In certain preferred embodiments, the invention is performed by detecting the presence of an CVHPN or a CVHPP.

[0056] In another aspect of the invention, the expression levels of the CVHGs are determined in a particular subject sample for which either diagnosis or prognosis information is desired. The level of expression of a number of CVHGs simultaneously provides an expression profile, which is essentially a “fingerprint” of the presence or activity of an CVHG or plurality of CVHGs that is unique to the state of the cell. In certain embodiments, comparison of relative levels of expression is indicative of the severity of CVH and CVH-related disorders, and as such permits for diagnostic and prognostic analysis. Moreover, by comparing relative expression profiles of CVHGs from tissue samples taken at different points in time, e.g., pre- and post-therapy and/or at different time points within a course of therapy, information regarding which genes are important in each of these stages is obtained. The identification of genes that are abnormally expressed in CVH versus normal tissue, as well as differentially expressed genes during CVH development, allows the use of this invention in a number of ways. For example, comparison of expression profiles of CVHGs at different stages of the disease

progression provides a method for long-term prognosis. In another example mentioned above, the efficacy of a particular treatment regime may be evaluated, including whether a particular drug will act to improve the long-term prognosis in a particular patient.

[0057] Similarly, CVHGs listed in Tables 4, 6 and 7 can also be used as targets of CVH treatment and as markers to monitor the efficacy of CVH treatment. The gene products from CVHGs of Tables 4, 6 and 7 may also be used in the treatment of CVH and CVH-related disorders.

[0058] The discovery of these differential expression patterns for individual or panels of CVHGs allows for screening test compounds with the goal of modulating a particular expression pattern. For example, screening can be done for compounds that will convert an expression profile for a poor prognosis to one for a better prognosis. In certain embodiments, this may be done by making biochips comprising sets of the significant CVHGs, which can then be used in these screens. These methods can also be done on the protein level; that is, protein expression levels of the CVHGs can be evaluated for diagnostic and prognostic purposes or to screen test compounds. For example, in relation to these embodiments, significant CVHGs may comprise CVHGs which are determined to have modulated activity or expression in response to a therapy regime. Alternatively, the modulation of the activity or expression of a CVHG may be correlated with the diagnosis or prognosis of CVH and CVH-related disorders.

[0059] In addition, the CVHGs listed in Tables 3-8 can be administered for gene therapy purposes, including the administration of antisense nucleic acids and RNAi. The CVHG products (including CVHPPs and CVHPNs) and modulator of CVHG products (such as anti-CVHPP antibodies) can also be administered as therapeutic drugs.

[0060] For example, the CVHG desmin has significantly increased expression in CVH tissue samples, relative to control tissue samples. The presence of increased mRNA for this gene (or any other CVHGs set forth in Tables 3 and 5), and increased levels of the protein products of this gene (or any other CVHGs set forth in Tables 3 and 5) serve as markers for CVH. Accordingly, amelioration of CVH can be achieved by modulating up-regulated CVH markers, such as desmin, to normal levels.

[0061] In another embodiment of the invention, a product of CVHG, either in the form of a polynucleotide or a polypeptide, can be used as a therapeutic compound of the invention. In yet other embodiments, a modulator of CVHG expression or the activity of an CVHG product may be used as a therapeutic compound of the invention, or may be used in combination with one or more other therapeutic compositions of the invention. Formulation of such compounds into pharmaceutical compositions is described in subsections below. Administration of such a therapeutic may suppress bioactivity of CVHG product, and therefore may be used to ameliorate CVH.

Sources of CVHG Products

[0062] The CVHG products (CVHPNs and CVHPPs) of the invention may be isolated from any tissue or cell of a subject. It will be apparent to one skilled in the art that bodily fluids, such as blood or feces, may also serve as sources from which the CVHG product of the invention may be assessed. A biological sample of the invention is obtained as a blood sample, a urine or feces sample, a colon biopsy sample. A biological sample may comprise biological components such

as blood plasma, serum, erythrocytes, leukocytes, blood platelets, lymphocytes, macrophages, fibroblast cells, mast cells, fat cells, neuronal cells, epithelial cells and the like. The tissue samples containing one or more of the CVHG product themselves may be useful in the methods of the invention, and one skilled in the art will be cognizant of the methods by which such samples may be conveniently obtained, stored and/or preserved.

Isolated Polynucleotides

[0063] One aspect of the invention pertains to isolated polynucleotides. Another aspect of the invention pertains to isolated polynucleotide fragments sufficient for use as hybridization probes to identify a CVHPN in a sample, as well as nucleotide fragments for use as PCR probes/primers of the amplification or mutation of the nucleic acid molecules which encode the CVHPP of the invention.

[0064] A CVHPN molecule of the present invention, e.g., a polynucleotide molecule having the nucleotide sequence of one of the CVHGs listed in Tables 3-8, or homologs thereof, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein, as well as sequence information known in the art. Using all or a portion of the polynucleotide sequence of one of the CVHGs listed Tables 3-8 (or a homolog thereof) as a hybridization probe, a CVHG of the invention or a CVHPN of the invention can be isolated using standard hybridization and cloning techniques.

[0065] A CVHPN of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The polynucleotide so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to CVHG nucleotide sequences of the invention can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.

[0066] Alternatively, there are numerous amplification techniques for obtaining a full length coding sequence from a partial cDNA sequence. Within such techniques, amplification is generally performed via PCR. Any of a variety of commercially available kits may be used to perform the amplification step. Primers may be designed using, for example, software well known in the art. Primers are preferably 22-30 nucleotides in length, have a GC content of at least 50% and anneal to the target sequence at temperatures of about 68° C. to 72° C. The amplified region may be sequenced as described above, and overlapping sequences assembled into a contiguous sequence.

[0067] One such amplification technique is inverse PCR, which uses restriction enzymes to generate a fragment in the known region of the gene. The fragment is then circularized by intramolecular ligation and used as a template for PCR with divergent primers derived from the known region. Within an alternative approach, sequences adjacent to a partial sequence may be retrieved by amplification with a primer to a linker sequence and a primer specific to a known region. The amplified sequences are typically subjected to a second round of amplification with the same linker primer and a second primer specific to the known region. A variation on this procedure, which employs two primers that initiate extension in opposite directions from the known sequence, is described in WO 96/38591.

[0068] Another such technique is known as “rapid amplification of cDNA ends” or RACE. This technique involves the use of an internal primer and an external primer, which hybridizes to a polyA region or vector sequence, to identify sequences that are 5' and 3' of a known sequence. Additional techniques include capture PCR (Lagerstrom et al., PCR Methods Applic. 1:11-19, 1991) and walking PCR (Parker et al., Nucl. Acids. Res. 19:3055-60, 1991). Other methods employing amplification may also be employed to obtain a full length cDNA sequence.

[0069] In certain instances, it is possible to obtain a full length cDNA sequence by analysis of sequences provided in an expressed sequence tag (EST) database, such as that available from GenBank. Searches for overlapping ESTs may generally be performed using well known programs (e.g., NCBI BLAST searches), and such ESTs may be used to generate a contiguous full length sequence. Full length DNA sequences may also be obtained by analysis of genomic fragments.

[0070] In another preferred embodiment, an isolated polynucleotide molecule of the invention comprises a polynucleotide molecule which is a complement of the nucleotide sequence of a CVHG listed in Tables 3-8, or homolog thereof, a CVHPN of the invention, or a portion of any of these nucleotide sequences. A polynucleotide molecule which is complementary to such a nucleotide sequence is one which is sufficiently complementary to the nucleotide sequence such that it can hybridize to the nucleotide sequence, thereby forming a stable duplex.

[0071] The polynucleotide molecule of the invention, moreover, can comprise only a portion of the polynucleotide sequence of a CVHG, for example, a fragment which can be used as a probe or primer. The probe/primer typically comprises a substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 7 or 15, preferably about 25, more preferably about 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 400 or more consecutive nucleotides of a CVHG or a CVHPN of the invention.

[0072] Probes based on the nucleotide sequence of an CVHG or an CVHPN of the invention can be used to detect transcripts or genomic sequences corresponding to the CVHG or CVHPN of the invention. In preferred embodiments, the probe comprises a label group attached thereto, e.g., the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic kit for identifying cells or tissue which misexpress (e.g., over- or under-express) a CVHG, or which have greater or fewer copies of an CVHG. For example, a level of a CVHG product in a sample of cells from a subject may be determined, or the presence of mutations or deletions of a CVHG of the invention may be assessed.

[0073] The invention further encompasses polynucleotide molecules that differ from the polynucleotide sequences of the CVHGs listed in Tables 3-8 but encode the same proteins as those encoded by the genes shown in Tables 3-8 due to degeneracy of the genetic code.

[0074] The invention also specifically encompasses homologs of the CVHGs listed in Tables 3-8 of other species. Gene homologs are well understood in the art and are available using databases or search engines such as the Pubmed-Entrez database.

[0075] The invention also encompasses polynucleotide molecules which are structurally different from the molecules described above (i.e., which have a slight altered sequence), but which have substantially the same properties as the molecules above (e.g., encoded amino acid sequences, or which are changed only in non-essential amino acid residues). Such molecules include allelic variants, and are described in greater detail in subsections herein.

[0076] In addition to the nucleotide sequences of the CVHGs listed in Tables 3-8, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the proteins encoded by the CVHGs listed in Tables 3-8 may exist within a population (e.g., the human population). Such genetic polymorphism in the CVHGs listed in Tables 3-8 may exist among individuals within a population due to natural allelic variation. An allele is one of a group of genes which occur alternatively at a given genetic locus. In addition it will be appreciated that DNA polymorphisms that affect RNA expression levels can also exist that may affect the overall expression level of that gene (e.g., by affecting regulation or degradation). As used herein, the phrase “allelic variant” includes a nucleotide sequence which occurs at a given locus or to a polypeptide encoded by the nucleotide sequence.

[0077] Polynucleotide molecules corresponding to natural allelic variants and homologs of the CVHGs can be isolated based on their homology to the CVHGs listed in Tables 3-8, using the cDNAs disclosed herein, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. Polynucleotide molecules corresponding to natural allelic variants and homologs of the CVHGs of the invention can further be isolated by mapping to the same chromosome or locus as the CVHGs of the invention.

[0078] In another embodiment, an isolated polynucleotide molecule of the invention is at least 15, 20, 25, 30, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000 or more nucleotides in length and hybridizes under stringent conditions to a polynucleotide molecule corresponding to a nucleotide sequence of an CVHG of the invention. Preferably, the isolated polynucleotide molecule of the invention hybridizes under stringent conditions to the sequence of one of the CVHGs set forth in Tables 3-8, or corresponds to a naturally-occurring polynucleotide molecule.

[0079] In addition to naturally-occurring allelic variants of the CVHG of the invention that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences of the CVHGs of the invention, thereby leading to changes in the amino acid sequence of the encoded proteins, without altering the functional activity of these proteins. For example, nucleotide substitutions leading to amino acid substitutions at “non-essential” amino acid residues can be made. A “non-essential” amino acid residue is a residue that can be altered from the wild-type sequence of a protein without altering the biological activity, whereas an “essential” amino acid residue is required for biological activity. For example, amino acid residues that are conserved among allelic variants or homologs of a gene (e.g., among homologs of a gene from different species) are predicted to be particularly unamenable to alteration.

[0080] In yet other aspects of the invention, polynucleotides of a CVHG may comprise one or more mutations. An isolated polynucleotide molecule encoding a protein with a mutation in a CVHPP of the invention can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of the gene encoding the CVHPP, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Such techniques are well known in the art. Mutations can be introduced into the CVHG of the invention by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. Alternatively, mutations can be introduced randomly along all or part of a coding sequence of a CVHG of the invention, such as by saturation mutagenesis, and the resultant mutants can be screened for biological activity to identify mutants that retain activity. Following mutagenesis, the encoded protein can be expressed recombinantly and the activity of the protein can be determined.

[0081] A polynucleotide may be further modified to increase stability in vivo. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends; the use of phosphorothioate or 2 O-methyl rather than phosphodiesterase linkages in the backbone; and/or the inclusion of nontraditional bases such as inosine, queosine and wybutosine, as well as acetyl-, methyl-, thio- and other modified forms of adenine, cytidine, guanine, thymine and uridine.

[0082] Another aspect of the invention pertains to isolated polynucleotide molecules, which are antisense to the CVHGs of the invention. An "antisense" polynucleotide comprises a nucleotide sequence which is complementary to a "sense" polynucleotide encoding a protein, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense polynucleotide can hydrogen bond to a sense polynucleotide. The antisense polynucleotide can be complementary to an entire coding strand of a gene of the invention or to only a portion thereof. In one embodiment, an antisense polynucleotide molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence of the invention. The term "coding region" includes the region of the nucleotide sequence comprising codons which are translated into amino acids. In another embodiment, the antisense polynucleotide molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence of the invention.

[0083] Antisense polynucleotides of the invention can be designed according to the rules of Watson and Crick base pairing. The antisense polynucleotide molecule can be complementary to the entire coding region of an mRNA corresponding to a gene of the invention, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense polynucleotide of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense polynucleotide can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense polynucleotides, e.g., phosphorothioate derivatives and

acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense polynucleotide include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenosine, uracil-5-oxyacetic acid (v), wybutosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense polynucleotide can be produced biologically using an expression vector into which a polynucleotide has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted polynucleotide will be of an antisense orientation to a target polynucleotide of interest, described further in the following subsection).

[0084] The antisense polynucleotide molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a CVHPP of the invention to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex or, for example, in the cases of an antisense polynucleotide molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense polynucleotide molecules of the invention include direct injection at a tissue site. Alternatively, antisense polynucleotide molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense polynucleotide molecules to peptides or antibodies which bind to cell surface receptors or antigens. The antisense polynucleotide molecules can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs comprising the antisense polynucleotide molecules are preferably placed under the control of a strong promoter.

[0085] In yet another embodiment, the antisense polynucleotide molecule of the invention is an α -anomeric polynucleotide molecule. An α -anomeric polynucleotide molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other. The antisense polynucleotide molecule can also comprise a 2'-o-methylribonucleotide or a chimeric RNA-DNA analogue.

[0086] In still another embodiment, an antisense polynucleotide of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded polynucleotide, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes) can be used to catalytically cleave mRNA transcripts of the

CVHGs of the invention to thereby inhibit translation of the mRNA. A ribozyme having specificity for a CVHPN can be designed based upon the nucleotide sequence of the CVHPN. For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a CVHG mRNA. Alternatively, mRNA transcribed from a CVHG can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. Alternatively, expression of a CVHG of the invention can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the CVHG (e.g., the promoter and/or enhancers) to form triple helical structures that prevent transcription of the gene in target cells.

[0087] Expression of the CVHGs of the invention can also be inhibited using RNA interference (“RNA_i”). This is a technique for post-transcriptional gene silencing (“PTGS”), in which target gene activity is specifically abolished with cognate double-stranded RNA (“dsRNA”). RNA_i resembles in many aspects PTGS in plants and has been detected in many invertebrates including the trypanosome, hydra, planaria, nematode and fruit fly (*Drosophila melanogaster*). It may be involved in the modulation of transposable element mobilization and antiviral state formation. RNA_i technology is disclosed, for example, in U.S. Pat. No. 5,919,619 and PCT Publication Nos. WO99/14346 and WO01/29058. Basically, dsRNA of about 21 nucleotides, homologous to the target gene, is introduced into the cell and a sequence specific reduction in gene activity is observed.

[0088] In yet another embodiment, the polynucleotide molecules of the present invention can be modified at the base moiety, sugar moiety or phosphate backbone to improve the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the polynucleotide molecules can be modified to generate peptide polynucleotides. As used herein, the terms “peptide polynucleotides” or “PNAs” refer to polynucleotide mimics, e.g., DNA mimics, in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleobases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomers can be performed using standard solid phase peptide synthesis protocols.

[0089] PNAs can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense agents for sequence-specific modulation of CVHG expression by, for example, inducing transcription or translation arrest or inhibiting replication. PNAs of the polynucleotide molecules of the invention can be used in the analysis of single base pair mutations in a gene, (e.g., by PNA-directed PCR clamping). They may also serve as artificial restriction enzymes when used in combination with other enzymes (e.g., S1 nucleases) or as probes or primers for DNA sequencing or hybridization.

[0090] In another embodiment, PNAs can be modified, (e.g., to enhance their stability or cellular uptake), by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of the polynucleotide molecules of the invention can be generated which may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes, (e.g., DNA polymerases), to

interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleobases, and orientation. The synthesis of PNA-DNA chimeras can be performed. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry. Modified nucleoside analogs, such as 5'-(4-methoxytrityl)amino-5'-deoxy-thymidine phosphoramidite, can be used as a spacer between the PNA and the 5' end of DNA. PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5' PNA segment and a 3' DNA segment. Alternatively, chimeric molecules can be synthesized with a 5' DNA segment and a 3' PNA segment.

[0091] In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane or the blood-kidney barrier (see, e.g. PCT Publication No. W089/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents or intercalating agents. To this end, the oligonucleotide may be conjugated to another molecule (e.g., a peptide, hybridization triggered cross-linking agent, transport agent, or hybridization-triggered cleavage agent). Finally, the oligonucleotide may be detectably labeled, either such that the label is detected by the addition of another reagent (e.g., a substrate for an enzymatic label), or is detectable immediately upon hybridization of the nucleotide (e.g., a radioactive label or a fluorescent label).

Isolated Polypeptides

[0092] Several aspects of the invention pertain to isolated CVHPPs, and biologically active portions thereof, as well as polypeptide fragments suitable for use as immunogens to raise anti-CVHPP antibodies. In one embodiment, native CVHPPs can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. Standard purification methods include electrophoretic, molecular, immunological and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reverse-phase HPLC chromatography, and chromatofocusing. For example, a CVHPP may be purified using a standard anti-CVHPP antibody column. Ultrafiltration and diafiltration techniques, in conjunction with protein concentration, are also useful. The degree of purification necessary will vary depending on the use of the CVHPP. In some instances no purification will be necessary.

[0093] In another embodiment, CVHPPs or mutated CVHPPs are produced by recombinant DNA techniques. Alternative to recombinant expression, a CVHPP or mutated CVHPP can be synthesized chemically using standard peptide synthesis techniques.

[0094] The invention also provides variants of CVHPPs. The variant of a CVHPP is substantially homologous to the native CVHPP encoded by an CVHG listed in Table 4, and retains the functional activity of the native CVHPP, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail above. Accordingly, in another embodiment, the variant of a CVHPP is a protein which comprises an amino acid sequence at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the amino acid sequence of the original CVHPP.

[0095] In a non-limiting example, as used herein, proteins are referred to as “homologs” and “homologous” where a first protein region and a second protein region are compared in terms of identity. To determine the percent identity of two amino acid sequences or of two polynucleotide sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or polynucleotide sequence for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a reference sequence aligned for comparison purposes is at least 30%, preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, and even more preferably at least 70%, 80%, or 90% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleotide “identity” is equivalent to amino acid or nucleotide “homology”). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

[0096] The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (J. Mol. Biol. 48:444-453, 1970) algorithm which has been incorporated into the GAP program in the GCG software package, using either a Blossum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package, using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6.

[0097] The polynucleotide and protein sequences of the present invention can further be used as a “query sequence” to perform a search against public databases to, for example, identify other family members or related sequences. Such searches can be performed using BLAST programs available at the BLAST website maintained by the National Center of biotechnology Information (NCBI), National Library of Medicine, Washington D.C. USA.

[0098] The invention also provides chimeric or fusion CVHPPs. Within a fusion CVHPP the polypeptide can correspond to all or a portion of a CVHPP. In a preferred embodiment, a fusion CVHPP comprises at least one biologically active portion of a CVHPP. Within the fusion protein, the term “operatively linked” is intended to indicate that the CVHPP-related polypeptide and the non-CVHPP-related polypeptide are fused in-frame to each other. The non-CVHPP-related polypeptide can be fused to the N-terminus or C-terminus of the CVHPP-related polypeptide.

[0099] A peptide linker sequence may be employed to separate the CVHPP-related polypeptide from non-CVHPP-related polypeptide components by a distance sufficient to ensure that each polypeptide folds into its secondary and tertiary structures. Such a peptide linker sequence is incorpo-

rated into the fusion protein using standard techniques well known in the art. Suitable peptide linker sequences may be chosen based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure that could interact with functional epitopes on the CVHPP-related polypeptide and non-CVHPP-related polypeptide; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. Preferred peptide linker sequences contain gly, asn and ser residues. Other near neutral amino acids, such as thr and ala may also be used in the linker sequence. Amino acid sequences which may be used as linkers are well known in the art. The linker sequence may generally be from 1 to about 50 amino acids in length. Linker sequences are not required when the CVHPP-related polypeptide and non-CVHPP-related polypeptide have non-essential N-terminal amino acid regions that can be used to separate the functional domains and prevent steric interference.

[0100] For example, in one embodiment, the fusion protein is a glutathione S-transferase (GST)-CVHPP fusion protein in which the CVHPP sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant CVHPPs.

[0101] The CVHPP-fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject in vivo, as described herein. The CVHPP-fusion proteins can be used to affect the bioavailability of a CVHPP substrate. CVHPP-fusion proteins may be useful therapeutically for the treatment of, or prevention of, damages caused by, for example, (i) aberrant modification or mutation of a CVHG; (ii) mis-regulation of a CVHG; and (iii) aberrant post-translational modification of a CVHPP.

[0102] Moreover, the CVHPP-fusion proteins of the invention can be used as immunogens to produce anti-CVHPP antibodies in a subject, to purify CVHPP ligands, and to identify molecules which inhibit the interaction of a CVHPP with a CVHPP substrate in screening assays.

[0103] Preferably, a CVHPP-chimeric or fusion protein of the invention is produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric gene sequence. Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). A CVHPP-encoding polynucleotide can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the CVHPP.

[0104] A signal sequence can be used to facilitate secretion and isolation of the secreted protein or other proteins of interest. Signal sequences are typically characterized by a core of hydrophobic amino acids which are generally cleaved from the mature protein during secretion in one or more cleavage events. Such signal peptides contain processing sites that allow cleavage of the signal sequence from the mature proteins as they pass through the secretory pathway. Thus, the invention pertains to the described polypeptides having a signal sequence, as well as to polypeptides from which the signal sequence has been proteolytically cleaved (i.e., the

cleavage products). In one embodiment, a polynucleotide sequence encoding a signal sequence can be operably linked in an expression vector to a protein of interest, such as a protein which is ordinarily not secreted or is otherwise difficult to isolate. The signal sequence directs secretion of the protein, such as from a eukaryotic host into which the expression vector is transformed, and the signal sequence is subsequently or concurrently cleaved. The protein can then be readily purified from the extracellular medium by art recognized methods. Alternatively, the signal sequence can be linked to the protein of interest using a sequence which facilitates purification, such as with a GST domain.

[0105] The present invention also pertains to variants of the CVHPPs of the invention which function as either agonists or as antagonists to the CVHPPs. In one embodiment, antagonists or agonists of CVHPPs are used as therapeutic agents. For example, antagonists of an up-regulated CVHG that can decrease the activity or expression of such a gene and therefore ameliorate CVH in a subject wherein the CVHG is abnormally increased in level or activity. In this embodiment, treatment of such a subject may comprise administering an antagonist wherein the antagonist provides decreased activity or expression of the targeted CVHG.

[0106] In certain embodiments, an agonist of the CVHPPs can retain substantially the same, or a subset, of the biological activities of the naturally occurring form of a CVHPP or may enhance an activity of a CVHPP. In certain embodiments, an antagonist of a CVHPP can inhibit one or more of the activities of the naturally occurring form of the CVHPP by, for example, competitively modulating an activity of a CVHPP. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the CVHPP.

[0107] Mutants of a CVHPP which function as either CVHPP agonists or as CVHPP antagonists can be identified by screening combinatorial libraries of mutants, e.g., truncation mutants, of a CVHPP for CVHPP agonist or antagonist activity. In certain embodiments, such mutants may be used, for example, as a therapeutic protein of the invention. A diverse library of CVHPP mutants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential CVHPP sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of CVHPP sequences therein. There are a variety of methods which can be used to produce libraries of potential CVHPP variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene is then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential CVHPP sequences. Methods for synthesizing degenerate oligonucleotides are known in the art.

[0108] In addition, libraries of fragments of a protein coding sequence corresponding to a CVHPP of the invention can be used to generate a diverse or heterogeneous population of CVHPP fragments for screening and subsequent selection of variants of a CVHPP. In one embodiment, a library of coding sequence fragments can be generated by treating a double-

stranded PCR fragment of a CVHPP coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double-stranded DNA, renaturing the DNA to form double-stranded DNA which can include sense/antisense pairs from different nicked products, removing single-stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal, C-terminal and internal fragments of various sizes of the CVHPP.

[0109] Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. The most widely used techniques, which are amenable to high-throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a technique which enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify CVHPP variants (Delgrave et al. Protein Engineering 6:327-331, 1993).

[0110] Portions of a CVHPP or variants of a CVHPP having less than about 100 amino acids, and generally less than about 50 amino acids, may also be generated by synthetic means, using techniques well known to those of ordinary skill in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain. Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer/Applied BioSystems Division (Foster City, Calif.), and may be operated according to the manufacturer's instructions.

[0111] Methods and compositions for screening for protein inhibitors or activators are known in the art (see U.S. Pat. Nos. 4,980,281, 5,266,464, 5,688,635, and 5,877,007, which are incorporated herein by reference).

[0112] It is contemplated in the present invention that CVHPPs are cleaved into fragments for use in further structural or functional analysis, or in the generation of reagents such as CVHPP and CVHPP-specific antibodies. This can be accomplished by treating purified or unpurified polypeptide with a proteolytic enzyme (i.e., a proteinase) including, but not limited to, serine proteinases (e.g., chymotrypsin, trypsin, plasmin, elastase, thrombin, subtilin) metal proteinases (e.g., carboxypeptidase A, carboxypeptidase B, leucine aminopeptidase, thermolysin, collagenase), thiol proteinases (e.g., papain, bromelain, Streptococcal proteinase, clostripain) and/or acid proteinases (e.g., pepsin, gastricsin, trypsinogen). Polypeptide fragments are also generated using chemical means such as treatment of the polypeptide with cyanogen bromide (CNBr), 2-nitro-5-thiocyanobenzoic acid, isobenzoyl acid, BNPA-skatole, hydroxylamine or a dilute acid solution. Recombinant techniques are also used to produce specific fragments of a CVHPP.

[0113] In addition, the invention also contemplates that compounds sterically similar to a particular CVHPP may be

formulated to mimic the key portions of the peptide structure, called peptidomimetics or peptide mimetics. Mimetics are peptide-containing molecules which mimic elements of polypeptide secondary structure. See, for example, U.S. Pat. No. 5,817,879 (incorporated by reference hereinafter in its entirety). The underlying rationale behind the use of peptide mimetics is that the peptide backbone of polypeptides exists chiefly to orient amino acid side chains in such a way as to facilitate molecular interactions, such as those of receptor and ligand. Recently, peptide and glycoprotein mimetic antigens have been described which elicit protective antibody to *Neisseria meningitidis* serogroup B, thereby demonstrating the utility of mimetic applications (Moe et al., Int. Rev. Immunol. 20:201-20, 2001; Berezin et al., J Mol Neurosci. 22:33-39, 2004). Successful applications of the peptide mimetic concept have thus far focused on mimetics of β -turns within polypeptides. Likely β -turn structures within a CVHPP can be predicted by computer-based algorithms. For example, U.S. Pat. No. 5,933,819, incorporated by reference hereinafter in its entirety, describes a neural network based method and system for identifying relative peptide binding motifs from limited experimental data. In particular, an artificial neural network (ANN) is trained with peptides with known sequence and function (i.e., binding strength) identified from a phage display library. The ANN is then challenged with unknown peptides, and predicts relative binding motifs. Analysis of the unknown peptides validate the predictive capability of the ANN. Once the component amino acids of the turn are determined, mimetics can be constructed to achieve a similar spatial orientation of the essential elements of the amino acid side chains, as discussed in U.S. Pat. No. 6,420,119 and U.S. Pat. No. 5,817,879, and in Kyte and Doolittle, J. Mol. Biol., 157:105-132, 1982; Moe and Granoff, Int. Rev. Immunol., 20(2):201-20, 2001; Granoff et al., J. Immunol., 167(11):6487-96, 2001 (each incorporated by reference hereinafter in its entirety).

Antibodies

[0114] In another aspect, the invention includes antibodies that are specific to CVHPPs of the invention or their variants. Preferably the antibodies are monoclonal, and most preferably, the antibodies are humanized, as per the description of antibodies described below.

[0115] An isolated CVHPP, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind the CVHPP using standard techniques for polyclonal and monoclonal antibody preparation. A full-length CVHPP can be used or, alternatively, the invention provides antigenic peptide fragments of the CVHPP for use as immunogens. The antigenic peptide of a CVHPP comprises at least 8 amino acid residues of an amino acid sequence encoded by an CVHG set forth in Tables 3-8 or an homolog thereof, and encompasses an epitope of a CVHPP such that an antibody raised against the peptide forms a specific immune complex with the CVHPP. Preferably, the antigenic peptide comprises at least 8 amino acid residues, more preferably at least 12 amino acid residues, even more preferably at least 16 amino acid residues, and most preferably at least 20 amino acid residues.

[0116] Immunogenic portions (epitopes) may generally be identified using well known techniques. Such techniques include screening polypeptides for the ability to react with antigen-specific antibodies, antisera and/or T-cell lines or clones. As used herein, antisera and antibodies are "antigen-

specific" if they bind to an antigen with a binding affinity equal to, or greater than 10^5 M^{-1} . Such antisera and antibodies may be prepared as described herein, and using well known techniques. An epitope of a CVHPP is a portion that reacts with such antisera and/or T-cells at a level that is not substantially less than the reactivity of the full length polypeptide (e.g., in an ELISA and/or T-cell reactivity assay). Such epitopes may react within such assays at a level that is similar to or greater than the reactivity of the full length polypeptide. Such screens may generally be performed using methods well known to those of ordinary skill in the art. For example, a polypeptide may be immobilized on a solid support and contacted with patient sera to allow binding of antibodies within the sera to the immobilized polypeptide. Unbound sera may then be removed and bound antibodies detected using, for example, ^{125}I -labeled Protein A.

[0117] Preferred epitopes encompassed by the antigenic peptide are regions of the CVHPP that are located on the surface of the protein, e.g., hydrophilic regions, as well as regions with high antigenicity.

[0118] A CVHPP immunogen typically is used to prepare antibodies by immunizing a suitable subject, (e.g., rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for example, recombinantly expressed CVHPP or a chemically synthesized CVHPP. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or a similar immunostimulatory agent. Immunization of a suitable subject with an immunogenic CVHPP preparation induces a polyclonal anti-CVHPP antibody response. Techniques for preparing, isolating and using antibodies are well known in the art.

[0119] Accordingly, another aspect of the invention pertains to monoclonal or polyclonal anti-CVHPP antibodies and immunologically active portions of the antibody molecules, including F(ab) and F(ab')₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin.

[0120] Polyclonal anti-CVHPP antibodies can be prepared as described above by immunizing a suitable subject with a CVHPP. The anti-CVHPP antibody titer in the immunized subject can be monitored over time by standard techniques, such as with an enzyme linked immunosorbent assay (ELISA) using immobilized CVHPP. If desired, the antibody molecules directed against CVHPPs can be isolated from the subject (e.g., from the blood) and further purified by well known techniques, such as protein A chromatography, to obtain the IgG fraction. At an appropriate time after immunization, e.g., when the anti-CVHPP antibody titers are highest, antibody-producing cells can be obtained from the subject and used to prepare monoclonal antibodies by standard techniques, such as the hybridoma technique, human B cell hybridoma technique, the EBV-hybridoma technique, or trioma techniques. The technology for producing monoclonal antibody hybridomas is well known. Briefly, an immortal cell line (typically a myeloma) is fused to lymphocytes (typically splenocytes) from a mammal immunized with a CVHPP immunogen as described above, and the culture supernatants of the resulting hybridoma cells are screened to identify a hybridoma producing a monoclonal antibody that binds to a CVHPP of the invention.

[0121] Any of the many well known protocols used for fusing lymphocytes and immortalized cell lines can be applied for the purpose of generating an anti-CVHPP mono-

clonal antibody. Moreover, the ordinarily skilled worker will appreciate that there are many variations of such methods which also would be useful. Typically, the immortal cell line (e.g., a myeloma cell line) is derived from the same mammalian species as the lymphocytes. For example, murine hybridomas can be made by fusing lymphocytes from a mouse immunized with an immunogenic preparation of the present invention with an immortalized mouse cell line. Preferred immortal cell lines are mouse myeloma cell lines that are sensitive to culture medium containing hypoxanthine, aminopterin and thymidine ("HAT medium"). Any of a number of myeloma cell lines can be used as a fusion partner according to standard techniques, e.g., the P3-NS1/1-Ag4-1, P3-x63-Ag8.653 or Sp210-Ag14 myeloma lines. These myeloma lines are available from ATCC. Typically, HAT-sensitive mouse myeloma cells are fused to mouse splenocytes using polyethylene glycol ("PEG"). Hybridoma cells resulting from the fusion are then selected using HAT medium, which kills unfused and unproductively fused myeloma cells (unfused splenocytes die after several days because they are not transformed). Hybridoma cells producing a monoclonal antibody of the invention are detected by screening the hybridoma culture supernatants for antibodies that bind to a CVHPP, e.g., using a standard ELISA assay.

[0122] Alternative to preparing monoclonal antibody-secreting hybridomas, a monoclonal anti-CVHPP antibody can be identified and isolated by screening a recombinant combinatorial immunoglobulin library (e.g., an antibody phage display library) with CVHPP to thereby isolate immunoglobulin library members that bind to a CVHPP. Kits for generating and screening phage display libraries are commercially available.

[0123] The anti-CVHPP antibodies also include "Single-chain Fv" or "scFv" antibody fragments. The scFv fragments comprise the V_H and V_L domains of antibody, wherein these domains are present in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the V_H and V_L domains which enables the scFv to form the desired structure for antigen binding.

[0124] Additionally, recombinant anti-CVHPP antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art.

[0125] Humanized antibodies are particularly desirable for therapeutic treatment of human subjects. Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')₂ or other antigen-binding subsequences of antibodies), which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues forming a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise

substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the constant regions being those of a human immunoglobulin consensus sequence. The humanized antibody will preferably also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.

[0126] Such humanized antibodies can be produced using transgenic mice which are incapable of expressing endogenous immunoglobulin heavy and light chain genes, but which can express human heavy and light chain genes. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide corresponding to a CVHPP of the invention. Monoclonal antibodies directed against the antigen can be obtained using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA and IgE antibodies.

[0127] Humanized antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a selected non-human monoclonal antibody, e.g., a murine antibody, is used to guide the selection of a humanized antibody recognizing the same epitope.

[0128] In a preferred embodiment, the antibodies to CVHPP are capable of reducing or eliminating the biological function of CVHPP, as is described below. That is, the addition of anti-CVHPP antibodies (either polyclonal or preferably monoclonal) to CVHPP (or cells containing CVHPP) may reduce or eliminate the CVHPP activity. Generally, at least a 25% decrease in activity is preferred, with at least about 50% being particularly preferred and about a 95-100% decrease being especially preferred.

[0129] An anti-CVHPP antibody can be used to isolate a CVHPP of the invention by standard techniques, such as affinity chromatography or immunoprecipitation. An anti-CVHPP antibody can facilitate the purification of natural CVHPPs from cells and of recombinantly produced CVHPPs expressed in host cells. Moreover, an anti-CVHPP antibody can be used to detect a CVHPP (e.g., in a cellular lysate or cell supernatant on the cell surface) in order to evaluate the abundance and pattern of expression of the CVHPP. Anti-CVHPP antibodies can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, for example, to determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase,

luciferin, and aequorin; and examples of suitable radioactive materials include ^{125}I , ^{131}I , ^{35}S or ^3H .

[0130] Anti-CVHPP antibodies of the invention are also useful for targeting a therapeutic to a cell or tissue comprising the antigen of the anti-CVHPP antibody. For example, a therapeutic, such as a small molecule, can be linked to the anti-CVHPP antibody in order to target the therapeutic to the cell or tissue comprising the CVHPP antigen. The method is particularly useful in connection with CVHPPs which are surface markers.

[0131] A therapeutic agent may be coupled (e.g., covalently bonded) to a suitable monoclonal antibody either directly or indirectly (e.g., via a linker group). A direct reaction between an agent and an antibody is possible when each possesses a substituent capable of reacting with the other. For example, a nucleophilic group, such as an amino or sulfhydryl group, on one may be capable of reacting with a carbonyl-containing group, such as an anhydride or an acid halide, or with an alkyl group containing a good leaving group (e.g., a halide) on the other.

[0132] Alternatively, it may be desirable to couple a therapeutic agent and an antibody via a linker group. A linker group can function as a spacer to distance an antibody from an agent in order to avoid interference with binding capabilities. A linker group can also serve to increase the chemical reactivity of a substituent on an agent or an antibody, and thus increase the coupling efficiency. An increase in chemical reactivity may also facilitate the use of agents, or functional groups on agents, which otherwise would not be possible.

[0133] It will be evident to those skilled in the art that a variety of bifunctional or polyfunctional reagents, both homo- and hetero-functional, may be employed as the linker group. Coupling may be effected, for example, through amino groups, carboxyl groups, sulfhydryl groups or oxidized carbohydrate residues. There are numerous references describing such methodology, e.g., U.S. Pat. No. 4,671,958, to Rodwell et al.

[0134] Where a therapeutic agent is more potent when free from the antibody portion of the immunoconjugates of the present invention, it may be desirable to use a linker group which is cleavable during or upon internalization into a cell. A number of different cleavable linker groups have been described. The mechanisms for the intracellular release of an agent from these linker groups include cleavage by reduction of a disulfide bond (e.g., U.S. Pat. No. 4,489,710, to Spittler), by irradiation of a photolabile bond (e.g., U.S. Pat. No. 4,625,014, to Senter et al.), by hydrolysis of derivatized amino acid side chains (e.g., U.S. Pat. No. 4,638,045, to Kohn et al.), by serum complement-mediated hydrolysis (e.g., U.S. Pat. No. 4,671,958, to Rodwell et al.), and acid-catalyzed hydrolysis (e.g., U.S. Pat. No. 4,569,789, to Blatler et al.).

[0135] It may be desirable to couple more than one agent to an antibody. In one embodiment, multiple molecules of an agent are coupled to one antibody molecule. In another embodiment, more than one type of agent may be coupled to one antibody. Regardless of the particular embodiment, immunoconjugates with more than one agent may be prepared in a variety of ways. For example, more than one agent may be coupled directly to an antibody molecule. Alternatively, linkers that provide multiple sites for attachment can be used.

[0136] As is well known in the art, a given polypeptide or polynucleotide may vary in its immunogenicity. It is often necessary therefore to couple the immunogen (e.g., a

polypeptide or polynucleotide) of the present invention with a carrier. Exemplary and preferred carriers are CRM197, *E. coli* (LT) toxin, *V. cholera* (CT) toxin, keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA). Other albumins such as ovalbumin, mouse serum albumin or rabbit serum albumin can also be used as carriers.

[0137] Where a CVHPP (or a fragment thereof) and a carrier protein are conjugated (i.e., covalently associated), conjugation may be any chemical method, process or genetic technique commonly used in the art. For example, a CVHPP (or a fragment thereof) and a carrier protein, may be conjugated by techniques, including, but not limited to: (1) direct coupling via protein functional groups (e.g., thiol-thiol linkage, amine-carboxyl linkage, amine-aldehyde linkage; enzyme direct coupling); (2) homobifunctional coupling of amines (e.g., using bis-aldehydes); (3) homobifunctional coupling of thiols (e.g., using bis-maleimides); (4) homobifunctional coupling via photoactivated reagents (5) heterobifunctional coupling of amines to thiols (e.g., using maleimides); (6) heterobifunctional coupling via photoactivated reagents (e.g., the β -carbonyldiazo family); (7) introducing amine-reactive groups into a poly- or oligosaccharide via cyanogen bromide activation or carboxymethylation; (8) introducing thiol-reactive groups into a poly- or oligosaccharide via a heterobifunctional compound such as maleimido-hydrazide; (9) protein-lipid conjugation via introducing a hydrophobic group into the protein and (10) protein-lipid conjugation via incorporating a reactive group into the lipid. Also, contemplated are heterobifunctional "non-covalent coupling" techniques such the Biotin-Avidin interaction. For a comprehensive review of conjugation techniques, see Aslam and Dent (Aslam and Dent, "Bioconjugation: Protein Coupling Techniques for the Biomedical Sciences," Macmillan Reference Ltd., London, England, 1998), incorporated hereinafter by reference in its entirety.

[0138] In a specific embodiment, antibodies to a CVHPP may be used to eliminate the CVHPP in vivo by activating the complement system or mediating antibody-dependent cellular cytotoxicity (ADCC), or cause uptake of the antibody coated cells by the receptor-mediated endocytosis (RE) system.

Vectors

[0139] Another aspect of the invention pertains to vectors containing a polynucleotide encoding a CVHPP, a variant of a CVHPP, or a portion thereof. One type of vector is a "plasmid," which includes a circular double-stranded DNA loop into which additional DNA segments can be ligated. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. Vectors also include expression vectors and gene delivery vectors.

[0140] The expression vectors of the invention comprise a polynucleotide encoding a CVHPP or a portion thereof in a form suitable for expression of the polynucleotide in a host cell, which means that the expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, and operatively linked to the polynucleotide sequence to be expressed. It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, and the like. The expression vectors of the invention can be

introduced into host cells to thereby produce proteins or peptides, such as CVHPPs, mutant forms of CVHPPs, CVHPP-fusion proteins, and the like.

[0141] The expression vectors of the invention can be designed for expression of CVHPPs in prokaryotic or eukaryotic cells. For example, CVHPPs can be expressed in bacterial cells such as *E. coli*, insect cells (using baculovirus expression vectors), yeast cells or mammalian cells. Alternatively, the expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.

[0142] The expression of proteins in prokaryotes is most often carried out in *E. coli* with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: 1) to increase expression of the recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia, Piscataway, N.J.), pMAL (New England Biolabs, Beverly, Mass.) and pRITS (Pharmacia, Piscataway, N.J.) which fuse glutathione S transferase (GST), maltose E binding protein, and protein A, respectively, to the target recombinant protein.

[0143] Purified fusion proteins can be utilized in CVHPP activity assays, (e.g., direct assays or competitive assays described in detail below), or to generate antibodies specific for CVHPPs.

[0144] One strategy to maximize recombinant protein expression in *E. coli* is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein. Another strategy is to alter the polynucleotide sequence of the polynucleotide to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in *E. coli*. Such alteration of polynucleotide sequences of the invention can be carried out by standard DNA synthesis techniques.

[0145] In another embodiment, the CVHPP expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1, pMFa, pJRY88, pYES2 and picZ (Invitrogen Corp, San Diego, Calif.).

[0146] Alternatively, CVHPPs of the invention can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf9 cells) include the pAc series and the pVL series.

[0147] In yet another embodiment, a polynucleotide of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 and pMT2PC. When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2 and 5, cytomegalovirus and Simian Virus 40. Target

gene expression from the pTrec vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21 (DE3) or HSLE174(DE3) from a resident prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter.

[0148] In another embodiment, the mammalian expression vector is capable of directing expression of the polynucleotide preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the polynucleotide). Tissue-specific regulatory elements are known in the art and may include epithelial cell-specific promoters. Other non-limiting examples of suitable tissue-specific promoters include the liver-specific promoter (e.g., albumin promoter), lymphoid-specific promoters, promoters of T cell receptors and immunoglobulins, neuron-specific promoters (e.g., the neurofilament promoter), pancreas-specific promoters (e.g., insulin promoter), and mammary gland-specific promoters (e.g., milk whey promoter). Developmentally-regulated promoters (e.g., the α -fetoprotein promoter) are also encompassed.

[0149] The invention provides a recombinant expression vector comprising a polynucleotide encoding a CVHPP cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to mRNA corresponding to a CVHG of the invention. Regulatory sequences operatively linked to a polynucleotide cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance, viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense polynucleotides are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced.

[0150] The invention further provides gene delivery vehicles for delivery of polynucleotides to cells, tissues, or a mammal for expression. For example, a polynucleotide sequence of the invention can be administered either locally or systemically in a gene delivery vehicle. These constructs can utilize viral or non-viral vector approaches in vivo or ex vivo modality. Expression of the coding sequence can be induced using endogenous mammalian or heterologous promoters. Expression of the coding sequence in vivo can be either constituted or regulated. The invention includes gene delivery vehicles capable of expressing the contemplated polynucleotides. The gene delivery vehicle is preferably a viral vector and, more preferably, a retroviral, lentiviral, adenoviral, adeno-associated viral (AAV), herpes viral, or alphavirus vector. The viral vector can also be an astrovirus, coronavirus, orthomyxovirus, papovavirus, paramyxovirus, parvovirus, picornavirus, poxvirus, togavirus viral vector.

[0151] The delivery of gene therapy constructs of this invention into cells is not limited to the above mentioned viral vectors. Other delivery methods and media may be employed such as, for example, nucleic acid expression vectors, poly-

cationic condensed DNA linked or unlinked to killed adenovirus alone, ligand linked DNA, liposomes, eukaryotic cell delivery vehicles cells, deposition of photopolymerized hydrogel materials, handheld gene transfer particle gun, ionizing radiation, nucleic charge neutralization or fusion with cell membranes. Particle mediated gene transfer may be employed. Briefly, DNA sequence can be inserted into conventional vectors that contain conventional control sequences for high level expression, and then be incubated with synthetic gene transfer molecules such as polymeric DNA-binding cations like polylysine, protamine, and albumin, linked to cell targeting ligands such as asialoorosomucoid, insulin, galactose, lactose or transferrin. Naked DNA may also be employed. Uptake efficiency of naked DNA may be improved using biodegradable latex beads. The method may be improved further by treatment of the beads to increase hydrophobicity and thereby facilitate disruption of the endosome and release of the DNA into the cytoplasm.

[0152] Another aspect of the invention pertains to the expression of CVHPPs using a regulatable expression system. Systems to regulate expression of therapeutic genes have been developed and incorporated into the current viral and nonviral gene delivery vectors. These systems are briefly described below:

[0153] Tet-on/off system. The Tet-system is based on two regulatory elements derived from the tetracycline-resistance operon of the *E. coli* Tn10 transposon: the tet repressor protein (TetR) and the Tet operator DNA sequence (tetO) to which TetR binds. The system consists of two components, a “regulator” and a “reporter” plasmid. The “regulator” plasmid encodes a hybrid protein containing a mutated Tet repressor (rtetR) fused to the VP16 activation domain of herpes simplex virus. The “reporter” plasmid contains a tet-responsive element (TRE), which controls the “reporter” gene of choice. The rtetR-VP16 fusion protein can only bind to the TRE, therefore activates the transcription of the “reporter” gene, in the presence of tetracycline. The system has been incorporated into a number of viral vectors including retrovirus, adenovirus and AAV.

[0154] Ecdysone system. The ecdysone system is based on the molting induction system found in *Drosophila*, but modified for inducible expression in mammalian cells. The system uses an analog of the *drosophila* steroid hormone ecdysone, muristerone A, to activate expression of the gene of interest via a heterodimeric nuclear receptor. Expression levels have been reported to exceed 200-fold over basal levels with no effect on mammalian cell physiology.

[0155] Progesterone system. The progesterone receptor is normally stimulated to bind to a specific DNA sequence and to activate transcription through an interaction with its hormone ligand. Conversely, the progesterone antagonist mifepristone (RU486) is able to block hormone-induced nuclear transport and subsequent DNA binding. A mutant form of the progesterone receptor that can be stimulated to bind through an interaction with RU486 has been generated. To generate a specific, regulatable transcription factor, the RU486-binding domain of the progesterone receptor has been fused to the DNA-binding domain of the yeast transcription factor GAL4 and the transactivation domain of the HSV protein VP16. The chimeric factor is inactive in the absence of RU486. The addition of hormone, however, induces a conformational change in the chimeric protein, and this change allows binding to a GAL4-binding site and the activation of transcription from promoters containing the GAL4-binding site.

[0156] Rapamycin system. Immunosuppressive agents, such as FK506 and rapamycin, act by binding to specific cellular proteins and facilitating their dimerization. For example, the binding of rapamycin to FK506-binding protein (FKBP) results in its heterodimerization with another rapamycin binding protein FRAP, which can be reversed by removal of the drug. The ability to bring two proteins together by addition of a drug potentiates the regulation of a number of biological processes, including transcription. A chimeric DNA-binding domain has been fused to the FKBP, which enables binding of the fusion protein to a specific DNA-binding sequence. A transcriptional activation domain also has been fused to FRAP. When these two fusion proteins are co-expressed in the same cell, a fully functional transcription factor can be formed by heterodimerization mediated by addition of rapamycin. The dimerized chimeric transcription factor can then bind to a synthetic promoter sequence containing copies of the synthetic DNA-binding sequence. This system has been successfully integrated into adenoviral and AAV vectors. Long term regulatable gene expression has been achieved in both mice and baboons.

Immunogens and Immunogenic Compositions

[0157] Within certain aspects, CVHPP, CVHPPN, CVHPP-specific T cell, CVHPP-presenting APC, CVHG-containing vectors, including but are not limited to expression vectors and gene delivery vectors, may be utilized as vaccines for CVH. Vaccines may comprise one or more such compounds/cells and an immunostimulant. An immunostimulant may be any substance that enhances or potentiates an immune response (antibody and/or cell-mediated) to an exogenous antigen. Examples of immunostimulants include adjuvants, biodegradable microspheres (e.g., polylactic galactide) and liposomes (into which the compound is incorporated). Vaccines within the scope of the present invention may also contain other compounds, which may be biologically active or inactive. For example, one or more immunogenic portions of other antigens may be present, either incorporated into a fusion polypeptide or as a separate compound, within the composition of vaccine.

[0158] A vaccine may contain DNA encoding one or more CVHPP or portion of CVHPP, such that the polypeptide is generated in situ. As noted above, the DNA may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression vectors, gene delivery vectors, and bacteria expression systems. Numerous gene delivery techniques are well known in the art. Appropriate nucleic acid expression systems contain the necessary DNA sequences for expression in the patient (such as a suitable promoter and terminating signal). Bacterial delivery systems involve the administration of a bacterium (such as *Bacillus-Calmette-Guerrin*) that expresses an immunogenic portion of the polypeptide on its cell surface or secretes such an epitope. In a preferred embodiment, the DNA may be introduced using a viral expression system (e.g., vaccinia or other pox virus, retrovirus, or adenovirus), which may involve the use of a non-pathogenic (defective), replication competent virus. Techniques for incorporating DNA into such expression systems are well known to those of ordinary skill in the art. The DNA may also be “naked,” as described, for example, in Ulmer et al., *Science* 259:1745-1749, 1993 and reviewed by Cohen, *Science* 259:1691-1692, 1993. The uptake of naked DNA may be increased by coating the DNA onto biodegradable beads, which are efficiently transported

into the cells. It will be apparent that a vaccine may comprise both a polynucleotide and a polypeptide component. Such vaccines may provide for an enhanced immune response.

[0159] It will be apparent that a vaccine may contain pharmaceutically acceptable salts of the polynucleotides and polypeptides provided herein. Such salts may be prepared from pharmaceutically acceptable non-toxic bases, including organic bases (e.g., salts of primary, secondary and tertiary amines and basic amino acids) and inorganic bases (e.g., sodium, potassium, lithium, ammonium, calcium and magnesium salts).

[0160] Any of a variety of immunostimulants may be employed in the vaccines of this invention. For example, an adjuvant may be included. As defined previously, an "adjuvant" is a substance that serves to enhance the immunogenicity of an antigen. Thus, adjuvants are often given to boost the immune response and are well known to the skilled artisan. Examples of adjuvants contemplated in the present invention include, but are not limited to, aluminum salts (alum) such as aluminum phosphate and aluminum hydroxide, *Mycobacterium tuberculosis*, *Bordetella pertussis*, bacterial lipopolysaccharides, aminoalkyl glucosamine phosphate compounds (AGP), or derivatives or analogs thereof, which are available from Corixa (Hamilton, Mont.), and which are described in U.S. Pat. No. 6,113,918; one such AGP is 2-[(R)-3-Tetradecanoyloxytetradecanoylamino]ethyl 2-Deoxy-4-O-phosphono-3-O—[(R)-3-tetradecanoyloxytetradecanoyl]-2-[(R)-3-tetradecanoyloxytetradecanoylamino]-b-D-glucopyranoside, which is also known as 529 (formerly known as RC529), which is formulated as an aqueous form or as a stable emulsion, MPL™ (3-O-deacylated monophosphoryl lipid A) (Corixa) described in U.S. Pat. No. 4,912,094, synthetic polynucleotides such as oligonucleotides containing a CpG motif (U.S. Pat. No. 6,207,646), polypeptides, saponins such as Quil A or STIMULON™ QS-21 (Antigenics, Framingham, Mass.), described in U.S. Pat. No. 5,057,540, a pertussis toxin (PT), or an *E. coli* heat-labile toxin (LT), particularly LT-K63, LT-R72, CT-S109, PT-K9/G129; see, e.g., International Patent Publication Nos. WO 93/13302 and WO 92/19265, cholera toxin (either in a wild-type or mutant form, e.g., wherein the glutamic acid at amino acid position 29 is replaced by another amino acid, preferably a histidine, in accordance with published International Patent Application number WO 00/18434). Various cytokines and lymphokines are suitable for use as adjuvants. One such adjuvant is granulocyte-macrophage colony stimulating factor (GM-CSF), which has a nucleotide sequence as described in U.S. Pat. No. 5,078,996. A plasmid containing GM-CSF cDNA has been transformed into *E. coli* and has been deposited with the American Type Culture Collection (ATCC), 1081 University Boulevard, Manassas, Va. 20110-2209, under Accession Number 39900. The cytokine IL-12 is another adjuvant which is described in U.S. Pat. No. 5,723,127. Other cytokines or lymphokines have been shown to have immune modulating activity, including, but not limited to, the interleukins 1-alpha, 1-beta, 2, 4, 5, 6, 7, 8, 10, 13, 14, 15, 16, 17 and 18, the interferons-alpha, beta and gamma, granulocyte colony stimulating factor, and the tumor necrosis factors alpha and beta, and are suitable for use as adjuvants.

[0161] Any vaccine provided herein may be prepared using well known methods that result in a combination of antigen, immune response enhancer and a suitable carrier or excipient. The compositions described herein may be administered as part of a sustained release formulation (i.e., a formulation

such as a capsule, sponge or gel (composed of polysaccharides, for example) that effects a slow release of compound following administration). Such formulations may generally be prepared using well known technology and administered by, for example, oral, rectal or subcutaneous implantation, or by implantation at the desired target site. Sustained-release formulations may contain a polypeptide, polynucleotide or antibody dispersed in a carrier matrix and/or contained within a reservoir surrounded by a rate controlling membrane.

[0162] Carriers for use within such formulations are bio-compatible, and may also be biodegradable; preferably the formulation provides a relatively constant level of active component release. Such carriers include microparticles of poly (lactide-co-glycolide), as well as polyacrylate, latex, starch, cellulose and dextran. Other delayed-release carriers include supramolecular biovectors, which comprise a non-liquid hydrophilic core (e.g., a cross-linked polysaccharide or oligosaccharide) and, optionally, an external layer comprising an amphiphilic compound, such as a phospholipid (see e.g., U.S. Pat. No. 5,151,254 and PCT applications WO 94/20078, WO/94/23701 and WO 96/06638). The amount of active compound contained within a sustained release formulation depends upon the site of implantation, the rate and expected duration of release and the nature of the condition to be treated or prevented.

[0163] Any of a variety of delivery vehicles may be employed within vaccines to facilitate production of an antigen-specific immune response that targets cancer cells. Delivery vehicles include antigen presenting cells (APCs), such as dendritic cells, macrophages, B cells, monocytes and other cells that may be engineered to be efficient APCs. Such cells may, but need not, be genetically modified to increase the capacity for presenting the antigen, to improve activation and/or maintenance of the T cell response, to have anti-CVH effects per se and/or to be immunologically compatible with the receiver (i.e., matched HLA haplotype). APCs may generally be isolated from any of a variety of biological fluids and organs, and may be autologous, allogeneic, syngeneic or xenogenic cells.

[0164] Certain preferred embodiments of the present invention use dendritic cells or progenitors thereof as APCs. Dendritic cells are highly potent APCs and have been shown to be effective as a physiological adjuvant for eliciting prophylactic or therapeutic anti-CVH immunity. In general, dendritic cells may be identified based on their typical shape (stellate in situ, with marked cytoplasmic processes (dendrites) visible in vitro), their ability to take up, process and present antigens with high efficiency and their ability to activate naive T cell responses. Dendritic cells may, of course, be engineered to express specific cell-surface receptors or ligands that are not commonly found on dendritic cells in vivo, and such modified dendritic cells are contemplated by the present invention. As an alternative to dendritic cells, secreted vesicles antigen-loaded dendritic cells (called exosomes) may be used within a vaccine (see Zitvogel et al., Nature Med. 4:594-600, 1998).

[0165] Dendritic cells and progenitors may be obtained from peripheral blood, bone marrow, lymph nodes, spleen, skin, umbilical cord blood or any other suitable tissue or fluid. For example, dendritic cells may be differentiated ex vivo by adding a combination of cytokines such as GM-CSF, IL-4, IL-13 and/or TNF α to cultures of monocytes harvested from peripheral blood. Alternatively, CD34 positive cells harvested from peripheral blood, umbilical cord blood or bone marrow may be differentiated into dendritic cells by adding to

the culture medium combinations of GM-CSF, IL-3, TNF α , CD40 ligand, LPS, flt3 ligand and/or other compound(s) that induce differentiation, maturation and proliferation of dendritic cells.

[0166] Dendritic cells are conveniently categorized as “immature” and “mature” cells, which allows a simple way to discriminate between two well characterized phenotypes. However, this nomenclature should not be construed to exclude all possible intermediate stages of differentiation. Immature dendritic cells are characterized as APC with a high capacity for antigen uptake and processing, which correlates with the high expression of Fcy receptor and mannose receptor. The mature phenotype is typically characterized by a lower expression of these markers, but a high expression of cell surface molecules responsible for T cell activation such as class I and class II MHC, adhesion molecules (e.g., CD54 and CD11) and costimulatory molecules (e.g., CD40, CD80, CD86 and 4-1BB).

[0167] APCs may generally be transfected with a polynucleotide encoding a CVHPP (or portion or other variant thereof) such that the CVHPP, or an immunogenic portion thereof, is expressed on the cell surface. Such transfection may take place ex vivo, and a composition or vaccine comprising such transfected cells may then be used for therapeutic purposes, as described herein. Alternatively, a gene delivery vehicle that targets a dendritic or other antigen presenting cell may be administered to a patient, resulting in transfection that occurs in vivo. In vivo and ex vivo transfection of dendritic cells, for example, may generally be performed using any methods known in the art, such as those described in WO 97/24447, or the gene gun approach described by Mahvi et al., *Immunology and cell Biology* 75:456-460, 1997. Antigen loading of dendritic cells may be achieved by incubating dendritic cells or progenitor cells with the CVHPP, DNA (naked or within a plasmid vector) or RNA; or with antigen-expressing recombinant bacterium or viruses (e.g., vaccinia, fowlpox, adenovirus or lentivirus vectors). Prior to loading, the polypeptide may be covalently conjugated to an immunological partner that provides T cell help (e.g., a carrier molecule). Alternatively, a dendritic cell may be pulsed with a non-conjugated immunological partner, separately or in the presence of the polypeptide.

[0168] Vaccines may be presented in unit-dose or multi-dose containers, such as sealed ampoules or vials. Such containers are preferably hermetically sealed to preserve sterility of the formulation until use. In general, formulations may be stored as suspensions, solutions or emulsions in oily or aqueous vehicles. Alternatively, a vaccine may be stored in a freeze-dried condition requiring only the addition of a sterile liquid carrier immediately prior to use.

Detection Methods

[0169] As discussed earlier, expression level of CVHGs may be used as a marker for CVH and CVH-related disorders. Detection and measurement of the relative amount of a CVHG product (polynucleotide or polypeptide) of the invention can be by any method known in the art. Typical methodologies for detection of a transcribed polynucleotide include RNA extraction from a cell or tissue sample, followed by hybridization of a labeled probe (i.e., a complementary polynucleotide molecule) specific for the target RNA to the extracted RNA and detection of the probe (i.e., Northern blotting).

[0170] Typical methodologies for peptide detection include protein extraction from a cell or tissue sample, followed by binding of an antibody specific for the target protein to the protein sample, and detection of the antibody. For example, detection of desmin may be accomplished using polyclonal antibody anti-desmin. Antibodies are generally detected by the use of a labeled secondary antibody. The label can be a radioisotope, a fluorescent compound, an enzyme, an enzyme co-factor, or ligand. Such methods are well understood in the art.

[0171] In certain embodiments, the CVHGs themselves (i.e., the DNA or cDNA) may serve as markers for CVH. For example, an increase of genomic copies of a CVHG, such as by duplication of the gene, may also be correlated with CVH and CVH-associated disorders.

[0172] Detection of specific polynucleotide molecules may also be assessed by gel electrophoresis, column chromatography, or direct sequencing, quantitative PCR (in the case of polynucleotide molecules), RT-PCR, or nested-PCR among many other techniques well known to those skilled in the art.

[0173] Detection of the presence or number of copies of all or a part of an CVHG of the invention may be performed using any method known in the art. Typically, it is convenient to assess the presence and/or quantity of a DNA or cDNA by Southern analysis, in which total DNA from a cell or tissue sample is extracted and hybridized with a labeled probe (i.e., a complementary DNA molecules). The probe is then detected and quantified. The label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Other useful methods of DNA detection and/or quantification include direct sequencing, gel electrophoresis, column chromatography, and quantitative PCR, as is known by one skilled in the art.

[0174] In certain embodiments, CVHPPs may serve as markers for CVH. Detection of specific polypeptide molecules may be assessed by gel electrophoresis, Western blot, column chromatography, or direct sequencing, among many other techniques well known to those skilled in the art.

Panels of CVHGs

[0175] The expression level of each CVHG may be considered individually, although it is within the scope of the invention to provide combinations of two or more CVHGs for use in the methods and compositions of the invention to increase the confidence of the analysis. In another aspect, the invention provides panels of the CVHGs of the invention. A panel of CVHGs comprises two or more CVHGs. A panel may also comprise 2-5, 5-15, 15-35, 35-50, or more than 50 CVHGs. In a preferred embodiment, these panels of CVHGs are selected such that the CVHGs within any one panel share certain features. For example, the CVHGs of a first panel may all relate to myelination in a CVH sample. Alternatively, CVHGs of a second panel may each exhibit differential regulation as compared to a first panel. Similarly, different panels of CVHGs may be composed of CVHGs representing different stages of CVH. Panels of the CVHGs of the invention may be made by independently selecting CVHGs from Tables 3-8, and may further be provided on biochips, as discussed below.

Screening Methods

[0176] The invention also provides methods (also referred to herein as “screening assays”) for identifying modulators, i.e., candidate or test compounds or agents comprising thera-

peutic moieties (e.g., peptides, peptidomimetics, peptoids, polynucleotides, small molecules or other drugs) which (a) bind to a CVHPP, or (b) have a modulatory (e.g., stimulatory or inhibitory) effect on the activity of a CVHPP or, more specifically, (c) have a modulatory effect on the interactions of the CVHPP with one or more of its natural substrates (e.g., peptide, protein, hormone, co-factor, or polynucleotide), or (d) have a modulatory effect on the expression of the CVHPPs. Such assays typically comprise a reaction between the CVHPP and one or more assay components. The other components may be either the test compound itself, or a combination of the test compound and a binding partner of the CVHPP.

[0177] To screen for compounds which interfere with binding of two proteins e.g., a CVHPP and its binding partner, a Scintillation Proximity Assay can be used. In this assay, the CVHPP is labeled with an isotope such as ^{125}I . The binding partner is labeled with a scintillant, which emits light when proximal to radioactive decay (i.e., when the CVHPP is bound to its binding partner). A reduction in light emission will indicate that a compound has interfered with the binding of the two proteins.

[0178] Alternatively a Fluorescence Energy Transfer (FRET) assay could be used. In a FRET assay of the invention, a fluorescence energy donor is comprised on one protein (e.g., a CVHPP) and a fluorescence energy acceptor is comprised on a second protein (e.g., a binding partner of the CVHPP). If the absorption spectrum of the acceptor molecule overlaps with the emission spectrum of the donor fluorophore, the fluorescent light emitted by the donor is absorbed by the acceptor. The donor molecule can be a fluorescent residue on the protein (e.g., intrinsic fluorescence such as a tryptophan or tyrosine residue), or a fluorophore which is covalently conjugated to the protein (e.g., fluorescein isothiocyanate, FITC). An appropriate donor molecule is then selected with the above acceptor/donor spectral requirements in mind.

[0179] Thus, in this example, a CVHPP is labeled with a fluorescent molecule (i.e., a donor fluorophore) and its binding partner is labeled with a quenching molecule (i.e., an acceptor). When the CVHPP and its binding partner are bound, fluorescence emission will be quenched or reduced relative the CVHPP alone. Similarly, a compound which can dissociate the interaction of the CVHPP-partner complex, will result in an increase in fluorescence emission, which indicates the compound has interfered with the binding of the CVHPP to its binding partner.

[0180] Another assay to detect binding or dissociation of two proteins is fluorescence polarization or anisotropy. In this assay, the investigated protein (e.g., a CVHPP) is labeled with a fluorophore with an appropriate fluorescence lifetime. The protein sample is then excited with vertically polarized light. The value of anisotropy is then calculated by determining the intensity of the horizontally and vertically polarized emission light. Next, the labeled protein (CVHPP) is mixed with a CVHPP binding partner and the anisotropy measured again. Because fluorescence anisotropy intensity is related to the rotational freedom of the labeled protein, the more rapidly a protein rotates in solution, the smaller the anisotropy value. Thus, if the labeled CVHPP is part of a complex (e.g., CVHPP-partner), the CVHPP rotates more slowly in solution (relative to free, unbound CVHPP) and the anisotropy intensity increases. Subsequently, a compound which can dissociate the interaction of the CVHPP-partner complex, will result

in a decrease in anisotropy (i.e., the labeled CVHPP rotates more rapidly), which indicates the compound has interfered with the binding of CVHPP to its binding partner.

[0181] A more traditional assay would involve labeling the CVHPP binding partner with an isotope such as ^{125}I , incubating with the CVHPP, then immunoprecipitating of the CVHPP. Compounds that increase the free CVHPP will decrease the precipitated counts. To avoid using radioactivity, the CVHPP binding partner could be labeled with an enzyme-conjugated antibody instead.

[0182] Alternatively, the CVHPP binding partner could be immobilized on the surface of an assay plate and the CVHPP could be labeled with a radioactive tag. A rise in the number of counts would identify compounds that had interfered with binding of the CVHPP and its binding partner.

[0183] Evaluation of binding interactions may further be performed using Biacore technology, wherein the CVHPP or its binding partner is bound to a micro chip, either directly by chemical modification or tethered via antibody-epitope association (e.g., antibody to the CVHPP), antibody directed to an epitope tag (e.g., His tagged) or fusion protein (e.g., GST). A second protein or proteins is/are then applied via flow over the "chip" and the change in signal is detected. Finally, test compounds are applied via flow over the "chip" and the change in signal is detected.

[0184] Once a series of potential compounds has been identified for a combination of CVHPP, CVHPP binding partner and ALS, a bioassay can be used to select the most promising candidates. For example, a cellular assay that measures cell proliferation in presence of the CVHPP and the CVHPP binding partner was described above. This assay could be modified to test the effectiveness of small molecules that interfere with binding of a CVHPP and its binding partner in enhancing cellular proliferation. An increase in cell proliferation would correlate with a compound's potency.

[0185] The test compounds of the present invention are generally either small molecules or biomolecules. Small molecules include, but are not limited to, inorganic molecules and small organic molecules. Biomolecules include, but are not limited to, naturally-occurring and synthetic compounds that have a bioactivity in mammals, such as lipids, steroids, polypeptides, polysaccharides, and polynucleotides. In one preferred embodiment, the test compound is a small molecule. In another preferred embodiment, the test compound is a biomolecule. One skilled in the art will appreciate that the nature of the test compound may vary depending on the nature of the CVHPP. For example, if the CVHPP is an orphan receptor having an unknown ligand, the test compound may be any of a number of biomolecules which may act as cognate ligand, including but not limited to, cytokines, lipid-derived mediators, small biogenic amines, hormones, neuropeptides, or proteases.

[0186] The test compounds of the present invention may be obtained from any available source, including systematic libraries of natural and/or synthetic compounds. Test compounds may also be obtained by any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; peptoid libraries (libraries of molecules having the functionalities of peptides, but with a novel, non-peptide backbone which are resistant to enzymatic degradation but which nevertheless remain bioactive); spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic

library methods using affinity chromatography selection. The biological library and peptoid library approaches are limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds. As used herein, the term "binding partner" refers to a molecule which serves as either a substrate for a CVHPP, or alternatively, as a ligand having binding affinity to the CVHPP.

Screening for Inhibitors of CVHPP

[0187] The invention provides methods of screening test compounds for inhibitors of CVHPP. The method of screening comprises obtaining samples from subjects diagnosed with or suspected of having CVH, contacting each separate aliquot of the samples with one of a plurality of test compounds, and comparing expression of one or more CVHGs in each of the aliquots to determine whether any of the test compounds provides a substantially altered level of expression or activity of an CVHG relative to samples with other test compounds or relative to an untreated sample or control sample. In addition, methods of screening may be devised by combining a test compound with a protein and thereby determining the effect of the test compound on the protein.

[0188] In addition, the invention is further directed to a method of screening for test compounds capable of modulating with the binding of a CVHPP and a binding partner, by combining the test compound, CVHPP, and binding partner together and determining whether binding of the binding partner and CVHPP occurs. The test compound may be either small molecules or a bioactive agent. As discussed below, test compounds may be provided from a variety of libraries well known in the art.

[0189] Modulators of CVHG expression, activity or binding ability are useful as therapeutic compositions of the invention. Such modulators (e.g., antagonists or agonists) may be formulated as pharmaceutical compositions, as described herein below. Such modulators may also be used in the methods of the invention, for example, to diagnose, treat, or prognose CVH.

High-Throughput Screening Assays

[0190] The invention provides methods of conducting high-throughput screening for test compounds capable of inhibiting activity or expression of a CVHPP of the present invention. In one embodiment, the method of high-throughput screening involves combining test compounds and the CVHPP and detecting the effect of the test compound on the CVHPP.

[0191] A variety of high-throughput functional assays well-known in the art may be used in combination to screen and/or study the reactivity of different types of activating test compounds. Since the coupling system is often difficult to predict, a number of assays may need to be configured to detect a wide range of coupling mechanisms. A variety of fluorescence-based techniques are well-known in the art and are capable of high-throughput and ultra high throughput screening for activity, including but not limited to BRET® or FRET® (both by Packard Instrument Co., Meriden, Conn.). The ability to screen a large volume and a variety of test compounds with great sensitivity permits analysis of the therapeutic targets of the invention to further provide potential inhibitors of CVH. For example, where the CVHG encodes an orphan receptor with an unidentified ligand, high-

throughput assays may be utilized to identify the ligand, and to further identify test compounds which prevent binding of the receptor to the ligand. The BIACORE® system may also be manipulated to detect binding of test compounds with individual components of the therapeutic target, to detect binding to either the encoded protein or to the ligand.

[0192] By combining test compounds with CVHPPs of the invention and determining the binding activity between them, diagnostic analysis can be performed to elucidate the coupling systems. Generic assays using cytosensor microphysiometer may also be used to measure metabolic activation, while changes in calcium mobilization can be detected by using the fluorescence-based techniques such as FLIPR® (Molecular Devices Corp, Sunnyvale, Calif.). In addition, the presence of apoptotic cells may be determined by TUNEL assay, which utilizes flow cytometry to detect free 3-OH termini resulting from cleavage of genomic DNA during apoptosis. As mentioned above, a variety of functional assays well-known in the art may be used in combination to screen and/or study the reactivity of different types of activating test compounds. Preferably, the high-throughput screening assay of the present invention utilizes label-free plasmon resonance technology as provided by BIACORE® systems (Biacore International AB, Uppsala, Sweden). Plasmon free resonance occurs when surface plasmon waves are excited at a metal/liquid interface. By reflecting directed light from the surface as a result of contact with a sample, the surface plasmon resonance causes a change in the refractive index at the surface layer. The refractive index change for a given change of mass concentration at the surface layer is similar for many bioactive agents (including proteins, peptides, lipids and polynucleotides), and since the BIACORE® sensor surface can be functionalized to bind a variety of these bioactive agents, detection of a wide selection of test compounds can thus be accomplished.

[0193] Therefore, the invention provides for high-throughput screening of test compounds for the ability to inhibit activity of a protein encoded by the CVHGs listed in Table 4, by combining the test compounds and the protein in high-throughput assays such as BIACORE®, or in fluorescence-based assays such as BRET®. In addition, high-throughput assays may be utilized to identify specific factors which bind to the encoded proteins, or alternatively, to identify test compounds which prevent binding of the receptor to the binding partner. In the case of orphan receptors, the binding partner may be the natural ligand for the receptor. Moreover, the high-throughput screening assays may be modified to determine whether test compounds can bind to either the encoded protein or to the binding partner (e.g., substrate or ligand) which binds to the protein.

Predictive Medicine

[0194] The present invention pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenetics and monitoring clinical trials are used for prognostic (predictive) purpose to thereby treat an individual prophylactically. Accordingly, one aspect of the present invention relates to diagnostic assays for determining CVHG expression and/or activity, in the context of a biological sample (e.g., blood, urine, feces, serum, cells, tissue) to thereby determine whether an individual is at risk for developing CVH associated with altered CVHG expression or activity. The invention also provides for prognostic (or pre-

dictive) assays for determining whether an individual is at risk of developing CVH associated with aberrant CVHG expression or activity.

[0195] For example, the number of copies of an CVHG can be assayed in a biological sample. Such assays can be used for prognostic or predictive purposes to thereby prophylactically treat an individual prior to the onset of CVH associated with aberrant CVHG protein, polynucleotide expression or activity.

[0196] Another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of CVHGs in clinical trials.

Diagnostic Assays

[0197] An exemplary method for detecting the presence or absence of a CVHPP or CVHPN in a biological sample involves contacting a biological sample with a compound or an agent capable of detecting the CVHPP or CVHPN (e.g., mRNA, genomic DNA). A preferred agent for detecting mRNA or genomic DNA corresponding to an CVHG or CVHPP of the invention is a labeled polynucleotide probe capable of hybridizing to a mRNA or genomic DNA of the invention. In a most preferred embodiment, the polynucleotides to be screened are arranged on a GeneChip®. Suitable probes for use in the diagnostic assays of the invention are described herein. A preferred agent for detecting a CVHPP of the invention is an antibody which specifically recognizes the CVHPP.

[0198] The diagnostic assays may also be used to quantify the amount of expression or activity of a CVHG in a biological sample. Such quantification is useful, for example, to determine the progression or severity of CVH and CVH-related disorders. Such quantification is also useful, for example, to determine the severity of CVH following treatment.

Determining Severity of CVH and CVH-Related Diseases

[0199] In the field of diagnostic assays, the invention also provides methods for determining the severity of CVH by isolating a sample from a subject (e.g., a colon biopsy), and detecting the presence, quantity and/or activity of one or more CVHG products in the sample relative to a second sample from a normal sample or control sample. In one embodiment, the expression levels of CVHGs in the two samples are compared, and a modulation in one or more CVHGs in the test sample indicates CVH. In other embodiments the modulation of 2, 3, 4 or more CVHGs indicates a severe case of CVH.

[0200] In another aspect, the invention provides CVHG products whose quantity or activity is correlated with the severity of CVH. The subsequent level of expression may further be compared to different expression profiles of various stages of the disease to confirm whether the subject has a matching profile. In yet another aspect, the invention provides CVHGs whose quantity or activity is correlated with a risk in a subject for developing CVH.

[0201] A preferred agent for detecting a CVHPP is an antibody capable of binding to the CVHPP, preferably an antibody with a detectable label. Antibodies can be polyclonal or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')₂) can be used. The term "labeled," with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the

probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect CVHG mRNA, protein or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of CVHG mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of CVHPP include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence. In vitro techniques for detection of CVHG genomic DNA include Southern hybridizations. Furthermore, in vivo techniques for detection of CVHPP include introducing into a subject a labeled anti-CVHPP antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.

[0202] In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a tissue or serum sample isolated by conventional means from a subject, e.g., a biopsy or blood draw.

Prognostic Assays

[0203] The diagnostic method described herein can be utilized to identify subjects having or at risk of developing CVH associated with aberrant CVHG expression or activity.

[0204] The assays described herein, such as the preceding or following assays, can be utilized to identify a subject having CVH associated with an aberrant level of CVHG activity or expression. Alternatively, the prognostic assays can be utilized to identify a subject at risk for developing CVH associated with aberrant levels of CVHG protein activity or polynucleotide expression. Thus, the present invention provides a method for identifying CVH associated with aberrant CVHG expression or activity in which a test sample is obtained from a subject and CVHPP or CVHPN (e.g., mRNA or genomic DNA) is detected, wherein the presence of CVHPP or CVHPN is diagnostic or prognostic for a subject having or at risk of developing CVH with aberrant CVHG expression or activity.

[0205] Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, polynucleotide, small molecule, or other drug candidate) to treat or prevent CVH associated with aberrant CVHG expression or activity, such as, for example, a cytokine. For example, such methods can be used to determine whether a subject can be effectively treated with an agent to inhibit CVH. Thus, the present invention provides methods for determining whether a subject can be effectively treated with an agent for CVH associated with aberrant CVHG expression or activity.

[0206] Prognostic assays can be devised to determine whether a subject undergoing treatment for CVH has a poor outlook for disease progression. In a preferred embodiment,

prognosis can be determined shortly after diagnosis, i.e., within a few days. By establishing expression profiles of different stages of CVHGs, from onset to later stages, an expression pattern may emerge to correlate a particular expression profile to increased likelihood of a poor prognosis. The prognosis may then be used to devise a more aggressive treatment program and enhance the likelihood of success.

[0207] The methods of the invention can also be used to detect genetic alterations in a CVHG, thereby determining if a subject with the altered gene is at risk for damage characterized by aberrant regulation in CVHG expression or activity. In preferred embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic alteration characterized by at least one alteration affecting the integrity of a CVHG, or the aberrant expression of the CVHG. For example, such genetic alterations can be detected by ascertaining the existence of at least one of the following: 1) deletion of one or more nucleotides from a CVHG; 2) addition of one or more nucleotides to a CVHG; 3) substitution of one or more nucleotides of a CVHG; 4) a chromosomal rearrangement of a CVHG; 5) alteration in the level of a messenger RNA transcript of a CVHG; 6) aberrant modification of a CVHG, such as of the methylation pattern of the genomic DNA; 7) the presence of a non-wild type splicing pattern of a messenger RNA transcript of a CVHG; 8) non-wild type level of a CVHPP; 9) allelic loss of a CVHG; and 10) inappropriate post-translational modification of a CVHPP. As described herein, there are a large number of assays known in the art, which can be used for detecting alterations in a CVHG or a CVHG product. A preferred biological sample is a blood sample isolated by conventional means from a subject.

[0208] In certain embodiments, detection of the alteration involves the use of a probe/primer in a polymerase chain reaction (PCR), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR), the latter of which can be particularly useful for detecting point mutations in the CVHG. This method can include the steps of collecting a sample of cells from a subject, isolating a polynucleotide sample (e.g., genomic, mRNA or both) from the cells of the sample, contacting the polynucleotide sample with one or more primers which specifically hybridize to a CVHG under conditions such that hybridization and amplification of the CVHG (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is understood that PCR and/or LCR may be desirable to be used as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.

[0209] Alternative amplification methods include: self-sustained sequence replication, transcriptional amplification system, Q-Beta Replicase, or any other polynucleotide amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of polynucleotide molecules if such molecules are present in very low numbers.

[0210] In an alternative embodiment, mutations in a CVHG from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and com-

pared. Differences in fragment length sizes between sample and control DNA indicate mutations in the sample DNA. Moreover, sequence specific ribozymes (see, for example, U.S. Pat. No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.

[0211] In other embodiments, genetic mutations in a CVHG can be identified by hybridizing sample and control polynucleotides, e.g., DNA or RNA, to high density arrays containing hundreds or thousands of oligonucleotide probes. For example, genetic mutations in a CVHG can be identified in two dimensional arrays containing light generated DNA probes. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This step is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.

[0212] In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the CVHG and detect mutations by comparing the sequence of the sample CVHG with the corresponding wild-type (control) sequence. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays, including sequencing by mass spectrometry.

[0213] Other methods for detecting mutations in a CVHG include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes. In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes by hybridizing (labeled) RNA or DNA containing the wild-type CVHG sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent which cleaves single-stranded regions of the duplex, which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S1 nuclease to enzymatically digest the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. In a preferred embodiment, the control DNA or RNA can be labeled for detection.

[0214] In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes) in defined systems for detecting and mapping point mutations in CVHG cDNAs obtained from samples of cells. For example, the mutY enzyme of *E. coli* cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches. According to an exemplary embodiment, a probe based on an CVHG sequence, e.g., a wild-type CVHG sequence, is hybridized to cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme,

and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, for example, U.S. Pat. No. 5,459,039.

[0215] In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in CVHGs. For example, single-strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type polynucleotides. Single-stranded DNA fragments of sample and control CVHG polynucleotides will be denatured and allowed to renature. The secondary structure of single-stranded polynucleotides varies according to sequence. The resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA) in which the secondary structure is more sensitive to a change in sequence. In a preferred embodiment, the subject method utilizes heteroduplex analysis to separate double-stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen et al. *Trends Genet.* 7:5, 1991).

[0216] In yet another embodiment the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE). When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example, by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA (Rosenbaum and Reissner *Biophys Chem* 265:12753, 1987).

[0217] Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, and selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions which permit hybridization only if a perfect match is found (Saiki et al. *Proc. Natl. Acad. Sci. USA* 86:6230, 1989). Such allele specific oligonucleotides are hybridized to PCR amplified target or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.

[0218] Alternatively, allele specific amplification technology which depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization) or at the extreme 3' end of one primer where, under appropriate conditions, mismatch can prevent or reduce polymerase extension. In addition, it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection. It is anticipated that, in certain embodiments, amplification may also be performed using Taq ligase for amplification. In such cases, ligation will occur only if there is a perfect match at the 3' end of the 5' sequence, thus making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.

[0219] The methods described herein may be performed, for example, by utilizing prepackaged diagnostic kits comprising at least one probe polynucleotide or antibody reagent

described herein, which may be conveniently used, e.g., in clinical settings to diagnose subjects exhibiting symptoms or family history of a disease or illness involving a CVHG.

[0220] Furthermore, any cell type or tissue in which a CVHG is expressed may be utilized in the prognostic or diagnostic assays described herein.

Monitoring Effects During Clinical Trials

[0221] Monitoring the influence of agents (e.g., drugs, small molecules, proteins, nucleotides) on the expression or activity of a CVHPP can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay, as described herein to decrease CVHG expression or activity, can be monitored in clinical trials of subjects exhibiting increased CVHG expression or activity. In such clinical trials, the expression or activity of an CVHG can be used as a "read-out" of the phenotype of a particular tissue.

[0222] For example, and not by way of limitation, CVHGs that are modulated in tissues by treatment with an agent can be identified. Thus, to study the effect of agents on the CVHPP in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of an CVHG. The levels of gene expression or a gene expression pattern can be quantified by Northern blot analysis, RT-PCR or GeneChip® as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of CVHPP. In this way, the gene expression pattern can serve as a read-out, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before treatment and at various points during treatment of the individual with the agent.

[0223] In a preferred embodiment, the present invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, polynucleotide, small molecule, or other drug candidate identified by the screening assays described herein) including the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of a CVHG protein or mRNA in the pre-administration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the CVHG protein or mRNA in the post-administration samples; (v) comparing the level of expression or activity of the CVHG protein or mRNA in the pre-administration sample with the CVHG protein or mRNA the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. According to such an embodiment, CVHG expression or activity may be used as an indicator of the effectiveness of an agent, even in the absence of an observable phenotypic response.

Methods of Treatment

[0224] The present invention provides for both prophylactic and therapeutic methods of treating a subject at risk for, susceptible to or diagnosed with CVH. With regard to both prophylactic and therapeutic methods of treatment, such treatments may be specifically tailored or modified, based on knowledge obtained from the field of pharmacogenomics. "Pharmacogenomics," as used herein, includes the application of genomics technologies such as gene sequencing, sta-

tistical genetics, and gene expression analysis to drugs in clinical development and on the market. More specifically, the term refers to the study of how a subject's genes determine his or her response to a drug (e.g., a subject's "drug response phenotype" or "drug response genotype"). Thus, another aspect of the invention provides methods for tailoring an individual's prophylactic or therapeutic treatment with either the CVHPP molecules of the present invention or CVHPP modulators (e.g., agonists or antagonists) according to that individual's drug response. Pharmacogenomics allows a clinician or physician to target prophylactic or therapeutic treatments to subjects who will most benefit from the treatment and to avoid treatment of subjects who will experience toxic drug-related side effects.

Prophylactic Methods

[0225] In one aspect, the invention provides a method for preventing in a subject CVH associated with aberrant CVHG expression or activity, by administering to the subject an CVHG product or an agent which modulates CVHG protein expression or activity.

[0226] Subjects at risk for CVH which is caused or contributed to by aberrant CVHG expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein.

[0227] Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the differential CVHG protein expression, such that CVH is prevented or, alternatively, delayed in its progression. Depending on the type of CVHG aberrancy (e.g., typically a modulation outside the normal standard deviation), for example, a CVHG product, CVHG agonist or antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein.

Therapeutic Methods

[0228] Another aspect of the invention pertains to methods of modulating CVHG protein expression or activity for therapeutic purposes. Accordingly, in an exemplary embodiment, the modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of a CVHG product activity associated with the cell. An agent that modulates CVHG product activity can be an agent as described herein, such as a polynucleotide (e.g., an antisense molecule) or a polypeptide (e.g., a dominant-negative mutant of a CVHPP), a naturally-occurring target molecule of a CVHPP (e.g., a CVHPP substrate), an anti-CVHPP antibody, a CVHG modulator (e.g., agonist or antagonist), a peptidomimetic of a CVHG protein agonist or antagonist, or other small molecules.

[0229] The invention further provides methods of modulating a level of expression of a CVHG of the invention, comprising administration to a subject having CVH, a variety of compositions which correspond to the CVHGs of Tables 3-8, including proteins or antisense oligonucleotides. The protein may be provided by further providing a vector comprising a polynucleotide encoding the protein to the cells. Alternatively, the expression levels of the CVHGs of the invention may be modulated by providing an antibody, a plurality of antibodies or an antibody conjugated to a therapeutic moiety. Treatment with the antibody may further be localized to the tissue comprising CVH. In another aspect, the invention provides methods for localizing a therapeutic moiety to CVH

tissue or cells comprising exposing the tissue or cells to an antibody which is specific to a protein encoded by the CVHGs of the invention. This method may therefore provide a means to inhibit expression of a specific gene corresponding to a CVHG listed in Tables 3-8.

Determining Efficacy of a Test Compound or Therapy

[0230] The invention also provides methods of assessing the efficacy of a test compound or therapy for inhibiting CVH in a subject. These methods involve isolating samples from a subject suffering from CVH, who is undergoing treatment or therapy, and detecting the presence, quantity, and/or activity of one or more CVHGs of the invention in the first sample relative to a second sample. Where the efficacy of a test compound is determined, the first and second samples are preferably sub-portions of a single sample taken from the subject, wherein the first portion is exposed to the test compound and the second portion is not. In one aspect of this embodiment, the CVHG is expressed at a substantially decreased level in the first sample, relative to the second. Most preferably, the level of expression in the first sample approximates (i.e., is less than the standard deviation for normal samples) the level of expression in a third control sample, taken from a control sample of normal tissue. This result suggests that the test compound inhibits the expression of the CVHG in the sample. In another aspect of this embodiment, the CVHG is expressed at a substantially increased level in the first sample, relative to the second. Most preferably, the level of expression in the first sample approximates (i.e., is less than the standard deviation for normal samples) the level of expression in a third control sample, taken from a control sample of normal tissue. This result suggests that the test compound augments the expression of the CVHG in the sample.

[0231] Where the efficacy of a therapy is being assessed, the first sample obtained from the subject is preferably obtained prior to provision of at least a portion of the therapy, whereas the second sample is obtained following provision of the portion of the therapy. The levels of CVHG product in the samples are compared, preferably against a third control sample as well, and correlated with the presence, or risk of presence, of CVH. Most preferably, the level of CVHG product in the second sample approximates the level of expression of a third control sample. In the present invention, a substantially decreased level of expression of a CVHG indicates that the therapy is efficacious for treating CVH.

Pharmacogenomics

[0232] The CVHG protein and polynucleotide molecules of the present invention, as well as agents, inhibitors or modulators which have a stimulatory or inhibitory effect on CVHG expression or activity as identified by a screening assay described herein, can be administered to individuals to treat (prophylactically or therapeutically) CVH associated with aberrant CVHG activity.

[0233] In conjunction with such treatment, pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, a physician or clinician may consider applying knowl-

edge obtained in relevant pharmacogenomics studies in determining whether to administer a CVHG product (polynucleotide or polypeptide) or CVHG modulator as well as tailoring the dosage and/or therapeutic regimen of treatment with a CVHG product or CVHG modulator.

[0234] Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare genetic defects or as naturally-occurring polymorphisms. For example, glucose-6-phosphate dehydrogenase deficiency (G6PD) is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.

[0235] One pharmacogenomics approach to identifying genes that predict drug response, known as “a genome-wide association,” relies primarily on a high-resolution map of the human genome consisting of already known gene-related sites (e.g., a “bi-allelic” gene marker map which consists of 60,000-100,000 polymorphic or variable sites on the human genome, each of which has two variants). Such a high-resolution genetic map can be compared to a map of the genome of each of a statistically substantial number of subjects taking part in a Phase II/III drug trial to identify genes associated with a particular observed drug response or side effect. Alternatively, such a high resolution map can be generated from a combination of some ten-million known single nucleotide polymorphisms (SNPs) in the human genome. As used herein, an “SNP” is a common alteration that occurs in a single nucleotide base in a stretch of DNA. For example, an SNP may occur once per every 1,000 bases of DNA. An SNP may be involved in a disease process. However, the vast majority of SNPs may not be disease associated. Given a genetic map based on the occurrence of such SNPs, individuals can be grouped into genetic categories depending on a particular pattern of SNPs in their individual genome. In such a manner, treatment regimens can be tailored to groups of genetically similar individuals, taking into account traits that may be common among such genetically similar individuals. Thus, mapping of the CVHGs of the invention to SNP maps of CVH patients may allow easier identification of these genes according to the genetic methods described herein.

[0236] Alternatively, a method termed the “candidate gene approach,” can be utilized to identify genes that predict drug response. According to this method, if a gene that encodes a drug target is known (e.g., a CVHG of the present invention), all common variants of that gene can be fairly easily identified in the population and it can be determined if having one version of the gene versus another is associated with a particular drug response.

[0237] As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some subjects do not obtain the expected drug effects or show exaggerated drug response and serious toxic-

ity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer and poor metabolizer. The prevalence of poor metabolizer phenotypes is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in poor metabolizers, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, poor metabolizers show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. The other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.

[0238] Alternatively, a method termed the “gene expression profiling” can be utilized to identify genes that predict drug response. For example, the gene expression of an animal dosed with a drug (e.g., CVHG expression in response to a CVHG modulator of the present invention) can give an indication whether gene pathways related to toxicity have been turned on.

[0239] Information generated from more than one of the above pharmacogenomics approaches can be used to determine appropriate dosage and treatment regimens for prophylactic or therapeutic treatment an individual. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a CVHG product or CVHG modulator, such as a modulator identified by one of the exemplary screening assays described herein.

Pharmaceutical Compositions

[0240] The invention is further directed to pharmaceutical compositions comprising the test compound, or bioactive agent, or an CVHG modulator (i.e., agonist or antagonist), which may further include a CVHG product, and can be formulated as described herein. Alternatively, these compositions may include an antibody which specifically binds to a CVHG protein of the invention and/or an antisense polynucleotide molecule which is complementary to a CVHG polynucleotide of the invention and can be formulated as described herein.

[0241] One or more of the CVHGs of the invention, fragments of CVHGs, CVHG products, fragments of CVHG products, CVHG modulators, or anti-CVHPP antibodies of the invention can be incorporated into pharmaceutical compositions suitable for administration.

[0242] As used herein the language “pharmaceutically acceptable carrier” is intended to include any and all solvents, solubilizers, fillers, stabilizers, binders, absorbents, bases, buffering agents, lubricants, controlled release vehicles, diluents, emulsifying agents, humectants, lubricants, dispersion media, coatings, antibacterial or antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well-known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the

compositions is contemplated. Supplementary agents can also be incorporated into the compositions.

[0243] The invention includes methods for preparing pharmaceutical compositions for modulating the expression or activity of a polypeptide or polynucleotide corresponding to a CVHG of the invention. Such methods comprise formulating a pharmaceutically acceptable carrier with an agent which modulates expression or activity of a CVHG. Such compositions can further include additional active agents. Thus, the invention further includes methods for preparing a pharmaceutical composition by formulating a pharmaceutically acceptable carrier with an agent which modulates expression or activity of a CVHG and one or more additional bioactive agents.

[0244] A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), intraperitoneal, transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine; propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfate; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[0245] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the injectable composition should be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

[0246] Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a fragment of a CVHPP or an anti-CVHPP antibody) in the required amount

in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0247] Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose; a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Stertes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

[0248] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a pressurized container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.

[0249] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the bioactive compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

[0250] The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

[0251] In one embodiment, the therapeutic moieties, which may contain a bioactive compound, are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from e.g. Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens)

can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art.

[0252] It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form, as used herein, includes physically discrete units suited as unitary dosages for the subject to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

[0253] Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compounds which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

[0254] The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that includes the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

[0255] The CVHGs of the invention can be inserted into gene delivery vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous administration, intraportal administration, intrabiliary administration, intra-arterial administration, direct injection into the liver parenchyma, by intramuscular injection, by inhalation, by perfusion, or by stereotactic injection. The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

[0256] The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

Kits

[0257] The invention also encompasses kits for detecting the presence of a CVHG product in a biological sample, the kit comprising reagents for assessing expression of the CVHGs of the invention. Preferably, the reagents may be an antibody or fragment thereof, wherein the antibody or fragment thereof specifically binds with a protein corresponding to a CVHG from Table 4. For example, antibodies of interest may be prepared by methods known in the art. Optionally, the kits may comprise a polynucleotide probe wherein the probe specifically binds with a transcribed polynucleotide corresponding to a CVHG selected from the group consisting of the CVHGs listed in Tables 3-8. The kits may also include an array of CVHGs arranged on a biochip, such as, for example, a GeneChip®. The kit may contain means for determining the amount of the CVHG protein or mRNA in the sample; and means for comparing the amount of the CVHG protein or mRNA in the sample with a control or standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect CVHG protein or polynucleotide

[0258] The invention further provides kits for assessing the suitability of each of a plurality of compounds for inhibiting CVH in a subject. Such kits include a plurality of compounds to be tested, and a reagent (i.e., antibody specific to corresponding proteins, or a probe or primer specific to corresponding polynucleotides) for assessing expression of a CVHG listed in Tables 3-8.

Arrays and Biochips

[0259] The invention also includes an array comprising a panel of CVHGs of the present invention. The array can be used to assay expression of one or more genes in the array.

[0260] It will be appreciated by one skilled in the art that the panels of CVHGs of the invention may conveniently be provided on solid supports, such as a biochip. For example, polynucleotides may be coupled to an array (e.g., a biochip using GeneChip® for hybridization analysis), to a resin (e.g., a resin which can be packed into a column for column chromatography), or a matrix (e.g., a nitrocellulose matrix for Northern blot analysis). The immobilization of molecules complementary to the CVHG(s), either covalently or noncovalently, permits a discrete analysis of the presence or activity of each CVHG in a sample. In an array, for example, polynucleotides complementary to each member of a panel of CVHGs may individually be attached to different, known locations on the array. The array may be hybridized with, for example, polynucleotides extracted from a blood or colon sample from a subject. The hybridization of polynucleotides from the sample with the array at any location on the array can be detected, and thus the presence or quantity of the CVHG and CVHG transcripts in the sample can be ascertained. In a preferred embodiment, an array based on a biochip is employed. Similarly, Western analyses may be performed on immobilized antibodies specific for CVHPPs hybridized to a protein sample from a subject.

[0261] It will also be apparent to one skilled in the art that the entire CVHG product (protein or polynucleotide) molecule need not be conjugated to the biochip support; a portion

of the CVHG product or sufficient length for detection purposes (i.e., for hybridization), for example a portion of the CVHG product which is 7, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 100 or more nucleotides or amino acids in length may be sufficient for detection purposes.

[0262] In one embodiment, the array can be used to assay gene expression in a tissue to ascertain tissue specificity of genes in the array. In this manner, a large number of genes can be simultaneously assayed for expression. This allows an expression profile to be developed showing a battery of genes specifically expressed in one or more tissues at a given point in time. In one embodiment the invention provides a kit comprising a brochure which comprises at least 5, more preferably 10, more preferably or more CVHGs, and the same CVHGs in computer readable form.

[0263] In addition to such qualitative determination, the invention allows the quantitation of gene expression in the biochip. Thus, not only tissue specificity, but also the level of expression of a battery of CVHGs in the tissue is ascertainable. Thus, CVHGs can be grouped on the basis of their tissue expression per se and level of expression in that tissue. As used herein, a "normal level of expression" refers to the level of expression of a gene provided in a control sample, typically the control is taken from either a non-diseased animal or from a subject who has not suffered from CVH. The determination of normal levels of expression is useful, for example, in ascertaining the relationship of gene expression between or among tissues. Thus, one tissue or cell type can be perturbed and the effect on gene expression in a second tissue or cell type can be determined. In this context, the effect of one cell type on another cell type in response to a biological stimulus can be determined. Such a determination is useful, for example, to know the effect of cell-cell interaction at the level of gene expression. If an agent is administered therapeutically to treat one cell type but has an undesirable effect on another cell type, the invention provides an assay to determine the molecular basis of the undesirable effect and thus provides the opportunity to co-administer a counteracting agent or otherwise treat the undesired effect. Similarly, even within a single cell type, undesirable biological effects can be determined at the molecular level. Thus, the effects of an agent on expression of other than the target gene can be ascertained and counteracted.

[0264] In another embodiment, the arrays can be used to monitor the time course of expression of one or more genes in the array. This can occur in various biological contexts, as disclosed herein, for example development and differentiation, disease progression, in vitro processes, such as cellular transformation and activation.

[0265] The array is also useful for ascertaining the effect of the expression of a gene on the expression of other genes in the same cell or in different cells. This provides, for example, for a selection of alternate molecular targets for therapeutic intervention if the ultimate or downstream target cannot be regulated.

[0266] Importantly, the invention provides arrays useful for ascertaining differential expression patterns of one or more genes identified in diseased tissue versus non-diseased tissue. This provides a battery of genes that serve as a molecular target for diagnosis or therapeutic intervention. In particular, biochips can be made comprising arrays not only of the CVHGs listed in Tables 3-8, but of CVHGs specific to subjects suffering from specific manifestations or stages of the disease.

[0267] In general, the probes are attached to the biochip in a wide variety of ways, as will be appreciated by those in the art. As described herein, the nucleic acids can either be synthesized first, with subsequent attachment to the biochip, or can be directly synthesized on the biochip.

[0268] The biochip comprises a suitable solid substrate. By "substrate" or "solid support" or other grammatical equivalents herein is meant any material that can be modified to contain discrete individual sites appropriate for the attachment or association of the nucleic acid probes and is amenable to at least one detection method. As will be appreciated by those in the art, the number of possible substrates are very large, and include, but are not limited to, glass and modified or functionalized glass, plastics (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, Teflon, etc.), polysaccharides, nylon or nitrocellulose, resins, silica or silica-based materials including silicon and modified silicon, carbon, metals, inorganic glasses, plastics, etc.

[0269] Generally the substrate is planar, although as will be appreciated by those in the art, other configurations of substrates may be used as well. For example, the probes may be placed on the inside surface of a tube, for flow-through sample analysis to minimize sample volume. Similarly, the substrate may be flexible, such as a flexible foam, including closed cell foams made of particular plastics.

[0270] In a preferred embodiment, the surface of the biochip and the probe may be derivatized with chemical functional groups for subsequent attachment of the two. Thus, for example, the biochip is derivatized with a chemical functional group including, but not limited to, amino groups, carboxy groups, oxo groups and thiol groups, with amino groups being particularly preferred. Using these functional groups, the probes can be attached using functional groups on the probes. For example, nucleic acids containing amino groups can be attached to surfaces comprising amino groups. Linkers, such as homo- or hetero-bifunctional linkers, may also be used.

[0271] In an embodiment, the oligonucleotides are synthesized as is known in the art, and then attached to the surface of the solid support. As will be appreciated by those skilled in the art, either the 5' or 3' terminus may be attached to the solid support, or attachment may be via an internal nucleoside.

[0272] In an additional embodiment, the immobilization to the solid support may be very strong, yet non-covalent. For example, biotinylated oligonucleotides can be made, which bind to surfaces covalently coated with streptavidin, resulting in attachment.

[0273] Alternatively, the oligonucleotides may be synthesized on the surface, as is known in the art. For example, photoactivation techniques utilizing photopolymerization compounds and techniques are used. In a preferred embodiment, the nucleic acids can be synthesized in situ, using well known photolithographic techniques.

[0274] Modifications to the above-described compositions and methods of the invention, according to standard techniques, will be readily apparent to one skilled in the art and are meant to be encompassed by the invention. This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application, as well as the Figures and Tables are incorporated herein by reference.

EXAMPLES

Example 1

Methods

(a) Visceral Sensitization Model

[0275] New born rats were sensitized by infusion of 0.2 mls of 0.5% acetic acid into the colon at P10, control animals received saline.

(b) CNI1493 Treatment:

[0276] At eight weeks of age, rats in four treatment groups: control+vehicle (n=3), control+cni-1493 (n=3), sensitized+vehicle (n=8), sensitized+cni-1493 (n=8) were tested after administration of drug (dissolved in 2.5% mannitol, injected i.p. at 5 mg/kg for four days) for sensitivity to colorectal distention (CRD). Vehicle injected animals received 2.5% mannitol in water.

(c) CRD Protocol for Measuring Colonic Sensitivity in Adult Rats

[0277] For electromyographic (EMG) measurements of visceromotor responses, under anesthesia (Nembutal, 50 mg/kg i.p.), two electrodes were implanted in the abdominal wall muscles and externalized behind the head. Rats were allowed a one week recovery time from this surgery. Under mild sedation (Brevital, 5 ml of 1% ip), a 7 cm flexible balloon constructed from a surgical glove finger attached to tygon tubing was inserted into the descending colon and rectum via the anus and held in place by taping the tubing to the tail. Rats were housed in small Lucite cubicles (20×8×8 cm) and were allowed to adapt for one hour. CRD was performed by rapidly inflating the balloon to constant pressure. Pressure was measured using a sphygmomanometer connected to a pressure transducer. Rats were given graded CRD (20, 40, 60, 80 mm Hg) applied for 20 seconds every 4 minutes.

[0278] The behavioral measurements consisted of visual observation of the abdominal withdrawal reflex (AWR) by blinded observers and the assignment of an AWR score:

- [0279]** 0, no response;
- [0280]** 1, brief head movement followed by immobility;
- [0281]** 2, contraction of abdominal muscles;
- [0282]** 3, lifting of abdomen;
- [0283]** 4, body arching and lifting of pelvic structures.

(d) Evaluation of the Colon for Inflammation/Damage

[0284] Descending colons were placed in 10% buffered formalin and portions were frozen for myeloperoxidase (MPO) assays. Haematoxylin & Eosin stained paraffin sections will be scored for inflammation by a pathologist.

(e) Tissue Isolation and RNA Preparation

[0285] Colons and S1 dorsal root ganglia were snap frozen in liquid nitrogen. Colon tissue RNA and S1 dorsal root ganglia RNA was prepared using RNAzol.

(f) Target Labeling and Gene Chip Array Analysis

[0286] An in vitro transcription reaction was performed using 500 ng cDNA which contained a T7 RNA polymerase promoter incorporated during RNA amplification. The cRNA or Target RNAs produced during this in vitro transcription reaction were labeled with biotin. Biotin-labeled Target

RNAs were fragmented to a mean size of 200 bases to facilitate their hybridization to probe sequences on the Gene Chip (Affymetrix) array. Each Target RNA sample was initially hybridized to a test array. This array contains a set of probes representing genes that are commonly expressed in the majority of cells (example Rat: actin, GAPDH, hexokinase, 5S rRNA, and B1/B2 repetitive elements). Test arrays confirmed the successful labeling of the target RNAs and prevented the use of degraded or non-representative target RNA samples. Success and consistency of RNA amplification between samples were also confirmed with these test arrays.

[0287] Hybridization of Gene Chip (Affymetrix) arrays was performed at 45° C. for 16 hours in 0.1 M MES pH6.6, 1 M sodium chloride, 0.02 M EDTA and 0.01% Tween 20. Four prokaryotic genes (bio B, bio C and bio D from the *E. coli* biotin synthesis pathway and the cre recombinase gene from P1 bacteriophage) were added to the hybridization cocktail as internal controls. These control RNAs were used to normalize expression levels between experiments. Because the control RNAs were added at varying copy number (Bio B, 1.5 pM; Bio C, 5 pM; Bio D, 25 pM and cre, 100 pM) they were also used in estimating relative abundance of RNA transcripts in the sample. Arrays were washed using both non-stringent (1 M NaCl, 25° C.) and stringent (1 M NaCl, 50° C.) conditions prior to staining with phycoerythrin streptavidin (10 ug/ml final). Gene Chip arrays were scanned using a Gene Array Scanner (Hewlett Packard) and analyzed using the Affymetric Gene Chip Analysis Suite 5.0 software.

[0288] Gene expression profiles were produced from Affymetrix rat genome 230A chips.

[0289] Single array analysis for each chip was performed by Affymetrix Microarray Suite (MAS) software to produce a detection call, present, absent or marginal and a signal intensity value for each gene that is a relative measure of abundance of the transcript. For comparison of signal intensity values between chips, all chips were scaled to an average intensity of 500. Genes called "Absent" across all chips and genes without a $|\text{Fold change}| \geq 2.0$ in at least one of the pairwise comparisons of chips from different treatment groups were excluded. The probe sets with absolute call "Absent" across all chips and $|\text{Fold change}| < 2.0$ in all of the possible pairwise comparisons were filtered out. These filters were applied as the first level filters to reduce the noise from the dataset. ANOVA was performed on the filtered dataset. Significant changes in gene expression were detected by analyzing signal intensity values by two-way ANOVA with 99% confidence limits. Genes were subjected to cluster analysis to identify genes associated with sensitization and treatment.

(g) Quantitative RT-PCR

[0290] Primer or primer/probe sets were designed using Primer Express software (Applied Biosystems, Foster City, Calif.) such that the amplicon spanned an intron/exon boundary where possible. Where ESTs were homologous to known genes, the sequence of the known gene was used. RT-PCR was performed using Applied Biosystems reagents and kits: Taqman Reverse Transcription Reagents N8080234 and Taqman PCR Core Reagents N8080228. PCR was performed on a GeneAmp 5700 Sequence Detection System (Applied Biosystems). Machine default PCR program was used: 2 min at 50° C., 10 min at 95° C., 45 cycles: 95° C. 15 sec, 60° C. 1 min. Fold change was calculated using delta Ct and/or relative standard curve procedures using GAPDH or b-actin as nor-

malizers for colon genes and PGP9.5 for DRG. Data is expressed as fold change relative to control, vehicle treated values.

Primer Probe Sequences (RAT):

[0291]

Desmin NM_022531
Forward primer (FP)
GTGGAGCGTGACAACTGATAG

Reverse primer (RP)
TGCGCTCTAGGTCAATTGCA

CEBP/delta NM_013154 Mar. 3, 2004 SYBR green
FP
CCGCCCCAATTGCTACAGT

RP
AGTCTGTGCGAAAAGTCTTTCTACAA

EST homologous to F-box proteins
FP
CCGTGTGCAAGTGTGTAGCAT

RP
GCCGCAGCCCGAAAG

PEP19
FP
GCTGGAGCAACCAATGGAAA

RP
TCTGTCTCTGGTGCATCCATGT

Probe
TCT TCT TGG ACC TTC TT CTG CCC ATC ATT

Insulin-Like Growth Factor Binding Protein 2 Colon 71
NM_013122

[0292]

FP 1001-1022
CAACCTCAAACAGTGCAAGATG

RP 1182-1163
TGGTTACTGACCCCTTTGG

Metalloproteinase ADAMTS-1
FP
AGGGACCGAAGTTACTTCCA

RP
CAGGTGTGGAGCCACATAA

Tubulin, beta 3
FP
GGGCCTTTGGACACCTATTCA

RP
GCCCTTTGGCCAGTTGT

PROBE
C ACC ACT CTG ACC GAA GAT AAA GTT GTC AGG

Argalb NM_053770 Feb. 19, 2004
FP
GAATCCCCACAGCCATTAGAAC

RP
GCGAGTTGTACAGACCTGCATT

-continued

Probe
ACA TGT CTG TGT CCT CAT CCG GCT TGT

Stathmin-like 2 (scgn10)
FP
TCGGAAGCTCCACGAACTCT

RP
CTCGCTCGTGCTCCCTCTT

(f) MPO Assay

[0293] Myeloperoxidase (MPO) assays were performed as described (Bhatia et al., Proc Natl Acad Sci USA 95:4760-4756, 1998). Frozen colon was homogenized in 20 mM phosphate buffer pH 7.4 and centrifuged at 10,000×g for 10 minutes at 4° C. Pellet was resuspended in 50 mM phosphate buffer, pH 6.0 containing 0.5% hexadecyltrimethylammonium bromide. Samples were subjected to one cycle of freeze thawing, were incubated at 60° C. for 2 hrs and centrifuged at 10,000×g for 5 min at 4° C. Change in absorbance at 655 nm was measured in reaction mix containing 1.6 mM TMB (Sigma) and 0.3 mM H₂O₂ on a Beckman DU-64 spectrophotometer. Activity was normalized to protein as measured in the extracts. Protein was measured by the BCA method (Pierce, Rockford, Ill.). Activity was expressed as the change in absorbance/min/mg protein.

Example 2

Chemical Treatment of Colon of P10 Rats Produces
CVH

[0294] Previous studies showed that either mechanical irritation or treatment with mustard oil of the colons of young rats between P7 and P12 produced chronic visceral hyperalgesia (ref). To determine whether treatment of the colon of young rats with acetic acid would produce visceral hyperalgesia in adults, the colon of P10 rats was infused with 0.5% acetic acid; control littermates received saline. Rats were tested at 8 weeks of age for sensitivity to CRD and colons were examined for histopathological evidence of inflammation. Adult rats treated with acetic acid on P10 exhibited increased sensitivity to CRD compared to controls (FIG. 1). Data was analyzed by two-way repeated measures ANOVA with distention pressure as the repeated factor and P10 treatment as a between group factor. There was a significant effect of P10 treatment (F 1, 12.98) $p < 0.003$, of distention pressure (F 7, 89.9) $p < 0.001$, and there was a significant interaction between distention pressure and P10 treatment (F 7, 4.04) $p < 0.001$. Means were compared with a Tukey test. Significant differences between AA treated and controls were found at distention pressures of 30 ($p = 0.004$), 40 ($p < 0.001$), 50 ($p < 0.001$), 60 ($p = 0.001$) and 70 ($p = 0.035$) mm Hg. Chemical treatment of colon of P10 rats produces chronic visceral hypersensitivity.

Example 3

Effect of CNI1493 on Visceral Hypersensitivity

[0295] Rats were treated for 4 days with CNI1493 and sensitivity to CRD was measured after treatment. Sensitivity to CRD was significantly reduced by drug treatment F(1, 5.46) $p = 0.05$ (FIG. 2) but was unchanged in vehicle treated rats. Data was analyzed by two-way repeated measures

ANOVA with distention pressure as the repeated factor and drug treatment as a between group factor. There was a significant effect of CNI1493 treatment (F 1, 16.96) $p=0.001$, of distention pressure (F 7, 28.55) $p<0.001$, but there was no significant interaction between distention pressure and CNI-1493 treatment (F 7, 1.94) $p=0.071$. Means were compared with a Tukey test. Significant differences between CNI-1493 treated and controls were found at distention pressures of 20 ($P=0.001$), 30 ($p=0.003$), 40 ($p<0.001$), 50 ($p=0.001$), 60 ($p<0.001$) and 70 ($p=0.015$) and 80 ($p=0.007$) mm Hg.

[0296] To determine whether P10 colon irritation produced chronic inflammation, H&E stained colon sections were examined for signs of inflammation and MPO activity in colon extracts was examined. No differences in appearance of the sections were noted between treatment groups and no overt signs of inflammation were observed. Mucosal architecture was normal, there was no cellular infiltrate, and there was no depletion of goblet cells. No differences were observed in colon histopathology (FIG. 3A-3D). There was a significant increase in MPO activity in the sensitized rats compared to controls (FIG. 3E). CNI-1493 treatment significantly lowered MPO activity in sensitized rats. These findings suggest that there was a low grade inflammation or increased lymphocytes present in sensitized rats.

Example 4

Gene Expression Profiles in Colon and S1 DRG

[0297] To determine the long term effects of P10 colon irritation and of subsequent CNI1493 treatment on gene expression in the colon, gene expression profiles of rat colons from each treatment group derived from Affymetrix rat genome 230A chips were subjected to cluster analysis to identify genes associated with sensitization and treatment. The analysis revealed that 114 genes were differentially expressed in sensitized/CVH colon (Table 3), 76 genes were differentially expressed in sensitized/CVH S1 DRG (Table 4), 660 genes were differentially expressed in CNI1493-treated colon (Table 5), and 137 genes were differentially expressed in CNI1493-treated S1 DRG (Table 6). Since CNI1493 treatment ameliorates CVH in the sensitized ani-

mals, genes differentially regulated by CNI1493 may also be related to the etiology of CVH. Accordingly, genes listed in Tables 3-8 are designated as CVH-related genes (CVHGs). Expression levels of a subset of genes from each group were confirmed by quantitative RT-PCR (Table 8).

TABLE 8

Comparison of chip results with RT-PCR				
	Gene			
	sen +	sen +	sen +	sen +
	veh	veh	CNI	CNI
	Chip	PCR	Chip	PCR
desmin	2.6	1.7	1.3	0.8
CCAAT/enhancerbinding (C/EBP) delta	2.4	2.2	2.3	1.6
EST similar to F-box proteins	2.4	1.9	1.2	0.6
neuron specific protein PEP-19	2.3	2.1	1.1	1.1
Insulin-like growth factor binding protein 2	2.2	2.6	0.9	0.7
ADAMTS1	2.1	2.0	1.1	0.8
tubulin, beta 3	2.1	2.9	1.5	1.3
ArgBP2	1.7	2.9	0.8	1.8
scgn10	1.5	1.3	1.1	0.4
BDNF	1.7	1.9	1.7	2.1
phosphodiesterase 3B	1.8	1.6	1.1	1.2
Trek2	2.1	1.5	1.7	0.9
TrkA precursor	0.7	0.8	0.7	0.7
interleukin 1 receptor, type 1	0.5	1.1	0.6	0.8
elongation factor 2 kinase	0.4	1.6	0.8	1.5

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 66

<210> SEQ ID NO 1

<211> LENGTH: 2236

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

```

cctcgccgca tccaactctcc ggccggccgc ctgccgcgcg cctcctccgt ggcgccgcca      60
gcctcgccgc cgccgtcacc atgagccagg cctactcgtc cagccagcgc gtgtcctcct      120
accgcgcgac ctteggcggc gccccggtct tcccgctcgg ctcccgcgtg agctcgcccg      180
tgttcccgcg ggcgcctttc ggctctaagg gctcctccag ctcggtgacg tcccgcgtgt      240
accaggtgtc gcgcacgtcg ggaggggcgc ggggcctggg gtcgctgcgg gccagccggc      300
tggggaccac ccgcacgccc tcctcctaag gcgcaggcga gctgctggac ttctcactgg      360

```

-continued

ccgacgcggt gaaccaggag tttctgacca cgcgcaccaa cgagaagggtg gagctgcagg	420
agctcaatga ccgttcgccca atctacatgg agaagggtgcg cttcctggag cagcagaacg	480
cgctcgccgc cgaagtgaac cgggtcaagg gcccgagacc gacgcgagtg gccgagctct	540
acgaggagga gctgcgggag ctgcggcgcc aggtggaggt gctcactaac cagcgcgcgc	600
gcgtcgacgt cgagcgcgac aacctgctcg acgacctgca gcggctcaag gccaagctgc	660
aggaggagat tcagttgaag gaagaagcag agaacaattt ggctgccttc cgagcggacg	720
tggatgcagc tactctagct cgcattgacc tggagcgagc aattgaatct ctcaacgagg	780
agatcgcggt ccttaagaaa gtgcataag aggagatccg tgagttgcag gctcagcttc	840
aggaacagca ggatccagggt gagatggaca tgtctaagcc agacctcact gccgcctca	900
gggatatccg ggctcagtat gagaccatcg cggctaagaa cttttctgaa gctgaggagt	960
ggtacaagtc gaagggtgtca gacctgacct aggcagccaa caagaacaac gacgccctgc	1020
gccaggccaa gcaggagatg atggaatacc gacaccagat ccagtccctac acctgcgaga	1080
ttgacgccct caagggcact aacgattccc tgatgaggca gatcggggaa ttggaggacc	1140
gatttgccag tgaggccagt ggctaccagg acaacattgc acgctggag gaggaatcc	1200
ggcacctcaa ggatgagatg gcccgccatc tgcgcgagta ccaggacctg ctcaacgtga	1260
agatggccct ggatgtggag attgccacct accggaagct gctggaggga gaggagagcc	1320
ggatcaatct ccccatccag acctactctg cctcaactt ccgagaaacc agccctgagc	1380
aaaggggttc tgaggccat accaagaaga cggatgatgat caagaccatc gagacacggg	1440
atggggagggt cgtcagttag gccacacagc agcagcatga agtgctctaa agacgagaga	1500
ccctctgcca ccagagaccg tcctcaccct tgctcctact gctccctgaa gcccagcctt	1560
cttcaccca ggacaccaca ccagcctca gtctccaaa tcacagcctc tgaccctcc	1620
tactggcca tccctcgtgg tccccaacag cgacatagcc catccctgcc tggtcacagg	1680
catgccccgg ccacctctgc ggacccacgc tgtgagcctt ggctgttggc agtgagttag	1740
cctggctctt gtgctggatg gagcccaggc gggagcgggt gccctgtccc tcccacctct	1800
gtgacctcag gcctacgctt tggctctgga gatagcccca gagcaggggt ttgggatact	1860
gcagggccag gactgagccc cgcagacctc ccagccctc agcccaggag agagaaagcc	1920
aggcaggtag cctgggggac tagccctgtg gagactgggg ggcttgaaat tgtcccgtg	1980
gtctcttact ttcctttccc cagcccaggg tggacttaga aagcaggggc tacaagaggg	2040
aatccccgaa ggtgctggag gtgggagcag gagattgaga aggagagaaa gtgggtgaga	2100
tgctggagaa gagaggagag gagagaggca gagagcggtc tcaggctggt gggaggggcg	2160
cccacctccc cagccctccc cccccctgc tgcaggggct ctggagagaa acaataaaga	2220
gattcacaca caagcc	2236

<210> SEQ ID NO 2

<211> LENGTH: 566

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

gccagaaccg gtggagcagc gaccctgag cagtgttctc tgtgctgagc ggcgggactg	60
agctgttag ttagagccaa catgagttag cgacaagggt ctggggcaac caatggaaaa	120

-continued

gacaagacat ctggtgaaaa tgatggacag aagaaagttc aagaagaatt tgacattgac	180
atggatgcac cagagacaga acgtgcagcg gtggccattc agtctcagtt cagaaaattc	240
cagaagaaga aggctgggtc tcagtcctag tgggagaacc cctcctagtt ccacctgaaa	300
acaccaaatt caaccatcat ctgtcaagaa attaaaagaa caacacccta gagagaagtc	360
atccacacac aatccacaca cgcataagaa acctccaatg catgtacaga aacctgtgat	420
atttatatccc ttgtaggaag gtatagacaa tgggaattgtg agtagcttaa tctctatgtt	480
tctctccatt ttcattcttc ctgcaactat tttccttgat gttgtaataa aatgaagtta	540
cgatgagtga attcaaaaaa aaaaaa	566

<210> SEQ ID NO 3
 <211> LENGTH: 1433
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 3

attcggggcg agggaggagg aagaagcgga ggaggcggt cccgctcgca gggccgtgca	60
cctgcccgcg cgcgcctcg ctcgctcgcc cgcgcgcgcg cgtgcccgc cgcagcatg	120
ctgcccagag tgggtgcccc cgcgctgcg ctgcccgcgc cgcgctgct gcccgtgctg	180
ccgctgctgc tgcgtctact gggcgcgagt ggcggcgcg gcgggcgcg cgcggaggtg	240
ctgttccgct gcccgcctg cacaccgag cgcctggcg cctgcccgc cccgcccgtt	300
gcgcgcccc cgcggtggc cgcagtgcc ggaggcgccc gcatgccatg cgcggagctc	360
gtccgggagc cgggtgctg ctgctgctg gtgtgcgccc ggctggaggg caggcgtgc	420
ggcgtctaca ccccgcctg cggccagggg ctgctgctg atccccacc gggctccgag	480
ctgcccctgc aggcgtggt catggcgag ggcacttggt agaagcgcc ggacgcccag	540
tatggcgcca gcccggagca ggttgacag aatggcgatg accactcaga aggaggcctg	600
gtggagaacc acgtggacag caccatgaac atgttggcg ggggaggcag tctggcccg	660
aagccccca agtcgggtat gaaggagctg gccgtgttc gggagaaggt cactgagcag	720
caccggcaga tgggcaaggg tggcaagcat caccttgcc tggaggagcc caagaagctg	780
cgaccacccc ctgccaggc tccctgcca caggaaactg accaggtcct ggagcggatc	840
tccacctgc gccttcgga tgagcgggg cctctggagc acctctact cctgcacatc	900
cccaactgtg acaagcatg cctgtacaac ctcaaacagt gcaagatgc tctgaacggg	960
cagcgtgggg agtgctggtg tgtgaacccc aacaccgga agctgatcca gggagcccc	1020
accatccggg gggaccccga gtgtcatctc ttctacaatg agcagcagga ggcttgccgg	1080
gtgcacaccc agcggatgca gtagaccga gccagccggt gcctggcgcc cctgcccccc	1140
gcccctctcc aaacaccgc agaaaacgga gaggcttggt gtggtgggtg ctggaggatt	1200
ttccagttct gacacacgta tttatatttg gaaagagacc agcaccgagc tcggcacctc	1260
cccggcctct ctcttccag ctgcagatgc cacacctgct ccttcttctg tccccgggg	1320
gaggaagggg gttgtggtcg gggagctggg gtacaggttt ggggaggggg aagagaaatt	1380
tttatttttg aaccctgtg tcccttttgc ataagattaa aggaagggaa agt	1433

<210> SEQ ID NO 4
 <211> LENGTH: 4670
 <212> TYPE: DNA

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 4

```

gcactcgctg gaaagcggct ccgagccagg ggctattgca aagccagggt gcgctaccgg      60
acggagaggg gagagccctg agcagagtga gcaacatcgc agccaaggcg gaggccgaag      120
aggggcgcca ggcaccaatc tccgcgttgc ctcagccccg gaggcgcccc agagcgcttc      180
ttgtcccagc agagccactc tgccctgcgc tgccctctcag tgtctccaac tttgcgctgg      240
aagaaaaact tcccgcgcgc cggcagaact gcagcgctc cttttagtga ctccgggagc      300
ttcggtgtga gccggtcttg cgcgccttc caacgaataa tagaaattgt taattttaac      360
aatccagagc aggccaacga ggctttgctc tcccgaccg aactaaaggc ccctcgctcc      420
gtgcgctgct acgagcggtg tctcctgggg ctccaatgca gcgagctgtg cccgaggggt      480
tcggaaggcg caagctgggc agcgacatgg ggaacgcgga gcgggctccg ggtctcggga      540
gctttgggcc cgtaccacg ctgctgctgc tcgccgcggc gctactggcc gtgtcggacg      600
cactcgggcg cccctccgag gaggacgagg agctagtggg gccggagctg gagcgcgccc      660
cgggacacgg gaccacgcgc ctccgcctgc acgcctttga ccagcagctg gatctggagc      720
tgcgccccga cagcagcttt ttggcgcccg gcttcacgct ccagaacgtg gggcgcaaat      780
ccgggtccga gacgcgcgtt ccggaaacgg acctggcgca ctgcttctac tccggcaccg      840
tgaatggcga tcccagctcg gctgcgccc tcagcctctg cgaggcgctg cgcggcgccct      900
tctacctgct gggggaggcg tatttcatcc agccgctgcc cgcgcgcagc gagcgccctg      960
ccaccgccgc cccaggggag aagccgcggc caccactaca gttccacctc ctgcggcgga     1020
atcggcaggg cgacgtcggc ggcacgtgcg gggtcgtgga cgacgagccc cggccgactg     1080
ggaaagcgga gaccgaagac gaggacgaag ggactgaggg cgaggacgaa ggggctcagt     1140
ggtcgcccga ggaccggca ctgcaaggcg taggacagcc cacaggaact ggaagcataa     1200
gaaagaagcg atttgtgtcc agtcaccgct atgtggaaac catgcttggtg gcagaccagt     1260
cgatggcaga attccacggc agtggctctaa agcattacct tctcacgttg ttttcgggtg     1320
cagccagatt gtacaaacac cccagcattc gtaattcagt tagcctgggtg gtggtgaaga     1380
tcttggtcat ccacgatgaa cagaaggggc cggaagtgac ctccaatgct gccctcactc     1440
tgcggaactt ttgcaactgg cagaagcagc acaaccacc cagtgaccgg gatgcagagc     1500
actatgacac agcaattctt ttcaccagac aggacttggt tgggtcccag acatgtgata     1560
ctcttgggat ggctgatgtt ggaactgtgt gtgatccgag cagaagctgc tccgtcatag     1620
aagatgatgg tttacaagct gccttcacca cagcccatga attaggccac gtgtttaaca     1680
tgccacatga tgatgcгааг cagtgtgcca gccttaatgg tgtgaaccag gattcccaca     1740
tgatggcgtc aatgcttttc aacctggacc acagccagcc ttggtctcct tgcagtgccct     1800
acatgattac atcattttctg gataatggtc atggggaatg tttgatggac aagcctcaga     1860
atccataca gctcccagcg gatctccctg gcacctcgta cgatgccaac cggcagtgcc     1920
agtttacatt tggggaggac tccaaacact gcccgatgc agccagcaca tgtagcacct     1980
tgtggtgtac cggcacctct ggtgggggtg tggtgtgtca aaccaaacac ttcccgtggg     2040
cggatggcac cagctgtgga gaagggaat ggtgtatcaa cggcaagtgt gtgaacaaaa     2100
ccgacagaaa gcattttgat acgccttttc atggaagctg gggaatgtgg gggccttggg     2160

```

-continued

gagactgttc	gagaacgtgc	ggtggaggag	tccagtacac	gatgagggaa	tgtgacaacc	2220
cagtcccaaa	gaatggaggg	aagtactgtg	aaggcaaacg	agtgcgctac	agatcctgta	2280
accttgagga	ctgtccagac	aataatggaa	aaaccttttag	agaggaacaa	tgtgaagcac	2340
acaacgagtt	ttcaaaagct	tcctttggga	gtgggcctgc	ggtggaatgg	attcccaagt	2400
acgctggcgt	ctcaccaaa	gacaggtgca	agctcatctg	ccaagccaaa	ggcattggct	2460
acttcttcgt	tttgagccc	aaggtttag	atggtactcc	atgtagccca	gattccacct	2520
ctgtctgtgt	gcaaggacag	tgtgtaaaag	ctggttgtga	tcgcatcata	gactccaaaa	2580
agaagtttga	taaatgtggt	gtttgcgggg	gaaatggatc	tacttgtaaa	aaaatatcag	2640
gatcagttac	tagtgcaaaa	cctggatata	atgatatacat	cacaattcca	actggagcca	2700
ccaacatcga	agtgaacag	cggaaccaga	ggggatccag	gaacaatggc	agctttcttg	2760
ccatcaaagc	tgctgatggc	acatatattc	ttaatggtga	ctacactttg	tccaccttag	2820
agcaagacat	tatgtacaaa	ggtgttgtct	tgaggtagag	cggctcctct	gcggcattgg	2880
aaagaattcg	cagcttttagc	cctctcaaa	agcccttgac	catccagggt	cttactgtgg	2940
gcaatgccct	tcgacctaaa	attaataaca	cctacttcgt	aaagaagaag	aaggaatctt	3000
tcaatgctat	ccccactttt	tcagcatggg	tcattgaaga	gtggggcgaa	tgttctaagt	3060
catgtgaatt	gggttggcag	agaagactgg	tagaatgccg	agacattaat	ggacagcctg	3120
cttccgagtg	tgcaaaggaa	gtgaagccag	ccagcaccag	accttgtgca	gaccatccct	3180
gccccagtg	gcagctgggg	gagtggtcat	catgttctaa	gacctgtggg	aagggttaca	3240
aaaaaagaag	cttgaagtgt	ctgtcccatg	atggaggggt	gttatctcat	gagagctgtg	3300
atcctttaa	gaaacctaaa	catttcatag	acttttgac	aatggcagaa	tgacagttaag	3360
tggtttaagt	ggtgttagct	ttgagggcaa	ggcaaagtga	ggaagggtg	gtgcagggaa	3420
agcaagaagg	ctggagggat	ccagcgtatc	ttgccagtaa	ccagttaggt	gtatcagtaa	3480
ggtgggatta	tgggggtaga	tagaaaagga	gttgaatcat	cagagtaaac	tgccagtgtc	3540
aaatttgata	ggatagttag	tgaggattat	taacctctga	gcagtgatat	agcataataa	3600
agccccgggc	attattatta	ttatttctt	tgttacatct	attacaagtt	tagaaaaaac	3660
aaagcaattg	tcaaaaaaag	ttagaactat	tacaaccct	gtttcctggt	acttatcaaa	3720
tacttagtat	catgggggtt	gggaaatgaa	aagtaggaga	aaagtgagat	tttactaaga	3780
cctgttttac	tttacctcac	taacaatggg	gggagaaaag	agtacaaata	ggatctttga	3840
ccagcactgt	ttatggctgc	tatggtttca	gagaatgttt	atacattatt	tctaccgaga	3900
attaaaaact	cagattgttc	aacatgagag	aaaggctcag	caacgtgaaa	taacgcaaat	3960
ggcttctct	ttcctttttt	ggaccatctc	agttcttatt	tgtgtaattc	attttgagga	4020
aaaaacaact	ccatgtattt	attcaagtgc	attaaagtct	acaatggaaa	aaaagcagtg	4080
aagcattaga	tgctggtaaa	agctagagga	gacacaatga	gcttagtacc	tccaacttcc	4140
tttcttctct	accatgtaac	cctgctttgg	gaatatggat	gtaagaagt	aacttgtgtc	4200
tcatgaaaa	cagtacaatc	acacaaggag	gatgaaacgc	cggaaacaaa	atgaggtgtg	4260
tagaacaggg	tcccacaggt	ttggggacat	tgagatcact	tgtcttgtgg	tggggagget	4320
gctgaggggt	agcaggtcca	tctccagcag	ctggtccaac	agtcgtatcc	tggtgaatgt	4380
ctgttcagct	cttctgtgag	aatatgat	tttccatag	tatatagtaa	aatatgttac	4440

-continued

tataaattac atgtacttta taagtattgg tttgggtgtt ccttccaaga aggactatag	4500
ttagtaataa atgcctataa taacatatat atttttatag atttatttct aatgaaaaaa	4560
actttttaa atatatcgctt ttgtggaagt gcatataaaa tagagtattt atacaatata	4620
tggtactaga aataaaagaa cacttttgga aaaaaaaaaa aaaaaaaaaa	4670

<210> SEQ ID NO 5
 <211> LENGTH: 3360
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <400> SEQUENCE: 5

cattttactt atggaaaaca gtgtggcata ttctgctgag cttcgccctg gaagaagcct	60
cttttatata tctcttcagg gaagagagaa gcaatgggca tgttagtata caatgatcac	120
agccacgcag gcctgaagc tgccttttgg acaggctgtt gactgccgtt ccaattagct	180
gattggagaa tgtggaatgc agagtataa tgctgcatat ctgctatcag gcagcagcaa	240
aggtttttgt cttgggaagg caagctttcc ctgcaatatt atctcagcag ctccctagct	300
gcttaccttg aaaacgaggg atccaaacgg aggggtgtgc actctgctaa cgtggtgcct	360
gtgcgtggct gtggcatatg agcggcaggt ctgaaaaagc aggtgtgtgc tgggacgggc	420
actggactgg aacgcaggcg gacgctctcg ggtttacctg cttcctgtta acagattgtg	480
ggctcccagg gcatatgtct gcacgctgag gccgaggcgg agaaggggct tctgagcgt	540
cccagtacac tgacagagac acttggattg gacttaatct taaacctctg gaggttcaaga	600
ccttttaaaa agggctaaat aaacaatctc tacatgtaaa agggccactga ctccctactc	660
ctctgtatag agcaactgtt gaactcagct gcctgtagga aaactgaaga ctttaataac	720
aaactctcca aggtgaaaat gaacacaggg cgtgattctc agtcaccaga ctacacaaaag	780
gttttagaag cgttcgacca aacctacaag ataaaagatc accaactcag agccagataa	840
cagtgaatgg aaactcagga ggtgccgtga gtcccatgag ttactatcag aggccgtttt	900
ccccctcggc atattctctc ccagcctcac tcaactccag cattgtcatg cagcacggca	960
cateccctga ttccacagac acatatcccc agcatgcgca gtctctggat ggcaccacca	1020
gcagctctat cccctgtgac cgatcctcag aggaagagaa gagagtgaca gtcacaaaag	1080
ccccgcatta cccagggatc gggcccggtg atgaatccgg aatccccaca gcaattagaa	1140
cgacagtga cgggcccagg gactgggtaca agacgatgtt taagcaaatt cacatgggtg	1200
acaagccgga tgatgacaca gacatgtata atactcctta tacatacaat gcagggtctgt	1260
acaaccacac ctacagtgtc cagtcacacc ctgctgcaaa gacccaaacc tacagacctc	1320
tttccaaaag ccaactccgac aacagcccca atgcctttaa ggatgcgtcc tccccagtg	1380
ctccccaca tgttccacct ccagtcgccg cgcttcgacc aagagatcgg tcttcaacag	1440
aaaagcatga ctgggaccc cagacagaaa aagtggacac aagaaaattt cgggtctgagc	1500
caaggagtat ttttgaatat gaacctggca agtcacatc tcttcagcat gaaagaccaa	1560
ctgatcgcat aaatccagat gacatagatt tagaaaatga gccctgggtat aaattctttt	1620
cagaactgga gtttgagcgc ccgcctccta aaaagcctct ggactatgtt caagatcatt	1680
cttctgggtg tttcaatgag gcctcctgt atcagtcctc tatagacaga agcctggaaa	1740
gaccatgag ttctgcaagc atggccagtg acttcaggaa gcggaggaag agcagacctg	1800

-continued

cagtgggtcc	accacggggc	ttgggagatc	aaagtgcgag	caggactagc	ccaggccgag	1860
tggacctccc	aggatcaagc	accactctta	caaagtcttt	cactagctct	tctccttctt	1920
ccccatcaag	agcaaaagac	cgtgagtccc	ctagaagtta	ctcatccact	ttgactgaca	1980
tggggagaag	tgcaccaagg	gaaagaagag	gaactccaga	aaaagagaaa	ttgcctgcaa	2040
aagctgttta	tgattttaag	gctcagacat	ctaaggagtt	gtcattttaag	aaaggagata	2100
ctgtctacat	cctcaggaaa	attgatcaaa	attggtatga	gggagaacac	cacgggagag	2160
tgggcatctt	cccgatctca	tacgtagaga	aactcacacc	tcttgagaaa	gcacagcctg	2220
caagaccacc	tccgccagcc	cagcccgag	aaatcggaga	agctatagcc	aaatacaact	2280
tcaacgcaga	cacaaatgtg	gagctgtcac	tgagaaaggg	agatagagtt	attcttctta	2340
aaagagttga	tcaaaactgg	tatgaaggta	aaatcccagg	aaccaacaga	caaggcatct	2400
tccctgtttc	ctatgtggag	gtcgtcaaga	agaacacaaa	aggtgctgag	gactaccctg	2460
accctccaat	accccacagc	tattctagt	ataggattca	cagcttgagc	tcaaataagc	2520
cacagcgtcc	tgtgtttact	catgaaaata	ttcaaggtgg	gggggaaccg	tttcaggctc	2580
tgtataacta	tactcccagg	aatgaagatg	agctggagct	cagagaaagt	gatgtcattg	2640
atgtcatgga	aaagtgtgat	gacggctgg	ttgtggggac	ctcaagaaga	accaaattct	2700
ttgttacttt	ccccgaaac	tacgtcaaga	ggctgtgaat	tgcgtccct	ccttctgtag	2760
aggccgcctg	ccagccatgc	acctgcgtca	acgcgcctga	aacccccgc	gggcctcccg	2820
ttgtcatgcc	ttacggtttc	caatgcgccg	tcaccatctc	cacctgccac	caaaccacca	2880
gcagagttagc	cgcgcgtgct	gtgagcctgg	ggacgacatg	gcaggctgg	ccccctccgt	2940
gaaagtgtgg	attcctactt	cctgctctaa	gctttgacac	gtcaaatgt	gggatcagaa	3000
agaaaaaat	catgatattt	aaaaatgttc	aaatatttga	ggcaaaaaaa	aaaaaaaaaa	3060
gtgtctccag	gaggctgtcc	agcctcgtgg	ctccatttca	acatctcccc	ccaggcgatg	3120
ttctccccc	agacgaccag	aaaattgttt	attggggaat	gctgtggttt	gcattttcat	3180
attcttcgct	tggcagtgtg	tattcttttc	acaagtttgc	ctagtgtctt	ggtttacaca	3240
atatgacaac	tgtaactgta	ctttagctat	tgtttgctg	cacatacatg	ttgtaatatg	3300
cacagtgatt	acaaccttta	aagcaagagg	aggcgagtta	atttgatga	gtgtgatttt	3360

<210> SEQ ID NO 6

<211> LENGTH: 724

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 6

gtagccggac	cctttgcctt	cgccactgct	cagcgtctgc	acatccctac	aatggctaaa	60
acagcaatgg	cctacaagga	aaaaatgaag	gagctgtcca	tgctgtcact	gatctgctct	120
tgcctttacc	cggaaacctg	caacatcaac	atctatactt	acgatgatat	ggaagtgaag	180
caaatcaaca	aacgtgcctc	tggccaggct	tttgagctga	tcttgaagcc	accatctcct	240
atctcagaag	ccccacgaac	tttagcttct	ccaaagaaga	aagacctgtc	cctggaggag	300
atccagaaga	aactggaggc	tgcagaggaa	agaagaaagt	ctcaggaggc	ccaggtgctg	360
aaacaattgg	cagagaagag	ggaacacgag	cgagaagtcc	ttcagaaggc	tttggaggag	420
aaacaacaact	tcagcaagat	ggcggaggaa	aagctgatcc	tgaaaatgga	acaaattaag	480

-continued

gaaaaccgtg aggcataatct agctgctatt attgaacgtc tgcaggaaaa ggagaggcat	540
gctgcggagg tgcgcaggaa caaggaactc caggttgaac tgtctgctg aagcaaggga	600
gggtctggca cccccacca atagtaaact cccctgccta tattataatg gatcatgcga	660
tatcaggatg gggaatgtat gacatggttt aaaaagaact cattataaaa aaaaaaaaaa	720
aaaa	724

<210> SEQ ID NO 7
 <211> LENGTH: 2961
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 7

aagagatgat ttctccatcc tgaacgtgca gcgagcttgt caggaagatc ggaggtgcca	60
agtagcagag aaagcatccc ccagctctga caggagagaca gcacatgtct aagggccaca	120
agccttgccc ctaccggagg agaagtcaat tttcttctcg aaaatactg aaaaaagaaa	180
tgaattcctt ccagcaacag ccaccgccat tcggcacagt gccaccacaa atgatgtttc	240
ctccaaactg gcagggggca gagaaggacg ctgctttect cgccaaggac ttcaactttc	300
tcactttgaa caatcagcca ccaccaggaa acaggagcca accaagggca atggggcccg	360
agaacaacct gtacagccag tacgagcaga aggtgcgccc ctgcattgac ctcatcgact	420
ccctgcgggc tctgggtgtg gagcaggacc tggccctgcc agccatcgcc gtcacgggg	480
accagagctc gggcaagagc tctgtgctgg aggcactgtc aggagtcgcg cttcccagag	540
gcagcggaat cgtaaccagg tgtccgctgg tgctgaaact gaaaaagcag ccctgtgagg	600
catgggcccg aaggatcagc taccggaaca ccgagctaga gcttcaggac cctggccagg	660
tggagaaaga gatacaciaa gcccgaaacg tcattggccg gaatggccg ggcatcagcc	720
atgagctcat cagcctggag atcacctccc ctgaggttcc agacctgacc atcattgacc	780
ttcccggcat caccaggggtg gctgtggaca accagccccg agacatcgga ctgcagatca	840
aggctctcat caagaagtac atccagaggc agcagacgat caacttggtg gtggttcct	900
gtaacgtgga cattgccacc acggaggcgc tgagcatggc ccatgagggt gacccggaag	960
gggacaggac catcggtatc ctgaccaaac cagatctaata ggacaggggc actgagaaaa	1020
gcgtcatgaa tgtgtgctgg aacctcacgt accccctcaa gaagggtac atgattgtga	1080
agtgcggggg ccagcaggag atcacaaaca ggctgagctt ggcagaggca accaagaaag	1140
aaattacatt ctttcaaaca catccatatt tcagagttct cctggaggag gggtcagcca	1200
cggttccccg actggcagaa agacttacca ctgaactcat catgcataac caaaaatcgc	1260
tcccggtgtt agaaggacaa ataagggaga gccaccagaa ggcgaccgag gagctgcggc	1320
gttgcggggc tgacatcccc agccaggagg ccgacaagat gttctttcta attgagaaaa	1380
tcaagatgtt taatcaggac atcgaaaagt tagtagaagg agaagaagtt gtaagggaga	1440
atgagacccc ttatataaac aaaatcagag aggatattta aaactgggta ggcatacttg	1500
caactaatac caaaaaagt aaaaatatta tccacgaaga agttgaaaaa tatgaaaagc	1560
agtatcgagg caaggagctt ctgggatttg tcaactacaa gacatttgag atcatcgtgc	1620
atcagtacat ccagcagctg gtggagcccg cccttagcat gctccagaaa gccatggaaa	1680
ttatccagca agctttcatt aacgtggcca aaaaacattt tggcgaattt ttcaacctta	1740

-continued

accaaactgt tcagagcacg attgaagaca taaaagtga acacacagca aaggcagaaa	1800
acatgatcca acttcagttc agaatggagc agatgggttt ttgtcaagat cagatttaca	1860
gtgttggtct gaagaaagtc cgagaagaga tttttaaccc tctggggacg ccttcacaga	1920
atatgaagtt gaactctcat tttcccagta atgagtcttc ggtttcctcc tttactgaaa	1980
taggcatcca cctgaatgcc tacttcttgg aaaccagcaa acgtctcgcc aaccagatcc	2040
catttataat tcagtatttt atgctccgag agaatggtga ctcttgacag aaagccatga	2100
tgcagatact acaggaaaaa aatcgctatt cctggctgct tcaagagcag agtgagaccg	2160
ctaccaagag aagaatcctt aaggagagaa tttaccggct cactcaggcg cgacacgcac	2220
tctgtcaatt ctccagcaaa gagatccact gaaggcgccg gatgcctgtg gttgttttct	2280
tgtgcgtact cattcattct aaggggagtc ggtgcaggat gccgcttctg ctttggggcc	2340
aaactcttct gtcactatca gtgtccatct ctactgtact ccctcagcat cagagcatgc	2400
atcaggggtc cacacaggct cagctctctc caccaccag ctcttccctg accttcacga	2460
agggatggct ctccagtcct tgggtcccg agcacacagt tacagtgtcc taagatactg	2520
ctatcattct tcgctaattt gtatttgtat tcccttcccc ctacaagatt atgagacccc	2580
agagggggaa ggtctgggtc aaattcttct tttgtatgtc cagtctcctg cacagcacct	2640
gcagcattgt aactgcttaa taaatgacat ctactgaac gaatgagtgc tgtgtaagtg	2700
atggagatac ctgaggctat tgctcaagcc caggccttgg acatttagtg actgttagcc	2760
ggtcccttct agatccagtg gccatgcccc ctgcttccca tggttcactg tcattgtgtt	2820
tcccagctc tccactcccc cgccagaaaag gagcctgagt gattctcttt tcttcttgtt	2880
tccctgatta tgatgagctt ccattgttct gttaagtctt gaagaggaat ttaataaagc	2940
aaagaaactt tttaaaaacg t	2961

<210> SEQ ID NO 8

<211> LENGTH: 1890

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 8

ggcaccagc gtccggcctg cgccttcccc ccaggcctgg aactgggtc aacacctgtg	60
acttcatgtg tgcgcgccg ccacacctgc agtcacacct gtacccccct ctgccaagag	120
atccataccg aggcagcgtc ggtggctaca agccctcagt ccacacctgt ggacacctgt	180
gacacctggc cacacgacct gtggccgcgg cctggcgtct gctgcgacag gagcccttac	240
ctcccctgtt ataacacctg accgccacct aactgccctt gcagaaggag caatggcctt	300
ggctcctgag agggcagccc cagcgtgtct gttcggagag tggctccttg gagagatcag	360
cagcggctgc tatgaggggc tgcagtggct ggacgaggcc cgcacctgtt tccgcgtgcc	420
ctggaagcac ttgcgcgcga aggacctgag cgaggccgac gcgcgcacct tcaaggcctg	480
ggctgtggcc cgcggcaggt ggccgcctag cagcagggga ggtggccgc cccccaggc	540
tgagactgcg gagcgcgccg gctggaaaac caacttccgc tgcgcaactgc gcagcacgcg	600
tcgcttcgtg atgctgcggg ataactcggg ggaccgggcc gaccgcaca aggtgtacgc	660
gctcagccgg gagctgtgct ggcgagaagg ccagggcacg gaccagactg aggcagaggc	720
ccccgcagct gtcccaccac cacagggtgg gccccaggg ccattcttgg cacacacaca	780

-continued

tgtctggactc caagccccag gccccctccc tgccccagct ggtgacaagg gggacctcct	840
gctccaggca gtgcaacaga gctgcctggc agaccatctg ctgacagcgt catggggggc	900
agatccagtc ccaaccaagg ctcttgagga gggacaagaa gggcttcccc tgactggggc	960
ctgtgctgga ggcccagggc tccctgctgg ggagctgtac gggtgggcag tagagacgac	1020
ccccagcccc gggccccagc ccgcggcact aacgacaggc gaggccgcgg cccagagtc	1080
cccgaccag gcagagccgt acctgtcacc ctccccaagc gcctgcaccg cggtgcaaga	1140
gcccagccca ggggcgctgg acgtgacct catgtacaag ggcgcacgg tgctgcagaa	1200
ggtggtggga cccccagct gcacgttctc atacggcccc ccagaccag ctgtccgggc	1260
cacagacccc cagcaggtag cattccccag ccctgccgag ctcccgacc agaagcagct	1320
gcgtacacg gaggaactgc tgcggcacgt gggccctggg ttgcacctgg agcttcgggg	1380
gccacagctg tgggcccgcg gcatgggcaa gtgcaagggtg tactgggagg tgggcggacc	1440
cccaggctcc gccagccct ccacccagc ctgcctgctg cctcggaact gtgacacccc	1500
catcttcgac ttcagagtct tcttccaaga gctggtggaa ttccgggcac ggcagcgccg	1560
tggctcccca cgctatacca tctacctggg ctccgggcag gacctgtcag ctgggaggcc	1620
caaggagaag agcctggtcc tgggtgaagct ggaaccctgg ctgtgccgag tgcacctaga	1680
gggcacgcag cgtgagggtg tgtcttcct ggatagcagc agcctcagcc tctgcctgtc	1740
cagcgccaac agcctctatg acgacatcga gtgcttcctt atggagctgg agcagccgc	1800
ctagaaccca gtctaagtag aactccagaa agctggagca gccacctag agctggccgc	1860
ggccgcccag tctaataaaa agaactccag	1890

<210> SEQ ID NO 9

<211> LENGTH: 2595

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 9

tcatattagt gcatttcttt gcagaggta cctcttttcc ttgtctctcg tcaggctctc	60
gacattgaca gagcctggac gttggaggaa gcccaggac gttggagggg taaagtaaaa	120
gtccacagtt accgtgagag aaaaaagagg gagaaagcag tgcagccaaa ctcggaagaa	180
aagagaggag gaaaaggact cgactttcac attggaacaa ccttctttcc agtgctaaag	240
gatctctgat ctggggaaca acaccctgga catggctcca gagatcaact tgccggggccc	300
aatgagcctc attgataaca ctaaagggca gctggtggtg aatccagaag ctctgaagat	360
cctatctgca attacgcagc ctgtggtggt ggtggcgatt gtgggcctct atcgcacagg	420
caaatcctac ctgatgaaca agctggctgg gaagaaaaac ggcttctctc taggctccac	480
agtgaagtct cacaccaagg gaatctggat gtggtgtgtg cctcatccca agaagccaga	540
acacacccca gttctgctcg aactgaggg cctgggagat atagagaagg gtgacaatga	600
gaatgactcc tggatctttg ccttggccat cctcctgagc agcacctctg tgtacaatag	660
catgggaacc atcaaccagc aggccatgga ccaacttcac tatgtgacag agctgacaga	720
tcgaaatcaag gaaaactcct cacctggtaa caattctgta gacgactcag ctgactttgt	780
gagctttttt ccagcatttg tgtggactct cagagatttc accctggaac tggaaagtaga	840
tggagaaccc atcactgctg atgactactt ggagctttcg ctaaagctaa gaaaaggtag	900

-continued

tgataagaaa agtaaaagct ttaatgatcc tcggttgtgc atccgaaagt tcttccccaa	960
gaggaagtgc ttcgtcttcg attggcccg cctaagaag taccttctc acctagagca	1020
gctaaaggag gaagagctga accctgattt catagaacaa gttgcagaat tttgttctta	1080
catectcagc cattccaatg tcaagactct ttcaggtggc attccagtca atgggcctcg	1140
tctagagagc ctggtgctga cctacgtcaa tgccatcagc agtggggatc tacctgcat	1200
ggagaacgca gtcctggcct tggcccagat agagaactca gccgcagtgg aaaaggctat	1260
tggccactat gaacagcaga tggggccagaa ggtgcagctg cccacggaaa cctccagga	1320
gctgctggac ctgcacaggg acagtgagag agaggccatt gaagtcttca tgaagaactc	1380
tttcaaggat gtggacaaa tgttccagag gaaattaggg gcccagttgg aagcaaggcg	1440
agatgacttt tgtaagcaga attccaaagc atcatcagat tgttgcattg ctttacttca	1500
ggatatattt ggccctttag aagaagatgt caagcaggga acattttcta aaccaggagg	1560
ttaccgtctc tttactcaga agctgcagga gctgaagaat aagtactacc aggtgccaag	1620
gaaggggata caggccaaag aggtgctgaa aaaatatttg gagtccaagg aggatgtggc	1680
tgatgcactt ctacagactg atcagtcact ctcagaaaag gaaaaagcga ttgaagtgga	1740
acgtataaag gctgaatctg cagaagctgc aaagaaaatg ttggaggaaa taaaaagaa	1800
gaatgaggag atgatggaac agaaagagaa gagttatcag gaacatgtga aacaattgac	1860
tgagaagatg gagagggaca gggcccagtt aatggcagag caagagaaga cctcgcctct	1920
taaaattcag gaacaggaac gccttctcaa ggagggattc gagaatgaga gcaagagact	1980
tcaaaaagac atatgggata tccagatgag aagcaaatca ttggagccaa tatgtaacat	2040
actctaaaag tccaaggagc aaaatttgcc tgtccagctc cctctccca agaacaaca	2100
tgaatgagca acttcagagt gtcaacaac tgccattaaa cttaactcaa aatcatgatg	2160
catgcatttt tgttgaaacca taaagtttgc aaagtaaagg ttaagtatga ggtcaatgtt	2220
ttacctacag agcaattcaa ctcatgctta tttatagtac taacttttaa tatgatcttt	2280
aactaaatcc tatatttgaa atcatacaca aggactcaag agagatattg tgtaactagg	2340
atgcattttc caatgagata tcttgagttt tctgttctgg gtagattttt ttctctcata	2400
tgaccacccc ttactgtata ttcagtccta tactcttatt cagggaattta actatggctg	2460
tagcataggg ctgaagtgtt gtgaatatga tgaaaatgtg atgagaccaa acaaaccatg	2520
gggcacagta gagcatcact cctgccaaag ggtctttgta tggcatgctg gctgcaaata	2580
aaggagatct gggac	2595

<210> SEQ ID NO 10

<211> LENGTH: 2459

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 10

tccttctactg aggagccaga gggaatcaat tccccaaagt gggttgagga gaacaggaga	60
tgagaaagc aagtgaaga cagtccattg ctctgtccac agtggagact ggacagtga	120
acccggggct ggagctcatg gaaaaagaag tagagcctga gggagcaag aggactgacg	180
cacaaggaca cagcctgggg gatggactgg gcccttcac ttaccagagg aggagtcggt	240
ggcctttcag caaagcaaga agtttctgca aaacacacgc cagattgttc aagaagatcc	300

-continued

tgttgggect gttgtgttg gectatgctg cctatctcct ggcagcttgc atcttgaatt	360
tccagagggc actggccttg tttgtcatca cctgcttggg gatctttgtc ctgggttcaact	420
cgtttttgaa aaagctcctg ggcaaaaaat taacaagatg tctgaagccc tttgaaaact	480
cccgcctgag gctttggacg aaatgggtgt ttgcaggagt ctcccttggtt ggccttatac	540
tgtggttggc tttagacaca gcccaaaggc cagagcagct gatccccttt gcaggaatct	600
gcatgttcat ccttatectc ttgctgct ccaaacacca cagcgagtg tcttgaggga	660
cagtgttttc gggcctaggt cttcaatttg tctttgggat cttggtcatc agaactgac	720
ttggatatac tgtatttcag tggctgggag agcagggtcca gattttcctg aactacactg	780
tggccggctc cagttttgtc ttggggata cactgggtcaa ggatgtcttt gcttttcagg	840
ccttaccat catcatttct ttggatgtg tgggtgccat tctctactac ctgggcctgg	900
tgcaatgggt agttcagaag gtcgcctggt ttttacaat cactatgggc accactgcta	960
cagagaccct ggctgtggca ggaaacatct ttgtgggtat gacagaggca cctctgctca	1020
tccgtcccta ccttggggac atgacactct ctgaaatcca tgcggtgatg actggagggt	1080
ttgccaccat ttctggcact gtgctgggag ccttcatagc ctttggggtt gatgcatcat	1140
cctgatttc tgcctctgtg atggccgccc cttgtgctct cgctcatca aagctagcgt	1200
atccggaagt ggaggagtcc aagttcaaga gtgaggaggg ggtaaagctg ccccgaggga	1260
aggagaggaa tgtcctggaa gctgccagca acggagccgt agatgccata ggccctgcta	1320
ctaagttagc agccaacctg attgcctttt tggctgtgtt ggccttcac aatgctgccc	1380
tctcctggct gggggaattg gtggacatac aggggctcac tttccaggtc atctgctcct	1440
atctcctaag gcccatgggt ttcattgatg gtgtagagtg gacagactgt ccaatgggtg	1500
ctgagatggt gggaatcaag ttcttcataa atgagtttgt ggcttatcag caactgtctc	1560
aatacaagaa caaacgtctc tctggaatgg aggagtggat tgaggagag aaacagtgga	1620
ttctctgtgag agctgaaatc attacaacat tttcactctg tggatttgcc aatcttagtt	1680
ccataggaat cacacttgga ggcttgacat caatagtacc tcaccggaag agtgacttgt	1740
ccaaggttgt ggtcagggcc ctcttcacag gggcctgtgt atcccttacc agtgectgta	1800
tggcaggaat cctctatgtc ccaggggag ctgaagctga ctgtgtctcc ttccaaaca	1860
caagtttcac caatagaacc tatgagacct acatgtgtg cagagggtc tttcagagta	1920
cttctctgaa tggcaccaac cctccttctt tttctggtcc ctgggaagat aaggagtcca	1980
gtgctatggc cttactaac tgctgtggat tctacaacaa tacctgtgt gcctaaggct	2040
gcttgatcta tttctataac agttttgatc ttaaaagctt tgtgattgca aagggtgtta	2100
tgtactcagg gtgccacaa ctcactcacc aagatgttta acagtaagta acagtaaatg	2160
taaaagattc attttgggcc gggctcagtg gctcacgcct gtaatcccag cgctttggga	2220
ggcgaggcgg ggcgatcgc agggtcagga gatcgagacc atcctggcta acacggtgaa	2280
acccgtctc tactaaaggt acaaaaaatt ggcgggaggt ggtgtcgggc gactgtagtc	2340
ccagctactc gcgagactga ggcaggagaa tggcgtgaat ccgggaggcg gagcttgacg	2400
cgagccggga tcgcgccact gtactccagc ctgggtgaca gacgagact ctgtctcag	2459

<210> SEQ ID NO 11

<211> LENGTH: 3972

<212> TYPE: DNA

-continued

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 11

```

gctgccgcgc cgcgcgccgc gcgcacccgc ccgctcgtcg tcccgcgcac cccgtagcgc      60
ctcgggctcc cgggccggac agaggagcca gcccggtgcg cccctccacc tctgtctcgg      120
ggggctttaa tgagacaccc accgctgctg tggggccggc ggggagcagc accgcgacgg      180
ggaccggggc tgggcgctgg agccagaatc ggaaccacga tgtgactccg ccgccgggga      240
cccgtagagt ttgtgtggac cccgagttcc accaggtgag aagagtgatg accatccttt      300
tccttactat ggttatttca tactttggtt gcatgaaggc tgcccccattg aaagaagcaa      360
acatccgagg acaaggtggc ttggcctacc caggtgtgcg gacctatggg actctggaga      420
gcgtgaatgg gcccgaaggc ggttcaagag gcttgacatc attggctgac actttcgaac      480
acgtgataga agagctgttg gatgaggacc agaaagttcg gccaatgaa gaaaacaata      540
aggacgcaga cttgtacacg tccaggggtg tgctcagtag tcaagtgcct ttggagcctc      600
ctcttctctt tctgtcggag gaatacaaaa attacctaga tgctgcaaac atgtccatga      660
gggtccggcg ccactctgac cctgcccgcc gaggggagct gagcgtgtgt gacagtatta      720
gtgagtgggt aacggcgggc gacaaaaaga ctgcagtggg catgtcgggc gggacgggtca      780
cagtccttga aaaggtccct gtatcaaaaag gccaactgaa gcaatacttc tacgagacca      840
agtgcaatcc catgggttac acaaaagaag gctgcagggg catagacaaa aggcatttga      900
actcccagtg ccgaactacc cagtcgtacg tgcgggcctt taccatggat agcaaaaaga      960
gaattggctg gcgattcata aggatagaca cttcttgtgt atgtacattg accattaaaa      1020
ggggaagata gtggatttat gttgtataga ttagattata ttgagacaaa aattatctat      1080
ttgtatatat acataacagg gtaaattatt cagttaagaa aaaaaataatt ttatgaactg      1140
catgtataaa tgaagtttat acagtacagt ggttctacaa tctatttatt ggacatgtcc      1200
atgaccagaa gggaaacagt catttgcgca caacttaaaa agtctgcatt acattccttg      1260
ataatgttgt ggtttgttgc cgttgccaa gactgaaaac ataaaaagtt aaaaaaata      1320
ataaattgca tgctgcttta attgtgaatt gataataaac tgcctctttt cagaaaaacag      1380
aaaaaaaaa caccacacac caacaaaaat ttgaaccaa acattccggt tacatttttag      1440
acagtaagta tcttcgttct tgtagtact atatctgttt tactgctttt aacttctgat      1500
agcgttgga ttaaaacaat gtcaagggtg tgtgttcatt gctttactgg cttaggggat      1560
gggggatggg gggatatatt ttgtttgttt tgtgtttttt ttctgtttgt ttgttttgtt      1620
ttttagtcc caccaggagt agagatgggg aaagaattcc tacaatatat attctggctg      1680
ataaaagata catttgtatg ttgtgaagat gtttgcaata tcgatcagat gactagaaag      1740
tgaataaaaa ttaaggcaac tgaacaaaaa aatgctcaca ctccacatcc cgtgatgcac      1800
ctcccaggcc ccgctcattc tttgggcgtt ggtcagagta agctgctttt gacggaagga      1860
cctatgtttg ctcaaacac attctttccc cccctcccc tctggtctcc tctttgtttt      1920
gttttaagga agaaaaatca gttgcgcgtt ctgaaatatt ttaccactgc tgtgaacaag      1980
tgaacacatt gtgtcacatc atgacactcg tataagcatg gagaacagtg attttttttt      2040
agaacagaaa acaacaaaaa ataaccocaa aatgaagatt attttttatg aggagtgaac      2100
atttgggtaa atcatggcta agcttaaaaa aaactcatgg tgaggcttaa caatgtcttg      2160

```

-continued

taagcaaaag gtagagccct gtatcaaccc agaaacacct agatcagaac aggaatccac	2220
attgccagtg acatgagact gaacagccaa atggaggcta tgtggagttg gcattgcatt	2280
taccggcagt gcgaggaggaa tttctgagtg gccatcccaa ggtctaggtg gaggtggggc	2340
atggtatttg agacattcca aaacgaaggc ctctgaagga ccttcagag gtggctcttg	2400
aatgacatgt gtcaagctgc ttggacctcg tgctttaagt gcctacatta tctaactgtg	2460
ctcaagaggt tctcgactgg aggaccacac tcaagccgac ttatgcccac catccacct	2520
ctggataatt ttgcataaaa ttggattagc ctggagcagg ttgggagcca aatgtggcat	2580
ttgtgatcat gagattgatg caatgagata gaagatgttt gctacctgaa cacttattgc	2640
tttgaacta gacttgagga aaccagggtt tatcttttga gaacttttg taagggaaaa	2700
gggaacagga aaagaaaccc caaactcagg ccgaatgatc aaggggaccc ataggaaatc	2760
ttgtccagag acaagacttc gggaagggtg ctggacattc agaacaccaa gacttgaagg	2820
tgcttgctc aatggaagag gccaggacag agctgacaaa attttgctcc ccagtgaagg	2880
ccacagcaac cttctgcccc tcctgtctgt tcattggagag ggtccctgcc tcacctctgc	2940
cattttgggt taggagaagt caagttggga gcctgaaata gtggttcttg gaaaaatgga	3000
tccccagtga aaactagagc tctaagccca ttcagcccat ttcacacctg aaaatgttag	3060
tgatcaccac ttggaccagc atccttaagt atcagaaagc cccaagcaat tgctgcatct	3120
tagtaggggt agggataagc aaaagaggat gttcaccata acccaggaat gaagatacca	3180
tcagcaaaga atttcaattt gttcagctct tcatttagag ctagtcttcc acagtaccat	3240
ctgaataacct ctttgaaaga aggaagactt tacgtagtgt agatttggtt tgtgtgtgtt	3300
gaaaatatta tctttgtaat tatttttaat atgtaaggaa tgcttggaat atctgctata	3360
tgtaacttt atgcagcttc cttttgaggg acaaatttaa aacaaacaac ccccatcac	3420
aaacttaaag gattgcaagg gccagatctg ttaagtgggt tcattaggaga cacatccagc	3480
aattgtgtgg tcagtggctc ttttacccea taagatacat cacagtcaca tgcttgatgg	3540
tttatgttga cctaagattt attttgtaa aatctctctc tgttggttgc gttcttggtc	3600
tgtttgggtt tgttttttaa agtcttgctg tggctctctt gtggcagaag tgtttcatgc	3660
atggcagcag gcctgttgct tttttatggc gattcccat gaaaatgtaa gtaaatgtct	3720
gtggccttgt tctctctatg gtaaagatat tattcaccat gtaaaacaaa aaacaatatt	3780
tattgtattt tagtatattt atataattat gttattgaaa aaaattggca ttaaaactta	3840
accgcatcag aacctattgt aaatacaagt tctatttaag tgtactaatt aacatataat	3900
atatgtttta aatatagaat ttttaatggt tttaaatata ttttcaaagt acataaaaaa	3960
aaaaaaaaaa aa	3972

<210> SEQ ID NO 12

<211> LENGTH: 4784

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 12

gaggcgacac tgagtctcca agtccggaga ggtgcccag ggaaaagagg cggcagctaa	60
actggctctg gagagaagcc ccttcgccc ctctctcag ccagcatgtc ccggactccg	120
ccgctcctca gtccgcgcgg tggggacccc gggccgtggc ggccggcgca gcctgacgg	180

-continued

gttgcgaaacc	agggggcgcc	ccgaacgcgg	gggttggggt	ctgggagcgc	gagcggccgc	240
tacggtacga	gcggggtgtg	ctgagtcctg	tggccacccc	cggccccagc	catgaggagg	300
gacgagcgag	acgccaaagc	catgcggtcc	ctgcagccgc	cggatggggc	cggctcgccc	360
cccagagatc	tgaggaaagg	ctacgtgaag	agctgcgtga	gccccctgcg	gcaggaccct	420
ccgcgcggct	tcttcttcca	cctctgcgcg	ttctgcaacg	tggagctgcg	gccgcgcgcg	480
gcctctcccc	agcagccgcg	gcgctgctcc	cccttctgcc	gggcgcgcct	ctcgtggggc	540
gccccggctg	cctttgtcct	cgcctgctg	ctgggcgcgg	aacccgagag	ctgggctgcc	600
ggggccgcct	ggctgcggac	gctgctgagc	gtgtgttcgc	acagcttgag	ccccctcttc	660
agcatcgctt	gtgccttctt	cttcctcacc	tgcttctcca	cccggaacca	gcggggaccc	720
ggccccggcc	ggagctgcgg	ctcctgggtg	ctgctggcgc	tgcgcgcctg	ctgttacctg	780
ggggaattct	tgggtgtgga	gtggtggtct	tggccttggg	gggatggcga	cgcagggtcc	840
gcggccccgc	acacgcccc	ggaggcggca	gcgggcaggt	tgctgctggt	gctgagctgc	900
gtagggtctg	tgctgacgct	cgcgcacccg	ctgcggctcc	ggcactgcgt	tctggtgctg	960
ctcctggcca	gcttcgtctg	gtgggtctcc	ttcaccagcc	tgcggctcgt	gcctcccgcc	1020
ctcaggccgc	tgctctccgg	cctggtgggg	ggcgtggct	gcctgctggc	cctgggggtt	1080
gataccttct	ttcaaatcag	ggaagcgctt	cttcactctc	gactgtccag	tgccgccgaa	1140
gaaaaagtgc	ctgtgatccg	accccgagg	aggtccagct	gcgtgtcggt	aggagaaact	1200
gcagccagtt	actatggcag	ttgcaaaata	ttcaggagac	cgtcgttgcc	ttgtatttcc	1260
agagaacaga	tgattctttg	ggattgggac	ttaaaacaat	ggatataagc	tcattatcaa	1320
aattctggag	tggaatagg	agttgatctt	tcagtgtctt	atgaggctcg	caatatggtg	1380
tcagatcttc	tgactgatcc	aagccttcca	ccacaagtca	tttctctctt	acggagtatt	1440
agtagcttaa	tgggtgcttt	ctcaggttcc	tgtaggccaa	agattaatcc	tctcacacca	1500
tttctgggat	tttaccctg	ttctgaaata	gaggacccag	ctgagaaagg	ggatagaaaa	1560
cttaacaagg	gactaaatag	gaatagtgtt	ccaactccac	agctgaggag	aagctcagga	1620
acttcaggat	tgctacctgt	tgaacagtct	tcaagggtgg	atcgtaataa	tggcaaaagg	1680
cctcaccaag	aatttgcat	ttcaagtcaa	ggatgctatc	taaatgggcc	ttttaattca	1740
aatctactga	ctatcccgaa	gcaaaggcca	tcttctgtat	cactgactca	ccatgtaggt	1800
ctcagaagag	ctgggtgttt	gtccagtctg	agtcctgtga	attcttccaa	ccatggacca	1860
gtgtctactg	gctctctaac	taatcgatca	cccatagaat	ttcctgatac	tgctgatttt	1920
cttaataaag	caagcgttat	cttgacagag	tctctgggca	atgcacctaa	tactccagat	1980
ttttatcagc	aacttagaaa	ttctgatagc	aatctgtgta	acagctgtgg	acatcaaatg	2040
ctgaaatatg	tttaacatc	tgaatcagat	ggtaacagatt	gctgcagtgg	aaaatcaggt	2100
gaagaagaaa	acattttctc	gaaagaatca	ttcaaactta	tggaaactca	acaagaagag	2160
gaaacagaga	agaaagacag	cagaaaatta	tttcagggaag	gtgataagtg	gctaacagaa	2220
gaggcacaga	gtgaacagca	aacaaatatt	gaacaggaag	tatcactgga	cctgatttta	2280
gtagaagagt	atgactcatt	aatagaaaag	atgagcaact	ggaattttcc	aatttttgaa	2340
ctttagagaa	agatgggaga	gaaatcagga	aggatttctc	gtcaggttat	gtatacctta	2400
tttcaagaca	ctgggtttatt	ggaaatat	aaaattccca	ctcaacaatt	tatgaactat	2460

-continued

tttcgtgcat tagaaaatgg ctatcgagac attccttata acaatcgat acatgccaca	2520
gatgtgctac atgcagtttg gtatctgaca acacggccag ttcttggett acagcagatc	2580
cacaatgggt gtggaacagg aatgaaaca gattctgatg gtagaattaa ccatgggcga	2640
attgcttata tttcttcgaa gagctgctct aatcctgatg agagtatatg ctgctgtct	2700
tcaaacattc ctgcattaga attgatggct ctatactggg cagctgccat gcatgattat	2760
gatacccccag ggaggacaaa tgcattttcta gtggctacaa atgcccctca ggcagtttta	2820
tacaatgaca gatctgttct ggaaaatcat catgctgctg cagcttgga tctatatctt	2880
tctcgcccag aatacaactt ccttcttcat cttgatcatg tggaaatcaa gcgctttcgt	2940
tttttagtca ttgaagcaat ccttgctacg gatcttaaaa agcattttga ttttctcgca	3000
gaattcaatg ccaaggcaaa tgatgtaaat agtaatggca tagaatggag taatgaaaat	3060
gatacgctct tggatgcca ggtgtgcatc aaactggcag atataaatgg cccagcaaaa	3120
gttcgagact tgcatttgaa atggacagaa ggcattgtca atgaatttta tgagcaggga	3180
gatgaagaag caaatcttgg tctgcccata agtccattca tggatcgctt ttctcctcaa	3240
ctagcaaaac tccaagaatc ttttatcacc cacatagtgg gtcccctgtg taactcctat	3300
gatgtgctg gtttgcatac aggtcagtgg ttagaagcag aagaggataa tgatactgaa	3360
agtggtgatg atgaagacgg tgaagaatta gatacagaag atgaagaaat ggaaaacaat	3420
ctaaatccaa aaccaccaag aaggaaaagc agacggcgaa tattttgtca gctaattgcac	3480
cacctcactg aaaaccacaa gatatggaag gaaatcgtag aggaagaaga aaaatgtaaa	3540
gctgatggga ataaactgca ggtggagaat tctccttac ctcaagcaga tgagattcag	3600
gtaattgaag aggcagatga agaggaatag cgacagtttg agtaaaagaa aagtcattat	3660
gaagaagccc agagggtgtg gcccaggggc agaaatcatt gcctagtgtt caccggtga	3720
ctctcaactg accattccca tgtggacagg ccttaatact gtgagaggat ccttgctctg	3780
ctggcagttt cccactccta tgcactttca caggaactag aaaactattc ttaaaccaaa	3840
aataccatcc gtgttgaccc atgttgacaga gcccttactt aaatccttca ctggtgtatg	3900
aatactttgt cataatgctg ctttgcgtgg tagtgagctc ttatttttca ctgggggtca	3960
gctataacta aaaactcaag tgacatatct cagttaccaa agtggccagg aactttttgc	4020
ttttatgaaa atagattcat attgtatttc ccagtgtgtc ttttatgtct ttgaatgttt	4080
tggagaaaaa tctatgcctg tctaaaaatg aatccagtgt tgcctttctg agggatttct	4140
gctcaatgca atacactgtt cagtgtctat ctcccagcta ggtttatcca tgaaggactg	4200
agtgccttt gtgtatttta acaaaatcca ggtgcatcaa tttctgatgc tttttactat	4260
tggtgattat ctactatgtg tgttttattt ctgctgagag tattcagggt tgcctatggc	4320
atcagaagtt tgaattccag tcttatctta tgttccatgg ctgaatttta aagctgttta	4380
ggtttaacaa tgaagggatt tattcttttag tcaaaattgt tgtttttact ctagctcagg	4440
attcgtatct ttaaagattt agttaatata aacacagcac agatttgtca gaagaaaaaa	4500
aatttgctgt aataccaaaa ctaacctcat caaagatata gaaaaaaga aatatagtga	4560
gccctaaagg acacatacat tgaataaata attggaacat gtggttatct ttagatccac	4620
atcttagctg tcatttgttc actctaaaac tgatgttcat ctttctgtta atttccctct	4680
gcctaaagag tacatgacag aatgaccta tcaactacta ttatttctga agcctaactg	4740

-continued

caagagtgat ttcttgagaa caagtaaaga actggctcgt gccg 4784

<210> SEQ ID NO 13

<211> LENGTH: 2710

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 13

```

gcaggcatcg tctctcccg tctcacagct accccgggct ggagcgtggg gagggggtaa    60
gggagccagc caactcgggg aaacttcggt gccagagatg actggggttt tcgggctttc    120
ccagccttcc catgccgggc cacacggcat tcattaaagt ggtggggcaa ctattggtgc    180
gtccagcccg ggcaggtttt gagctgcaga gaccctgtcc cggtagcagc gctttgccac    240
cgagtgcacc caggacgcag tggccgccag cccgggtctc ctgctggggg ccggcgagtg    300
cagggagact ttgcgccacg atgttttgtt ttcctgccgc aggaacgcta ggcagtctct    360
ttccaccaga cttaaccgcg ctgaagcaat agccatggaa gttcggcgcg cacagagggg    420
gacagaaccg cttggagcgg catctttctt ggatgttttt tctctacaca gacttctttc    480
tttcttggtt ggccgttccc gcagcagcac cgggtgtgcca gccaagagc gccactaacg    540
ggcaaccccc ggctccggct ccgactccaa ctccgcgcct gtccatttcc tcccagacca    600
cagtgttagc caggatggaa ggcacctccc aagggggctt gcagaccgtc atgaagtggg    660
agacggtggt tgccatcttt gtggttgttg tgggtctacct tgtaactggc ggtcttgtct    720
tccgggcatt ggagcagccc tttgagagca gccagaagaa taccatcgcc ttggagaagg    780
cggaattcct gcgggatcat gtctgtgtga gccccagga gctggagacg ttgatccagc    840
atgctcttga tgctgacaat gcgggagtcg gtccaatagg aaactcttcc aacaacagca    900
gccactggga cctcggcagt gcctttttct ttgctggaac tgtcattacg accatagggg    960
atgggaatat tgctccgagc actgaaggag gcaaaatctt ttgtatttta tatgccatct   1020
ttggaattcc actctttggt ttcttattgg ctggaattgg agaccaactt ggaaccatct   1080
ttgggaaaag cattgcaaga gtggagaagg tctttcgaag aaagcaagtg agtcagacca   1140
agatccgggt catctcaacc atcctgttca tcttgcccggt ctgcattgtg tttgtgacga   1200
tccctgctgt catctttaag tacatcgagg gctggacggc cttggagtcc atttactttg   1260
tggtggtcac tctgaccacg gtgggctttg gtgattttgt ggcaggggga aacgctggca   1320
tcaattatcg ggagtgggat aagcccttag tgtggttttg gatccttgtt ggccttgccct   1380
actttgcagc tgtcctcagt atgatcggag attggctacg ggttctgtcc aaaaagacaa   1440
aagaagaggt gggtaaatc aaggcccatg cggcagagtg gaaggccaat gtcacggctg   1500
agttccggga gacacggcga aggctcagcg tggagatcca cgataagctg cagcgggagg   1560
ccaccatccg cagcatggag cgcggcgggc tgggcctgga ccagcgggccc cactcactgg   1620
acatgctgtc ccccgagaag cgctctgtct ttgctgcct ggacaccggc cgcttcaagg   1680
cctcatccca ggagagcatc aacaaccggc ccaacaacct gcgcctgaag gggccggagc   1740
agctgaacaa gcatgggcag ggtgcgtccg aggacaacat catcaacaag ttcgggtcca   1800
cctccagact caccaagagg aaaaacaagg acctcaaaaa gaccttgccc gagggcgttc   1860
agaaaatcta caagaccttc cggaattact ccttgacgga ggagaagaaa gagggaggaga   1920
cgaaaaagat gtgtaactca gacaactcca gcacagccat gctgacggac tgtatccagc   1980

```

-continued

agcacgctga gttggagaac ggaatgatac ccacggacac caaagaccgg gagccggaga	2040
acaactcatt acttgaagac agaaactaaa tgtgaaggac attggtcttg gactgagcgt	2100
tgtgtgtgtg tgtgtgtgtg tgtttttaat attcacactg agacatgtgc cttaaacaga	2160
cttttttagtc caaaattaca tagcattgaa gaatatattt cactgtgccca taaacaactg	2220
aaagcttgct ctgccaaaag gaatcagaga acaagaactt catttcagat agcaaacgca	2280
ggacacacca agagtgtccg tgcacgtagc cggttctggc cgtacatgtt aagggcattt	2340
cagtggcagt gctgtacccc tgggcagtgc tacctgggca cacacgtaga caagggcagc	2400
tattccttag accagcctcc tgaaagaaac aggtgtgtct ttttagtgga gtcgtagtaa	2460
tatgtgcaca cacagaaggg gacctgattg ggtgggagct ggttatgtgt aactagcgtt	2520
ggagttgaca ttttggcatg tgctctgagc ttgaattttg ataccaacca ttcagtgcac	2580
catacctagt ctttctatgc tccaaatgaa tgtctgtggg gacctgagag cacctggaat	2640
ttgttggaag cagatcagag cacacgtacg aaaaggtgca attgcttttc tcatgacaaa	2700
agaaaaaaaa	2710

<210> SEQ ID NO 14

<211> LENGTH: 2391

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 14

atgctgcgag gcggacggcg cgggcagctt ggctggcaca gctgggctgc ggggccgggc	60
agcctgctgg cttggctgat actgcatct cggggcgccg caccctgccc cgatgcctgc	120
tgccccacg gctcctcggg actgcgatgc acccgggatg gggccctgga tagcctccac	180
cacctgcccg gcgcagagaa cctgactgag ctctacatcg agaaccagca gcactctgag	240
catctggagc tccgtgatct gaggggctg ggggagctga gaaacctcac catcgtgaag	300
agtggctccc gtttctgtgc gccagatgcc ttccatttca ctctcggct cagtcgctg	360
aatctctcct tcaacgctct ggagtctctc tccggaaaa ctgtgcaggg cctctcctta	420
caggaaactg tctgtcggg gaacctctg cactgttctt gtgccctgcg ctggctacag	480
cgctgggagg aggagggact gggcggagt cctgaacaga agctgcagtg tcatgggcaa	540
gggcccctg cccacatgcc caatgccagc tgtggtgtgc ccacgctgaa ggtccagggt	600
cccaatgcct cgggtgatgt gggggacgac gtgctgctgc ggtgccaggt ggagggcgcg	660
ggcctggagc aggccggctg gatcctcaca gagctggagc agtcagccac ggtgatgaaa	720
tctgggggtc tgccatccct ggggctgacc ctggccaatg tcaccagtga cctcaacagg	780
aagaactgta cgtgctgggc agagaacgat gtgggcccgg cagaggtctc tgttcaggtc	840
aacgtctcct tcccggccag tgtgcagctg cacacggcgg tggagatgca ccactggtgc	900
atccccttct ctgtggatgg gcagccggca ccgtctctgc gctggctctt caatggctcc	960
gtgtcaatg agaccagctt catcttcact gagttcctgg agccggcagc caatgagacc	1020
gtgcggcacg ggtgtctgcg cctcaaccag cccaccacg tcaacaacgg caactacacg	1080
ctgtggctg ccaacccctt cggccaggcc tccgctctca tcatggctgc ctcatggac	1140
aaccctttcg agttcaaccc cgaggacccc atccctgtct cctctctgcc ggtggacact	1200
aacagcacat ctggagaccc ggtggagaag aaggacgaaa caccttttgg ggtctcgggtg	1260

-continued

gctgtgggccc	tggccgtctt	tgcctgcctc	ttcctttteta	cgctgctcct	tgtgctcaac	1320
aaatgtggac	ggagaaacaa	gtttgggac	aaccgcccgg	ctgtgctggc	tccagaggat	1380
gggctggcca	tgtccctgca	tttcatgaca	ttgggtggca	gctccctgtc	ccccaccgag	1440
ggcaaaggct	ctgggctcca	aggccacatc	atcgagaacc	cacaatactt	cagtgatgcc	1500
tgtgttcacc	acatcaagcg	ccgggacatc	gtgctcaagt	gggagctggg	ggagggcgcc	1560
tttgggaagg	tcttctctgc	tgagtgccac	aacctcctgc	ctgagcagga	caagatgctg	1620
gtggctgtca	aggcactgaa	ggaggcgtcc	gagagtgtct	ggcaggactt	ccaacgtgag	1680
gctgagctgc	tcaccatgct	gcagcaccag	cacatcgtgc	gcttcttcgg	cgtctgcacc	1740
gagggccgcc	ccctgctcat	ggtcttcgag	tatatgcggc	acggggacct	caaccgcttc	1800
ctccgatccc	atggacccca	tgccaagctg	ctggctgggtg	gggaggatgt	ggctccaggc	1860
cccttgggtc	tggggcagct	gctggccgtg	gctagccagg	tcgctgcggg	gatgggtgtac	1920
ctggcgggtc	tgcattttgt	gcaccgggac	ctggccacac	gcaactgtct	agtgggccag	1980
ggactgggtg	tcaagattgg	tgattttggc	atgagcaggg	atatctacag	caccgactat	2040
taccgtgtgg	gagggccgac	catgtgtccc	attcgctgga	tgcgcgccga	gagcatcctg	2100
taccgtaagt	tcaccaccga	gagcgacgtg	tggagcttcg	gcgtgggtgct	ctgggagatc	2160
ttcacctacg	gcaagcagcc	ctggtaccag	ctctccaaca	cggagggaat	cgactgcac	2220
acgcagggac	gtgagttgga	gcggccacgt	gcctgcccac	cagaggtcta	cgccatcatg	2280
cggggctgct	ggcagcggga	gccccagcaa	gcgcacagca	tcaaggatgt	gcacgcccgg	2340
ctgcaagccc	tggcccaggc	acctcctgtc	tacctggatg	tcttgggcta	g	2391

<210> SEQ ID NO 15

<211> LENGTH: 4909

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 15

tagacgcacc	ctctgaagat	ggtgactccc	tcttgagaag	ctggaccacct	tggtaaaaga	60
caaggccttc	tccaagaaga	atatgaaagt	gttactcaga	cttatttggt	tcatagctct	120
actgatttct	tctctggagg	ctgataaatg	caaggaacgt	gaagaaaaaa	taattttagt	180
gtcatctgca	aatgaaattg	atgttcgtcc	ctgtcctctt	aaccctaatg	aacacaaagg	240
cactataact	tgggtataag	atgacagcaa	gacacctgta	tctacagaac	aagcctccag	300
gattcatcaa	cacaaagaga	aacttttggt	tgttcctgct	aagggtggagg	attcaggaca	360
ttactattgc	gtggtaagaa	attcatctta	ctgcctcaga	attaaaataa	gtgcaaaatt	420
tgtggagaat	gagcctaact	tatgttataa	tgcacaagcc	atatttaagc	agaaactacc	480
cgttgcagga	gacggaggac	ttgtgtgccc	ttatatggag	ttttttaaaa	atgaaaataa	540
tgagttacct	aaattacagt	ggtataagga	ttgcaaacct	ctacttcttg	acaatataca	600
ctttagtggg	gtcaaagata	ggctcatcgt	gatgaatgtg	gctgaaaagc	atagagggaa	660
ctatacttgt	catgcatcct	acacatactt	gggcaagcaa	tatcctatta	cccgggtaat	720
agaatttatt	actctagagg	aaaacaaacc	cacaaggcct	gtgattgtga	gccagctaa	780
tgagacaatg	gaagtagact	tgggatccca	gatacaattg	atctgtaatg	tcaccggcca	840
gttgagtgc	attgcttact	ggaagtggaa	tgggtcagta	attgatgaag	atgaccaggt	900

-continued

gctaggggaa gactattaca gtgtggaaaa tcttgcaaac aaaagaagga gtaccctcat	960
cacagtgttt aatatatcgg aaattgaaag tagattttat aaacatccat ttacctgttt	1020
tgccaagaat acacatggta tagatgcagc atatatccag ttaatatatc cagtactactaa	1080
tttcagaag cacatgattg gtatatgtgt cacgttgaca gtcataattg tgtgttctgt	1140
tttcatctat aaaatcttca agattgacat tgtgcttttg tacagggtatt cctgctatga	1200
ttttctccca ataaaagctt cagatggaaa gacctatgac gcatatatac tgtatccaaa	1260
gactgttggg gaagggtcta cctctgactg tgatattttt gtgtttaaag tcttgccctga	1320
ggtcttgga aaacagtgtg gatataagct gttcatttat ggaagggtg actacgttgg	1380
ggaagacatt gttgaggtca ttaatgaaaa cgtaaagaaa agcagaagac tgattatcat	1440
tttagtcaga gaaacatcag gcttcagctg gctgggtggg tcatctgaag agcaaatagc	1500
catgtataat gctcttggtc aggatggaat taaagttgtc ctgcttgagc tggagaaaat	1560
ccaagactat gagaaaaatgc cagaatcgat taaattcatt aagcagaaac atggggctat	1620
ccgctgggtca ggggacttta cacagggtacc acagtctgca aagacaaggt tctggaagaa	1680
tgacaggtac cacatgccag tccagcgacg gtcaccttca tctaaacacc agttactgtc	1740
accagccact aaggagaaa tgcaagaga ggctcacgtg cctctcgggt agcatggaga	1800
agttgccaa agttctttag gtgctcctg tcttatggcg ttgcaggcca ggttatgcct	1860
catgctgact tgcagagttc atggaatgta actatateat cctttatccc tgaggteacc	1920
tggaatcaga ttattaaggg aataagccat gacgtcaata gcagcccagg gcacttcaga	1980
gtagagggtc tgggaagatc ttttaaaaag gcagtaggcc cgggtgtggg gctcacgcct	2040
ataatcccag cactttggga ggctgaagtg ggtggatcac cagaggtcag gagttcgaga	2100
ccagcccagc caacatggca aaacccatc tctactaaaa atacaaaaat gagctaggca	2160
tggtggcaca cgctgtaat cccagctaca cctgaggctg aggcaggaga attgcttgaa	2220
ccggggagac ggaggttgca gtgagccgag tttgggccac tgcactctag cctggcaaca	2280
gagcaagact ccgtctcaaa aaaagggcaa taaatgcct ctctgaatgt ttgaactgcc	2340
aagaaaaggc atggagacag cgaactagaa gaaagggcaa gaaggaaata gccaccgtct	2400
acagatggct tagttaagtc atccacagcc caaggcgagg gctatgcctt gtctggggac	2460
cctgtagagt cactgacctt ggagcggctc tctgagagg tgctgcaggc aaagtgcagc	2520
tgacacctca ctgaggaagg gagacatatt cttggagaac tttccatctg cttgtatttt	2580
ccatacacat cccagccag aagttaggtt ccgaagaccg aattttatct tacagagcct	2640
gaaaactcac ttcaatgaac aaagggtatc tccaggatcc caaagttttg aagtcattct	2700
agctttccac agggaggaga gaacttaaaa aagcaacagt agcagggaat tgatccactt	2760
cttaatgctt tctcctctg catgaccatc ctgtcctttg ttattatcct gcattttacg	2820
tctttggagg aacagctccc tagtggtctc ctccgtctgc aatgtccctt gcacagccca	2880
cacatgaacc atccttccca tgatgcgctt cttctgtcat cccgctcctg ctgaaacacc	2940
tcccaggggc tccacctgtt caggagctga agcccatgct tcccaccag catgtcactc	3000
ccagaccacc tccctgcctt gtcctccagc ttcctctcgc tgtcctgctg tgtgaattcc	3060
cagggtggcc tgggtggcat gtcgcctgcc cccagcactc ctctgtctct gctcttgctt	3120
cgaccttcc tctcctttg ctaggagggc cttctcgcat tttctctagc tgatcagaat	3180

-continued

tttaccaaaa	ttcagaacat	cctccaattc	cacagtctct	gggagacttt	ccctaagagg	3240
cgacttcctc	tccagccttc	tctctctggt	caggcccact	gcagagatgg	tggtagcac	3300
atctgggagg	ctggtctccc	tccagctgga	attgctgctc	tctgaggagg	aggctgtggt	3360
ggctgtctct	gtccctcact	gccttccagg	agcaatttgc	acatgtaaca	tagatttatg	3420
taatgcttta	tgtttaaaaa	cattccccaa	ttatcttatt	taatttttgc	aattattcta	3480
attttatata	tagagaaagt	gacctatttt	ttaaaaaaat	cacactctaa	gttctattga	3540
acctaggact	tgagcctcca	tttctggctt	ctagtctggt	gttctgagta	cttgatttca	3600
ggtaataaac	ggtccccctc	cactccacac	tggcacgttt	gtgagaagaa	atgacatttt	3660
gctaggaagt	gaccgagtct	aggaatgctt	ttattcaaga	caccaaattc	caaacttcta	3720
aatgttgga	ttttcaaaaa	ttgtgtttag	attttatgaa	aaactcttct	actttcatct	3780
attctttccc	tagaggcaaa	catttcttaa	aatgtttcat	tttcattaaa	aatgaaagcc	3840
aaatttatat	gccaccgatt	gcaggacaca	agcacagttt	taagagtgtg	atgaacatgg	3900
agaggacttt	tggtttttat	atttctcgta	tttaatatgg	gtgaacacca	acttttattt	3960
ggaataataa	tttctctcct	aaacaaaaac	acattgagtt	taagtctctg	actcttgctt	4020
ttccacctgc	tttctctcgg	gcccgccttg	cctgcttgaa	ggaacagtgc	tgttctggag	4080
ctgctgttcc	aacagacagg	gcctagcttt	catttgacac	acagactaca	gccagaagcc	4140
catggagcag	ggatgtcacg	tcttgaaaag	cctattagat	gttttcaaaa	tttaattttg	4200
cagattattt	tagtctgtca	tccagaaaat	gtgtcagcat	gcatagtgct	aagaaagcaa	4260
gccaatattg	aaacttaggt	tagtgacaaa	attggccaga	gagtgggggt	gatgatgacc	4320
aagaattaca	agtagaatgg	cagctggaat	ttaaggaggg	acaagaatca	atggataagc	4380
gtgggtggag	gaagatccaa	acagaaaagt	gcaaagttaa	tccccatctt	ccaagggttg	4440
aattctggag	gaagaagaca	cattcctagt	tccccgtgaa	cttcctttga	cttattgtcc	4500
ccactaaaa	aaaacaaaa	acttttaattg	ccttccacat	taattagatt	ttcttgcaat	4560
ttttttatgg	cattttttta	aagatgcctt	aagtgttgaa	gaagagtttg	caaatgcaac	4620
aaaaatatta	attaccgggt	gttaaaactg	gtttagcaca	atttatattt	tccctctctt	4680
gcctttctta	tttgcaataa	aaggtattga	gccatttttt	aaatgacatt	tttgataaat	4740
tatgtttgta	ctagttgatg	aaggagtgtt	ttttaacctg	tttatataat	tttgagcag	4800
aagccaaatt	ttttgtatat	taaagcacca	aattcatgta	cagcatgcat	cacggatcaa	4860
tagactgtac	ttattttcca	ataaaatttt	caaactttgt	actgttaaa		4909

<210> SEQ ID NO 16

<211> LENGTH: 3599

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 16

ggccctcgcg	cccttctcgg	gatcactccg	actgccccgc	gcctctgcca	actcctctgg	60
accctcgcg	ccgtgggcag	cggctgccgc	gcctgtctgc	cagaggagg	accttcgcct	120
ctgcatttgt	ccagtaactc	tggctgtgcc	ggatactgct	tgggtaaaa	gggcacccca	180
ggaacatggc	agacgaagat	ctcatcttcc	gcctggaagg	cgttgatggc	ggccagtcct	240
cccagctgg	ccatgatggt	gattctgatg	gggacagcga	cgatgaggaa	ggttacttca	300

-continued

tctgccccat	cacggatgac	ccaagctcga	accagaatgt	caattccaag	gttaataagt	360
actacagcaa	cctaacaaaa	agtgagcgg	atagctccag	cgggtccccg	gcaaactcct	420
tccacttcaa	ggaagcctgg	aagcacgcaa	tccagaaggc	caagcacatg	cccgacccct	480
gggctgagtt	ccacctggaa	gatattgcc	ccgaacgtgc	tactcgacac	aggtacaacg	540
ccgtcaccgg	ggaatggctg	gatgatgaag	ttctgatcaa	gatggcatct	cagcccttcg	600
gccgaggagc	aatgagggag	tgcttcgcga	cgaagaagct	ctccaacttc	ttgcatgccc	660
agcagtggaa	gggcgcctcc	aactacgtgg	cgaagcgcta	catcgagccc	gtagaccggg	720
atgtgtactt	tgaggacgtg	cgtctacaga	tggaggccaa	gctctggggg	gaggagtata	780
atcggcacia	gcccccaag	caggtggaca	tcctgcagat	gtgcatcatc	gagctgaagg	840
acagaccggg	caagcccctc	ttccacctgg	agcactacat	cgagggcaag	tacatcaagt	900
acaactccaa	ctctggcttt	gtccgcgatg	acaacatccg	cctgacgccg	caggccttca	960
gccacttcac	ttttgagcgt	tccggccatc	agctgatagt	gggtggacatc	caggggagttg	1020
gggactctta	cactgaccca	cagatccaca	cggagacggg	cactgacttt	ggagacggca	1080
acctaggtgt	ccgcgggatg	gcgctcttct	tctactctca	tgcttgcac	cggatttgcg	1140
agagcatggg	ccttgctccc	tttgacctct	cgccccggga	gagggatgca	gtgaatcaga	1200
acaccaagct	gctgcaatca	gccaagacca	tcttgagagg	aacagaggaa	aatgtggga	1260
gcccccgagt	aaggaccctc	tctgggagcc	ggccaccctc	gctccgtccc	ctttcagaga	1320
actctggaga	cgagaacatg	agcgacgtga	ccttcgactc	tctcccttct	tccccatctt	1380
cggccacacc	acacagccag	aagctagacc	acctccattg	gccagtgttc	agtgcctcg	1440
ataacatggc	atccagagac	catgatcatc	tagacaacca	ccgggagtct	gagaatagtg	1500
gggacagcgg	atacccagct	gagaagcggg	gtgagctgga	tgaccctgag	ccccgagaac	1560
atggccactc	atacagtaat	cggaagtacg	agtctgacga	agacagcctg	ggcagctctg	1620
gacgggtatg	tgtagagaag	tggaatctcc	tcaactcctc	ccgcctccac	ctgccgaggg	1680
cttcggccgt	ggccctggaa	gtgcaaaagg	ttaatgctct	ggacctcgaa	aagaaaatcg	1740
ggaagtccat	tttggggaag	gtccatctgg	ccatgggtcg	ctaccacgag	gggtggcgct	1800
tctgcgagaa	gggcgaggag	tgggaccagg	agtcggctgt	cttccacctg	gagcacgcag	1860
ccaacctggg	cgagctggag	gccatcgtgg	gcctgggact	catgtactcg	cagttgcctc	1920
atcacatcct	agccgatgtc	tctctgaagg	agacagaaga	gaacaaaacc	aaaggatttg	1980
attacttact	aaaggccgct	gaagctggcg	acaggcagtc	catgatccta	gtggcgcgag	2040
cttttgactc	tggccagaac	ctcagcccgg	acaggtgcc	agactggcta	gaggccctgc	2100
actggtacaa	cactgccttg	gagatgacgg	actgtgatga	gggcgggtgag	tacgacggaa	2160
tgcaggacga	gccccggtac	atgatgctgg	ccagggaggg	cgagatgctg	ttcacaggag	2220
gtacagggct	ggagaaggac	ccgcagagat	caggggactt	gtatacccag	gcagcagagg	2280
cagcgatgga	agccatgaag	ggccgactgg	ccaaccagta	ctacaaaag	gctgaagagg	2340
cctgggcccc	gatggaggag	taaccaggaa	aatcactgcc	ggctagtccc	aagcaaacgg	2400
gctaggagga	aagattaaaa	aaacaacaac	aacaacttat	ttagtttggg	gaggggaagc	2460
atttttaagt	gtgttgtaaa	atcaaatttt	atatttcatt	ttttgactct	tgaaaaatgt	2520
ctttgctcct	tggcagctac	cagcagagac	tctatagctg	tctcttaggg	cagtattttg	2580

-continued

gggaagtggg gcttgaagaa gcagcctaata gaaccaacat accgttttgt gtgtgggttt	2640
ttttgtttgt ttgtttgttt gttttgagac agagtcttgc tctgtcacc aggtggagt	2700
gcagtgcacat gatcttagct cactgcaacc tccgcctcct gggttcaagt gattctcctg	2760
cctcagcctc ccaagttagct gggattactg gtgcacacca ccacactcag ctaatttttg	2820
catttttagt agagatgggg ttccaccatg ttggccaggc tggctctgaa ctctggact	2880
taagtgcagc tcccgcctca gtctcccaaa gcgctgggat tacaggcagg agccactgag	2940
cccagccaag acttcagtgt tgactgcttt ggaggcacia acccatgcaa gcgttagttc	3000
caaagtgcag tgtgtaccct taaatgaaca atgaagcagg taaaattacc cttgaaaaaa	3060
atcccttgga ccaccataa atgacagtga ctttttcaat atggactcat catagccagt	3120
ttccttttg aagttggaac tgatcacctt tttgtcatct gtaccagatc agtagttggc	3180
ttgtgttaca ttttgtgtgt gtgtgtgcgt gttttaaac agtgcataa aattgtatgt	3240
taaatgtaag taactttaag ttgacttata tcttcacagt aatcaagcct cagtaattc	3300
atgcttttta aattcagcca gccccctc tctgaaattt tattatgtaa ataatttg	3360
ttccctgatc actcggttaa gttcttagtt gtatgtcatc tctctctag caggaattgg	3420
caaaactttt tgtaagggg tagaaagtga agattttagg ctttgaggc catatagcct	3480
ctgtgcataa tgctcagccc tgctgttgta atgtaaaagc tgccacagac actacatgaa	3540
cacgaatgag tgtggctggt gttccaataa aactttattt acacaaaaaa aaaaaaaaa	3599

<210> SEQ ID NO 17

<211> LENGTH: 1288

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 17

acaccagccc tcagtcactg ggagaagaac ctctcatacc ctgggtgctc cagtccccag	60
ctcactcagc cacacacacc atgtgtgaag aggagaccac cgcgctcgtg tgtgacaatg	120
gctctggcct gtgcaaggca ggcttcgcag gagatgatgc ccccgggcgt gtcttcccct	180
ccattgtggg ccgcctcgc caccagggtg tgatgggtgg aatgggccag aaagacagct	240
atgtggggga tgaggctcag agcaagcag ggatcctaac tctcaatac ccattgaac	300
acggcatcat caccaactgg gatgacatgg agaagatctg gcaccactcc ttctacaatg	360
agctgcgtgt agcacctgaa gagcacccca cctgctcac agaggctccc ctaaatccca	420
aggccaacag ggaaaagatg acccagatca tgtttgaaac cttcaatgct cctgccatgt	480
acgtcgccat tcaagctgtg ctctccctct atgcctctgg ccgcacgaca ggcacgtcc	540
tggattcagg tgatggcgtc acccacaatg tcccaccta tgaaggctat gccctgcccc	600
atgccatcat gcgcctggac ttggctggcc gtgacctcac ggactacctc atgaagatcc	660
tcacagagag aggcatttcc tttgtgacca cagctgagag agaaattgtg cgagacatca	720
aggagaagct gtgctatgtg gccctggatt ttgagaatga gatggccaca gcagcttcct	780
cttccctccct ggagaagagc tatgagctgc cagatgggca ggttatcacc attggcaatg	840
agcgcttcgg ctgcctgag accctcttcc agccttctt tattggcatg gagtccgctg	900
gaattcatga gacaacctac aattccatca tgaagtgtga cattgacatc cgtaaggact	960
tatatgccaa caatgtcctc tctgggggca ccaccatgta ccctggcatt gctgacagga	1020

-continued

tgcagaagga gatcacagcc ctggccccc	gcaccatgaa gatcaagatt attgctcccc	1080
cagagcggaa gtactcagtc tggatcgggg	gctctatcct ggctctctc tccaccttc	1140
agcagatgtg gatcagcaag cctgagtatg	atgaggcagg gcctccatt gtccacagga	1200
agtgttcta aagtcaaac aggttctcca	aggatccct cgagactact ctgttaccag	1260
tcataaaca ttaaaccta caagcctt		1288

<210> SEQ ID NO 18

<211> LENGTH: 6861

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 18

gcctgggagg tgcgtcagat ccgagctcgc catccagttt cctctccact agtccccca	60
gttgagatc tgggaccaac aaggcaccat ggcgcagaag ggccaactca gtgacgatga	120
gaagttcctc tttgtggaca aaaacttcat caacagccca gtggcccagg ctgactgggc	180
cgccaagaga ctgctctggg tcccctcgga gaagcagggc ttcgaggcag ccagcattaa	240
ggaggagaag ggggatgagg tggttgtgga gctggtggag aatggcaaga aggtcacggt	300
tgggaaagat gacatccaga agatgaaccc acccaagttc tccaaggtgg aggacatggc	360
ggagctgacg tgctcaacg aagcctcgt gctacacaac ctgaggggagc ggtacttctc	420
agggctaata tatacgtact ctggcctctt ctgctgtgtg gtcaaccctc ataaacacct	480
gcccacttac tcggagaaga tcgtcgacat gtacaagggc aagaagaggc acgagatgcc	540
gcctcacatc tacgccatcg cagacacggc ctaccggagc atgcttcaag atcgggagga	600
ccagtccatt ctatgcacag gcgagtctgg agccgggaaa accgaaaaca ccaagaaggt	660
cattcagtac ctggccgtgg tggcctcctc ccacaagggc aagaaagaca caagtatcac	720
gggagagctg gaaaagcagc ttctacaagc aaaccgatt ctggaggctt tcggcaacgc	780
caaaacagtg aagaacgaca actcctcacg attcggcaaa tcatccgca tcaacttcga	840
cgtcacgggt tacatcgtgg gagccaacat tgagacctat ctgctagaaa aatcacgggc	900
aattcgccaa gccagagacg agaggacatt ccacatcttt tactacatga ttgctggagc	960
caaggagaag atgagaagtg acttgctttt ggagggttc acaactaca ccttcctctc	1020
caatggcttt gtgccatcc cagcagccca ggatgatgag atgttccagg aaaccgtgga	1080
ggccatggca atcatgggtt tcagcgagga ggagcagcta tccatattga aggtggtatc	1140
atcggctctg cagcttggaa atatcgtctt caagaaggaa agaaacacag accaggcgtc	1200
catgccagat aacacagctg ctcaaaaagt ttgccacctc atgggaatta atgtgacaga	1260
tttcaccaga tccatctca ctctcgtat caaggttggg cgagatgtgg tacagaaagc	1320
tcagacaaaa gaacaggctg actttgctgt agaggctttg gccaaaggca catatgagcg	1380
ccttttccgc tggatactca cccgcgtgaa caaagccctg gacaagacc atcggcaagg	1440
ggcttccttc ctgggagatc tggatatagc tggatttgag atctttgagg tgaactcctt	1500
cgagcagctg tgcataact acaccaacga gaagctgcag cagctcttca accacaccat	1560
gttcacacctg gagcaggagg agtaccagcg cgagggcac gagtggaact tcacgactt	1620
tgggctggac ctacagccct gcacagagct catcgagcga ccgaacaacc ctccaggtgt	1680
gctggccctg ctggacgagg aatgctggtt ccccaaagcc acggacaagt ctttcgtgga	1740

-continued

gaagctgtgc	acggagcagg	gcagccaccc	caagttccag	aagcccaagc	agctcaagga	1800
caagactgag	ttctccatca	tccattatgc	tgggaagggtg	gactataatg	cgagtgcctg	1860
gctgaccaag	aatatggacc	cgctgaatga	caacgtgact	tccttgctca	atgcctcctc	1920
cgacaagttt	gtggccgacc	tgtggaagga	cgtggaccgc	atcgtggggc	tggaccagat	1980
ggccaagatg	acggagagct	cgctgccag	cgctccaag	accaagaagg	gcatgttccg	2040
cacagtgggg	cagctgtaca	aggagcagct	gggcaagctg	atgaccacgc	tacgcaacac	2100
cacgccaac	ttcgtgcgt	gcatcatccc	caaccacgag	aagaggtccg	gcaagctgga	2160
tgcgttcctg	gtgctggagc	agctgcgggtg	caatgggggtg	ctggaaggca	ttcgcacatg	2220
ccggcagggc	ttccccaacc	ggatcgtctt	ccaggagtgc	cgccaacgct	acgagatcct	2280
ggcgcgcaat	gccatcccca	aaggcttcat	ggacgggaag	caggcctgca	ttctcatgat	2340
caaagccctg	gaacttgacc	ccaacttata	caggataggg	cagagcaaaa	tcttcttccg	2400
aactggcgct	ctggcccacc	tagaggagga	gcgagatttg	aagatcacccg	atgtcatcat	2460
ggccttccag	gcgatgtgtc	gtggctactt	ggccagaaag	gcttttgcca	agaggcagca	2520
gcagctgacc	gccatgaagg	tgattcagag	gaactgcgcc	gcctacctca	agctgcggaa	2580
ctggcagtg	tggagcctt	tcaccaaagt	gaagccactg	ctgcaggtga	cacggcagga	2640
ggaggagatg	caggccaagg	aggatgaact	gcagaagacc	aaggagcggc	agcagaaggc	2700
agagaatgag	cttaaggagc	tggaaacagaa	gcactcgcag	ctgaccgagg	agaagaacct	2760
gctacaggaa	cagctgcagg	cagagacaga	gctgtatgca	gaggctgagg	agatgcgggt	2820
gcggctggcg	gccaagaagc	aggagctgga	ggagatactg	catgagatgg	aggcccgcct	2880
ggaggaggag	gaagacagg	gccagcagct	acaggctgaa	aggaagaaga	tggcccagca	2940
gatgctggac	cttgaagaac	agctggagga	ggaggaagct	gccaggcaga	agctgcaact	3000
tgagaaggtc	acggctgagg	ccaagatcaa	gaaactggag	gatgagatcc	tggtcatgga	3060
tgatcagaac	aataaactat	caaaagaacg	aaaactcctt	gaggagagga	ttagtgactt	3120
aacgacaaat	cttgacagaag	aggaagaaaa	ggccaagaat	cttaccaagc	tgaaaaacaa	3180
gcatgaatct	atgatttcag	aactggaagt	gcggctaaag	aaggaagaga	agagccgaca	3240
ggagctggag	aagctgaaac	ggaagctgga	gggtgatgcc	agcgacttcc	acgagcagat	3300
cgctgacctc	caggcgcaga	tcgcagagct	caagatgcag	ctggccaaga	aggaggagga	3360
gctgcaggcg	gccctggcca	ggcttgacga	tgaaatcgct	cagaagaaca	atgccctgaa	3420
gaagatccgg	gagctggagg	gccacatctc	agacctccag	gaggacctgg	actcagagcg	3480
ggcggccagg	aacaaggctg	aaaagcagaa	gcgagacctc	ggcgaggagc	tggaggccct	3540
aaagacagag	ctggaagaca	cactggacag	cacagccact	cagcaggagc	tcaggggccaa	3600
gagggagcag	gaggtgacgg	tgctgaagaa	ggccctggat	gaagagacgc	ggctccatga	3660
ggctcaggtc	caggagatga	ggcagaaaca	cgcacaggcg	gtggaggagc	tcacagagca	3720
gcttgagcag	ttcaagagg	ccaaggcgaa	cctagacaag	aataagcaga	cgctggagaa	3780
agagaacgca	gacctggccg	gggagctgcg	ggctcctggc	caggccaagc	aggaggtgga	3840
acataagaag	aagaagctgg	aggcgcaggt	gcaggagctg	cagtccaagt	gcagcgatgg	3900
ggagcggggc	cgggcggagc	tcaatgacaa	agtccacaag	ctgcagaatg	aagttgagag	3960
cgtcacagg	atgcttaacg	aggccgagg	gaaggccatt	aagctggcca	aggacgtggc	4020

-continued

gtccctcagt	tcccagctcc	aggacaccca	ggagctgctt	caagaagaaa	cccggcagaa	4080
gctcaacgtg	tctacgaagc	tgcgccagct	ggaggaggag	cggaaacagcc	tgcaagacca	4140
gctggacgag	gagatggagg	ccaagcagaa	cctggagcgc	cacatctcca	ctctcaacat	4200
ccagctctcc	gactcgaaga	agaagctgca	ggactttgcc	agcaccgtgg	aagctctgga	4260
agaggggaag	aagaggttcc	agaaggagat	cgagaacctc	accagcagct	acgaggagaa	4320
ggcgcccgct	tatgataaac	tggaaaagac	caagaacagg	cttcagcagg	agctggacga	4380
cctggttggt	gatttggaac	accagcggca	actcgtgtcc	aacctggaaa	agaagcagag	4440
gaaatttgat	cagttgttag	ccgaggagaa	aaacatctct	tccaaatcgc	cggatgagag	4500
ggacagagct	gaggcagaag	ccaggagaaa	ggaaaccaag	gcctgtccc	tggtcgggc	4560
ccttgaagag	gccttgaag	ccaaagagga	actcgagcgg	accaacaaaa	tgctcaaagc	4620
cgaaatggaa	gacctggtca	gctccaagga	tgacgtgggc	aagaacgtcc	atgagctgga	4680
gaagtccaag	cgggccctgg	agaccagat	ggaggagatg	aagacgcagc	tggaagagct	4740
ggaggacgag	ctgaagcca	cggaggagcgc	caactgcgg	ctggaagtca	acatgcaggc	4800
gctcaagggc	cagttcgaaa	gggatctcca	agcccgggac	gagcagaatg	aggagaagag	4860
gaggcaactg	cagagacagc	ttcacgagta	tgagacggaa	ctggaagacg	agcgaaagca	4920
acgtgccctg	gcagctgcag	caaagaagaa	gctggaaggg	gacctgaaag	acctggagct	4980
tcaggccgac	tctgccatca	aggggaggga	ggaagccatc	aagcagctac	gcaaactgca	5040
ggctcagatg	aaggactttc	aaagagagct	ggaagatgcc	cgtgcctcca	gagatgagat	5100
ctttgccaca	gccaaagaga	atgagaagaa	agccaagagc	ttggaagcag	acctcatgca	5160
gctacaagag	gacctcgccg	ccgctgagag	ggctcgcaa	caagcggacc	tcgagaagga	5220
ggaactggca	gaggagctgg	ccagtagcct	gtcgggaagg	aacgcactcc	aggacgagaa	5280
gcgcgcctg	gaggcccgga	tcgcccagct	ggaggaggag	ctggaggagg	agcaggggca	5340
catggaggcc	atgagcgacc	gggtccgcaa	agccacacag	caggccgagc	agctcagcaa	5400
cgagctggcc	acagagcgca	gcacggccca	gaagaatgag	agtgccgggc	agcagctcga	5460
gcggcagaac	aaggagctcc	ggagcaagct	ccacgagatg	gagggggccg	tcaagtccaa	5520
gttcaagtcc	accatcgccg	cgctggaggc	caagattgca	cagctggagg	agcaggtcga	5580
gcaggaggcc	agagagaaac	aggcgccac	caagtcgctg	aagcagaaag	acaagaagct	5640
gaaggaatc	ttgctgcagg	tggaggacga	gcgcaagatg	gccgagcagt	acaaggagca	5700
ggcagagaaa	ggcaatgcca	gggtcaagca	gctcaagagg	cagctggagg	aggcagagga	5760
ggagtccag	cgcatacaac	ccaacgcag	gaagctgcag	cgggagctgg	atgaggccac	5820
ggagagcaac	gaggccatgg	gccgcgaggt	gaacgcactc	aagagcaagc	tcaggcgagg	5880
aaacgagacc	tctttcgctc	cttctagaag	gtctggagga	cgtagagtta	ttgaaatgc	5940
agatggttct	gaggagggaa	cggacactcg	agacgcagac	ttcaatggaa	ccaaggccag	6000
tgaataagca	actttctaca	gttttgacc	acggcaagaa	aacaaaaaac	caaaacaaac	6060
aaacaaaaaa	aaccacaaca	caaccagaa	caaagcaaaa	cccagcagac	tgtacttagc	6120
attgtctaaa	tccattctca	aattccaaat	atcacagaca	cccctcacac	aaggaatata	6180
aaaaccacca	ccctccagcc	tgggcaacgt	agtaaaacct	catctatata	agaattttaaa	6240
aataagctgg	gcgtgggtgt	acacacctgt	ggtcccagct	actagggagg	ctgagccagg	6300

-continued

```

aagaacgctc cagcccagga cttcgaggct gcaatgagct ataattgcat cattgcactc 6360
cagcctgggc aacagagacc ctgtctcaac caccaccacc accaccaccc ctactacccc 6420
tgtattcaag gtaaaaattg aagtttgat gatgtaagag atgagaaaaa cccaacagga 6480
aacacagaca catcctccag ttctatcaat ggattgtgca gacactgagt ttttagaaaa 6540
acatatccac ggtaaccggt ccctggcaat tctgtttaca tgaatatggg agaaagtcac 6600
cgaaatgggt gccgcgggcc cccactccca attcattccc taacctgcaa acctttccaa 6660
cttctcacgt caggcctttg agaattcttt cccctctctc tggtttccac acctcagaca 6720
cgcacagttc accaagtgcc ttctgtagtc acatgaattg aaaaggagac gctgctccca 6780
cggaggggag caggaatgct gcaactgtta caccctgact gtgcttaaaa acactttcac 6840
taataaatgg ttataaatca c 6861

```

```

<210> SEQ ID NO 19
<211> LENGTH: 1243
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 19

```

```

ggacgcaacc atctgcggaa aggatagggg ggaggaagac ttaacactgc aacaacaggt 60
acaaaaaaga aggaaactca gtaacaggac ccagaggacc attatatatt gctctatatt 120
ctaggtcgcc cactttacac ttccttctca tgcacttggg caataccacg cccgctgacc 180
acactggcga cttccctctc tgctgcccct ccgtgaagtc agaccactc tcggggccaa 240
gaaaggtgac cgggcttctc tccggcttgc taagcagagg ccggaagcgg tggtttttag 300
cggctctctg ggtagcaggg tgggtgtgata gcggcagcga ggggctcgga gaggtgctcg 360
gattctcgta gctgtgccg gacttaacca ccaccatgct gagcaaaaga acaaagacca 420
agaccaagaa gcgcctcag cgtgcaacat ccaatgtgtt tgctatgttt gaccagtcgc 480
agattcagga gttcaaagag gccttcaaca tgattgatca gaacagagat ggtttcatcg 540
acaaggaaga tttgcatgat atgcttgctt cattggggaa gaatccaact gatgagtatc 600
tagatgccat gatgaatgag gctccaggcc ccatcaattt caccatgttc ctcaccatgt 660
ttggtgagaa gttaaatggc acagatcctg aagatgtcat cagaaatgcc tttgcttgct 720
ttgatgaaga agcaactggc accatacagg aagattactt gagagagctg ctgacaacca 780
tgggggatcg gtttacagat gaggaagtgg atgagctgta cagagaagca cctattgata 840
aaaaggggaa tttcaattac atcgagtcca cgcgcctcct gaaacatgga gccaaagaca 900
aagatgactg aaataacttc aaattocagc caaacgttcc ttgttgccac tttgggtatt 960
ctgagatttt ctcttgcatg cccttagctt tacagctttt gcatttctcg ttgtatttat 1020
tctcagccat tttgggcata tgtatcttta taatcagact ggaaacggga ctttctatta 1080
atatcatttt cagaataaaa aataggataa tttaacctac cagcccttct cccccaataa 1140
ctgtggtcta tacagagtca atatatTTTT tcggagaaag ttattcgctc gattttttct 1200
gaatcataat taaactttat gataaaaata aaaaaaaaaa aaa 1243

```

```

<210> SEQ ID NO 20
<211> LENGTH: 878
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

```

-continued

<400> SEQUENCE: 20

```

aggaagtgtc ggcgccgcca ctgtccggcc acagcctaac gctcttcgct gtcgtttgcg      60
gtctcggcag ggcgcccccg ttctgggtgtt tggcgtcggga attaaacaac caccatgtcg      120
agcaaaaagg caaagaccaa gaccaccaag aagcgccctc agcgtgcaac atccaatgtg      180
tttgccatgt ttgaccagtc acagattcag gagttcaaag aggccttcaa catgattgat      240
cagaacagag atgggttcat cgacaaggaa gatttgcatg atatgcttgc ttctctaggg      300
aagaatccca ctgatgcata ccttgatgcc atgatgaatg aggccccagg gccaatcaat      360
ttcaccatgt tctgaccat gtttggtgag aagttaaag gcacagatcc tgaagatgtc      420
atcagaaaacg cctttgcttg ctttgatgaa gaagcaacag gtaccattca ggaagattac      480
ctaagagagc tgctgacaac catgggggat cggtttacag atgaggaagt ggatgagctg      540
tacagagaag cacctattga caaaaagggg aatttcaatt acatcgagtt cacacgcac      600
ctgaaacatg gagccaaaga caaagatgac tgaaagaact ttagctaaaa tcttcagtt      660
acattgtctt actctctttt acttctcaga cacttcccc accctcatag aacctgttgc      720
atgcaactta gtttcacagc ttgcctctt ctttttgatg tatttattcc agacctttct      780
gccacttagc acttgataa tcagactgga aatggggatg aggggtgtaaa ttgtattgaa      840
aaagatcgcg aataaaaatc aacaaagtgt gaaagccc      878

```

<210> SEQ ID NO 21

<211> LENGTH: 1681

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 21

```

agttggaggg aggcagggaa tctggcttga ttggcgtgct gagacgcacc tggcgcaacc      60
ctcccttctg aatcgaagtt caagtcccg ggacactgca accatgaagg agagacgggc      120
ccccagcca gtcgtggcca gatgtaagct cgttctggtc ggggacgtgc agtgtgggaa      180
gaccgcgatg ttgcaagtgt tagcgaagga ttgctatcca gagacctatg tgcccaccgt      240
gttcgaaaat tacacagcct gtttggagac agaggaacag aggggtggagc ttagtctctg      300
ggatacctca ggatctccct actacgataa tgtccgtcca ctctgctaca gcgactcgga      360
tgcagtatta ctatgttttg acatcagccg tccagagaca gtggacagcg cactcaagaa      420
gtggaggaca gaaatcctag attattgtcc cagcaccgcg gttttgctca ttggtgcaa      480
gacagacctg cgaacagacc tgagtactct gatggagctg tcccaccaga agcaggcgcc      540
catctcctat gagcagggtt gtgcaatagc aaagcagctg ggtgcagaaa tctacctgga      600
aggetcagct ttcacctcag aaaagagcat ccacagcatc tttcgagcg catccatgct      660
gtgtctgaac aagcctagcc cactgcccc gaagagccct gtccgaagcc tctccaaacg      720
actgtccac ctcccagtc gctctgaact catctcttct accttcaaga aggaaaaggc      780
caaaagctgt tccattatgt gaagtggaaa ttggaggggg gagacaaccc cctacttcct      840
cccttggggg gcagaggcac ggggagaggg aggatgagac aatttaggac actggacatg      900
agtttttcag atggccacgg tgagggttg gaaggagaca ggaatggggc gaggaaggag      960
ccaggcccg catgaggacc tgacgtgag agagaacat catacccaa gccaggcact      1020
agattttgga gggggcgact accccagtc ccccccgct ccagaggaag gaaagctgtg      1080

```

-continued

```

ggggacgggg ggcacgtctg cctcatgggc ttggggggcct acagcagcct caccttcagc 1140
ttcatgcctc ttccacacag cgtttccatg caggtcaggg gatgggaggg gtccctgagc 1200
ccttcctctc cctctcaagg aggcagcaac ggagagtggg gaagtggagc ggcagctccc 1260
ttgggggctt agcccagggt cttcgtaact gcaatcgga gtgcaggggc tggtcagagc 1320
caatgagaag gaaacctcat ctttgcatag cccatgcctc atggagaggt gacatcatac 1380
attcacatgc ttctcaccta agtccccagg gtccaaggga gaagcccag acccccttct 1440
cttgacagag gtgggggttg tgggtgctga ggggcagggc tgggtggggg tcaccagact 1500
ttttctgccc ttaggtagt acagctggca tttgtttat agactcttgt ctttgaatt 1560
ggggggaggg ggggagtgtt tcaatctgtt atatgttctg tgtttaatga agaaaacct 1620
tttattaatg aaaaataata tacatataaa gaaaaaaaaa aaaaagaaaa aaaaaaaaaa 1680
a 1681

```

```

<210> SEQ ID NO 22
<211> LENGTH: 865
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 22

```

```

ctcaaacacc gcctgctaaa aatacccgac tggaggagca taaaagcgca gccgagccca 60
gcgccccgca cttttctgag cagacgtcca gagcagagtc agccagcatg accgagcgcc 120
gcgtccccct ctgcgtcctg cggggcccca gctgggaccc cttccgcgac tggtagccgc 180
atagccgcct cttcgaccag gccttcgggc tgccccggct gccggaggag tggtcgcagt 240
ggtaggcggc cagcagctgg ccaggtctac tgccccctt gcccccgcgc gccatcgaga 300
gccccgcagt ggccgcgccc gcctacagcc gcgcgctcag ccggcaactc agcagcgggg 360
tctcgagat ccggcacact gcggaccgct ggcgcgtgtc cctggatgtc aaccacttcg 420
ccccggacga gctgacggtc aagaccaagg atggcgtggt ggagatcacc ggcaagcacg 480
aggagcgcca ggacgagcat ggctacatct cccggtgctt cagcgggaaa tacacgtgc 540
ccccggtgt ggacccacc caagtttctt cctcctgtc cctgagggc aactgaccg 600
tggaggcccc catgcccagg ctagccacgc agtccaacga gatcaccatc ccagtcacct 660
tcgagtcgcg ggcccagctt gggggcccag aagctgcaaa atccgatgag actgccgcca 720
agtaaagcct tagcctggat gccacccctt gctgccgcca ctggctgtgc ctccccgcc 780
acctgtgtgt tcttttgata catttatctt ctgtttttct caaataaagt tcaaagcaac 840
cacctgtaaa aaaaaaaaaa aaaaa 865

```

```

<210> SEQ ID NO 23
<211> LENGTH: 3890
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 23

```

```

gcacctgggc acctgggcag ccgccgcggc gctggctaga cgtgcgcgat ggagggcgac 60
ggcggggacc catgggcctt ggcgctgtg cgcaccttcg acgcgggcga gttcacgggc 120
tgggagaagg tgggctcggg cggcttcggg caggtgtaca aggtgcgcca tgtccactgg 180
aagacctggc tggccatcaa gtgctcgccc agcctgcacg tcgacgacag ggagcgcatg 240

```

-continued

gagcttttgg aagaagccaa gaagatggag atggccaagt ttcgctacat cctgcctgtg	300
tatggcatct gccgcgaacc tgtcggcctg gtcattggagt acatggagac gggctccctg	360
gaaaagctgc tggtctcgga gccattgcc a tgggatctcc ggttcggaat catccacgag	420
acggcgggtg gcatgaactt cctgcactgc atggccccgc cactcctgca cctggacctc	480
aagcccgca acatcctgct ggatgccac taccacgtca agatttctga ttttggctg	540
gccaaagtca acgggctgtc ccaactcgc gacctcagca tggatggcct gtttggcaca	600
atcgctacc tccctccaga gcgcacagg gagaagagcc ggctcttcga caccaagcac	660
gatgtataca gctttcgcat cgtcatctgg ggcgtgctca cacagaagaa gccgtttgca	720
gatgagaaga acatcctgca catcatggg aaggtgggtga agggccaccg ccccgagctg	780
ccgccctgtg gcagagcccg gccgcggccc tgcagccacc tgatacgct catgcagcgg	840
tgctggcagg gggatcccg agttaggccc acctccaag aaattacttc tgaaccgag	900
gacctgtgtg aaaagcctga tgacgaagt aaagaaactg ctcatgatct ggacgtgaaa	960
agcccccg agccaggag cgaggtggg cctgcgaggc tcaagcgggc ctctgcccc	1020
accttcgata acgactacag cctctccgag ctgctctcac agctggactc tggagtttcc	1080
caggctgtcg agggccccga ggagctcagc cgcagctcct ctgagtccaa gctgccatcg	1140
tccggcagtg ggaagaggct ctcggggggtg tctcgggtgg actccgcctt ctcttcaga	1200
ggatcactgt cgtgtcctt tgagcgggaa ccttcaacca gcgatctggg caccacagac	1260
gtccagaaga agaagcttgt ggatgccatc gtgtccgggg acaccagcaa actgatgaag	1320
atcctgcagc cgcaggagct ggacctggca ctggacagcg gtgccagcct gctgcacctg	1380
gcggtggagg cggggcaaga ggagtgcgc aagtggctgc tgcacaaca tgccaacccc	1440
aaactgagca accgtagggg ctccaccccg ttgcacatgg ccgtggagag gagggtgcgg	1500
ggtgtcgtgg agctcctgct ggcgcggaag atcagtgtca acgccaagga tgaggaccag	1560
tgacagccc tccactttgc agcccagaac ggggacgagt ctgacacacg gctgctgttg	1620
gagaagaacg cctcgtcaa cgaggtggac tttgagggcc ggacgcccac gcacgtggcc	1680
tgccagcacg ggcaggagaa tatcgtgcgc atcctgctgc gccgagcggt ggacgtgagc	1740
ctgcagggca aggatgcctg gctgccactg cactacgctg cctggcaggg ccacctgccc	1800
atcgtcaagc tgctggccaa gcagccgggg gtgagtgtga acgccagac gctggatggg	1860
aggacgcat tgcacctggc cgcacagcgc gggcactacc gcgtggcccg catcctcacc	1920
gacctgtgct ccgacgtcaa cgtctgcagc ctgctggcac agacaccct gcacgtggcc	1980
gcggagacgg ggcacacgag cactgccagg ctgctcctgc atcggggcgc tggcaaggag	2040
gccatgacct cagacggcta caccgctctg cactggctg cccgcaacgg acaactggcc	2100
actgtcaagc tgcttctgca ggagaaggcc gatgtgctgg cccggggacc cctgaaccag	2160
acggcgtgc acctggtgct cgcacacggg cactcggagg tggaggagga gttggtcagc	2220
gccgatgtca ttgacctgtt cgacgagcag gggctcagcg cgctgcacct ggcgcccag	2280
ggcgggcacg cacagacggt ggagactctg ctacggcatg gggccacat caacctgcag	2340
agcctcaagt tccaggggcg ccatggcccc gccgccagc tcctgcggcg aagcaagacc	2400
tagctggctg cctgcggaga cgggggtcc acgtggggct cttgtcctgt cctgtgttcc	2460
tcgtggggat ggaacgatcc tgcgtggggc cctgttgtgg cttacctaaa tgttaaccaa	2520

-continued

gcagaggtga catggtgcc tccaggaggcg gctgctgctg accggagtggt cccctccagg	2580
tgaagctggc tcagggtgcac atgcccgctc catcatcgat ctaggcacct gctgtctgaa	2640
gggaccgtgg gtcagaatca ttctgttggtg ctccctaatgg gtcgctgagg ctgggtctctc	2700
agtgatgaag ccccgaggcgt ggaagcatcc actctctcct gagcgagacc accttggggt	2760
gctggagctc accagtcctg agggagggtgc aggggaaact gtgtttttta tcttcataca	2820
tgacggtggg cagagaggcc tgtcttaag tttccatgga attgttttat aaaatatctt	2880
aagagatgaa taccttatca gctgttgctt gaaacctgtt aaaaatgttc ataacttgg	2940
atagtctagt ctctaaatga tgactaagta gtggggttgg ctttgaatac aatgttttat	3000
gcaacaagga acgaatggta gcagccagct ttgcggggcg tatgtgtggc cagctcttaa	3060
ccattccagt ctattacttg ggtgagtcct tgtggacaac cacacacacg tgcccacatg	3120
gtactagctg ccgttcgttt ctgctgcct aagatgtttt ggcaactcta gagccacagg	3180
cctaagtcat taaaaaatc tccctttgta acctcagtc tggggactga ggcgagcccc	3240
ctcaggtcgc tggagtcac cagtcttggg gaagagggtgc aggagaagct gtgtttttta	3300
tctccacacg cagtatgaag ataaaattac atagtattac ctgacatag acagtattac	3360
ctaggtagat gcactgctca cctgcgcct tcccagctct ctttttgggt aggtgatttg	3420
ggatagggat agtgttttgg ggtatggggg gagtgtttct gacctgcttt gcagacgtgc	3480
ctccgcacct cagcagtttg ggggtgtggc ccagggcggg tcttgatgt aaaagatgtg	3540
gccatctagc ctgtaactt cactgtcacc tgtgtcccat aggtgtcctt ctgaatactg	3600
ttattagaat aagtttggg cagaacgtga cctgcgtgc aaacatgtac cgtggcctgg	3660
tatatgatag agattgatat taatgtacca tgtatgttaa tgtgaatctg tgggcaggat	3720
acttttccat ggcagaaat atccaagctg ttgaaactgg ctatgtttta atatgcctca	3780
ttgtgccttt actgttgtgt ggactgcgtg agggacaaga agttccattt gatgtcaata	3840
aagcaaagta cttgcctact tttttgaagc tgaaaaaaaa aaaaaaaaaa	3890

<210> SEQ ID NO 24

<211> LENGTH: 894

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 24

cgctacacgc agcgcccttt gtgacaccag ggcctgtgtg ctttaactag ggcgttgga	60
cctgttgccc acacagaccg ccctgcagtt tcagactgga gggcggtgga cggctactca	120
gcggcccaac tctctgcag ccttctctc cgcaaatgt cagcctccac ctctcgcac	180
cggcccatca aggggatcct gaaaaacaaa agctcgtcgg gttcctcggg ggcgacttcc	240
ggtcagcagt ctggagggac tattcaagat gtgaagagaa agaaatccca aaagtgggac	300
gaatcaagca tccttgccgc acaccgcgca acgtacagag attacgattt aatgaaggca	360
aatgagcccc gcacttccta catgagtgtg caagataatg gggagattc agtgccgat	420
gtcgaaggag aagattcagt gcgtgggtgc gaaggaaaagg aagccaccga tgcttccgac	480
cacagctgtg aggtggacga gcaagagagc agtgaggcct acatgagaaa aatcctctc	540
cacaaacagg agaaaaagcg gcagttcgaa atgagaagaa ggcttcacta caacgaagaa	600
ttgaacatca aattagctag acaattaatg tggaaagagc taaaaagtga agataatgaa	660

-continued

aacgaagaaa cgccacaagg cacgaacgaa gagaagactg ctgcggaaga atcagaggaa	720
gctcctctga cgggtggact gcaaaccag tcattgcgacc cttagaagat gcctgtctca	780
cccttgcaat tgtttgtgaa tatgtgacgc ttagaagata tctgcttcac ccttgcaatt	840
gtttgtgaaa tacaaacctt gttactgtaa aaaaaaaaaa aaaaaaaaaa aaaa	894

<210> SEQ ID NO 25
 <211> LENGTH: 1574
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 25

tcaccacggc ggcagccctt taaaccctc acccagccag cgccccatcc tgtctgtccg	60
aaccagaca caagtcttca ctccctctcg cgagccctga ggaagccttg tgagtgcatt	120
ggctggggct tggagggaag ttgggctgga gctggacagg agcagtgggt gcatttcagg	180
caggctctcc tgaggctcca ggcgcagct ccagctccct ggctaggga acccaccctc	240
tcagtcagca tgggggcccc agctccaggc aggggtgggt ggatcactag cgtcctggat	300
ctctctcaga ctgggcagcc ccgggctcat tgaatgccc cggatgactt ggctagtga	360
gaggaattga tggaaaccac cggggtgaga gggaggtccc ccatctcagc cagccacatc	420
cacaagggtg gtgtaagggt gcaggcgccg gccggtagg ccaaggctct actgtctgtt	480
gcccctccag gagaacttcc aaggagcttt cccagacat ggccaacaag ggtccttctt	540
atggcatgag ccgcgaagtg cagtccaaaa tcgagaagaa gtatgacgag gagctggagg	600
agcggctggt ggagtggatc atagtgcagt gtggccctga tgtgggccgc ccagaccgtg	660
ggcgcttggg ctccaggtc tggctgaaga atggcgtgat tctgagcaag ctggtgaaca	720
gcctgtaccc tgatggctcc aagccggtga aggtgccga gaaccacccc tccatggtct	780
tcaagcagat ggagcagggt gctcagttcc tgaaggcggc tgaggactat ggggtcatca	840
agactgacat gttccagact gttgacctct ttgaaggcaa agacatggca gcagtgcaga	900
ggacctgat ggctttgggc agcttggcag tgaccaagaa tgatgggcac taccgtggag	960
atcccaactg gtttatgaag aaagcgcagg agcataagag ggaattcaca gagagccagc	1020
tgcaggaggg aaagcatgtc attggccttc agatgggcag caacagaggg gcctcccagg	1080
ccggcatgac aggtacgga cgacctggc agatcatcag ttagagcgga gagggctagc	1140
cctgagcccc gccctcccc agctccttgg ctgcagccat cccgcttagc ctgctcacc	1200
cacaccgtg tggtaacctc agccctggcc aagctttgag gctctgtcac tgagcaatgg	1260
taactgcacc tgggcagctc ctccctgtgc cccagcctc agcccaactt cttaccgaa	1320
agcatcactg ccttggcccc tccctcccg ctgcccccat cacctctact gtctcctccc	1380
tgggctaagc aggggagaag cgggctggg gtagcctgga tgtgggcaa gtccactgtc	1440
ctccttggcg gaaaaagccc attgaagaag aaccagccca gcctgcccc tatctgtcc	1500
tggaatatct ttggggttgg aactcaaaaa aaaaaaaaaa aaatcaatct tttctcaaaa	1560
aaaaaaaaa aaaa	1574

<210> SEQ ID NO 26
 <211> LENGTH: 3700
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens

-continued

<400> SEQUENCE: 26

agccgccgcc	acccgccgcg	cccgaccccc	gggaggcccc	gccagcccgc	gggagaggcc	60
cagcgggagt	cgcggaacag	caggccccgag	cccaccgcgc	cgggcccccg	acgccgcgcg	120
gaaaagatga	atttacaacc	aattttcttg	attggactga	tcagttcagt	ttgctgtgtg	180
tttgctcaaa	cagatgaaaa	tagatgttta	aaagcaaatg	ccaaatcatg	tggagaatgt	240
atacaagcag	ggccaaattg	tgggtggtgc	acaaattcaa	catttttaca	ggaaggaaat	300
cctacttctg	cacgatgtga	tgatttagaa	gccttaaaaa	agaagggttg	ccctccagat	360
gacatagaaa	atcccagagg	ctccaaagat	ataaagaaaa	ataaaaatgt	aaccaaccgt	420
agcaaaggaa	cagcagagaa	gctcaagcca	gaggatatta	ctcagatcca	accacagcag	480
ttggttttgc	gattaagatc	aggggagcca	cagacattta	cattaaaatt	caagagagct	540
gaagactatc	ccattgacct	ctactacctt	atggacctgt	cttactcaat	gaaagacgat	600
ttggagaatg	taaaaagtct	tggaaacagat	ctgatgaatg	aaatgaggag	gattacttcg	660
gacttcagaa	ttggatttgg	ctcatttgtg	gaaaagactg	tgatgcctta	cattagcaca	720
acaccagcta	agctcaggaa	cccttgccaca	agtgaacaga	actgcaccag	cccatttagc	780
tacaaaaaatg	tgctcagctc	tactaataaa	ggagaagtat	ttaatgaact	tgttggaaaa	840
cagcgcatat	ctggaatttt	ggattctcca	gaagtggtt	tcgatgccat	catgcaagtt	900
gcagtttgtg	gatcactgat	tggctggagg	aatgttacac	ggctgctggt	gttttccaca	960
gatgccgggt	ttcactttgc	tggagatggg	aaacttgggt	gcattgtttt	accaaagtat	1020
ggacaatgtc	acctggaaaa	taatatgtac	acaatgagcc	attattatga	ttatccttct	1080
attgctcacc	ttgtccagaa	actgagtga	aataatattc	agacaatttt	tgcagttact	1140
gaagaatttc	agcctgttta	caaggagctg	aaaaacttga	tcctaagtc	agcagtagga	1200
acattatctg	caaattctag	caatgtaatt	cagttgatca	ttgatgcata	caattccctt	1260
tcctcagaag	tcattttgga	aaacggcaaa	ttgtcagaag	gagtaacaat	aagttacaaa	1320
tcttactgca	agaacggggt	gaatggaaca	ggggaataatg	gaagaaatg	ttccaatatt	1380
tccattggag	atgaggttca	atttgaaatt	agcataactt	caaataagtg	tccaaaaaag	1440
gattctgaca	gctttaaaa	taggcctctg	ggctttacgg	aggaagtaga	ggttattctt	1500
cagtacatct	gtgaatgtga	atgccaaagc	gaaggcatcc	ctgaaagtcc	caagtgtcat	1560
gaaggaatg	ggacatttga	gtgtggcgcg	tgcaggtgca	atgaaggcg	tgttggtaga	1620
cattgtgaat	gcagcacaga	tgaagttaac	agtgaagaca	tggatgctta	ctgcaggaaa	1680
gaaaacagtt	cagaaatctg	cagtaacaat	ggagagtgcg	tctgcggaca	gtgtgtttgt	1740
aggaagagg	ataatacaaa	tgaaatttat	tctggcaaat	tctgcgagtg	tgataatttc	1800
aactgtgata	gatccaatgg	cttaatttgt	ggaggaaatg	gtgtttgcaa	gtgtcgtgtg	1860
tgtgagtgc	accccaacta	cactggcagt	gcattgtgact	gttctttgga	tactagtact	1920
tgtgaagcca	gcaacggaca	gatctgcaat	ggccggggca	tctgcgagtg	tggtgtctgt	1980
aagtgtacag	atccgaagtt	tcaagggcaa	acgtgtgaga	tgtgtcagac	ctgccttggt	2040
gtctgtgctg	agcataaaga	atgtgttcag	tgcagagcct	tcaataaagg	agaaaagaaa	2100
gacacatgca	cacaggaatg	ttcctatttt	aacattacca	aggtagaaag	tcgggacaaa	2160
ttacccagc	cgggtccaacc	tgatcctgtg	tccattgtga	aggagaagga	tgttgacgac	2220

-continued

tggttggttct	atatttacgta	ttcagtgaaat	gggaacaacg	aggtcacggt	tcatgttggtg	2280
gagaatccag	agtggtccac	tggtccagac	atcattccaa	ttgtagctgg	tgtggttgct	2340
ggaattgttc	ttattggcct	tgcattactg	ctgatatgga	agcttttaat	gataattcat	2400
gacagaagg	agtttgctaa	atttgaaaag	gagaaaatga	atgccaaatg	ggacacgggt	2460
gaaaatccta	tttataagag	tgccgtaaca	actgtggcca	atccgaagta	tgagggaata	2520
tgagtactgc	ccgtgcaa	atccacaacac	tgaatgcaaa	gtagcaattt	ccatagtcac	2580
agttaggtag	ctttagggca	atattgccat	gggttttactc	atgtgcaggt	tttgaataatg	2640
tacaatatgt	ataattttta	aaatgtttta	ttattttgaa	aataatgttg	taattcatgc	2700
cagggactga	caaaagactt	gagacaggat	ggttattcct	gtcagctaag	gtcacattgt	2760
gcctttttga	cctttttctc	ctggactatt	gaaatcaagc	ttattggatt	aagtgatatt	2820
tctatagcga	ttgaaagggc	aatagttaaa	gtaatgagca	tgatgagagt	ttctgttaat	2880
catgtattaa	aactgatttt	tagctttaca	aatatgtcag	tttgacagta	tgacagaatcc	2940
aaagtaaatg	tctgtctagc	tagttaagga	ttgttttaaa	tctgttattt	tgctatttgc	3000
ctgttagaca	tgactgatga	catatctgaa	agacaagtat	gttgagagtt	gctgggtgaa	3060
aatacgtttg	aaatagtgtg	tctacaaagg	ccatgggaaa	aattcagaga	gttaggaagg	3120
aaaaaccaat	agcttttaaa	cctgtgtgcc	attttaagag	ttacttaaatg	tttggttaact	3180
tttatgcctt	cactttacaa	attcaagcct	tagataaaag	aaccgagcaa	ttttctgcta	3240
aaaagtcctt	gatttagcac	tattttacata	caggccatac	tttacaagt	atttgctgaa	3300
tggggacctt	ttgagtgtaa	tttattttat	tatttttatt	ttgtttaaatg	tctgggtgctt	3360
tctatcacct	cttctaactc	tttaattgtat	ttgtttgcaa	ttttgggga	agactttttt	3420
atgagtactt	tttctttgaa	gttttagcgg	tcaatttgcc	tttttaata	acatgtgaag	3480
ttatactgtg	gctatgcaac	agctctcacc	tacgcgagtc	ttactttgag	ttagtgccat	3540
aacagaccac	tgtatgttta	cttctcacca	tttgagttgc	ccatcttggt	tcacactagt	3600
cacattcttg	ttttaagtgc	ctttagtgtt	aacagttcac	tttttacagt	gctattttact	3660
gaagttattt	attaaatatg	cctaaaatac	ttaaatcgga			3700

<210> SEQ ID NO 27

<211> LENGTH: 6407

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 27

agtctgcggg	cctccggggc	tgccgagagg	ccggagcgtc	gcggcggaga	ggacgagacc	60
gggacaagac	cagggcagga	gggagccggc	cagccgcgag	aaccccgac	gcccggcaag	120
atgctgtcct	tgccgctgca	gacgggcccc	gagaaggccg	agctccagga	gctcaacgcc	180
cggctctatg	actacgtgtg	tcgggtgcgg	gagctggagc	gcgaaaacct	actcctggag	240
gaggagctgc	gcggccggcg	cgggcgagag	ggcctgtggg	ccgaggggca	ggcccgcctgc	300
gccgaggagg	cgcgcagctt	gcggcagcag	ctggacgagc	tgagctgggc	cactgcgctg	360
gcggagggcg	agcgggacgc	tctgcggcgc	gagctgcggg	agctgcagcg	cctggatgcg	420
gaggagcgcg	ccgcccgcg	ccgcctggac	gccgagctgg	gtgcgcagca	gcgcgagctg	480
caggaggcgc	tgggcgcgcg	cgccgccttc	gaggcgctgc	tgggcgcgact	gcaggccgag	540

-continued

cgccgagggc	tcgacgcggc	ccacgaacgc	gacgtgaggg	agctgcgcgc	gcgcgcggcc	600
agccttacca	tgcatttcgc	cgcccgccgc	accggccccc	ccgcgcgcgc	gccacgcctg	660
cgggagggtgc	acgacagcta	cgcactgctg	gtggccgagt	cgtggcgagg	gacggtgacg	720
ctgtacgagg	acgaggtgcg	cgagctggag	gaggcgctgc	ggcgcgccca	ggagagcaga	780
ctccaggcgg	aggaagagac	gcggctgtgc	gcgcaggagg	cagaggcgct	gcggcgcgag	840
gcgctcgggt	tggagcagct	gcgcgcgcgg	ctggaggacg	cgtgctgctg	gatgcgcgag	900
gagtacggga	tacagggcca	ggagcggcag	agagtgattg	actgcctgga	ggatgagaag	960
gcaacctca	ccttgcccat	ggctgactgg	ctgcgggact	atcaggacct	cctgcagggtg	1020
aagaccggcc	tcagtttgga	ggtggcgacc	taccgggcct	tattggaagg	agaaagtaat	1080
ccagagatag	tgatctgggc	tgagcacgtt	gaaaacatgc	cgtcagaatt	cagaaacaaa	1140
tcctatcact	ataccgactc	actactacag	agggaaaatg	aaaggaatct	attttcaagg	1200
cagaaagcac	ccttgccaag	tttcaatcac	agctcggcac	tgtattctaa	cctgtcagggtg	1260
caccgtggat	ctcagacggg	cacatctatt	ggagggtgatg	ccagaagagg	cttcttgggc	1320
tcgggatatt	cttcctcggc	cactaccacg	caggaaaact	catacggaaa	agccgtcagc	1380
agtcaaacca	acgtcagaac	tttctctcca	acctatggcc	ttttaagaaa	tactgagggt	1440
caagtgaaaa	cattccctga	cagaccacaa	gccggagata	caaggagggt	ccccgtttac	1500
atagggtgaag	attccacaat	tgcccgcgag	tcgtaccggg	atcgccgaga	caagggtggca	1560
gcagggtgctt	cggaaagcac	acgggtcaaat	gagaggaccg	tcattctggg	aaagaaaaca	1620
gaagtgaag	ccacgaggga	gcaagaaaga	aacagaccag	aaacctccg	aacaaagcca	1680
gaagagaaaa	tgttcgatgc	taaagagaag	gcttccgagg	agagaaacct	aagatgggaa	1740
gaattgacaa	agttagataa	ggaagcgaga	cagagagaaa	gccagcagat	gaaggagaag	1800
gctaaggaga	aggactcact	gaaggagaag	agtggtgcgag	agagagaggt	gccgattagt	1860
ctagaagtat	cccaggacag	aagagcagag	gtgtccccga	aaggtttgca	gacgcctgtg	1920
aaggatgctg	gtggtgggac	cggtagagag	gcagaagcaa	gagagctacg	gttcagggttg	1980
ggcaccagtg	atgccactgg	ttctctgcaa	ggcgattcca	tgacagaaac	cgtagcagaa	2040
aacatcggtta	ccagtatcct	gaagcagttc	actcagttct	cagagacaga	agcatctgct	2100
gattcttttc	cagacacaaa	agtcacttac	gtggacagga	aagagcttcc	tggggaaagg	2160
aaaacaaaga	ctgaaatact	tgtggagtct	aaactgactg	aggatgttga	tgtttccgat	2220
gaagctggcc	tggactacct	tttaagcaag	gatattaagg	aagtggggct	gaaaggcaag	2280
tcagccgagc	agatgatagg	agacatcatc	aacctcgccc	tgaaaggagg	ggaggggaga	2340
gcaaaggctg	tcaacgtgga	gatcgtggag	gagcccgtag	gttatgtcag	cggggagaag	2400
ccggaggagt	tttcgctccc	attcaaagtg	gaggaggctg	aagatgtgtc	gccaggcccc	2460
tgggggttgg	tttaaggagga	ggaagggttat	ggagaaagcg	atgtcacatt	ctcagttaat	2520
cagcatcgaa	ggaccaagca	gcctcaggag	aacacgactc	acgtggaaga	agtgcagag	2580
gcagggtgatt	cagagggcga	gcagagttat	tttgtgtcca	ctccagatga	acccccggg	2640
gggcacgaca	gagatgacgg	ctcggtgtac	gggcagatcc	acatcgagga	ggaatccacc	2700
atcagggtact	cttggcagga	tgaaatcgtg	caggggactc	gaaggaggac	acagaaggac	2760
ggtgcagtg	gcgagaaggt	tgtgaagccc	ttggatgtcc	cagcgccctc	tctggagggg	2820

-continued

gacctggggtt ccactcactg gaaagaacaa gctagaagcg gtgaatttca tgccgaaccc	2880
acagtcattg aaaaagaaat taaaataccc cacgaattcc acacctccat gaagggcac	2940
tcctccaagg agccccggca gcagctgggtg gaagtcacg ggcagctgga ggaaccctt	3000
cccagcgca tgagggagga gctgtccgcc ctcaccagag aggggcaggg tgggccggg	3060
agcgtttccg tggatgtcaa gaaggtccag ggtgctgggtg gcagttccgt gacctggtt	3120
gctgaagtca acgtctcaca aactgtggat gccgatcgg tagacctgga ggaggtgagc	3180
aaagatgagg ccagttagat ggagaaggct gtggagtcgg tggttcggga gagcctgagc	3240
aggcaacgca gccacgcgc tggcagccca gatgaggaag gtggagcgga ggcggcggt	3300
gctggcattc gctttaggcg ttgggccacc cgggagctgt acatcccttc aggcgagagc	3360
gaggttgctg gtggggcctc tcacagctcg ggacagcgca cccccaggg ccagtgctg	3420
gccactgtgg aggtcagcag cccacaggc tttgccagt cacaggtgct ggaggatgtg	3480
agccaggctg caaggcacat aaaactcggc ccctctgaag tctggaggac tgagcgaatg	3540
tcatatgaag gacctactgc agaagtgggt gagatggatg tgagtaacgt agaggcgatc	3600
cgagccgga cacaggaagc gggagctctc ggtgtgtctg accgtggttc ctggagagac	3660
gcggacagta ggaatgacca ggcagttggt gtgagcttta aggcctctgc tggggaagga	3720
gaccaggccc acagagaaca gggcaaggag caggccatgt ttgataagaa ggtgcagctc	3780
cagagaatgg tagaccaaag gtcggtgatt tcagatgaaa agaaagtgc cctcctctat	3840
ctagacaatg agggaggaga gaatgatggg cattgggtttt aataagcaga aacattttgt	3900
tttaatggca gcctgttgge gacgtgcaa catccaaagg ccttaactta tttaagagg	3960
ccgagggagt ctatgaaat cccccctttt ttactttttt aaagagtact cccggcatgg	4020
tcaatttcct ttatagttaa tccgtaaagg tttccagtta attcatgcct taaaaggcac	4080
tgcaatttta tttttgagtt gggactttta caaaacactt ttttcctgg agtcttctct	4140
ccacttctgg agatgaattt ctatgttttg cacctggcca cagacatggc ttgcatctgt	4200
ttgaaactac aattaattat agatgtcaaa acattaacca gattaaagta atatatttaa	4260
gagtaaatat tgcttgcatg tgctaatatg aaataacaga ctaacatttt aggggaaaaa	4320
taataacaat ttagactcta aaaagtcttt tcaaaaagaa atgggaaata ggcagactgt	4380
ttatgttaaa aaaattcttg ctaaatgatt tcacttttag gaaaaatta cttgccatat	4440
agagctaaat tcactttaag acttgaatga attgctttct atgtacagaa ctttaacaa	4500
tatagtattt atggcgagga cagctgtagt ctgttgatg atttcacatt ctatttgac	4560
aggttccttg gcactggtag ggtagatgat tattgggaat cgcttacagt accatttcat	4620
tttttggcac taggtcatta agtagcacac agtctgaatg cctttttctg gagtggccag	4680
ttcctatcag actgtgcaga cttgcgcttc tctgcacct atcccttagc acccaaacat	4740
ttaatttcac tgggtgggag tagacctga agacaatgaa gagaatgccg ataactcagac	4800
tgacagtgga ccggcaagct ggctgtgtac aggaaaattg gaagcacaca gtggactgtg	4860
cctcttaaag atgcctttcc caaccctcca ttcattggat gcaggctttt ctgagctcaa	4920
gggtgaaaga tgaatacaat aacaaccatg aaccacctc acggaagctt tttttgact	4980
ttgaacagaa gtcattgcag ttgggggtgt ttgtccaggg aaacagtta ttaaatagaa	5040
ggatgttttg gggaaggaaac tggatatctc tcctgcagcc cagcaccgag ataccagga	5100

-continued

cgggcctggg	gggcgagaaa	ggcccccatg	ctcatgggcc	gcgagtggtg	gacctgtaga	5160
taggcaccac	cgagttaag	atactgggat	gagcatgctt	cattggattc	attttatttt	5220
acacgtcagt	attgttttaa	agtttctgtc	tgtaaagtgt	agcatcatat	ataaaaagag	5280
tttcgctagc	agcgcatttt	ttttagtcca	ggctagcttc	tttcacataa	tgctgtctca	5340
gctgtatttc	cagtaacaca	gcatcatcac	actgactgtg	gcgcactggg	gaataacagt	5400
ctgagctagc	accaccctca	gccagggtac	aacgacagca	ctggaggggc	ttccctctca	5460
gattcacctg	gaggccctca	gacccccagg	gtgcacgtct	ccccaggctc	tgggagtggc	5520
taccgcaggt	agtttctgga	gagcacgttt	tcttcattga	taagtggagg	agaaatgcag	5580
cacagctttc	aagatactat	tttaaaaaa	ccatgaatca	gatagggaaa	gaaagttagt	5640
tggaatggca	agtttaaacc	tttgtgtccc	atctgccaaa	tgaactagtg	attgtcagac	5700
tggtatggag	gtgactgctt	tgtaagggtt	tgctgtttct	aatacagaca	gagatgtgct	5760
gattttgttt	tagctgtaac	aggtaatggt	ttttggatag	atgattgact	ggtgagaatt	5820
tggtcaaggt	gacagcctcc	tgtctgatga	caggacagac	tggtggtgag	gagtctaagt	5880
gggctcagtt	tgatgtcagt	gtctgggctc	atgacttgta	aatggaagct	gatgtgaaca	5940
ggtaattaat	attatgaccc	acttctattt	actttgggaa	atatcttgga	tcttaattat	6000
catctgcaag	tttcaagaag	tattctgcca	aaagtattta	caagtatgga	ctcatgagct	6060
attgttggtt	gctaaatgtg	aatcacgcgg	gagtgagtgt	gcccttcaca	ctgtgacatt	6120
gtgacattgt	gacaagctcc	atgtccttta	aaatcagcca	ctctgcacac	aagagaaatc	6180
aacttcgtgg	ttggatgggg	ccggaacaca	accagtcttt	ttgtatttat	tggtactgag	6240
acaaaacagt	actcactgag	tgtttttcag	tttcctactg	gtggttttga	tattgtttgt	6300
ttaagatgta	tatttagaat	gacatcatct	aagaagctga	ttttgctaaa	ctcctgttcc	6360
ctacaatggg	aaatgtcaca	agaatgtgca	aaaataaaaa	tctgagg		6407

<210> SEQ ID NO 28

<211> LENGTH: 1295

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 28

cacgtcagcc	ggggctagaa	aaggcggcgg	ggctggggccc	agcgaggtga	cagcctcgct	60
tggaacgaga	gcccggcccg	acgcgcgcct	gagcgcgcgg	ctcttcagcc	tggaacggccc	120
ggcgcgccgc	gcgccttgcc	ctgcggagcc	tgcgccttc	tacgaaccgg	gccgggcggg	180
caagccgggc	cgcggggcgg	agccaggggc	cctaggcgag	ccaggcgccg	ccgccccgcg	240
catgtacgac	gacgagagcg	ccatcgactt	cagcgcctac	atcgactcca	tgccgcgcgt	300
gcccaccctg	gagctgtgcc	acgacgagct	cttcgccgac	ctcttcaaca	gcaatcacia	360
ggcgggcggc	gcggggcccc	tggagcttct	tcccggcggc	cccgcgcgcc	ccttggggccc	420
gggccttgcc	gtccccgcgc	tgctcaagcg	cgagcccgac	tggggcgacg	gcgacgcgcc	480
cggtctgctg	ttggccgcgc	aggtggccgc	gtgcgcacag	accgtggtga	gcttggcggc	540
cgcagggcag	cccaccccg	ccacgtcgcc	ggagccgcgg	cgcagcagcc	ccaggcagac	600
ccccgcgcgc	ggccccgcgc	gggagaagag	cgccggcaag	agggggcccg	accgcggcag	660
ccccgagtac	cggcagcggc	gcgagcgcaa	caacatcgcc	gtgcgcaaga	gccgcgacaa	720

-continued

ggccaagcgg cgcaaccagg agatgcagca gaagtgggtg gagctgtcgg ctgagaacga	780
gaagctgcac cagcgcgtgg agcagctcac gcgggacctg gccggcctcc ggcagttctt	840
caagcagctg cccagcccgc ctttcctgcc ggccgcccgg acagcagact gccggtaacg	900
cgcgcccggg gcgggagaga ctcagcaacg acccatacct cagaccgcac ggcccgagc	960
ggagcgcgcc ctgccctggc gcagccagag ccgcccgggtg cccgctgcag tttcttgga	1020
cataggagcg caaagaagct acagcctgga cttaccacca ctaaaactgcg agagaagcta	1080
aacgtgttta ttttccctta aattatTTTT gtaatggtag ctttttctac atcttactcc	1140
tgttgatgca gctaaggtac atttgtaaaa agaaaaaaaa ccagactttt cagacaaacc	1200
ctttgtattg tagataagag gaaaagactg agcatgctca cttttttata ttaattttta	1260
cagtatttgt aagaataaag cagcatttga aatcg	1295

<210> SEQ ID NO 29

<211> LENGTH: 1526

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 29

ggccactgct caccatgcac ataaccagc tcaaccggga gtgcctgctg cacctcttct	60
cttccttaga caaggacagc aggaagagcc ttgccaggac ctgctcccag ctccacgacg	120
tgtttgagga ccccgactc tggtcctgct tgcacttccg ttccctcact gaactccaga	180
aggacaactt cctcctgggc ccggcactcc gcagcctctc catctgctgg cactccagcc	240
gcgtgcaggt gtgcagcatt gaggactggc tcaagagtgc cttccagaga agcatctgca	300
gccggcacga gaggcctggc aatgatttcc tcctccgggt gtgcgacagg ctttctgctg	360
tgcgctcccc acggaggcgg gagggcctg caccgtctc ggggactccg atcgccgttg	420
gaccgaaatc acctcggtgg ggaggacctg accactcgga gttcgccgac ttgcgctcgg	480
gggtgacggg ggccagggt gccgcgcgca ggggtctggg gagcctccgg gcggagcgac	540
ccagcgagac ccgcgcggct ccggaggtgt cctggggacc gccacctcca ggagccccgg	600
tgttgatctc ggtgaagcag gaggagggga agcaggggag cacgggcaga aggagccacc	660
gagccgctcc tccttgcggt ttgcccgc cgcgcgtctg cccgccacc tttcctgggg	720
cggatgcgtt ccgcagtgga ccgcactcgc gattgtagaa aattcgctcc caattgttga	780
atgettacat aaactgcata gttaccata ttttctactg ttctcataag ggaaaaagaa	840
atgatttga agaaaaaaaa agcctcaaac taaacaaaaa caaaaccagc agccctggct	900
aagcttttga taatggaacc attataagct gacaagctag atttttcacc tgttgattt	960
gctggacatg agcacaagcc taggcttcca atttgaattt cagggtgta gtcactgatg	1020
tgtcacattt agtgaaggct ctcgccccc cggcagccgc ctggtcctgg gtcactgggg	1080
agaattctgg gtgggtggaa gaggcgagga gcactgtgat gggcgctgtt cacactccgg	1140
ctccaccag cgcagctgc gacaaagccc tttaccctc ccaggccagg tgtttcttct	1200
gtgtgaaaga ggagcttgat ccctactcac aggttcctta attcattgct caaagaggga	1260
aacagcaagg aaaaagacaa attctgttct catgaagctt accttctagt gggggaagag	1320
acaacaggta actggtatat aagagggtag aagggccagg tgcggtggct caatgcctgt	1380
aatcccagca ctttaggagg ccaagatggg cgattcacga ggtcaggaga tcgagaccat	1440

-continued

```
cctggctaac aaggtgaaac ccccgctctgt actaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1500
aaaaaaaaa aaaaaaaaaa aaaaaa 1526
```

```
<210> SEQ ID NO 30
<211> LENGTH: 1353
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
```

```
<400> SEQUENCE: 30
```

```
atgcggggaga tctgtcacat ccaggccggc cagtgcggca accagatcgg ggccaagtgc 60
tggaagtca tcagtgatga gcatggcatc gacccagcg gcaactacgt gggcgactcg 120
gacttgacgc tggagcggat cagcgtctac tacaacgagg cctcttctca caagtacgtg 180
cctcgagcca ttctggtgga cctggaaccc ggaacatgg acagtgtccg ctccaggggcc 240
tttggaatc tcttcaggcc tgacaatttc atctttggtc agagtggggc cgcaacaac 300
tgggccaagg gtactacac ggagggggcg gagctggtgg attcggtcct ggatgtggtg 360
cggaaggagt gtgaaaactg cgactgcctg cagggtcttc agctgaccca ctccgtgggg 420
ggcggcacgg gctccggcat gggcacgttg ctcatcagca aggtgctga ggagtatccc 480
gaccgcatca tgaacacctt cagcgtcgtg ccctcaccca aggtgtcaga cagggtggtg 540
gagccctaca acgccacgct gtccatccac cagctggtgg agaacacgga tgagacctac 600
tgcatcgaca acgaggcgct ctacgacatc tgcttcgca ccctcaagct ggccacgccc 660
acctacgggg acctcaacca cctggtatcg gccacatga gcggagtcac cacctccttg 720
cgcttcccg gccagctcaa cgctgacctg cgcaagctgg ccgtcaacat ggtgcccttc 780
ccgcgcctgc acttcttcat gcccggcttc gccccctca cagccgggg cagccagcag 840
tacggggccc tgacctgccc cgagctcacc cagcagatgt tcgatgcaa gaacatgatg 900
ggcgctgcg acccgcgcca cgcccgctac ctgacggtgg ccaccgtgtt ccggggccgc 960
atgtccatga aggaggtgga cgagcagatg ctggccatcc agagcaagaa cagcagctac 1020
ttcgtggagt ggatcccaa caactgaag gtggccgtgt gtgacatccc gcccgcgggc 1080
ctcaagatgt cctccacctt catcgggaac agcacggcca tccaggagct gttcaagcgc 1140
atctccgagc agttcacggc catgttccgg cgcaaggcct tcctgcactg gtacacgggc 1200
gagggcatgg acgagatgga gttcaccgag gccgagagca acatgaacga cctggtgtcc 1260
gagtaccagc agtaccagga cgccacggcc gaggaagagg gcgagatgta cgaagacgac 1320
gaggaggagt cggaggccca gggccccaag tga 1353
```

```
<210> SEQ ID NO 31
<211> LENGTH: 2853
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
```

```
<400> SEQUENCE: 31
```

```
gctctgctcc aggcattgac cacaatgtgg gtgcttacac ctgctgcttt tgctgggaag 60
ctcttgagtg tgttcaggca acctctgagc tctctgtgga ggagcctggt cccgctgttc 120
tgctggtgta gggcaacctt ctggctgcta gctaccaaga ggagaaagca gcagctggtc 180
ctgagagggc cagatgagac caaagaggag gaagaggacc ctctctgccc caccaccca 240
accagcgtca actatcactt cactcgccag tgcaactaca aatgcggctt ctgtttccac 300
```

-continued

acagccaaaa catcctttgt gctgcccctt gaggaagcaa agagaggatt gcttttgctt	360
aaggaagctg gtatggagaa gatcaacttt tcaggtggag agccatttct tcaagaccgg	420
ggagaatacc tgggcaagtt ggtgaggttc tgcaaagtag agttgctggc gccagcgtg	480
agcatcgtga gcaatggaag cctgatccgg gagaggtggt tccagaatta tggtagtat	540
ttggacattc tcgctatctc ctgtgacagc tttgacgagg aagtcaatgt ccttattggc	600
cgtggccaag gaaagaagaa ccatgtggaa aaccttcaa agctgaggag gtggtgtagg	660
gattatagag tcgctttcaa gataaattct gtcattaatc gtttcaacgt ggaagaggac	720
atgacggaac agatcaaagc actaaacct gtccgctgga aagtgttcca gtgcctctta	780
attgaggggt agaattgtgg agaagatgct ctaagagaag cagaaagatt tgttattggt	840
gatgaagaat ttgaaagatt cttggagcgc cacaagaag tgtcctgctt ggtgcctgaa	900
tctaaccaga agatgaaaga ctccctacct attctggatg aatatatgcg ctttctgaac	960
tgtagaaagg gacggaagga cccttccaag tccatcctgg atgttggtgt agaagaagct	1020
ataaaattca gtggatttga tgaaaagatg tttctgaagc gaggagggaa atacatatgg	1080
agtaaggctg atctgaagct ggattggtag agcggaaagt ggaacgagac ttcaacacac	1140
cagtgggaaa actcctagag taactgccat tgtctgcaat actatcccgt tggattttcc	1200
cagtggctga aaacctgatt ttctgctgca cgtggcatct gattacctgt ggtcactgaa	1260
cacacgaata acttgatag caaatcctga gacaatggaa aaccattaac tttacttcat	1320
tggcttataa ccttgttgtt attgaaacag cacttctggt tttgagtttg ttttagctaa	1380
aaagaaggaa tacacacagg aataatgacc ccaaaaatgc ttagataagg cccctataca	1440
caggacctga catttagctc aatgatgcgt ttgtaagaaa taagctctag tgatatctgt	1500
gggggcaaaa ttaattttgg atttgatttt ttaaaacaat gtttactgcg atttctatat	1560
ttccattttg aaactatttc ttgttccagg tttgttcatt tgacagagtc agtatttttt	1620
gccaaatata cagataacca gttttcacat ctgagacatt acaaagtata tgcctcaatt	1680
atttctgctg gttataatgc tttttttttt ttgcctttat gccattgcag tcttgacttt	1740
tttactgtga tgtacagaaa tagtcaacag atgtttccaa gaacatatga tatgataatc	1800
ctaccaattt tcaagaagtc tctagaaaga gataacacat ggaagacgg cgtggtgcag	1860
cccagccac ggtgcctggt ccatgaatgc tggctaceta tgtgtgtggt acctgttgtg	1920
tccctttctc ttcaaagatc cctgagcaaa acaaagatac gctttccatt tgatgatgga	1980
gttgacatgg aggcagtgct tgcattgctt tgttcgccta tcatctggcc acatgaggct	2040
gtcaagcaaa agaataggag tgtagttgag tagctggttg gccctacatt tctgagaagt	2100
gacgttacac tgggttgga taagatatcc taaaatcacg ctggaacctt gggcaaggaa	2160
gaatgtgagc aagagtagag agagtgcctg gatttcatgt cagtgaagcc atgtcaccat	2220
atcatatttt tgaatgaact ctgagtcagt tgaaataggg taccatctag gtcagtttaa	2280
gaagagtcag ctgagagaaa gcaagcataa gggaaaatgt cacgtaaact agatcaggga	2340
acaaaatcct ctccctgtgg aaatatccca tgcagtttgt tgatacaact tagtatctta	2400
ttgctaaaaa aaaaatttct tatcattggt tcaaaaaagc aaaatcatgg aaaatttttg	2460
ttgtccaggc aaataaaagg tcattttaat ttaaaaaaaa aaaaaaaaaa aaaaaaaaaa	2520
aaaaggccaa ggaaaaaaa tattcctact taaattttta gtctataatt caatttaaat	2580

-continued

atgtgtgtgt ctcattccagg ataggatagg ttgtcttcta ttttccattt tacctattta	2640
ctttttttgt aagaaaagag aagaatgaat tctaaagatg ttcccatgg gttttgattg	2700
tgtctaagct atgatgacct tcatataatc agcataaaca taaaacaaat tttttactta	2760
acatgagtgc actttactaa tcctcatggc acagtggctc acgctgttaa tcccagcact	2820
tggggaggac aatgtggggt ggatcacgag gtc	2853

<210> SEQ ID NO 32

<211> LENGTH: 6853

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 32

atacatagac ttccgttaaa accagaatga ggaaaatact tttctctagc atcgtaggag	60
gaagaaaaca aacacatcag atattttcag cactaaaaga gatggttttc cccacatata	120
tgtaaaagaa atttgcaaga ctactggatt ttgatctcat ggttcagtg ggtgaatagg	180
tggccttttg tgatctccta catcaccttg gaagtggagc ttcttcggtt tcttctagag	240
tcagtttggg atcagaatgg caaagcaact taaccctcca gaaaatacag atgattggac	300
aaaagaggat gtaaatcagt ggtagaag tcataagatt gacaaaaac acagggaaat	360
tttgactgaa caagacgtga atggagcagt cttgaagtgg ttaaaaaaag aacatcttgt	420
tgatatgggc atcacacatg gaccagctat tcaaatagaa gaactattca aagaattgcg	480
gaaaacagcc attgaagatt cgattcagac atctaagatg ggaaagccca gtaaaaatgc	540
tcctaaagac caaactgtgt ctcaaaagga acgtagagaa acttcaaagc aaaaacaaaa	600
gggtaaagag aaccagata tggctaatac gtctgcaatg agtacaactg ctaaagggtc	660
taagtacta aaagttgagc tcatagaaga taaaatagat tatacaaagg aaaggcaacc	720
atccatagac ctgacatgtg tatcatatcc atttgatgaa ttcagtaac catatcggtta	780
caagttggat tttagtctac agcctgaaac aggaccaggc aatctcattg atccgataca	840
tgaattcaaa gccttcacaa atacagcaac agccacagaa gaggatgtca agatgaaatt	900
tagcaatgag gttttccgat ttgcttcagc ttgtatgaat tcacgtacca atggcactat	960
tcattttgga gtcaaaagaca aaccccatgg gaaaattggt ggcatcaaag tcaccaatga	1020
taccaaggaa gccctcatta accatttcaa tctgatgata aacaagtatt ttgaagacca	1080
tcaagtccaa caagcaaaga agtgcattcg agagccaaga tttgtggaag ttttactgcc	1140
aaatagtact ctatctgaca gatttggtaa tgaagtggac attattccac agttctctga	1200
atgccaatat gattatttcc agattaaaat gcaaaattac aacaacaaaa tatgggaaca	1260
aagtaaaaaa ttctcactat ttgtgcgaga tgggaccagc tctaaggaca ttacgaaaaa	1320
taaagttgat ttcagagcat ttaaagcaga ttttaaaaca ctggcagagt ccagaaaagc	1380
agcagaagaa aaattcagag caaaaacaaa taaaaaagaa agagagggac caaagttggt	1440
taaattattg acaggaaatc aagatttggt agataattca tactatgaac agtacattct	1500
tgtaacaaat aaatgccacc cagatcaaac aaaacactta gatttcctga aggaaattaa	1560
atggtttgct gtattggagt ttgatcctga gtctaacatc aatggagtggt tcaaagctta	1620
caaagaaagc cgagtagcaa accttcactt tccaagtgtat tatgtagaac agaaaaccac	1680
accaaatgag acgatttcta ctctaaatct ttaccatcaa cccagctgga ttttctgcaa	1740

-continued

tggcagggtta gaccttgaca gtgaaaaata taaacccttt gatccaagtt cctggcaaag	1800
agaaagagct tctgatgtca ggaaactgat ttcatttctt acacatgaag acataatgcc	1860
aagagggaag tttttggtgg ttttctatt actgtcctct gtggatgacc caagagatcc	1920
cctcattgag actttctgtg ctttctacca ggatctcaaa ggaatggaaa atatactgtg	1980
tatttgtgtg caccacaca tatttcaggg atggaaagat ctacttgaag caagattaat	2040
aaaacaccaa gatgaaattt caagccaatg ttttctgct ttaagccttg aagagatcaa	2100
tggcactatt cttaactaa aatctgtgac tcaatcttca aaaaggcttt tgccatctat	2160
tggtttatcg actgtccttc tgaaaaagga agaagatgc atgactgtc tggaattat	2220
ctgtgaaat gaatgtgagg gtacactgtt agagaaggac aaaaaaat tccttgaatt	2280
caaggcatca aaagaggaag acttctatcg aggtggcaaa gtgtcatggt ggaacttcta	2340
cttctcttct gaaagtatt ctccacctt tgtcaaaagg gataaatatg aaagacttga	2400
agcaatgatt caaaactgtg cagattcttc taaaccaaca agtaccaaaa ttattcatct	2460
gtatcatcat ccaggctgtg ggggaactac cttggctatg cacattctct gggaactaag	2520
gaagaaatc agatgtgctg tgctgaaaa caagacagtg gatttttctg aaattggaga	2580
acaggtaacc agtttaata cctatggggc aatgaaccgt caggaatagc tacctgtact	2640
actccttgtt gatgattttg aagaacaaga taatgtctat cttctgcagt actctattca	2700
aacagctata gctaaaaagt acattcgata tgaaaaacct ctggtgatta tcctaaattg	2760
tatgagatca caaaactctg aaaaagtgc aaggatccca gacagtattg ccgtaataca	2820
gcaactctct cccaaagaac agagagcttt tgagcttaaa ttgaaagaaa tcaaagaaca	2880
gcataaaaac tttgaggatt tttattcctt tatgatcatg aaaaccaatt ttaataaaga	2940
atacatagaa aatgtggtcc ggaatatcct gaaagggcag aatattttca ccaagggaagc	3000
aaagctcttt tcttttctg ctcttcttaa ttcatatgtg cctgatacca ccatttcact	3060
atcacagtgt gaaaaattct taggaattgg aaacaagaag gctttctggg ggacagaaaa	3120
atttgaagac aagatgggca cctactctac aattctgata aaaacagagg tcatcgaatg	3180
tgggaactac tgtggagtac gcacatttca ctcttgatt gcagagttct cactggaaga	3240
attgaagaaa agctatcacc tgaataaaa tcaaatatg ttggatatgc taactgagaa	3300
tttgttcttc gatactggta tgggaaaaag taaatttttg caagatatgc acacactcct	3360
actcacaaga caccgcgatg aacatgaagg tgaaacagga aattggtttt ccccatctat	3420
tgaagcatta cataaagatg aaggaaatga agcagttgaa gctgtattgc ttgaaagtat	3480
ccatcggttc aacccaaatg cattcatttg ccaagcgttg gcaagacatt tctacattaa	3540
aaagaaggac tttggcaatg ctctaaactg ggcaaaacaa gcaaaaatca tagaacctga	3600
caattcttat atctcagata cactgggtca agtctacaaa agtaaaataa gatgggtgat	3660
agaggaaaac ggaggaaacg ggaacatttc agttgatgat ctaattgtc ttttgattt	3720
agcagaacat gcctcaagtg cattcaaaga atctcaacag caaagtgaag atagagagta	3780
tgaagtgaag gaaagattgt atccgaagtc aaaaaggcgg tatgatactt acaatatagc	3840
tggttatcaa ggagagatag aagttgggct ttacacaatc caaattctcc agtcatttc	3900
tttttttgat aataaaaatg agctatctaa aagatatatg gtcaattttg tatcaggaag	3960
tagtgatatt ccaggggatc caaacaatga atataaatta gccctcaaaa actatatctc	4020

-continued

ttatttaact	aaattgaaat	tttctttgaa	aaagtccttt	gatttttttg	atgaatactt	4080
tgctctgcta	aaaccagga	acaatattaa	gcaaatgaa	gaggccaaa	ctcggagaaa	4140
gggtggctga	tattttaaga	aatatgtaga	tatatcttgt	ctcttagaag	aatcacaaaa	4200
caacacaggt	cttgatcaa	agttcagtga	gccacttcaa	gtagagagat	gcaggagaaa	4260
cctagtagct	ttaaaagcag	acaagttttc	tgggctcttg	gaatatctta	tcaaaagtca	4320
agaggatgct	ataagcacta	tgaaatgtat	agtgaacgaa	tatacttttc	tcttagaaca	4380
atgcactgtc	aaaatccagt	caaaagaaaa	gctaaatttc	atcttgcca	acattattct	4440
ctcctgtatc	caacctacct	ccagattagt	aaagccagtt	gaaaaactaa	aagatcagct	4500
tcgagaagtc	ttgcaaccaa	taggactgac	ttatcagttt	tcagaaccgt	attttctagc	4560
ttccctctta	ttctggccag	aaaatcaaca	actagatcaa	cattctgaac	aatgaaaga	4620
gtatgctcaa	gcactaaaa	attctttcaa	ggggcaatat	aaacatatgc	atcgtacaaa	4680
gcaaccaatt	gcatatttct	ttcttgga	aggtaaaaga	ctggaaagac	ttgttcacaa	4740
aggaaaaatt	gaccagtgtc	ttaagaagac	accagatatt	aattccttgt	ggcagagtgg	4800
agatgtgtgg	aaggaggaaa	aagtccaaga	acttttgctt	cgtttacaag	gtcgagctga	4860
aaacaattgt	ttatatatag	aatatggaat	caatgaaaa	atcacatac	ccatcactcc	4920
cgctttttta	ggtcaactta	gaagtggcag	aagcatagag	aaggtgtctt	tttacctggg	4980
attttccatt	ggaggccac	ttgcttatga	cattgaaatt	gtttaagagc	ctgatatctt	5040
tctccaaga	atttgatctc	agtaccatt	taattttttt	ggactcaaga	tctatgcttt	5100
aaaccggcaa	ggttatagat	acagcctcta	gctcttcaga	tctgtacatg	cagtatttaa	5160
tttctctta	aacatgttat	gagttctaca	aagacaatag	tgaanaagga	aggagtgaga	5220
tatatgaaa	gtagcaata	tgctccttgg	tttggttaac	atcattgatg	acaaaataat	5280
aaggagctat	gactggagtc	aggagaagtt	agtgtataa	gctggctaca	cagaaccca	5340
ctacttacca	ggcatggatt	gaagaagatt	gtctactcaa	atggcattta	gacattagaa	5400
tgcttgaggaa	aatatttctc	aaagacagca	aaaacctctc	aaactgagga	gcaacattta	5460
ttcttactaa	gcagatcctc	aatgtatcat	gtgcttgga	ctcaaggatc	ttccaaaaca	5520
gaggaccaac	cagtcttctg	aaggtcatgc	ccacagaagt	catcagacct	taccaaagta	5580
ggttgaggaa	ttagattgcc	ttttcatgca	gtgagattca	gttaagcaaa	aatgaaattt	5640
gtctctatag	ctaattagct	tatcaactcc	cctccaaaca	aacaattaaa	aaaaaaacat	5700
acagacactc	aaattccaca	agctaataa	caaaagggac	tctgtgaga	agactaatga	5760
gtcctcctac	cagaagatgc	caatgtactg	gcagattaac	atacaacctc	tgttttgaa	5820
aaaaacaacc	agcgatagct	aatcaaaatg	taattttccc	ctaataaaat	tatggatatg	5880
ggcagtcctc	aatggctgcc	aaaaccatta	agtggaaagc	tgattaaaaa	acaaaaattt	5940
ctaattggatt	tatcaaatgc	tcccaaatcc	tgataaatat	taacatcaca	gagggaagcc	6000
agacattatg	ggcctggaag	tactatagga	gtgcacacat	caccctgac	atggctctgc	6060
caataatta	aacctgaatt	tgatcaggtc	tctggatctt	atttgcaatt	caaaagaaat	6120
tttaaaaaa	tcctactaac	accaccacaa	atatgcaatc	agcaatatcc	agaaagggga	6180
aattcacagg	acaaaacct	ggttttcttt	tttggtttct	tcaacaaaa	aagaaagaaa	6240
ttgcaaagga	ccaaaaaat	gttggggaat	ctatacat	taagggactt	aacaactaaa	6300

-continued

```

gggcaacata tagacttttag atcctaattt gagcaaaatc taaaatcaat tattaggcaa 6360
tcagaaaaat ttgaacacag actagatatt tgaggatatt aaggactat attattgaag 6420
attccatggt tatgtttttt aaagagttca tgccttttag agatacat taaagtattt 6480
gtaaataaat gacatgatct agaatcagta attttgtgtt tgggggtgtg ggggtgtgaa 6540
agggagtag aaccgaaaca agattagtcc tgagttaaca atggctgcaa gctggatata 6600
tggaattcag cacacttttc tccctcttac tgattatgct tttgaaattt tctcttgtaa 6660
aacatttaga aaacaaaaac aaaaaaatg tgatttgttt ctgtcttcaa aatctcatta 6720
gaattttttc actggaggaa gattttccct tgcttctgca taaaatttta actccataac 6780
ttataagctc actctttatt gttactttct aattgacaaa taaaaattgt atattaaaaa 6840
aaaaaaaaaa aaa 6853

```

```

<210> SEQ ID NO 33
<211> LENGTH: 672
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 33

```

```

aacacatcca agcttaagac ggtgaggcca gcttcacatt ctcaggaact ctccttcttt 60
gggtctggct gaagttgagg atctcttact ctctaggcca cggaattaac ccgagcaggc 120
atggaggcct ctgctctcac ctcacagca gtgaccagtg tggccaaagt ggtcagggtg 180
gcctctggct ctgccgtagt ttgcccctg gccaggattg ctacagtgtg gattggagga 240
gttgtggcca tggcggtgtg gcccatggtg ctcagtgccca tgggcttcac tgcggcggga 300
atgcctcgt cctccatagc agccaagatg atgtccgcgg cggccattgc caatgggggt 360
ggagttgcct cgggcagcct tgtggctact ctgcagtcac tgggagcaac tggactctcc 420
ggattgacca agttcatcct gggctccatt gggcttgcca ttgcggctgt cattgcgagg 480
ttctactagc tccctgcccc tcgcctgca gagaagagaa ccatgccagg ggagaaggca 540
cccagccatc ctgaccagc gaggagccaa ctatcccaaa tatacctggg gtgaaatata 600
ccaaattctg catctccaga ggaaaataag aaataaagat gaattgtgc aactcttaa 660
aaaaaaaaaa aa 672

```

```

<210> SEQ ID NO 34
<211> LENGTH: 469
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 34

```

```

Met Ser Gln Ala Tyr Ser Ser Ser Gln Arg Val Ser Ser Tyr Arg Arg
1           5           10           15

Thr Phe Gly Gly Ala Pro Val Phe Pro Leu Gly Ser Pro Leu Ser Ser
20           25           30

Pro Val Phe Pro Arg Ala Pro Phe Gly Ser Lys Gly Ser Ser Ser Ser
35           40           45

Val Thr Ser Arg Val Tyr Gln Val Ser Arg Thr Ser Gly Gly Ala Gly
50           55           60

Gly Leu Gly Ser Leu Arg Ala Ser Arg Leu Gly Thr Thr Arg Thr Pro
65           70           75           80

Ser Ser Tyr Gly Ala Gly Glu Leu Leu Asp Phe Ser Leu Ala Asp Ala

```

-continued

85					90					95					
Val	Asn	Gln	Glu	Phe	Leu	Thr	Thr	Arg	Thr	Asn	Glu	Lys	Val	Glu	Leu
			100					105					110		
Gln	Glu	Leu	Asn	Asp	Arg	Ser	Pro	Ile	Tyr	Met	Glu	Lys	Val	Arg	Phe
		115					120					125			
Leu	Glu	Gln	Gln	Asn	Ala	Leu	Ala	Glu	Val	Asn	Arg	Leu	Lys	Gly	
		130					135					140			
Arg	Glu	Pro	Thr	Arg	Val	Ala	Glu	Leu	Tyr	Glu	Glu	Glu	Leu	Arg	Glu
		145					150					155			160
Leu	Arg	Arg	Gln	Val	Glu	Val	Leu	Thr	Asn	Gln	Arg	Ala	Arg	Val	Asp
			165					170						175	
Val	Glu	Arg	Asp	Asn	Leu	Leu	Asp	Asp	Leu	Gln	Arg	Leu	Lys	Ala	Lys
			180					185					190		
Leu	Gln	Glu	Glu	Ile	Gln	Leu	Lys	Glu	Glu	Ala	Glu	Asn	Asn	Leu	Ala
		195					200					205			
Ala	Phe	Arg	Ala	Asp	Val	Asp	Ala	Ala	Thr	Leu	Ala	Arg	Ile	Asp	Leu
		210					215					220			
Glu	Arg	Arg	Ile	Glu	Ser	Leu	Asn	Glu	Glu	Ile	Ala	Phe	Leu	Lys	Lys
		225					230					235			240
Val	His	Glu	Glu	Glu	Ile	Arg	Glu	Leu	Gln	Ala	Gln	Leu	Gln	Glu	Gln
			245					250						255	
Gln	Val	Gln	Val	Glu	Met	Asp	Met	Ser	Lys	Pro	Asp	Leu	Thr	Ala	Ala
			260					265					270		
Leu	Arg	Asp	Ile	Arg	Ala	Gln	Tyr	Glu	Thr	Ile	Ala	Ala	Lys	Asn	Ile
		275					280					285			
Ser	Glu	Ala	Glu	Glu	Trp	Tyr	Lys	Ser	Lys	Val	Ser	Asp	Leu	Thr	Gln
		290					295					300			
Ala	Ala	Asn	Lys	Asn	Asn	Asp	Ala	Leu	Arg	Gln	Ala	Lys	Gln	Glu	Met
		305					310					315			320
Met	Glu	Tyr	Arg	His	Gln	Ile	Gln	Ser	Tyr	Thr	Cys	Glu	Ile	Asp	Ala
			325					330						335	
Leu	Lys	Gly	Thr	Asn	Asp	Ser	Leu	Met	Arg	Gln	Met	Arg	Glu	Leu	Glu
			340					345					350		
Asp	Arg	Phe	Ala	Ser	Glu	Ala	Ser	Gly	Tyr	Gln	Asp	Asn	Ile	Ala	Arg
		355					360					365			
Leu	Glu	Glu	Glu	Ile	Arg	His	Leu	Lys	Asp	Glu	Met	Ala	Arg	His	Leu
		370					375					380			
Arg	Glu	Tyr	Gln	Asp	Leu	Leu	Asn	Val	Lys	Met	Ala	Leu	Asp	Val	Glu
		385					390					395			400
Ile	Ala	Thr	Tyr	Arg	Lys	Leu	Leu	Glu	Gly	Glu	Glu	Ser	Arg	Ile	Asn
			405					410						415	
Leu	Pro	Ile	Gln	Thr	Tyr	Ser	Ala	Leu	Asn	Phe	Arg	Glu	Thr	Ser	Pro
			420					425					430		
Glu	Gln	Arg	Gly	Ser	Glu	Val	His	Thr	Lys	Lys	Thr	Val	Met	Ile	Lys
		435					440					445			
Thr	Ile	Glu	Thr	Arg	Asp	Gly	Glu	Val	Val	Ser	Glu	Ala	Thr	Gln	Gln
		450					455					460			
Gln	His	Glu	Val	Leu											
		465													

-continued

<211> LENGTH: 62
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 35

Met Ser Glu Arg Gln Gly Ala Gly Ala Thr Asn Gly Lys Asp Lys Thr
1 5 10 15

Ser Gly Glu Asn Asp Gly Gln Lys Lys Val Gln Glu Glu Phe Asp Ile
20 25 30

Asp Met Asp Ala Pro Glu Thr Glu Arg Ala Ala Val Ala Ile Gln Ser
35 40 45

Gln Phe Arg Lys Phe Gln Lys Lys Lys Ala Gly Ser Gln Ser
50 55 60

<210> SEQ ID NO 36
<211> LENGTH: 328
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 36

Met Leu Pro Arg Val Gly Cys Pro Ala Leu Pro Leu Pro Pro Pro Pro
1 5 10 15

Leu Leu Pro Leu Leu Pro Leu Leu Leu Leu Leu Gly Ala Ser Gly
20 25 30

Gly Gly Gly Gly Ala Arg Ala Glu Val Leu Phe Arg Cys Pro Pro Cys
35 40 45

Thr Pro Glu Arg Leu Ala Ala Cys Gly Pro Pro Pro Val Ala Pro Pro
50 55 60

Ala Ala Val Ala Ala Val Ala Gly Gly Ala Arg Met Pro Cys Ala Glu
65 70 75 80

Leu Val Arg Glu Pro Gly Cys Gly Cys Cys Ser Val Cys Ala Arg Leu
85 90 95

Glu Gly Glu Ala Cys Gly Val Tyr Thr Pro Arg Cys Gly Gln Gly Leu
100 105 110

Arg Cys Tyr Pro His Pro Gly Ser Glu Leu Pro Leu Gln Ala Leu Val
115 120 125

Met Gly Glu Gly Thr Cys Glu Lys Arg Arg Asp Ala Glu Tyr Gly Ala
130 135 140

Ser Pro Glu Gln Val Ala Asp Asn Gly Asp Asp His Ser Glu Gly Gly
145 150 155 160

Leu Val Glu Asn His Val Asp Ser Thr Met Asn Met Leu Gly Gly Gly
165 170 175

Gly Ser Ala Gly Arg Lys Pro Leu Lys Ser Gly Met Lys Glu Leu Ala
180 185 190

Val Phe Arg Glu Lys Val Thr Glu Gln His Arg Gln Met Gly Lys Gly
195 200 205

Gly Lys His His Leu Gly Leu Glu Glu Pro Lys Lys Leu Arg Pro Pro
210 215 220

Pro Ala Arg Thr Pro Cys Gln Gln Glu Leu Asp Gln Val Leu Glu Arg
225 230 235 240

Ile Ser Thr Met Arg Leu Pro Asp Glu Arg Gly Pro Leu Glu His Leu
245 250 255

Tyr Ser Leu His Ile Pro Asn Cys Asp Lys His Gly Leu Tyr Asn Leu
260 265 270

-continued

Lys Gln Cys Lys Met Ser Leu Asn Gly Gln Arg Gly Glu Cys Trp Cys
 275 280 285

Val Asn Pro Asn Thr Gly Lys Leu Ile Gln Gly Ala Pro Thr Ile Arg
 290 295 300

Gly Asp Pro Glu Cys His Leu Phe Tyr Asn Glu Gln Gln Glu Ala Cys
 305 310 315 320

Gly Val His Thr Gln Arg Met Gln
 325

<210> SEQ ID NO 37
 <211> LENGTH: 967
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 37

Met Gln Arg Ala Val Pro Glu Gly Phe Gly Arg Arg Lys Leu Gly Ser
 1 5 10 15

Asp Met Gly Asn Ala Glu Arg Ala Pro Gly Ser Arg Ser Phe Gly Pro
 20 25 30

Val Pro Thr Leu Leu Leu Leu Ala Ala Ala Leu Leu Ala Val Ser Asp
 35 40 45

Ala Leu Gly Arg Pro Ser Glu Glu Asp Glu Glu Leu Val Val Pro Glu
 50 55 60

Leu Glu Arg Ala Pro Gly His Gly Thr Thr Arg Leu Arg Leu His Ala
 65 70 75 80

Phe Asp Gln Gln Leu Asp Leu Glu Leu Arg Pro Asp Ser Ser Phe Leu
 85 90 95

Ala Pro Gly Phe Thr Leu Gln Asn Val Gly Arg Lys Ser Gly Ser Glu
 100 105 110

Thr Pro Leu Pro Glu Thr Asp Leu Ala His Cys Phe Tyr Ser Gly Thr
 115 120 125

Val Asn Gly Asp Pro Ser Ser Ala Ala Ala Leu Ser Leu Cys Glu Gly
 130 135 140

Val Arg Gly Ala Phe Tyr Leu Leu Gly Glu Ala Tyr Phe Ile Gln Pro
 145 150 155 160

Leu Pro Ala Ala Ser Glu Arg Leu Ala Thr Ala Ala Pro Gly Glu Lys
 165 170 175

Pro Pro Ala Pro Leu Gln Phe His Leu Leu Arg Arg Asn Arg Gln Gly
 180 185 190

Asp Val Gly Gly Thr Cys Gly Val Val Asp Asp Glu Pro Arg Pro Thr
 195 200 205

Gly Lys Ala Glu Thr Glu Asp Glu Asp Glu Gly Thr Glu Gly Glu Asp
 210 215 220

Glu Gly Ala Gln Trp Ser Pro Gln Asp Pro Ala Leu Gln Gly Val Gly
 225 230 235 240

Gln Pro Thr Gly Thr Gly Ser Ile Arg Lys Lys Arg Phe Val Ser Ser
 245 250 255

His Arg Tyr Val Glu Thr Met Leu Val Ala Asp Gln Ser Met Ala Glu
 260 265 270

Phe His Gly Ser Gly Leu Lys His Tyr Leu Leu Thr Leu Phe Ser Val
 275 280 285

Ala Ala Arg Leu Tyr Lys His Pro Ser Ile Arg Asn Ser Val Ser Leu

-continued

290					295					300					
Val 305	Val	Val	Lys	Ile	Leu 310	Val	Ile	His	Asp	Glu 315	Gln	Lys	Gly	Pro	Glu 320
Val	Thr	Ser	Asn	Ala	Ala	Leu	Thr	Leu	Arg	Asn 330	Phe	Cys	Asn	Trp	Gln
Lys	Gln	His	Asn	Pro	Pro	Ser	Asp	Arg	Asp	Ala	Glu	His	Tyr	Asp	Thr
Ala	Ile	Leu	Phe	Thr	Arg	Gln	Asp	Leu	Cys	Gly	Ser	Gln	Thr	Cys	Asp
Thr	Leu	Gly	Met	Ala	Asp	Val	Gly	Thr	Val	Cys	Asp	Pro	Ser	Arg	Ser
Cys 385	Ser	Val	Ile	Glu	Asp	Asp	Gly	Leu	Gln	Ala	Ala	Phe	Thr	Thr	Ala
His	Glu	Leu	Gly	His	Val	Phe	Asn	Met	Pro	His	Asp	Asp	Ala	Lys	Gln
Cys	Ala	Ser	Leu	Asn	Gly	Val	Asn	Gln	Asp	Ser	His	Met	Met	Ala	Ser
Met	Leu	Ser	Asn	Leu	Asp	His	Ser	Gln	Pro	Trp	Ser	Pro	Cys	Ser	Ala
Tyr	Met	Ile	Thr	Ser	Phe	Leu	Asp	Asn	Gly	His	Gly	Glu	Cys	Leu	Met
Asp 465	Lys	Pro	Gln	Asn	Pro	Ile	Gln	Leu	Pro	Gly	Asp	Leu	Pro	Gly	Thr
Ser	Tyr	Asp	Ala	Asn	Arg	Gln	Cys	Gln	Phe	Thr	Phe	Gly	Glu	Asp	Ser
Lys	His	Cys	Pro	Asp	Ala	Ala	Ser	Thr	Cys	Ser	Thr	Leu	Trp	Cys	Thr
Gly	Thr	Ser	Gly	Gly	Val	Leu	Val	Cys	Gln	Thr	Lys	His	Phe	Pro	Trp
Ala	Asp	Gly	Thr	Ser	Cys	Gly	Glu	Gly	Lys	Trp	Cys	Ile	Asn	Gly	Lys
Cys 545	Val	Asn	Lys	Thr	Asp	Arg	Lys	His	Phe	Asp	Thr	Pro	Phe	His	Gly
Ser	Trp	Gly	Met	Trp	Gly	Pro	Trp	Gly	Asp	Cys	Ser	Arg	Thr	Cys	Gly
Gly	Gly	Val	Gln	Tyr	Thr	Met	Arg	Glu	Cys	Asp	Asn	Pro	Val	Pro	Lys
Asn	Gly	Gly	Lys	Tyr	Cys	Glu	Gly	Lys	Arg	Val	Arg	Tyr	Arg	Ser	Cys
Asn	Leu	Glu	Asp	Cys	Pro	Asp	Asn	Asn	Gly	Lys	Thr	Phe	Arg	Glu	Glu
Gln 625	Cys	Glu	Ala	His	Asn	Glu	Phe	Ser	Lys	Ala	Ser	Phe	Gly	Ser	Gly
Pro	Ala	Val	Glu	Trp	Ile	Pro	Lys	Tyr	Ala	Gly	Val	Ser	Pro	Lys	Asp
Arg	Cys	Lys	Leu	Ile	Cys	Gln	Ala	Lys	Gly	Ile	Gly	Tyr	Phe	Phe	Val
Leu	Gln	Pro	Lys	Val	Val	Asp	Gly	Thr	Pro	Cys	Ser	Pro	Asp	Ser	Thr
Ser	Val	Cys	Val	Gln	Gly	Gln	Cys	Val	Lys	Ala	Gly	Cys	Asp	Arg	Ile

-continued

```

Ile Asp Ser Lys Lys Lys Phe Asp Lys Cys Gly Val Cys Gly Gly Asn
705          710          715          720

Gly Ser Thr Cys Lys Lys Ile Ser Gly Ser Val Thr Ser Ala Lys Pro
          725          730          735

Gly Tyr His Asp Ile Ile Thr Ile Pro Thr Gly Ala Thr Asn Ile Glu
          740          745          750

Val Lys Gln Arg Asn Gln Arg Gly Ser Arg Asn Asn Gly Ser Phe Leu
          755          760          765

Ala Ile Lys Ala Ala Asp Gly Thr Tyr Ile Leu Asn Gly Asp Tyr Thr
          770          775          780

Leu Ser Thr Leu Glu Gln Asp Ile Met Tyr Lys Gly Val Val Leu Arg
785          790          795          800

Tyr Ser Gly Ser Ser Ala Ala Leu Glu Arg Ile Arg Ser Phe Ser Pro
          805          810          815

Leu Lys Glu Pro Leu Thr Ile Gln Val Leu Thr Val Gly Asn Ala Leu
          820          825          830

Arg Pro Lys Ile Lys Tyr Thr Tyr Phe Val Lys Lys Lys Lys Glu Ser
          835          840          845

Phe Asn Ala Ile Pro Thr Phe Ser Ala Trp Val Ile Glu Glu Trp Gly
          850          855          860

Glu Cys Ser Lys Ser Cys Glu Leu Gly Trp Gln Arg Arg Leu Val Glu
865          870          875          880

Cys Arg Asp Ile Asn Gly Gln Pro Ala Ser Glu Cys Ala Lys Glu Val
          885          890          895

Lys Pro Ala Ser Thr Arg Pro Cys Ala Asp His Pro Cys Pro Gln Trp
          900          905          910

Gln Leu Gly Glu Trp Ser Ser Cys Ser Lys Thr Cys Gly Lys Gly Tyr
          915          920          925

Lys Lys Arg Ser Leu Lys Cys Leu Ser His Asp Gly Gly Val Leu Ser
          930          935          940

His Glu Ser Cys Asp Pro Leu Lys Lys Pro Lys His Phe Ile Asp Phe
945          950          955          960

Cys Thr Met Ala Glu Cys Ser
          965

```

<210> SEQ ID NO 38

<211> LENGTH: 620

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 38

```

Met Ser Tyr Tyr Gln Arg Pro Phe Ser Pro Ser Ala Tyr Ser Leu Pro
1          5          10          15

Ala Ser Leu Asn Ser Ser Ile Val Met Gln His Gly Thr Ser Leu Asp
          20          25          30

Ser Thr Asp Thr Tyr Pro Gln His Ala Gln Ser Leu Asp Gly Thr Thr
          35          40          45

Ser Ser Ser Ile Pro Leu Tyr Arg Ser Ser Glu Glu Glu Lys Arg Val
          50          55          60

Thr Val Ile Lys Ala Pro His Tyr Pro Gly Ile Gly Pro Val Asp Glu
65          70          75          80

Ser Gly Ile Pro Thr Ala Ile Arg Thr Thr Val Asp Arg Pro Lys Asp

```

-continued

85							90					95				
Trp	Tyr	Lys	Thr	Met	Phe	Lys	Gln	Ile	His	Met	Val	His	Lys	Pro	Asp	
			100				105						110			
Asp	Asp	Thr	Asp	Met	Tyr	Asn	Thr	Pro	Tyr	Thr	Tyr	Asn	Ala	Gly	Leu	
			115				120						125			
Tyr	Asn	Pro	Pro	Tyr	Ser	Ala	Gln	Ser	His	Pro	Ala	Ala	Lys	Thr	Gln	
			130				135						140			
Thr	Tyr	Arg	Pro	Leu	Ser	Lys	Ser	His	Ser	Asp	Asn	Ser	Pro	Asn	Ala	
			145				150						155			
Phe	Lys	Asp	Ala	Ser	Ser	Pro	Val	Pro	Pro	Pro	His	Val	Pro	Pro	Pro	
			165				170						175			
Val	Pro	Pro	Leu	Arg	Pro	Arg	Asp	Arg	Ser	Ser	Thr	Glu	Lys	His	Asp	
			180				185						190			
Trp	Asp	Pro	Pro	Asp	Arg	Lys	Val	Asp	Thr	Arg	Lys	Phe	Arg	Ser	Glu	
			195				200						205			
Pro	Arg	Ser	Ile	Phe	Glu	Tyr	Glu	Pro	Gly	Lys	Ser	Ser	Ile	Leu	Gln	
			210				215						220			
His	Glu	Arg	Pro	Thr	Asp	Arg	Ile	Asn	Pro	Asp	Asp	Ile	Asp	Leu	Glu	
			225				230						235			
Asn	Glu	Pro	Trp	Tyr	Lys	Phe	Phe	Ser	Glu	Leu	Glu	Phe	Gly	Arg	Pro	
			245				250						255			
Pro	Pro	Lys	Lys	Pro	Leu	Asp	Tyr	Val	Gln	Asp	His	Ser	Ser	Gly	Val	
			260				265						270			
Phe	Asn	Glu	Ala	Ser	Leu	Tyr	Gln	Ser	Ser	Ile	Asp	Arg	Ser	Leu	Glu	
			275				280						285			
Arg	Pro	Met	Ser	Ser	Ala	Ser	Met	Ala	Ser	Asp	Phe	Arg	Lys	Arg	Arg	
			290				295						300			
Lys	Ser	Glu	Pro	Ala	Val	Gly	Pro	Pro	Arg	Gly	Leu	Gly	Asp	Gln	Ser	
			305				310						315			
Ala	Ser	Arg	Thr	Ser	Pro	Gly	Arg	Val	Asp	Leu	Pro	Gly	Ser	Ser	Thr	
			325				330						335			
Thr	Leu	Thr	Lys	Ser	Phe	Thr	Ser	Ser	Ser	Pro	Ser	Ser	Pro	Ser	Arg	
			340				345						350			
Ala	Lys	Asp	Arg	Glu	Ser	Pro	Arg	Ser	Tyr	Ser	Ser	Thr	Leu	Thr	Asp	
			355				360						365			
Met	Gly	Arg	Ser	Ala	Pro	Arg	Glu	Arg	Arg	Gly	Thr	Pro	Glu	Lys	Glu	
			370				375						380			
Lys	Leu	Pro	Ala	Lys	Ala	Val	Tyr	Asp	Phe	Lys	Ala	Gln	Thr	Ser	Lys	
			385				390						395			
Glu	Leu	Ser	Phe	Lys	Lys	Gly	Asp	Thr	Val	Tyr	Ile	Leu	Arg	Lys	Ile	
			405				410						415			
Asp	Gln	Asn	Trp	Tyr	Glu	Gly	Glu	His	His	Gly	Arg	Val	Gly	Ile	Phe	
			420				425						430			
Pro	Ile	Ser	Tyr	Val	Glu	Lys	Leu	Thr	Pro	Pro	Glu	Lys	Ala	Gln	Pro	
			435				440						445			
Ala	Arg	Pro	Pro	Pro	Pro	Ala	Gln	Pro	Gly	Glu	Ile	Gly	Glu	Ala	Ile	
			450				455						460			
Ala	Lys	Tyr	Asn	Phe	Asn	Ala	Asp	Thr	Asn	Val	Glu	Leu	Ser	Leu	Arg	
			465				470						475			
Lys	Gly	Asp	Arg	Val	Ile	Leu	Leu	Lys	Arg	Val	Asp	Gln	Asn	Trp	Tyr	
			485				490						495			

-continued

Glu Gly Lys Ile Pro Gly Thr Asn Arg Gln Gly Ile Phe Pro Val Ser
 500 505 510
 Tyr Val Glu Val Val Lys Lys Asn Thr Lys Gly Ala Glu Asp Tyr Pro
 515 520 525
 Asp Pro Pro Ile Pro His Ser Tyr Ser Ser Asp Arg Ile His Ser Leu
 530 535 540
 Ser Ser Asn Lys Pro Gln Arg Pro Val Phe Thr His Glu Asn Ile Gln
 545 550 555 560
 Gly Gly Gly Glu Pro Phe Gln Ala Leu Tyr Asn Tyr Thr Pro Arg Asn
 565 570 575
 Glu Asp Glu Leu Glu Leu Arg Glu Ser Asp Val Ile Asp Val Met Glu
 580 585 590
 Lys Cys Asp Asp Gly Trp Phe Val Gly Thr Ser Arg Arg Thr Lys Phe
 595 600 605
 Phe Gly Thr Phe Pro Gly Asn Tyr Val Lys Arg Leu
 610 615 620

<210> SEQ ID NO 39
 <211> LENGTH: 179
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 39

Met Ala Lys Thr Ala Met Ala Tyr Lys Glu Lys Met Lys Glu Leu Ser
 1 5 10 15
 Met Leu Ser Leu Ile Cys Ser Cys Phe Tyr Pro Glu Pro Arg Asn Ile
 20 25 30
 Asn Ile Tyr Thr Tyr Asp Asp Met Glu Val Lys Gln Ile Asn Lys Arg
 35 40 45
 Ala Ser Gly Gln Ala Phe Glu Leu Ile Leu Lys Pro Pro Ser Pro Ile
 50 55 60
 Ser Glu Ala Pro Arg Thr Leu Ala Ser Pro Lys Lys Lys Asp Leu Ser
 65 70 75 80
 Leu Glu Glu Ile Gln Lys Lys Leu Glu Ala Ala Glu Glu Arg Arg Lys
 85 90 95
 Ser Gln Glu Ala Gln Val Leu Lys Gln Leu Ala Glu Lys Arg Glu His
 100 105 110
 Glu Arg Glu Val Leu Gln Lys Ala Leu Glu Glu Asn Asn Asn Phe Ser
 115 120 125
 Lys Met Ala Glu Glu Lys Leu Ile Leu Lys Met Glu Gln Ile Lys Glu
 130 135 140
 Asn Arg Glu Ala Asn Leu Ala Ala Ile Ile Glu Arg Leu Gln Glu Lys
 145 150 155 160
 Glu Arg His Ala Ala Glu Val Arg Arg Asn Lys Glu Leu Gln Val Glu
 165 170 175
 Leu Ser Gly

<210> SEQ ID NO 40
 <211> LENGTH: 715
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 40

-continued

Met	Ser	Lys	Ala	His	Lys	Pro	Trp	Pro	Tyr	Arg	Arg	Arg	Ser	Gln	Phe
1				5					10					15	
Ser	Ser	Arg	Lys	Tyr	Leu	Lys	Lys	Glu	Met	Asn	Ser	Phe	Gln	Gln	Gln
			20					25					30		
Pro	Pro	Pro	Phe	Gly	Thr	Val	Pro	Pro	Gln	Met	Met	Phe	Pro	Pro	Asn
			35				40					45			
Trp	Gln	Gly	Ala	Glu	Lys	Asp	Ala	Ala	Phe	Leu	Ala	Lys	Asp	Phe	Asn
	50					55					60				
Phe	Leu	Thr	Leu	Asn	Asn	Gln	Pro	Pro	Pro	Gly	Asn	Arg	Ser	Gln	Pro
65					70					75					80
Arg	Ala	Met	Gly	Pro	Glu	Asn	Asn	Leu	Tyr	Ser	Gln	Tyr	Glu	Gln	Lys
				85					90					95	
Val	Arg	Pro	Cys	Ile	Asp	Leu	Ile	Asp	Ser	Leu	Arg	Ala	Leu	Gly	Val
			100					105					110		
Glu	Gln	Asp	Leu	Ala	Leu	Pro	Ala	Ile	Ala	Val	Ile	Gly	Asp	Gln	Ser
		115					120					125			
Ser	Gly	Lys	Ser	Ser	Val	Leu	Glu	Ala	Leu	Ser	Gly	Val	Ala	Leu	Pro
	130					135					140				
Arg	Gly	Ser	Gly	Ile	Val	Thr	Arg	Cys	Pro	Leu	Val	Leu	Lys	Leu	Lys
145					150					155					160
Lys	Gln	Pro	Cys	Glu	Ala	Trp	Ala	Gly	Arg	Ile	Ser	Tyr	Arg	Asn	Thr
			165					170						175	
Glu	Leu	Glu	Leu	Gln	Asp	Pro	Gly	Gln	Val	Glu	Lys	Glu	Ile	His	Lys
			180					185					190		
Ala	Gln	Asn	Val	Met	Ala	Gly	Asn	Gly	Arg	Gly	Ile	Ser	His	Glu	Leu
		195					200					205			
Ile	Ser	Leu	Glu	Ile	Thr	Ser	Pro	Glu	Val	Pro	Asp	Leu	Thr	Ile	Ile
	210					215					220				
Asp	Leu	Pro	Gly	Ile	Thr	Arg	Val	Ala	Val	Asp	Asn	Gln	Pro	Arg	Asp
225					230					235					240
Ile	Gly	Leu	Gln	Ile	Lys	Ala	Leu	Ile	Lys	Lys	Tyr	Ile	Gln	Arg	Gln
			245					250						255	
Gln	Thr	Ile	Asn	Leu	Val	Val	Val	Pro	Cys	Asn	Val	Asp	Ile	Ala	Thr
			260					265					270		
Thr	Glu	Ala	Leu	Ser	Met	Ala	His	Glu	Val	Asp	Pro	Glu	Gly	Asp	Arg
		275				280						285			
Thr	Ile	Gly	Ile	Leu	Thr	Lys	Pro	Asp	Leu	Met	Asp	Arg	Gly	Thr	Glu
	290					295					300				
Lys	Ser	Val	Met	Asn	Val	Val	Arg	Asn	Leu	Thr	Tyr	Pro	Leu	Lys	Lys
305				310						315					320
Gly	Tyr	Met	Ile	Val	Lys	Cys	Arg	Gly	Gln	Gln	Glu	Ile	Thr	Asn	Arg
			325					330						335	
Leu	Ser	Leu	Ala	Glu	Ala	Thr	Lys	Lys	Glu	Ile	Thr	Phe	Phe	Gln	Thr
			340					345					350		
His	Pro	Tyr	Phe	Arg	Val	Leu	Leu	Glu	Glu	Gly	Ser	Ala	Thr	Val	Pro
		355				360						365			
Arg	Leu	Ala	Glu	Arg	Leu	Thr	Thr	Glu	Leu	Ile	Met	His	Ile	Gln	Lys
	370					375					380				
Ser	Leu	Pro	Leu	Leu	Glu	Gly	Gln	Ile	Arg	Glu	Ser	His	Gln	Lys	Ala
385				390						395					400
Thr	Glu	Glu	Leu	Arg	Arg	Cys	Gly	Ala	Asp	Ile	Pro	Ser	Gln	Glu	Ala

-continued

405					410					415					
Asp	Lys	Met	Phe	Phe	Leu	Ile	Glu	Lys	Ile	Lys	Met	Phe	Asn	Gln	Asp
			420					425					430		
Ile	Glu	Lys	Leu	Val	Glu	Gly	Glu	Glu	Val	Val	Arg	Glu	Asn	Glu	Thr
		435					440					445			
Arg	Leu	Tyr	Asn	Lys	Ile	Arg	Glu	Asp	Phe	Lys	Asn	Trp	Val	Gly	Ile
	450					455					460				
Leu	Ala	Thr	Asn	Thr	Gln	Lys	Val	Lys	Asn	Ile	Ile	His	Glu	Glu	Val
465					470					475					480
Glu	Lys	Tyr	Glu	Lys	Gln	Tyr	Arg	Gly	Lys	Glu	Leu	Leu	Gly	Phe	Val
				485					490					495	
Asn	Tyr	Lys	Thr	Phe	Glu	Ile	Ile	Val	His	Gln	Tyr	Ile	Gln	Gln	Leu
			500					505					510		
Val	Glu	Pro	Ala	Leu	Ser	Met	Leu	Gln	Lys	Ala	Met	Glu	Ile	Ile	Gln
		515					520					525			
Gln	Ala	Phe	Ile	Asn	Val	Ala	Lys	Lys	His	Phe	Gly	Glu	Phe	Phe	Asn
	530					535					540				
Leu	Asn	Gln	Thr	Val	Gln	Ser	Thr	Ile	Glu	Asp	Ile	Lys	Val	Lys	His
545					550					555					560
Thr	Ala	Lys	Ala	Glu	Asn	Met	Ile	Gln	Leu	Gln	Phe	Arg	Met	Glu	Gln
				565					570					575	
Met	Val	Phe	Cys	Gln	Asp	Gln	Ile	Tyr	Ser	Val	Val	Leu	Lys	Lys	Val
			580					585					590		
Arg	Glu	Glu	Ile	Phe	Asn	Pro	Leu	Gly	Thr	Pro	Ser	Gln	Asn	Met	Lys
		595					600					605			
Leu	Asn	Ser	His	Phe	Pro	Ser	Asn	Glu	Ser	Ser	Val	Ser	Ser	Phe	Thr
	610						615				620				
Glu	Ile	Gly	Ile	His	Leu	Asn	Ala	Tyr	Phe	Leu	Glu	Thr	Ser	Lys	Arg
625					630					635					640
Leu	Ala	Asn	Gln	Ile	Pro	Phe	Ile	Ile	Gln	Tyr	Phe	Met	Leu	Arg	Glu
				645					650					655	
Asn	Gly	Asp	Ser	Leu	Gln	Lys	Ala	Met	Met	Gln	Ile	Leu	Gln	Glu	Lys
			660					665					670		
Asn	Arg	Tyr	Ser	Trp	Leu	Leu	Gln	Glu	Gln	Ser	Glu	Thr	Ala	Thr	Lys
		675					680					685			
Arg	Arg	Ile	Leu	Lys	Glu	Arg	Ile	Tyr	Arg	Leu	Thr	Gln	Ala	Arg	His
	690						695				700				
Ala	Leu	Cys	Gln	Phe	Ser	Ser	Lys	Glu	Ile	His					
705					710					715					
<210> SEQ ID NO 41															
<211> LENGTH: 503															
<212> TYPE: PRT															
<213> ORGANISM: Homo sapiens															
<400> SEQUENCE: 41															
Met	Ala	Leu	Ala	Pro	Glu	Arg	Ala	Ala	Pro	Arg	Val	Leu	Phe	Gly	Glu
1				5					10					15	
Trp	Leu	Leu	Gly	Glu	Ile	Ser	Ser	Gly	Cys	Tyr	Glu	Gly	Leu	Gln	Trp
			20					25					30		
Leu	Asp	Glu	Ala	Arg	Thr	Cys	Phe	Arg	Val	Pro	Trp	Lys	His	Phe	Ala
	35						40					45			

-continued

Arg	Lys	Asp	Leu	Ser	Glu	Ala	Asp	Ala	Arg	Ile	Phe	Lys	Ala	Trp	Ala
50					55					60					
Val	Ala	Arg	Gly	Arg	Trp	Pro	Pro	Ser	Ser	Arg	Gly	Gly	Gly	Pro	Pro
65					70					75				80	
Pro	Glu	Ala	Glu	Thr	Ala	Glu	Arg	Ala	Gly	Trp	Lys	Thr	Asn	Phe	Arg
				85					90					95	
Cys	Ala	Leu	Arg	Ser	Thr	Arg	Arg	Phe	Val	Met	Leu	Arg	Asp	Asn	Ser
			100					105					110		
Gly	Asp	Pro	Ala	Asp	Pro	His	Lys	Val	Tyr	Ala	Leu	Ser	Arg	Glu	Leu
	115						120						125		
Cys	Trp	Arg	Glu	Gly	Pro	Gly	Thr	Asp	Gln	Thr	Glu	Ala	Glu	Ala	Pro
	130					135					140				
Ala	Ala	Val	Pro	Pro	Pro	Gln	Gly	Gly	Pro	Pro	Gly	Pro	Phe	Leu	Ala
145					150				155					160	
His	Thr	His	Ala	Gly	Leu	Gln	Ala	Pro	Gly	Pro	Leu	Pro	Ala	Pro	Ala
			165					170						175	
Gly	Asp	Lys	Gly	Asp	Leu	Leu	Leu	Gln	Ala	Val	Gln	Gln	Ser	Cys	Leu
		180						185					190		
Ala	Asp	His	Leu	Leu	Thr	Ala	Ser	Trp	Gly	Ala	Asp	Pro	Val	Pro	Thr
	195						200					205			
Lys	Ala	Pro	Gly	Glu	Gly	Gln	Glu	Gly	Leu	Pro	Leu	Thr	Gly	Ala	Cys
	210					215					220				
Ala	Gly	Gly	Pro	Gly	Leu	Pro	Ala	Gly	Glu	Leu	Tyr	Gly	Trp	Ala	Val
225					230				235					240	
Glu	Thr	Thr	Pro	Ser	Pro	Gly	Pro	Gln	Pro	Ala	Ala	Leu	Thr	Thr	Gly
			245					250						255	
Glu	Ala	Ala	Ala	Pro	Glu	Ser	Pro	His	Gln	Ala	Glu	Pro	Tyr	Leu	Ser
			260					265					270		
Pro	Ser	Pro	Ser	Ala	Cys	Thr	Ala	Val	Gln	Glu	Pro	Ser	Pro	Gly	Ala
	275						280					285			
Leu	Asp	Val	Thr	Ile	Met	Tyr	Lys	Gly	Arg	Thr	Val	Leu	Gln	Lys	Val
	290				295						300				
Val	Gly	His	Pro	Ser	Cys	Thr	Phe	Leu	Tyr	Gly	Pro	Pro	Asp	Pro	Ala
305					310					315				320	
Val	Arg	Ala	Thr	Asp	Pro	Gln	Gln	Val	Ala	Phe	Pro	Ser	Pro	Ala	Glu
			325					330						335	
Leu	Pro	Asp	Gln	Lys	Gln	Leu	Arg	Tyr	Thr	Glu	Glu	Leu	Leu	Arg	His
		340						345						350	
Val	Ala	Pro	Gly	Leu	His	Leu	Glu	Leu	Arg	Gly	Pro	Gln	Leu	Trp	Ala
	355					360						365			
Arg	Arg	Met	Gly	Lys	Cys	Lys	Val	Tyr	Trp	Glu	Val	Gly	Gly	Pro	Pro
	370				375						380				
Gly	Ser	Ala	Ser	Pro	Ser	Thr	Pro	Ala	Cys	Leu	Leu	Pro	Arg	Asn	Cys
385					390					395				400	
Asp	Thr	Pro	Ile	Phe	Asp	Phe	Arg	Val	Phe	Phe	Gln	Glu	Leu	Val	Glu
			405					410						415	
Phe	Arg	Ala	Arg	Gln	Arg	Arg	Gly	Ser	Pro	Arg	Tyr	Thr	Ile	Tyr	Leu
		420					425						430		
Gly	Phe	Gly	Gln	Asp	Leu	Ser	Ala	Gly	Arg	Pro	Lys	Glu	Lys	Ser	Leu
	435						440					445			
Val	Leu	Val	Lys	Leu	Glu	Pro	Trp	Leu	Cys	Arg	Val	His	Leu	Glu	Gly

-continued

450	455	460
Thr Gln Arg Glu Gly Val Ser Ser Leu Asp Ser Ser Ser Leu Ser Leu		
465	470	475 480
Cys Leu Ser Ser Ala Asn Ser Leu Tyr Asp Asp Ile Glu Cys Phe Leu		
	485	490 495
Met Glu Leu Glu Gln Pro Ala		
500		

<210> SEQ ID NO 42
 <211> LENGTH: 591
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 42

Met Ala Pro Glu Ile Asn Leu Pro Gly Pro Met Ser Leu Ile Asp Asn		
1	5	10 15
Thr Lys Gly Gln Leu Val Val Asn Pro Glu Ala Leu Lys Ile Leu Ser		
	20	25 30
Ala Ile Thr Gln Pro Val Val Val Val Ala Ile Val Gly Leu Tyr Arg		
	35	40 45
Thr Gly Lys Ser Tyr Leu Met Asn Lys Leu Ala Gly Lys Lys Asn Gly		
	50	55 60
Phe Ser Leu Gly Ser Thr Val Lys Ser His Thr Lys Gly Ile Trp Met		
65	70	75 80
Trp Cys Val Pro His Pro Lys Lys Pro Glu His Thr Leu Val Leu Leu		
	85	90 95
Asp Thr Glu Gly Leu Gly Asp Ile Glu Lys Gly Asp Asn Glu Asn Asp		
	100	105 110
Ser Trp Ile Phe Ala Leu Ala Ile Leu Leu Ser Ser Thr Phe Val Tyr		
	115	120 125
Asn Ser Met Gly Thr Ile Asn Gln Gln Ala Met Asp Gln Leu His Tyr		
	130	135 140
Val Thr Glu Leu Thr Asp Arg Ile Lys Ala Asn Ser Ser Pro Gly Asn		
145	150	155 160
Asn Ser Val Asp Asp Ser Ala Asp Phe Val Ser Phe Phe Pro Ala Phe		
	165	170 175
Val Trp Thr Leu Arg Asp Phe Thr Leu Glu Leu Glu Val Asp Gly Glu		
	180	185 190
Pro Ile Thr Ala Asp Asp Tyr Leu Glu Leu Ser Leu Lys Leu Arg Lys		
	195	200 205
Gly Thr Asp Lys Lys Ser Lys Ser Phe Asn Asp Pro Arg Leu Cys Ile		
	210	215 220
Arg Lys Phe Phe Pro Lys Arg Lys Cys Phe Val Phe Asp Trp Pro Ala		
225	230	235 240
Pro Lys Lys Tyr Leu Ala His Leu Glu Gln Leu Lys Glu Glu Glu Leu		
	245	250 255
Asn Pro Asp Phe Ile Glu Gln Val Ala Glu Phe Cys Ser Tyr Ile Leu		
	260	265 270
Ser His Ser Asn Val Lys Thr Leu Ser Gly Gly Ile Pro Val Asn Gly		
	275	280 285
Pro Arg Leu Glu Ser Leu Val Leu Thr Tyr Val Asn Ala Ile Ser Ser		
	290	295 300

-continued

Gly	Asp	Leu	Pro	Cys	Met	Glu	Asn	Ala	Val	Leu	Ala	Leu	Ala	Gln	Ile	305	310	315	320
Glu	Asn	Ser	Ala	Ala	Val	Glu	Lys	Ala	Ile	Ala	His	Tyr	Glu	Gln	Gln	325	330	335	
Met	Gly	Gln	Lys	Val	Gln	Leu	Pro	Thr	Glu	Thr	Leu	Gln	Glu	Leu	Leu	340	345	350	
Asp	Leu	His	Arg	Asp	Ser	Glu	Arg	Glu	Ala	Ile	Glu	Val	Phe	Met	Lys	355	360	365	
Asn	Ser	Phe	Lys	Asp	Val	Asp	Gln	Met	Phe	Gln	Arg	Lys	Leu	Gly	Ala	370	375	380	
Gln	Leu	Glu	Ala	Arg	Arg	Asp	Asp	Phe	Cys	Lys	Gln	Asn	Ser	Lys	Ala	385	390	395	400
Ser	Ser	Asp	Cys	Cys	Met	Ala	Leu	Leu	Gln	Asp	Ile	Phe	Gly	Pro	Leu	405	410	415	
Glu	Glu	Asp	Val	Lys	Gln	Gly	Thr	Phe	Ser	Lys	Pro	Gly	Gly	Tyr	Arg	420	425	430	
Leu	Phe	Thr	Gln	Lys	Leu	Gln	Glu	Leu	Lys	Asn	Lys	Tyr	Tyr	Gln	Val	435	440	445	
Pro	Arg	Lys	Gly	Ile	Gln	Ala	Lys	Glu	Val	Leu	Lys	Lys	Tyr	Leu	Glu	450	455	460	
Ser	Lys	Glu	Asp	Val	Ala	Asp	Ala	Leu	Leu	Gln	Thr	Asp	Gln	Ser	Leu	465	470	475	480
Ser	Glu	Lys	Glu	Lys	Ala	Ile	Glu	Val	Glu	Arg	Ile	Lys	Ala	Glu	Ser	485	490	495	
Ala	Glu	Ala	Ala	Lys	Lys	Met	Leu	Glu	Glu	Ile	Gln	Lys	Lys	Asn	Glu	500	505	510	
Glu	Met	Met	Glu	Gln	Lys	Glu	Lys	Ser	Tyr	Gln	Glu	His	Val	Lys	Gln	515	520	525	
Leu	Thr	Glu	Lys	Met	Glu	Arg	Asp	Arg	Ala	Gln	Leu	Met	Ala	Glu	Gln	530	535	540	
Glu	Lys	Thr	Leu	Ala	Leu	Lys	Leu	Gln	Glu	Gln	Glu	Arg	Leu	Leu	Lys	545	550	555	560
Glu	Gly	Phe	Glu	Asn	Glu	Ser	Lys	Arg	Leu	Gln	Lys	Asp	Ile	Trp	Asp	565	570	575	
Ile	Gln	Met	Arg	Ser	Lys	Ser	Leu	Glu	Pro	Ile	Cys	Asn	Ile	Leu		580	585	590	

<210> SEQ ID NO 43

<211> LENGTH: 658

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 43

Met	Glu	Lys	Ala	Ser	Gly	Arg	Gln	Ser	Ile	Ala	Leu	Ser	Thr	Val	Glu	1	5	10	15
Thr	Gly	Thr	Val	Asn	Pro	Gly	Leu	Glu	Leu	Met	Glu	Lys	Glu	Val	Glu	20	25	30	
Pro	Glu	Gly	Ser	Lys	Arg	Thr	Asp	Ala	Gln	Gly	His	Ser	Leu	Gly	Asp	35	40	45	
Gly	Leu	Gly	Pro	Ser	Thr	Tyr	Gln	Arg	Arg	Ser	Arg	Trp	Pro	Phe	Ser	50	55	60	
Lys	Ala	Arg	Ser	Phe	Cys	Lys	Thr	His	Ala	Arg	Leu	Phe	Lys	Lys	Ile	65	70	75	80

-continued

Leu	Leu	Gly	Leu	Leu	Cys	Leu	Ala	Tyr	Ala	Ala	Tyr	Leu	Leu	Ala	Ala
			85						90					95	
Cys	Ile	Leu	Asn	Phe	Gln	Arg	Ala	Leu	Ala	Leu	Phe	Val	Ile	Thr	Cys
			100					105					110		
Leu	Val	Ile	Phe	Val	Leu	Val	His	Ser	Phe	Leu	Lys	Lys	Leu	Leu	Gly
		115					120					125			
Lys	Lys	Leu	Thr	Arg	Cys	Leu	Lys	Pro	Phe	Glu	Asn	Ser	Arg	Leu	Arg
		130				135					140				
Leu	Trp	Thr	Lys	Trp	Val	Phe	Ala	Gly	Val	Ser	Leu	Val	Gly	Leu	Ile
145					150				155						160
Leu	Trp	Leu	Ala	Leu	Asp	Thr	Ala	Gln	Arg	Pro	Glu	Gln	Leu	Ile	Pro
			165					170						175	
Phe	Ala	Gly	Ile	Cys	Met	Phe	Ile	Leu	Ile	Leu	Phe	Ala	Cys	Ser	Lys
			180					185					190		
His	His	Ser	Ala	Val	Ser	Trp	Arg	Thr	Val	Phe	Ser	Gly	Leu	Gly	Leu
		195					200					205			
Gln	Phe	Val	Phe	Gly	Ile	Leu	Val	Ile	Arg	Thr	Asp	Leu	Gly	Tyr	Thr
		210				215					220				
Val	Phe	Gln	Trp	Leu	Gly	Glu	Gln	Val	Gln	Ile	Phe	Leu	Asn	Tyr	Thr
225					230				235						240
Val	Ala	Gly	Ser	Ser	Phe	Val	Phe	Gly	Asp	Thr	Leu	Val	Lys	Asp	Val
			245						250					255	
Phe	Ala	Phe	Gln	Ala	Leu	Pro	Ile	Ile	Ile	Phe	Phe	Gly	Cys	Val	Val
			260				265						270		
Ser	Ile	Leu	Tyr	Tyr	Leu	Gly	Leu	Val	Gln	Trp	Val	Val	Gln	Lys	Val
		275				280					285				
Ala	Trp	Phe	Leu	Gln	Ile	Thr	Met	Gly	Thr	Thr	Ala	Thr	Glu	Thr	Leu
	290				295						300				
Ala	Val	Ala	Gly	Asn	Ile	Phe	Val	Gly	Met	Thr	Glu	Ala	Pro	Leu	Leu
305				310					315						320
Ile	Arg	Pro	Tyr	Leu	Gly	Asp	Met	Thr	Leu	Ser	Glu	Ile	His	Ala	Val
			325					330					335		
Met	Thr	Gly	Gly	Phe	Ala	Thr	Ile	Ser	Gly	Thr	Val	Leu	Gly	Ala	Phe
		340					345						350		
Ile	Ala	Phe	Gly	Val	Asp	Ala	Ser	Ser	Leu	Ile	Ser	Ala	Ser	Val	Met
		355				360					365				
Ala	Ala	Pro	Cys	Ala	Leu	Ala	Ser	Ser	Lys	Leu	Ala	Tyr	Pro	Glu	Val
		370			375						380				
Glu	Glu	Ser	Lys	Phe	Lys	Ser	Glu	Glu	Gly	Val	Lys	Leu	Pro	Arg	Gly
385				390					395						400
Lys	Glu	Arg	Asn	Val	Leu	Glu	Ala	Ala	Ser	Asn	Gly	Ala	Val	Asp	Ala
			405					410						415	
Ile	Gly	Leu	Ala	Thr	Asn	Val	Ala	Ala	Asn	Leu	Ile	Ala	Phe	Leu	Ala
		420				425							430		
Val	Leu	Ala	Phe	Ile	Asn	Ala	Ala	Leu	Ser	Trp	Leu	Gly	Glu	Leu	Val
		435				440					445				
Asp	Ile	Gln	Gly	Leu	Thr	Phe	Gln	Val	Ile	Cys	Ser	Tyr	Leu	Leu	Arg
		450				455				460					
Pro	Met	Val	Phe	Met	Met	Gly	Val	Glu	Trp	Thr	Asp	Cys	Pro	Met	Val
465				470					475						480

-continued

Ala	Glu	Met	Val	Gly	Ile	Lys	Phe	Phe	Ile	Asn	Glu	Phe	Val	Ala	Tyr
				485					490					495	
Gln	Gln	Leu	Ser	Gln	Tyr	Lys	Asn	Lys	Arg	Leu	Ser	Gly	Met	Glu	Glu
			500					505					510		
Trp	Ile	Glu	Gly	Glu	Lys	Gln	Trp	Ile	Ser	Val	Arg	Ala	Glu	Ile	Ile
		515					520					525			
Thr	Thr	Phe	Ser	Leu	Cys	Gly	Phe	Ala	Asn	Leu	Ser	Ser	Ile	Gly	Ile
		530				535					540				
Thr	Leu	Gly	Gly	Leu	Thr	Ser	Ile	Val	Pro	His	Arg	Lys	Ser	Asp	Leu
545					550					555					560
Ser	Lys	Val	Val	Val	Arg	Ala	Leu	Phe	Thr	Gly	Ala	Cys	Val	Ser	Leu
				565					570					575	
Ile	Ser	Ala	Cys	Met	Ala	Gly	Ile	Leu	Tyr	Val	Pro	Arg	Gly	Ala	Glu
			580					585					590		
Ala	Asp	Cys	Val	Ser	Phe	Pro	Asn	Thr	Ser	Phe	Thr	Asn	Arg	Thr	Tyr
		595					600					605			
Glu	Thr	Tyr	Met	Cys	Cys	Arg	Gly	Leu	Phe	Gln	Ser	Thr	Ser	Leu	Asn
	610					615					620				
Gly	Thr	Asn	Pro	Pro	Ser	Phe	Ser	Gly	Pro	Trp	Glu	Asp	Lys	Glu	Phe
625					630				635						640
Ser	Ala	Met	Ala	Leu	Thr	Asn	Cys	Cys	Gly	Phe	Tyr	Asn	Asn	Thr	Val
				645					650					655	

Cys Ala

<210> SEQ ID NO 44
 <211> LENGTH: 247
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 44

Met	Thr	Ile	Leu	Phe	Leu	Thr	Met	Val	Ile	Ser	Tyr	Phe	Gly	Cys	Met
1			5						10					15	
Lys	Ala	Ala	Pro	Met	Lys	Glu	Ala	Asn	Ile	Arg	Gly	Gln	Gly	Gly	Leu
			20					25					30		
Ala	Tyr	Pro	Gly	Val	Arg	Thr	His	Gly	Thr	Leu	Glu	Ser	Val	Asn	Gly
		35				40						45			
Pro	Lys	Ala	Gly	Ser	Arg	Gly	Leu	Thr	Ser	Leu	Ala	Asp	Thr	Phe	Glu
	50					55					60				
His	Val	Ile	Glu	Glu	Leu	Leu	Asp	Glu	Asp	Gln	Lys	Val	Arg	Pro	Asn
65					70				75					80	
Glu	Glu	Asn	Asn	Lys	Asp	Ala	Asp	Leu	Tyr	Thr	Ser	Arg	Val	Met	Leu
			85					90						95	
Ser	Ser	Gln	Val	Pro	Leu	Glu	Pro	Pro	Leu	Leu	Phe	Leu	Leu	Glu	Glu
			100					105					110		
Tyr	Lys	Asn	Tyr	Leu	Asp	Ala	Ala	Asn	Met	Ser	Met	Arg	Val	Arg	Arg
		115					120					125			
His	Ser	Asp	Pro	Ala	Arg	Arg	Gly	Glu	Leu	Ser	Val	Cys	Asp	Ser	Ile
		130				135					140				
Ser	Glu	Trp	Val	Thr	Ala	Ala	Asp	Lys	Lys	Thr	Ala	Val	Asp	Met	Ser
145					150				155					160	
Gly	Gly	Thr	Val	Thr	Val	Leu	Glu	Lys	Val	Pro	Val	Ser	Lys	Gly	Gln
				165					170					175	

-continued

Leu Lys Gln Tyr Phe Tyr Glu Thr Lys Cys Asn Pro Met Gly Tyr Thr
 180 185 190
 Lys Glu Gly Cys Arg Gly Ile Asp Lys Arg His Trp Asn Ser Gln Cys
 195 200 205
 Arg Thr Thr Gln Ser Tyr Val Arg Ala Leu Thr Met Asp Ser Lys Lys
 210 215 220
 Arg Ile Gly Trp Arg Phe Ile Arg Ile Asp Thr Ser Cys Val Cys Thr
 225 230 235 240
 Leu Thr Ile Lys Arg Gly Arg
 245

<210> SEQ ID NO 45

<211> LENGTH: 1112

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 45

Met Arg Arg Asp Glu Arg Asp Ala Lys Ala Met Arg Ser Leu Gln Pro
 1 5 10 15
 Pro Asp Gly Ala Gly Ser Pro Pro Glu Ser Leu Arg Asn Gly Tyr Val
 20 25 30
 Lys Ser Cys Val Ser Pro Leu Arg Gln Asp Pro Pro Arg Gly Phe Phe
 35 40 45
 Phe His Leu Cys Arg Phe Cys Asn Val Glu Leu Arg Pro Pro Pro Ala
 50 55 60
 Ser Pro Gln Gln Pro Arg Arg Cys Ser Pro Phe Cys Arg Ala Arg Leu
 65 70 75 80
 Ser Leu Gly Ala Leu Ala Ala Phe Val Leu Ala Leu Leu Gly Ala
 85 90 95
 Glu Pro Glu Ser Trp Ala Ala Gly Ala Ala Trp Leu Arg Thr Leu Leu
 100 105 110
 Ser Val Cys Ser His Ser Leu Ser Pro Leu Phe Ser Ile Ala Cys Ala
 115 120 125
 Phe Phe Phe Leu Thr Cys Phe Leu Thr Arg Thr Lys Arg Gly Pro Gly
 130 135 140
 Pro Gly Arg Ser Cys Gly Ser Trp Trp Leu Leu Ala Leu Pro Ala Cys
 145 150 155 160
 Cys Tyr Leu Gly Asp Phe Leu Val Trp Gln Trp Trp Ser Trp Pro Trp
 165 170 175
 Gly Asp Gly Asp Ala Gly Ser Ala Ala Pro His Thr Pro Pro Glu Ala
 180 185 190
 Ala Ala Gly Arg Leu Leu Leu Val Leu Ser Cys Val Gly Leu Leu Leu
 195 200 205
 Thr Leu Ala His Pro Leu Arg Leu Arg His Cys Val Leu Val Leu Leu
 210 215 220
 Leu Ala Ser Phe Val Trp Trp Val Ser Phe Thr Ser Leu Gly Ser Leu
 225 230 235 240
 Pro Ser Ala Leu Arg Pro Leu Leu Ser Gly Leu Val Gly Gly Ala Gly
 245 250 255
 Cys Leu Leu Ala Leu Gly Leu Asp His Phe Phe Gln Ile Arg Glu Ala
 260 265 270
 Pro Leu His Pro Arg Leu Ser Ser Ala Ala Glu Glu Lys Val Pro Val
 275 280 285

-continued

Ile	Arg	Pro	Arg	Arg	Arg	Ser	Ser	Cys	Val	Ser	Leu	Gly	Glu	Thr	Ala	290	295	300
Ala	Ser	Tyr	Tyr	Gly	Ser	Cys	Lys	Ile	Phe	Arg	Arg	Pro	Ser	Leu	Pro	305	310	315
Cys	Ile	Ser	Arg	Glu	Gln	Met	Ile	Leu	Trp	Asp	Trp	Asp	Leu	Lys	Gln	325	330	335
Trp	Tyr	Lys	Pro	His	Tyr	Gln	Asn	Ser	Gly	Gly	Gly	Asn	Gly	Val	Asp	340	345	350
Leu	Ser	Val	Leu	Asn	Glu	Ala	Arg	Asn	Met	Val	Ser	Asp	Leu	Leu	Thr	355	360	365
Asp	Pro	Ser	Leu	Pro	Pro	Gln	Val	Ile	Ser	Ser	Leu	Arg	Ser	Ile	Ser	370	375	380
Ser	Leu	Met	Gly	Ala	Phe	Ser	Gly	Ser	Cys	Arg	Pro	Lys	Ile	Asn	Pro	385	390	395
Leu	Thr	Pro	Phe	Pro	Gly	Phe	Tyr	Pro	Cys	Ser	Glu	Ile	Glu	Asp	Pro	405	410	415
Ala	Glu	Lys	Gly	Asp	Arg	Lys	Leu	Asn	Lys	Gly	Leu	Asn	Arg	Asn	Ser	420	425	430
Leu	Pro	Thr	Pro	Gln	Leu	Arg	Arg	Ser	Ser	Gly	Thr	Ser	Gly	Leu	Leu	435	440	445
Pro	Val	Glu	Gln	Ser	Ser	Arg	Trp	Asp	Arg	Asn	Asn	Gly	Lys	Arg	Pro	450	455	460
His	Gln	Glu	Phe	Gly	Ile	Ser	Ser	Gln	Gly	Cys	Tyr	Leu	Asn	Gly	Pro	465	470	475
Phe	Asn	Ser	Asn	Leu	Leu	Thr	Ile	Pro	Lys	Gln	Arg	Ser	Ser	Ser	Val	485	490	495
Ser	Leu	Thr	His	His	Val	Gly	Leu	Arg	Arg	Ala	Gly	Val	Leu	Ser	Ser	500	505	510
Leu	Ser	Pro	Val	Asn	Ser	Ser	Asn	His	Gly	Pro	Val	Ser	Thr	Gly	Ser	515	520	525
Leu	Thr	Asn	Arg	Ser	Pro	Ile	Glu	Phe	Pro	Asp	Thr	Ala	Asp	Phe	Leu	530	535	540
Asn	Lys	Pro	Ser	Val	Ile	Leu	Gln	Arg	Ser	Leu	Gly	Asn	Ala	Pro	Asn	545	550	555
Thr	Pro	Asp	Phe	Tyr	Gln	Gln	Leu	Arg	Asn	Ser	Asp	Ser	Asn	Leu	Cys	565	570	575
Asn	Ser	Cys	Gly	His	Gln	Met	Leu	Lys	Tyr	Val	Ser	Thr	Ser	Glu	Ser	580	585	590
Asp	Gly	Thr	Asp	Cys	Cys	Ser	Gly	Lys	Ser	Gly	Glu	Glu	Glu	Asn	Ile	595	600	605
Phe	Ser	Lys	Glu	Ser	Phe	Lys	Leu	Met	Glu	Thr	Gln	Gln	Glu	Glu	Glu	610	615	620
Thr	Glu	Lys	Lys	Asp	Ser	Arg	Lys	Leu	Phe	Gln	Glu	Gly	Asp	Lys	Trp	625	630	635
Leu	Thr	Glu	Glu	Ala	Gln	Ser	Glu	Gln	Gln	Thr	Asn	Ile	Glu	Gln	Glu	645	650	655
Val	Ser	Leu	Asp	Leu	Ile	Leu	Val	Glu	Glu	Tyr	Asp	Ser	Leu	Ile	Glu	660	665	670
Lys	Met	Ser	Asn	Trp	Asn	Phe	Pro	Ile	Phe	Glu	Leu	Val	Glu	Lys	Met	675	680	685

-continued

Gly	Glu	Lys	Ser	Gly	Arg	Ile	Leu	Ser	Gln	Val	Met	Tyr	Thr	Leu	Phe
690						695					700				
Gln	Asp	Thr	Gly	Leu	Leu	Glu	Ile	Phe	Lys	Ile	Pro	Thr	Gln	Gln	Phe
705					710					715					720
Met	Asn	Tyr	Phe	Arg	Ala	Leu	Glu	Asn	Gly	Tyr	Arg	Asp	Ile	Pro	Tyr
				725					730					735	
His	Asn	Arg	Ile	His	Ala	Thr	Asp	Val	Leu	His	Ala	Val	Trp	Tyr	Leu
			740					745					750		
Thr	Thr	Arg	Pro	Val	Pro	Gly	Leu	Gln	Gln	Ile	His	Asn	Gly	Cys	Gly
		755					760					765			
Thr	Gly	Asn	Glu	Thr	Asp	Ser	Asp	Gly	Arg	Ile	Asn	His	Gly	Arg	Ile
	770					775					780				
Ala	Tyr	Ile	Ser	Ser	Lys	Ser	Cys	Ser	Asn	Pro	Asp	Glu	Ser	Tyr	Gly
785					790					795					800
Cys	Leu	Ser	Ser	Asn	Ile	Pro	Ala	Leu	Glu	Leu	Met	Ala	Leu	Tyr	Val
				805					810					815	
Ala	Ala	Ala	Met	His	Asp	Tyr	Asp	His	Pro	Gly	Arg	Thr	Asn	Ala	Phe
			820					825					830		
Leu	Val	Ala	Thr	Asn	Ala	Pro	Gln	Ala	Val	Leu	Tyr	Asn	Asp	Arg	Ser
		835					840					845			
Val	Leu	Glu	Asn	His	His	Ala	Ala	Ser	Ala	Trp	Asn	Leu	Tyr	Leu	Ser
	850					855					860				
Arg	Pro	Glu	Tyr	Asn	Phe	Leu	Leu	His	Leu	Asp	His	Val	Glu	Phe	Lys
865					870					875					880
Arg	Phe	Arg	Phe	Leu	Val	Ile	Glu	Ala	Ile	Leu	Ala	Thr	Asp	Leu	Lys
				885					890					895	
Lys	His	Phe	Asp	Phe	Leu	Ala	Glu	Phe	Asn	Ala	Lys	Ala	Asn	Asp	Val
			900					905					910		
Asn	Ser	Asn	Gly	Ile	Glu	Trp	Ser	Asn	Glu	Asn	Asp	Arg	Leu	Leu	Val
		915					920					925			
Cys	Gln	Val	Cys	Ile	Lys	Leu	Ala	Asp	Ile	Asn	Gly	Pro	Ala	Lys	Val
	930					935					940				
Arg	Asp	Leu	His	Leu	Lys	Trp	Thr	Glu	Gly	Ile	Val	Asn	Glu	Phe	Tyr
945					950					955					960
Glu	Gln	Gly	Asp	Glu	Glu	Ala	Asn	Leu	Gly	Leu	Pro	Ile	Ser	Pro	Phe
				965					970					975	
Met	Asp	Arg	Ser	Ser	Pro	Gln	Leu	Ala	Lys	Leu	Gln	Glu	Ser	Phe	Ile
			980					985					990		
Thr	His	Ile	Val	Gly	Pro	Leu	Cys	Asn	Ser	Tyr	Asp	Ala	Ala	Gly	Leu
		995					1000					1005			
Leu	Pro	Gly	Gln	Trp	Leu	Glu	Ala	Glu	Glu	Asp	Asn	Asp	Thr	Glu	
	1010					1015					1020				
Ser	Gly	Asp	Asp	Glu	Asp	Gly	Glu	Glu	Leu	Asp	Thr	Glu	Asp	Glu	
	1025					1030					1035				
Glu	Met	Glu	Asn	Asn	Leu	Asn	Pro	Lys	Pro	Pro	Arg	Arg	Lys	Ser	
	1040					1045					1050				
Arg	Arg	Arg	Ile	Phe	Cys	Gln	Leu	Met	His	His	Leu	Thr	Glu	Asn	
	1055					1060					1065				
His	Lys	Ile	Trp	Lys	Glu	Ile	Val	Glu	Glu	Glu	Glu	Lys	Cys	Lys	
	1070					1075					1080				
Ala	Asp	Gly	Asn	Lys	Leu	Gln	Val	Glu	Asn	Ser	Ser	Leu	Pro	Gln	

-continued

1085	1090	1095
Ala Asp Glu Ile Gln Val Ile	Glu Glu Ala Asp Glu	Glu Glu
1100	1105	1110
<210> SEQ ID NO 46 <211> LENGTH: 538 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 46		
Met Phe Phe Leu Tyr Thr Asp Phe Phe Leu Ser Leu Val Ala Val Pro		
1	5	10 15
Ala Ala Ala Pro Val Cys Gln Pro Lys Ser Ala Thr Asn Gly Gln Pro		
	20	25 30
Pro Ala Pro Ala Pro Thr Pro Thr Pro Arg Leu Ser Ile Ser Ser Arg		
	35	40 45
Ala Thr Val Val Ala Arg Met Glu Gly Thr Ser Gln Gly Gly Leu Gln		
	50	55 60
Thr Val Met Lys Trp Lys Thr Val Val Ala Ile Phe Val Val Val Val		
	65	70 75 80
Val Tyr Leu Val Thr Gly Gly Leu Val Phe Arg Ala Leu Glu Gln Pro		
	85	90 95
Phe Glu Ser Ser Gln Lys Asn Thr Ile Ala Leu Glu Lys Ala Glu Phe		
	100	105 110
Leu Arg Asp His Val Cys Val Ser Pro Gln Glu Leu Glu Thr Leu Ile		
	115	120 125
Gln His Ala Leu Asp Ala Asp Asn Ala Gly Val Ser Pro Ile Gly Asn		
	130	135 140
Ser Ser Asn Asn Ser Ser His Trp Asp Leu Gly Ser Ala Phe Phe Phe		
	145	150 155 160
Ala Gly Thr Val Ile Thr Thr Ile Gly Tyr Gly Asn Ile Ala Pro Ser		
	165	170 175
Thr Glu Gly Gly Lys Ile Phe Cys Ile Leu Tyr Ala Ile Phe Gly Ile		
	180	185 190
Pro Leu Phe Gly Phe Leu Leu Ala Gly Ile Gly Asp Gln Leu Gly Thr		
	195	200 205
Ile Phe Gly Lys Ser Ile Ala Arg Val Glu Lys Val Phe Arg Lys Lys		
	210	215 220
Gln Val Ser Gln Thr Lys Ile Arg Val Ile Ser Thr Ile Leu Phe Ile		
	225	230 235 240
Leu Ala Gly Cys Ile Val Phe Val Thr Ile Pro Ala Val Ile Phe Lys		
	245	250 255
Tyr Ile Glu Gly Trp Thr Ala Leu Glu Ser Ile Tyr Phe Val Val Val		
	260	265 270
Thr Leu Thr Thr Val Gly Phe Gly Asp Phe Val Ala Gly Gly Asn Ala		
	275	280 285
Gly Ile Asn Tyr Arg Glu Trp Tyr Lys Pro Leu Val Trp Phe Trp Ile		
	290	295 300
Leu Val Gly Leu Ala Tyr Phe Ala Ala Val Leu Ser Met Ile Gly Asp		
	305	310 315 320
Trp Leu Arg Val Leu Ser Lys Lys Thr Lys Glu Glu Val Gly Glu Ile		
	325	330 335

```
<210> SEQ ID NO 47
<211> LENGTH: 796
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 47
```

Met	Leu	Arg	Gly	Gly	Arg	Arg	Gly	Gln	Leu	Gly	Trp	His	Ser	Trp	Ala
1			5						10					15	
Ala	Gly	Pro	Gly	Ser	Leu	Leu	Ala	Trp	Leu	Ile	Leu	Ala	Ser	Ala	Gly
			20					25					30		
Ala	Ala	Pro	Cys	Pro	Asp	Ala	Cys	Cys	Pro	His	Gly	Ser	Ser	Gly	Leu
		35					40					45			
Arg	Cys	Thr	Arg	Asp	Gly	Ala	Leu	Asp	Ser	Leu	His	His	Leu	Pro	Gly
	50					55					60				
Ala	Glu	Asn	Leu	Thr	Glu	Leu	Tyr	Ile	Glu	Asn	Gln	Gln	His	Leu	Gln
65					70					75					80
His	Leu	Glu	Leu	Arg	Asp	Leu	Arg	Gly	Leu	Gly	Glu	Leu	Arg	Asn	Leu
			85					90					95		
Thr	Ile	Val	Lys	Ser	Gly	Leu	Arg	Phe	Val	Ala	Pro	Asp	Ala	Phe	His
			100					105					110		
Phe	Thr	Pro	Arg	Leu	Ser	Arg	Leu	Asn	Leu	Ser	Phe	Asn	Ala	Leu	Glu
		115					120					125			
Ser	Leu	Ser	Trp	Lys	Thr	Val	Gln	Gly	Leu	Ser	Leu	Gln	Glu	Leu	Val
	130					135					140				
Leu	Ser	Gly	Asn	Pro	Leu	His	Cys	Ser	Cys	Ala	Leu	Arg	Trp	Leu	Gln
145					150					155					160

-continued

Arg	Trp	Glu	Glu	Glu	Gly	Leu	Gly	Gly	Val	Pro	Glu	Gln	Lys	Leu	Gln	165	170	175
Cys	His	Gly	Gln	Gly	Pro	Leu	Ala	His	Met	Pro	Asn	Ala	Ser	Cys	Gly	180	185	190
Val	Pro	Thr	Leu	Lys	Val	Gln	Val	Pro	Asn	Ala	Ser	Val	Asp	Val	Gly	195	200	205
Asp	Asp	Val	Leu	Leu	Arg	Cys	Gln	Val	Glu	Gly	Arg	Gly	Leu	Glu	Gln	210	215	220
Ala	Gly	Trp	Ile	Leu	Thr	Glu	Leu	Glu	Gln	Ser	Ala	Thr	Val	Met	Lys	225	230	235
Ser	Gly	Gly	Leu	Pro	Ser	Leu	Gly	Leu	Thr	Leu	Ala	Asn	Val	Thr	Ser	245	250	255
Asp	Leu	Asn	Arg	Lys	Asn	Val	Thr	Cys	Trp	Ala	Glu	Asn	Asp	Val	Gly	260	265	270
Arg	Ala	Glu	Val	Ser	Val	Gln	Val	Asn	Val	Ser	Phe	Pro	Ala	Ser	Val	275	280	285
Gln	Leu	His	Thr	Ala	Val	Glu	Met	His	His	Trp	Cys	Ile	Pro	Phe	Ser	290	295	300
Val	Asp	Gly	Gln	Pro	Ala	Pro	Ser	Leu	Arg	Trp	Leu	Phe	Asn	Gly	Ser	305	310	315
Val	Leu	Asn	Glu	Thr	Ser	Phe	Ile	Phe	Thr	Glu	Phe	Leu	Glu	Pro	Ala	325	330	335
Ala	Asn	Glu	Thr	Val	Arg	His	Gly	Cys	Leu	Arg	Leu	Asn	Gln	Pro	Thr	340	345	350
His	Val	Asn	Asn	Gly	Asn	Tyr	Thr	Leu	Leu	Ala	Ala	Asn	Pro	Phe	Gly	355	360	365
Gln	Ala	Ser	Ala	Ser	Ile	Met	Ala	Ala	Phe	Met	Asp	Asn	Pro	Phe	Glu	370	375	380
Phe	Asn	Pro	Glu	Asp	Pro	Ile	Pro	Val	Ser	Phe	Ser	Pro	Val	Asp	Thr	385	390	395
Asn	Ser	Thr	Ser	Gly	Asp	Pro	Val	Glu	Lys	Lys	Asp	Glu	Thr	Pro	Phe	405	410	415
Gly	Val	Ser	Val	Ala	Val	Gly	Leu	Ala	Val	Phe	Ala	Cys	Leu	Phe	Leu	420	425	430
Ser	Thr	Leu	Leu	Val	Leu	Asn	Lys	Cys	Gly	Arg	Arg	Asn	Lys	Phe		435	440	445
Gly	Ile	Asn	Arg	Pro	Ala	Val	Leu	Ala	Pro	Glu	Asp	Gly	Leu	Ala	Met	450	455	460
Ser	Leu	His	Phe	Met	Thr	Leu	Gly	Gly	Ser	Ser	Leu	Ser	Pro	Thr	Glu	465	470	475
Gly	Lys	Gly	Ser	Gly	Leu	Gln	Gly	His	Ile	Ile	Glu	Asn	Pro	Gln	Tyr	485	490	495
Phe	Ser	Asp	Ala	Cys	Val	His	His	Ile	Lys	Arg	Arg	Asp	Ile	Val	Leu	500	505	510
Lys	Trp	Glu	Leu	Gly	Glu	Gly	Ala	Phe	Gly	Lys	Val	Phe	Leu	Ala	Glu	515	520	525
Cys	His	Asn	Leu	Leu	Pro	Glu	Gln	Asp	Lys	Met	Leu	Val	Ala	Val	Lys	530	535	540
Ala	Leu	Lys	Glu	Ala	Ser	Glu	Ser	Ala	Arg	Gln	Asp	Phe	Gln	Arg	Glu	545	550	555

-continued

Ala	Glu	Leu	Leu	Thr	Met	Leu	Gln	His	Gln	His	Ile	Val	Arg	Phe	Phe
				565					570					575	
Gly	Val	Cys	Thr	Glu	Gly	Arg	Pro	Leu	Leu	Met	Val	Phe	Glu	Tyr	Met
			580					585					590		
Arg	His	Gly	Asp	Leu	Asn	Arg	Phe	Leu	Arg	Ser	His	Gly	Pro	Asp	Ala
		595					600					605			
Lys	Leu	Leu	Ala	Gly	Gly	Glu	Asp	Val	Ala	Pro	Gly	Pro	Leu	Gly	Leu
	610					615					620				
Gly	Gln	Leu	Leu	Ala	Val	Ala	Ser	Gln	Val	Ala	Ala	Gly	Met	Val	Tyr
	625				630					635					640
Leu	Ala	Gly	Leu	His	Phe	Val	His	Arg	Asp	Leu	Ala	Thr	Arg	Asn	Cys
				645					650					655	
Leu	Val	Gly	Gln	Gly	Leu	Val	Val	Lys	Ile	Gly	Asp	Phe	Gly	Met	Ser
			660					665					670		
Arg	Asp	Ile	Tyr	Ser	Thr	Asp	Tyr	Tyr	Arg	Val	Gly	Gly	Arg	Thr	Met
		675					680					685			
Leu	Pro	Ile	Arg	Trp	Met	Pro	Pro	Glu	Ser	Ile	Leu	Tyr	Arg	Lys	Phe
		690				695					700				
Thr	Thr	Glu	Ser	Asp	Val	Trp	Ser	Phe	Gly	Val	Val	Leu	Trp	Glu	Ile
	705				710					715					720
Phe	Thr	Tyr	Gly	Lys	Gln	Pro	Trp	Tyr	Gln	Leu	Ser	Asn	Thr	Glu	Ala
			725						730					735	
Ile	Asp	Cys	Ile	Thr	Gln	Gly	Arg	Glu	Leu	Glu	Arg	Pro	Arg	Ala	Cys
		740					745					750			
Pro	Pro	Glu	Val	Tyr	Ala	Ile	Met	Arg	Gly	Cys	Trp	Gln	Arg	Glu	Pro
		755					760					765			
Gln	Gln	Arg	His	Ser	Ile	Lys	Asp	Val	His	Ala	Arg	Leu	Gln	Ala	Leu
	770					775						780			
Ala	Gln	Ala	Pro	Pro	Val	Tyr	Leu	Asp	Val	Leu	Gly				
	785				790					795					

<210> SEQ ID NO 48

<211> LENGTH: 569

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 48

Met	Lys	Val	Leu	Leu	Arg	Leu	Ile	Cys	Phe	Ile	Ala	Leu	Leu	Ile	Ser
1				5					10					15	
Ser	Leu	Glu	Ala	Asp	Lys	Cys	Lys	Glu	Arg	Glu	Glu	Lys	Ile	Ile	Leu
			20					25					30		
Val	Ser	Ser	Ala	Asn	Glu	Ile	Asp	Val	Arg	Pro	Cys	Pro	Leu	Asn	Pro
		35					40					45			
Asn	Glu	His	Lys	Gly	Thr	Ile	Thr	Trp	Tyr	Lys	Asp	Asp	Ser	Lys	Thr
	50					55					60				
Pro	Val	Ser	Thr	Glu	Gln	Ala	Ser	Arg	Ile	His	Gln	His	Lys	Glu	Lys
	65				70					75				80	
Leu	Trp	Phe	Val	Pro	Ala	Lys	Val	Glu	Asp	Ser	Gly	His	Tyr	Tyr	Cys
			85					90						95	
Val	Val	Arg	Asn	Ser	Ser	Tyr	Cys	Leu	Arg	Ile	Lys	Ile	Ser	Ala	Lys
			100					105					110		
Phe	Val	Glu	Asn	Glu	Pro	Asn	Leu	Cys	Tyr	Asn	Ala	Gln	Ala	Ile	Phe
		115					120					125			

-continued

Lys	Gln	Lys	Leu	Pro	Val	Ala	Gly	Asp	Gly	Gly	Leu	Val	Cys	Pro	Tyr	130	135	140
Met	Glu	Phe	Phe	Lys	Asn	Glu	Asn	Asn	Glu	Leu	Pro	Lys	Leu	Gln	Trp	145	150	155
Tyr	Lys	Asp	Cys	Lys	Pro	Leu	Leu	Leu	Asp	Asn	Ile	His	Phe	Ser	Gly	165	170	175
Val	Lys	Asp	Arg	Leu	Ile	Val	Met	Asn	Val	Ala	Glu	Lys	His	Arg	Gly	180	185	190
Asn	Tyr	Thr	Cys	His	Ala	Ser	Tyr	Thr	Tyr	Leu	Gly	Lys	Gln	Tyr	Pro	195	200	205
Ile	Thr	Arg	Val	Ile	Glu	Phe	Ile	Thr	Leu	Glu	Glu	Asn	Lys	Pro	Thr	210	215	220
Arg	Pro	Val	Ile	Val	Ser	Pro	Ala	Asn	Glu	Thr	Met	Glu	Val	Asp	Leu	225	230	235
Gly	Ser	Gln	Ile	Gln	Leu	Ile	Cys	Asn	Val	Thr	Gly	Gln	Leu	Ser	Asp	245	250	255
Ile	Ala	Tyr	Trp	Lys	Trp	Asn	Gly	Ser	Val	Ile	Asp	Glu	Asp	Asp	Pro	260	265	270
Val	Leu	Gly	Glu	Asp	Tyr	Tyr	Ser	Val	Glu	Asn	Pro	Ala	Asn	Lys	Arg	275	280	285
Arg	Ser	Thr	Leu	Ile	Thr	Val	Leu	Asn	Ile	Ser	Glu	Ile	Glu	Ser	Arg	290	295	300
Phe	Tyr	Lys	His	Pro	Phe	Thr	Cys	Phe	Ala	Lys	Asn	Thr	His	Gly	Ile	305	310	315
Asp	Ala	Ala	Tyr	Ile	Gln	Leu	Ile	Tyr	Pro	Val	Thr	Asn	Phe	Gln	Lys	325	330	335
His	Met	Ile	Gly	Ile	Cys	Val	Thr	Leu	Thr	Val	Ile	Ile	Val	Cys	Ser	340	345	350
Val	Phe	Ile	Tyr	Lys	Ile	Phe	Lys	Ile	Asp	Ile	Val	Leu	Trp	Tyr	Arg	355	360	365
Asp	Ser	Cys	Tyr	Asp	Phe	Leu	Pro	Ile	Lys	Ala	Ser	Asp	Gly	Lys	Thr	370	375	380
Tyr	Asp	Ala	Tyr	Ile	Leu	Tyr	Pro	Lys	Thr	Val	Gly	Glu	Gly	Ser	Thr	385	390	395
Ser	Asp	Cys	Asp	Ile	Phe	Val	Phe	Lys	Val	Leu	Pro	Glu	Val	Leu	Glu	405	410	415
Lys	Gln	Cys	Gly	Tyr	Lys	Leu	Phe	Ile	Tyr	Gly	Arg	Asp	Asp	Tyr	Val	420	425	430
Gly	Glu	Asp	Ile	Val	Glu	Val	Ile	Asn	Glu	Asn	Val	Lys	Lys	Ser	Arg	435	440	445
Arg	Leu	Ile	Ile	Ile	Leu	Val	Arg	Glu	Thr	Ser	Gly	Phe	Ser	Trp	Leu	450	455	460
Gly	Gly	Ser	Ser	Glu	Glu	Gln	Ile	Ala	Met	Tyr	Asn	Ala	Leu	Val	Gln	465	470	475
Asp	Gly	Ile	Lys	Val	Val	Leu	Leu	Glu	Leu	Glu	Lys	Ile	Gln	Asp	Tyr	485	490	495
Glu	Lys	Met	Pro	Glu	Ser	Ile	Lys	Phe	Ile	Lys	Gln	Lys	His	Gly	Ala	500	505	510
Ile	Arg	Trp	Ser	Gly	Asp	Phe	Thr	Gln	Gly	Pro	Gln	Ser	Ala	Lys	Thr	515	520	525

-continued

Arg Phe Trp Lys Asn Val Arg Tyr His Met Pro Val Gln Arg Arg Ser
 530 535 540

Pro Ser Ser Lys His Gln Leu Leu Ser Pro Ala Thr Lys Glu Lys Leu
 545 550 555 560

Gln Arg Glu Ala His Val Pro Leu Gly
 565

<210> SEQ ID NO 49

<211> LENGTH: 725

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 49

Met Ala Asp Glu Asp Leu Ile Phe Arg Leu Glu Gly Val Asp Gly Gly
 1 5 10 15

Gln Ser Pro Arg Ala Gly His Asp Gly Asp Ser Asp Gly Asp Ser Asp
 20 25 30

Asp Glu Glu Gly Tyr Phe Ile Cys Pro Ile Thr Asp Asp Pro Ser Ser
 35 40 45

Asn Gln Asn Val Asn Ser Lys Val Asn Lys Tyr Tyr Ser Asn Leu Thr
 50 55 60

Lys Ser Glu Arg Tyr Ser Ser Ser Gly Ser Pro Ala Asn Ser Phe His
 65 70 75 80

Phe Lys Glu Ala Trp Lys His Ala Ile Gln Lys Ala Lys His Met Pro
 85 90 95

Asp Pro Trp Ala Glu Phe His Leu Glu Asp Ile Ala Thr Glu Arg Ala
 100 105 110

Thr Arg His Arg Tyr Asn Ala Val Thr Gly Glu Trp Leu Asp Asp Glu
 115 120 125

Val Leu Ile Lys Met Ala Ser Gln Pro Phe Gly Arg Gly Ala Met Arg
 130 135 140

Glu Cys Phe Arg Thr Lys Lys Leu Ser Asn Phe Leu His Ala Gln Gln
 145 150 155 160

Trp Lys Gly Ala Ser Asn Tyr Val Ala Lys Arg Tyr Ile Glu Pro Val
 165 170 175

Asp Arg Asp Val Tyr Phe Glu Asp Val Arg Leu Gln Met Glu Ala Lys
 180 185 190

Leu Trp Gly Glu Glu Tyr Asn Arg His Lys Pro Pro Lys Gln Val Asp
 195 200 205

Ile Met Gln Met Cys Ile Ile Glu Leu Lys Asp Arg Pro Gly Lys Pro
 210 215 220

Leu Phe His Leu Glu His Tyr Ile Glu Gly Lys Tyr Ile Lys Tyr Asn
 225 230 235 240

Ser Asn Ser Gly Phe Val Arg Asp Asp Asn Ile Arg Leu Thr Pro Gln
 245 250 255

Ala Phe Ser His Phe Thr Phe Glu Arg Ser Gly His Gln Leu Ile Val
 260 265 270

Val Asp Ile Gln Gly Val Gly Asp Leu Tyr Thr Asp Pro Gln Ile His
 275 280 285

Thr Glu Thr Gly Thr Asp Phe Gly Asp Gly Asn Leu Gly Val Arg Gly
 290 295 300

Met Ala Leu Phe Phe Tyr Ser His Ala Cys Asn Arg Ile Cys Glu Ser
 305 310 315 320

-continued

Met	Gly	Leu	Ala	Pro	Phe	Asp	Leu	Ser	Pro	Arg	Glu	Arg	Asp	Ala	Val	325	330	335
Asn	Gln	Asn	Thr	Lys	Leu	Leu	Gln	Ser	Ala	Lys	Thr	Ile	Leu	Arg	Gly	340	345	350
Thr	Glu	Glu	Lys	Cys	Gly	Ser	Pro	Arg	Val	Arg	Thr	Leu	Ser	Gly	Ser	355	360	365
Arg	Pro	Pro	Leu	Leu	Arg	Pro	Leu	Ser	Glu	Asn	Ser	Gly	Asp	Glu	Asn	370	375	380
Met	Ser	Asp	Val	Thr	Phe	Asp	Ser	Leu	Pro	Ser	Ser	Pro	Ser	Ser	Ala	385	390	395
Thr	Pro	His	Ser	Gln	Lys	Leu	Asp	His	Leu	His	Trp	Pro	Val	Phe	Ser	405	410	415
Asp	Leu	Asp	Asn	Met	Ala	Ser	Arg	Asp	His	Asp	His	Leu	Asp	Asn	His	420	425	430
Arg	Glu	Ser	Glu	Asn	Ser	Gly	Asp	Ser	Gly	Tyr	Pro	Ser	Glu	Lys	Arg	435	440	445
Gly	Glu	Leu	Asp	Asp	Pro	Glu	Pro	Arg	Glu	His	Gly	His	Ser	Tyr	Ser	450	455	460
Asn	Arg	Lys	Tyr	Glu	Ser	Asp	Glu	Asp	Ser	Leu	Gly	Ser	Ser	Gly	Arg	465	470	475
Val	Cys	Val	Glu	Lys	Trp	Asn	Leu	Leu	Asn	Ser	Ser	Arg	Leu	His	Leu	485	490	495
Pro	Arg	Ala	Ser	Ala	Val	Ala	Leu	Glu	Val	Gln	Arg	Leu	Asn	Ala	Leu	500	505	510
Asp	Leu	Glu	Lys	Lys	Ile	Gly	Lys	Ser	Ile	Leu	Gly	Lys	Val	His	Leu	515	520	525
Ala	Met	Val	Arg	Tyr	His	Glu	Gly	Gly	Arg	Phe	Cys	Glu	Lys	Gly	Glu	530	535	540
Glu	Trp	Asp	Gln	Glu	Ser	Ala	Val	Phe	His	Leu	Glu	His	Ala	Ala	Asn	545	550	555
Leu	Gly	Glu	Leu	Glu	Ala	Ile	Val	Gly	Leu	Gly	Leu	Met	Tyr	Ser	Gln	565	570	575
Leu	Pro	His	His	Ile	Leu	Ala	Asp	Val	Ser	Leu	Lys	Glu	Thr	Glu	Glu	580	585	590
Asn	Lys	Thr	Lys	Gly	Phe	Asp	Tyr	Leu	Leu	Lys	Ala	Ala	Glu	Ala	Gly	595	600	605
Asp	Arg	Gln	Ser	Met	Ile	Leu	Val	Ala	Arg	Ala	Phe	Asp	Ser	Gly	Gln	610	615	620
Asn	Leu	Ser	Pro	Asp	Arg	Cys	Gln	Asp	Trp	Leu	Glu	Ala	Leu	His	Trp	625	630	635
Tyr	Asn	Thr	Ala	Leu	Glu	Met	Thr	Asp	Cys	Asp	Glu	Gly	Gly	Glu	Tyr	645	650	655
Asp	Gly	Met	Gln	Asp	Glu	Pro	Arg	Tyr	Met	Met	Leu	Ala	Arg	Glu	Ala	660	665	670
Glu	Met	Leu	Phe	Thr	Gly	Gly	Tyr	Gly	Leu	Glu	Lys	Asp	Pro	Gln	Arg	675	680	685
Ser	Gly	Asp	Leu	Tyr	Thr	Gln	Ala	Ala	Glu	Ala	Ala	Met	Glu	Ala	Met	690	695	700
Lys	Gly	Arg	Leu	Ala	Asn	Gln	Tyr	Tyr	Gln	Lys	Ala	Glu	Glu	Ala	Trp	705	710	715
																		720

-continued

Ala Gln Met Glu Glu
725

<210> SEQ ID NO 50

<211> LENGTH: 376

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 50

Met Cys Glu Glu Glu Thr Thr Ala Leu Val Cys Asp Asn Gly Ser Gly
1 5 10 15

Leu Cys Lys Ala Gly Phe Ala Gly Asp Asp Ala Pro Arg Ala Val Phe
20 25 30

Pro Ser Ile Val Gly Arg Pro Arg His Gln Gly Val Met Val Gly Met
35 40 45

Gly Gln Lys Asp Ser Tyr Val Gly Asp Glu Ala Gln Ser Lys Arg Gly
50 55 60

Ile Leu Thr Leu Lys Tyr Pro Ile Glu His Gly Ile Ile Thr Asn Trp
65 70 75 80

Asp Asp Met Glu Lys Ile Trp His His Ser Phe Tyr Asn Glu Leu Arg
85 90 95

Val Ala Pro Glu Glu His Pro Thr Leu Leu Thr Glu Ala Pro Leu Asn
100 105 110

Pro Lys Ala Asn Arg Glu Lys Met Thr Gln Ile Met Phe Glu Thr Phe
115 120 125

Asn Val Pro Ala Met Tyr Val Ala Ile Gln Ala Val Leu Ser Leu Tyr
130 135 140

Ala Ser Gly Arg Thr Thr Gly Ile Val Leu Asp Ser Gly Asp Gly Val
145 150 155 160

Thr His Asn Val Pro Ile Tyr Glu Gly Tyr Ala Leu Pro His Ala Ile
165 170 175

Met Arg Leu Asp Leu Ala Gly Arg Asp Leu Thr Asp Tyr Leu Met Lys
180 185 190

Ile Leu Thr Glu Arg Gly Tyr Ser Phe Val Thr Thr Ala Glu Arg Glu
195 200 205

Ile Val Arg Asp Ile Lys Glu Lys Leu Cys Tyr Val Ala Leu Asp Phe
210 215 220

Glu Asn Glu Met Ala Thr Ala Ala Ser Ser Ser Ser Leu Glu Lys Ser
225 230 235 240

Tyr Glu Leu Pro Asp Gly Gln Val Ile Thr Ile Gly Asn Glu Arg Phe
245 250 255

Arg Cys Pro Glu Thr Leu Phe Gln Pro Ser Phe Ile Gly Met Glu Ser
260 265 270

Ala Gly Ile His Glu Thr Thr Tyr Asn Ser Ile Met Lys Cys Asp Ile
275 280 285

Asp Ile Arg Lys Asp Leu Tyr Ala Asn Asn Val Leu Ser Gly Gly Thr
290 295 300

Thr Met Tyr Pro Gly Ile Ala Asp Arg Met Gln Lys Glu Ile Thr Ala
305 310 315 320

Leu Ala Pro Ser Thr Met Lys Ile Lys Ile Ile Ala Pro Pro Glu Arg
325 330 335

Lys Tyr Ser Val Trp Ile Gly Gly Ser Ile Leu Ala Ser Leu Ser Thr
340 345 350

-continued

Phe Gln Gln Met Trp Ile Ser Lys Pro Glu Tyr Asp Glu Ala Gly Pro
 355 360 365

Ser Ile Val His Arg Lys Cys Phe
 370 375

<210> SEQ ID NO 51
 <211> LENGTH: 1972
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 51

Met Ala Gln Lys Gly Gln Leu Ser Asp Asp Glu Lys Phe Leu Phe Val
 1 5 10 15

Asp Lys Asn Phe Ile Asn Ser Pro Val Ala Gln Ala Asp Trp Ala Ala
 20 25 30

Lys Arg Leu Val Trp Val Pro Ser Glu Lys Gln Gly Phe Glu Ala Ala
 35 40 45

Ser Ile Lys Glu Glu Lys Gly Asp Glu Val Val Val Glu Leu Val Glu
 50 55 60

Asn Gly Lys Lys Val Thr Val Gly Lys Asp Asp Ile Gln Lys Met Asn
 65 70 75 80

Pro Pro Lys Phe Ser Lys Val Glu Asp Met Ala Glu Leu Thr Cys Leu
 85 90 95

Asn Glu Ala Ser Val Leu His Asn Leu Arg Glu Arg Tyr Phe Ser Gly
 100 105 110

Leu Ile Tyr Thr Tyr Ser Gly Leu Phe Cys Val Val Val Asn Pro Tyr
 115 120 125

Lys His Leu Pro Ile Tyr Ser Glu Lys Ile Val Asp Met Tyr Lys Gly
 130 135 140

Lys Lys Arg His Glu Met Pro Pro His Ile Tyr Ala Ile Ala Asp Thr
 145 150 155 160

Ala Tyr Arg Ser Met Leu Gln Asp Arg Glu Asp Gln Ser Ile Leu Cys
 165 170 175

Thr Gly Glu Ser Gly Ala Gly Lys Thr Glu Asn Thr Lys Lys Val Ile
 180 185 190

Gln Tyr Leu Ala Val Val Ala Ser Ser His Lys Gly Lys Lys Asp Thr
 195 200 205

Ser Ile Thr Gly Glu Leu Glu Lys Gln Leu Leu Gln Ala Asn Pro Ile
 210 215 220

Leu Glu Ala Phe Gly Asn Ala Lys Thr Val Lys Asn Asp Asn Ser Ser
 225 230 235 240

Arg Phe Gly Lys Phe Ile Arg Ile Asn Phe Asp Val Thr Gly Tyr Ile
 245 250 255

Val Gly Ala Asn Ile Glu Thr Tyr Leu Leu Glu Lys Ser Arg Ala Ile
 260 265 270

Arg Gln Ala Arg Asp Glu Arg Thr Phe His Ile Phe Tyr Tyr Met Ile
 275 280 285

Ala Gly Ala Lys Glu Lys Met Arg Ser Asp Leu Leu Leu Glu Gly Phe
 290 295 300

Asn Asn Tyr Thr Phe Leu Ser Asn Gly Phe Val Pro Ile Pro Ala Ala
 305 310 315 320

Gln Asp Asp Glu Met Phe Gln Glu Thr Val Glu Ala Met Ala Ile Met

-continued

325								330					335				
Gly	Phe	Ser	Glu	Glu	Gln	Leu	Ser	Ile	Leu	Lys	Val	Val	Ser	Ser			
			340				345					350					
Val	Leu	Gln	Leu	Gly	Asn	Ile	Phe	Lys	Lys	Glu	Arg	Asn	Thr	Asp			
		355				360					365						
Gln	Ala	Ser	Met	Pro	Asp	Asn	Thr	Ala	Ala	Gln	Lys	Val	Cys	His	Leu		
	370					375					380						
Met	Gly	Ile	Asn	Val	Thr	Asp	Phe	Thr	Arg	Ser	Ile	Leu	Thr	Pro	Arg		
385					390					395				400			
Ile	Lys	Val	Gly	Arg	Asp	Val	Val	Gln	Lys	Ala	Gln	Thr	Lys	Glu	Gln		
			405					410						415			
Ala	Asp	Phe	Ala	Val	Glu	Ala	Leu	Ala	Lys	Ala	Thr	Tyr	Glu	Arg	Leu		
			420				425						430				
Phe	Arg	Trp	Ile	Leu	Thr	Arg	Val	Asn	Lys	Ala	Leu	Asp	Lys	Thr	His		
		435					440					445					
Arg	Gln	Gly	Ala	Ser	Phe	Leu	Gly	Ile	Leu	Asp	Ile	Ala	Gly	Phe	Glu		
		450				455					460						
Ile	Phe	Glu	Val	Asn	Ser	Phe	Glu	Gln	Leu	Cys	Ile	Asn	Tyr	Thr	Asn		
465				470						475				480			
Glu	Lys	Leu	Gln	Gln	Leu	Phe	Asn	His	Thr	Met	Phe	Ile	Leu	Glu	Gln		
			485					490						495			
Glu	Glu	Tyr	Gln	Arg	Glu	Gly	Ile	Glu	Trp	Asn	Phe	Ile	Asp	Phe	Gly		
			500				505						510				
Leu	Asp	Leu	Gln	Pro	Cys	Ile	Glu	Leu	Ile	Glu	Arg	Pro	Asn	Asn	Pro		
		515					520					525					
Pro	Gly	Val	Leu	Ala	Leu	Leu	Asp	Glu	Glu	Cys	Trp	Phe	Pro	Lys	Ala		
		530				535					540						
Thr	Asp	Lys	Ser	Phe	Val	Glu	Lys	Leu	Cys	Thr	Glu	Gln	Gly	Ser	His		
545				550						555				560			
Pro	Lys	Phe	Gln	Lys	Pro	Lys	Gln	Leu	Lys	Asp	Lys	Thr	Glu	Phe	Ser		
			565					570						575			
Ile	Ile	His	Tyr	Ala	Gly	Lys	Val	Asp	Tyr	Asn	Ala	Ser	Ala	Trp	Leu		
		580					585						590				
Thr	Lys	Asn	Met	Asp	Pro	Leu	Asn	Asp	Asn	Val	Thr	Ser	Leu	Leu	Asn		
		595					600					605					
Ala	Ser	Ser	Asp	Lys	Phe	Val	Ala	Asp	Leu	Trp	Lys	Asp	Val	Asp	Arg		
		610				615					620						
Ile	Val	Gly	Leu	Asp	Gln	Met	Ala	Lys	Met	Thr	Glu	Ser	Ser	Leu	Pro		
625					630					635				640			
Ser	Ala	Ser	Lys	Thr	Lys	Lys	Gly	Met	Phe	Arg	Thr	Val	Gly	Gln	Leu		
			645					650						655			
Tyr	Lys	Glu	Gln	Leu	Gly	Lys	Leu	Met	Thr	Thr	Leu	Arg	Asn	Thr	Thr		
		660					665						670				
Pro	Asn	Phe	Val	Arg	Cys	Ile	Ile	Pro	Asn	His	Glu	Lys	Arg	Ser	Gly		
		675					680					685					
Lys	Leu	Asp	Ala	Phe	Leu	Val	Leu	Glu	Gln	Leu	Arg	Cys	Asn	Gly	Val		
		690				695					700						
Leu	Glu	Gly	Ile	Arg	Ile	Cys	Arg	Gln	Gly	Phe	Pro	Asn	Arg	Ile	Val		
705				710					715					720			
Phe	Gln	Glu	Phe	Arg	Gln	Arg	Tyr	Glu	Ile	Leu	Ala	Ala	Asn	Ala	Ile		
			725					730						735			

-continued

Pro	Lys	Gly	Phe	Met	Asp	Gly	Lys	Gln	Ala	Cys	Ile	Leu	Met	Ile	Lys	740	745	750	
Ala	Leu	Glu	Leu	Asp	Pro	Asn	Leu	Tyr	Arg	Ile	Gly	Gln	Ser	Lys	Ile	755	760	765	
Phe	Phe	Arg	Thr	Gly	Val	Leu	Ala	His	Leu	Glu	Glu	Arg	Asp	Leu		770	775	780	
Lys	Ile	Thr	Asp	Val	Ile	Met	Ala	Phe	Gln	Ala	Met	Cys	Arg	Gly	Tyr	785	790	795	800
Leu	Ala	Arg	Lys	Ala	Phe	Ala	Lys	Arg	Gln	Gln	Gln	Leu	Thr	Ala	Met	805	810	815	
Lys	Val	Ile	Gln	Arg	Asn	Cys	Ala	Ala	Tyr	Leu	Lys	Leu	Arg	Asn	Trp	820	825	830	
Gln	Trp	Trp	Arg	Leu	Phe	Thr	Lys	Val	Lys	Pro	Leu	Leu	Gln	Val	Thr	835	840	845	
Arg	Gln	Glu	Glu	Glu	Met	Gln	Ala	Lys	Glu	Asp	Glu	Leu	Gln	Lys	Thr	850	855	860	
Lys	Glu	Arg	Gln	Gln	Lys	Ala	Glu	Asn	Glu	Leu	Lys	Glu	Leu	Glu	Gln	865	870	875	880
Lys	His	Ser	Gln	Leu	Thr	Glu	Glu	Lys	Asn	Leu	Leu	Gln	Glu	Gln	Leu	885	890	895	
Gln	Ala	Glu	Thr	Glu	Leu	Tyr	Ala	Glu	Ala	Glu	Glu	Met	Arg	Val	Arg	900	905	910	
Leu	Ala	Ala	Lys	Lys	Gln	Glu	Leu	Glu	Glu	Ile	Leu	His	Glu	Met	Glu	915	920	925	
Ala	Arg	Leu	Glu	Glu	Glu	Glu	Asp	Arg	Gly	Gln	Gln	Leu	Gln	Ala	Glu	930	935	940	
Arg	Lys	Lys	Met	Ala	Gln	Gln	Met	Leu	Asp	Leu	Glu	Glu	Gln	Leu	Glu	945	950	955	960
Glu	Glu	Glu	Ala	Ala	Arg	Gln	Lys	Leu	Gln	Leu	Glu	Lys	Val	Thr	Ala	965	970	975	
Glu	Ala	Lys	Ile	Lys	Lys	Leu	Glu	Asp	Glu	Ile	Leu	Val	Met	Asp	Asp	980	985	990	
Gln	Asn	Asn	Lys	Leu	Ser	Lys	Glu	Arg	Lys	Leu	Leu	Glu	Glu	Arg	Ile	995	1000	1005	
Ser	Asp	Leu	Thr	Thr	Asn	Leu	Ala	Glu	Glu	Glu	Glu	Lys	Ala	Lys		1010	1015	1020	
Asn	Leu	Thr	Lys	Leu	Lys	Asn	Lys	His	Glu	Ser	Met	Ile	Ser	Glu		1025	1030	1035	
Leu	Glu	Val	Arg	Leu	Lys	Lys	Glu	Glu	Lys	Ser	Arg	Gln	Glu	Leu		1040	1045	1050	
Glu	Lys	Leu	Lys	Arg	Lys	Leu	Glu	Gly	Asp	Ala	Ser	Asp	Phe	His		1055	1060	1065	
Glu	Gln	Ile	Ala	Asp	Leu	Gln	Ala	Gln	Ile	Ala	Glu	Leu	Lys	Met		1070	1075	1080	
Gln	Leu	Ala	Lys	Lys	Glu	Glu	Glu	Leu	Gln	Ala	Ala	Leu	Ala	Arg		1085	1090	1095	
Leu	Asp	Asp	Glu	Ile	Ala	Gln	Lys	Asn	Asn	Ala	Leu	Lys	Lys	Ile		1100	1105	1110	
Arg	Glu	Leu	Glu	Gly	His	Ile	Ser	Asp	Leu	Gln	Glu	Asp	Leu	Asp		1115	1120	1125	

-continued

Ser Glu	Arg Ala	Ala Arg	Asn Lys	Ala Glu	Lys Gln	Lys Arg	Asp		
1130			1135		1140				
Leu Gly	Glu Glu	Leu Glu	Ala Leu	Lys Thr	Glu Leu	Glu Asp	Thr		
1145			1150		1155				
Leu Asp	Ser Thr	Ala Thr	Gln Gln	Glu Leu	Arg Ala	Lys Arg	Glu		
1160			1165		1170				
Gln Glu	Val Thr	Val Leu	Lys Lys	Ala Leu	Asp Glu	Glu Thr	Arg		
1175			1180		1185				
Ser His	Glu Ala	Gln Val	Gln Glu	Met Arg	Gln Lys	His Ala	Gln		
1190			1195		1200				
Ala Val	Glu Glu	Leu Thr	Glu Gln	Leu Glu	Gln Phe	Lys Arg	Ala		
1205			1210		1215				
Lys Ala	Asn Leu	Asp Lys	Asn Lys	Gln Thr	Leu Glu	Lys Glu	Asn		
1220			1225		1230				
Ala Asp	Leu Ala	Gly Glu	Leu Arg	Val Leu	Gly Gln	Ala Lys	Gln		
1235			1240		1245				
Glu Val	Glu His	Lys Lys	Lys Lys	Leu Glu	Ala Gln	Val Gln	Glu		
1250			1255		1260				
Leu Gln	Ser Lys	Cys Ser	Asp Gly	Glu Arg	Ala Arg	Ala Glu	Leu		
1265			1270		1275				
Asn Asp	Lys Val	His Lys	Leu Gln	Asn Glu	Val Glu	Ser Val	Thr		
1280			1285		1290				
Gly Met	Leu Asn	Glu Ala	Glu Gly	Lys Ala	Ile Lys	Leu Ala	Lys		
1295			1300		1305				
Asp Val	Ala Ser	Leu Ser	Ser Gln	Leu Gln	Asp Thr	Gln Glu	Leu		
1310			1315		1320				
Leu Gln	Glu Glu	Thr Arg	Gln Lys	Leu Asn	Val Ser	Thr Lys	Leu		
1325			1330		1335				
Arg Gln	Leu Glu	Glu Glu	Arg Asn	Ser Leu	Gln Asp	Gln Leu	Asp		
1340			1345		1350				
Glu Glu	Met Glu	Ala Lys	Gln Asn	Leu Glu	Arg His	Ile Ser	Thr		
1355			1360		1365				
Leu Asn	Ile Gln	Leu Ser	Asp Ser	Lys Lys	Lys Leu	Gln Asp	Phe		
1370			1375		1380				
Ala Ser	Thr Val	Glu Ala	Leu Glu	Glu Gly	Lys Lys	Arg Phe	Gln		
1385			1390		1395				
Lys Glu	Ile Glu	Asn Leu	Thr Gln	Gln Tyr	Glu Glu	Lys Ala	Ala		
1400			1405		1410				
Ala Tyr	Asp Lys	Leu Glu	Lys Thr	Lys Asn	Arg Leu	Gln Gln	Glu		
1415			1420		1425				
Leu Asp	Asp Leu	Val Val	Asp Leu	Asp Asn	Gln Arg	Gln Leu	Val		
1430			1435		1440				
Ser Asn	Leu Glu	Lys Lys	Gln Arg	Lys Phe	Asp Gln	Leu Leu	Ala		
1445			1450		1455				
Glu Glu	Lys Asn	Ile Ser	Ser Lys	Tyr Ala	Asp Glu	Arg Asp	Arg		
1460			1465		1470				
Ala Glu	Ala Glu	Ala Arg	Glu Lys	Glu Thr	Lys Ala	Leu Ser	Leu		
1475			1480		1485				
Ala Arg	Ala Leu	Glu Glu	Ala Leu	Glu Ala	Lys Glu	Glu Leu	Glu		
1490			1495		1500				
Arg Thr	Asn Lys	Met Leu	Lys Ala	Glu Met	Glu Asp	Leu Val	Ser		

-continued

1505	1510	1515
Ser Lys Asp Asp Val Gly	Lys Asn Val His Glu	Leu Glu Lys Ser
1520	1525	1530
Lys Arg Ala Leu Glu Thr	Gln Met Glu Glu Met	Lys Thr Gln Leu
1535	1540	1545
Glu Glu Leu Glu Asp Glu	Leu Gln Ala Thr Glu	Asp Ala Lys Leu
1550	1555	1560
Arg Leu Glu Val Asn Met	Gln Ala Leu Lys Gly	Gln Phe Glu Arg
1565	1570	1575
Asp Leu Gln Ala Arg Asp	Glu Gln Asn Glu Glu	Lys Arg Arg Gln
1580	1585	1590
Leu Gln Arg Gln Leu His	Glu Tyr Glu Thr Glu	Leu Glu Asp Glu
1595	1600	1605
Arg Lys Gln Arg Ala Leu	Ala Ala Ala Lys Lys	Lys Leu Glu
1610	1615	1620
Gly Asp Leu Lys Asp Leu	Glu Leu Gln Ala Asp	Ser Ala Ile Lys
1625	1630	1635
Gly Arg Glu Glu Ala Ile	Lys Gln Leu Arg Lys	Leu Gln Ala Gln
1640	1645	1650
Met Lys Asp Phe Gln Arg	Glu Leu Glu Asp Ala	Arg Ala Ser Arg
1655	1660	1665
Asp Glu Ile Phe Ala Thr	Ala Lys Glu Asn Glu	Lys Lys Ala Lys
1670	1675	1680
Ser Leu Glu Ala Asp Leu	Met Gln Leu Gln Glu	Asp Leu Ala Ala
1685	1690	1695
Ala Glu Arg Ala Arg Lys	Gln Ala Asp Leu Glu	Lys Glu Glu Leu
1700	1705	1710
Ala Glu Glu Leu Ala Ser	Ser Leu Ser Gly Arg	Asn Ala Leu Gln
1715	1720	1725
Asp Glu Lys Arg Arg Leu	Glu Ala Arg Ile Ala	Gln Leu Glu Glu
1730	1735	1740
Glu Leu Glu Glu Glu Gln	Gly Asn Met Glu Ala	Met Ser Asp Arg
1745	1750	1755
Val Arg Lys Ala Thr Gln	Gln Ala Glu Gln Leu	Ser Asn Glu Leu
1760	1765	1770
Ala Thr Glu Arg Ser Thr	Ala Gln Lys Asn Glu	Ser Ala Arg Gln
1775	1780	1785
Gln Leu Glu Arg Gln Asn	Lys Glu Leu Arg Ser	Lys Leu His Glu
1790	1795	1800
Met Glu Gly Ala Val Lys	Ser Lys Phe Lys Ser	Thr Ile Ala Ala
1805	1810	1815
Leu Glu Ala Lys Ile Ala	Gln Leu Glu Glu Gln	Val Glu Gln Glu
1820	1825	1830
Ala Arg Glu Lys Gln Ala	Ala Thr Lys Ser Leu	Lys Gln Lys Asp
1835	1840	1845
Lys Lys Leu Lys Glu Ile	Leu Leu Gln Val Glu	Asp Glu Arg Lys
1850	1855	1860
Met Ala Glu Gln Tyr Lys	Glu Gln Ala Glu Lys	Gly Asn Ala Arg
1865	1870	1875
Val Lys Gln Leu Lys Arg	Gln Leu Glu Glu Ala	Glu Glu Glu Ser
1880	1885	1890

-continued

Gln Arg Ile Asn Ala Asn Arg Arg Lys Leu Gln Arg Glu Leu Asp
 1895 1900 1905

Glu Ala Thr Glu Ser Asn Glu Ala Met Gly Arg Glu Val Asn Ala
 1910 1915 1920

Leu Lys Ser Lys Leu Arg Arg Gly Asn Glu Thr Ser Phe Val Pro
 1925 1930 1935

Ser Arg Arg Ser Gly Gly Arg Arg Val Ile Glu Asn Ala Asp Gly
 1940 1945 1950

Ser Glu Glu Glu Thr Asp Thr Arg Asp Ala Asp Phe Asn Gly Thr
 1955 1960 1965

Lys Ala Ser Glu
 1970

<210> SEQ ID NO 52
 <211> LENGTH: 171
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 52

Met Ser Ser Lys Arg Thr Lys Thr Lys Thr Lys Lys Arg Pro Gln Arg
 1 5 10 15

Ala Thr Ser Asn Val Phe Ala Met Phe Asp Gln Ser Gln Ile Gln Glu
 20 25 30

Phe Lys Glu Ala Phe Asn Met Ile Asp Gln Asn Arg Asp Gly Phe Ile
 35 40 45

Asp Lys Glu Asp Leu His Asp Met Leu Ala Ser Leu Gly Lys Asn Pro
 50 55 60

Thr Asp Glu Tyr Leu Asp Ala Met Met Asn Glu Ala Pro Gly Pro Ile
 65 70 75 80

Asn Phe Thr Met Phe Leu Thr Met Phe Gly Glu Lys Leu Asn Gly Thr
 85 90 95

Asp Pro Glu Asp Val Ile Arg Asn Ala Phe Ala Cys Phe Asp Glu Glu
 100 105 110

Ala Thr Gly Thr Ile Gln Glu Asp Tyr Leu Arg Glu Leu Leu Thr Thr
 115 120 125

Met Gly Asp Arg Phe Thr Asp Glu Glu Val Asp Glu Leu Tyr Arg Glu
 130 135 140

Ala Pro Ile Asp Lys Lys Gly Asn Phe Asn Tyr Ile Glu Phe Thr Arg
 145 150 155 160

Ile Leu Lys His Gly Ala Lys Asp Lys Asp Asp
 165 170

<210> SEQ ID NO 53
 <211> LENGTH: 172
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 53

Met Ser Ser Lys Lys Ala Lys Thr Lys Thr Thr Lys Lys Arg Pro Gln
 1 5 10 15

Arg Ala Thr Ser Asn Val Phe Ala Met Phe Asp Gln Ser Gln Ile Gln
 20 25 30

Glu Phe Lys Glu Ala Phe Asn Met Ile Asp Gln Asn Arg Asp Gly Phe
 35 40 45

-continued

```

Ile Asp Lys Glu Asp Leu His Asp Met Leu Ala Ser Leu Gly Lys Asn
 50          55          60
Pro Thr Asp Ala Tyr Leu Asp Ala Met Met Asn Glu Ala Pro Gly Pro
65          70          75          80
Ile Asn Phe Thr Met Phe Leu Thr Met Phe Gly Glu Lys Leu Asn Gly
      85          90          95
Thr Asp Pro Glu Asp Val Ile Arg Asn Ala Phe Ala Cys Phe Asp Glu
      100         105         110
Glu Ala Thr Gly Thr Ile Gln Glu Asp Tyr Leu Arg Glu Leu Leu Thr
      115         120         125
Thr Met Gly Asp Arg Phe Thr Asp Glu Glu Val Asp Glu Leu Tyr Arg
      130         135         140
Glu Ala Pro Ile Asp Lys Lys Gly Asn Phe Asn Tyr Ile Glu Phe Thr
      145         150         155         160
Arg Ile Leu Lys His Gly Ala Lys Asp Lys Asp Asp
      165         170

```

```

<210> SEQ ID NO 54
<211> LENGTH: 232
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 54

```

```

Met Lys Glu Arg Arg Ala Pro Gln Pro Val Val Ala Arg Cys Lys Leu
 1          5          10         15
Val Leu Val Gly Asp Val Gln Cys Gly Lys Thr Ala Met Leu Gln Val
      20         25         30
Leu Ala Lys Asp Cys Tyr Pro Glu Thr Tyr Val Pro Thr Val Phe Glu
      35         40         45
Asn Tyr Thr Ala Cys Leu Glu Thr Glu Glu Gln Arg Val Glu Leu Ser
      50         55         60
Leu Trp Asp Thr Ser Gly Ser Pro Tyr Tyr Asp Asn Val Arg Pro Leu
      65         70         75         80
Cys Tyr Ser Asp Ser Asp Ala Val Leu Leu Cys Phe Asp Ile Ser Arg
      85         90         95
Pro Glu Thr Val Asp Ser Ala Leu Lys Lys Trp Arg Thr Glu Ile Leu
      100        105        110
Asp Tyr Cys Pro Ser Thr Arg Val Leu Leu Ile Gly Cys Lys Thr Asp
      115        120        125
Leu Arg Thr Asp Leu Ser Thr Leu Met Glu Leu Ser His Gln Lys Gln
      130        135        140
Ala Pro Ile Ser Tyr Glu Gln Gly Cys Ala Ile Ala Lys Gln Leu Gly
      145        150        155        160
Ala Glu Ile Tyr Leu Glu Gly Ser Ala Phe Thr Ser Glu Lys Ser Ile
      165        170        175
His Ser Ile Phe Arg Thr Ala Ser Met Leu Cys Leu Asn Lys Pro Ser
      180        185        190
Pro Leu Pro Gln Lys Ser Pro Val Arg Ser Leu Ser Lys Arg Leu Leu
      195        200        205
His Leu Pro Ser Arg Ser Glu Leu Ile Ser Ser Thr Phe Lys Lys Glu
      210        215        220
Lys Ala Lys Ser Cys Ser Ile Met

```

```

<210> SEQ ID NO 56
<211> LENGTH: 784
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 56

Met Glu Gly Asp Gly Gly Thr Pro Trp Ala Leu Ala Leu Leu Arg Thr
1          5          10          15
Phe Asp Ala Gly Glu Phe Thr Gly Trp Glu Lys Val Gly Ser Gly Gly
          20          25          30
Phe Gly Gln Val Tyr Lys Val Arg His Val His Trp Lys Thr Trp Leu
          35          40          45
Ala Ile Lys Cys Ser Pro Ser Leu His Val Asp Asp Arg Glu Arg Met
          50          55          60
Glu Leu Leu Glu Glu Ala Lys Lys Met Glu Met Ala Lys Phe Arg Tyr
65          70          75          80
Ile Leu Pro Val Tyr Gly Ile Cys Arg Glu Pro Val Gly Leu Val Met
          85          90          95
Glu Tyr Met Glu Thr Gly Ser Leu Glu Lys Leu Leu Ala Ser Glu Pro

```

-continued

100						105					110				
Leu	Pro	Trp	Asp	Leu	Arg	Phe	Arg	Ile	Ile	His	Glu	Thr	Ala	Val	Gly
115						120					125				
Met	Asn	Phe	Leu	His	Cys	Met	Ala	Pro	Pro	Leu	Leu	His	Leu	Asp	Leu
130						135					140				
Lys	Pro	Ala	Asn	Ile	Leu	Leu	Asp	Ala	His	Tyr	His	Val	Lys	Ile	Ser
145						150					155		160		
Asp	Phe	Gly	Leu	Ala	Lys	Cys	Asn	Gly	Leu	Ser	His	Ser	His	Asp	Leu
165						170							175		
Ser	Met	Asp	Gly	Leu	Phe	Gly	Thr	Ile	Ala	Tyr	Leu	Pro	Pro	Glu	Arg
180						185							190		
Ile	Arg	Glu	Lys	Ser	Arg	Leu	Phe	Asp	Thr	Lys	His	Asp	Val	Tyr	Ser
195						200					205				
Phe	Ala	Ile	Val	Ile	Trp	Gly	Val	Leu	Thr	Gln	Lys	Lys	Pro	Phe	Ala
210						215					220				
Asp	Glu	Lys	Asn	Ile	Leu	His	Ile	Met	Val	Lys	Val	Val	Lys	Gly	His
225						230					235		240		
Arg	Pro	Glu	Leu	Pro	Pro	Val	Cys	Arg	Ala	Arg	Pro	Arg	Ala	Cys	Ser
245						250							255		
His	Leu	Ile	Arg	Leu	Met	Gln	Arg	Cys	Trp	Gln	Gly	Asp	Pro	Arg	Val
260						265							270		
Arg	Pro	Thr	Phe	Gln	Glu	Ile	Thr	Ser	Glu	Thr	Glu	Asp	Leu	Cys	Glu
275						280					285				
Lys	Pro	Asp	Asp	Glu	Val	Lys	Glu	Thr	Ala	His	Asp	Leu	Asp	Val	Lys
290						295					300				
Ser	Pro	Pro	Glu	Pro	Arg	Ser	Glu	Val	Val	Pro	Ala	Arg	Leu	Lys	Arg
305						310					315		320		
Ala	Ser	Ala	Pro	Thr	Phe	Asp	Asn	Asp	Tyr	Ser	Leu	Ser	Glu	Leu	Leu
325						330							335		
Ser	Gln	Leu	Asp	Ser	Gly	Val	Ser	Gln	Ala	Val	Glu	Gly	Pro	Glu	Glu
340						345							350		
Leu	Ser	Arg	Ser	Ser	Ser	Glu	Ser	Lys	Leu	Pro	Ser	Ser	Gly	Ser	Gly
355						360					365				
Lys	Arg	Leu	Ser	Gly	Val	Ser	Ser	Val	Asp	Ser	Ala	Phe	Ser	Ser	Arg
370						375					380				
Gly	Ser	Leu	Ser	Leu	Ser	Phe	Glu	Arg	Glu	Pro	Ser	Thr	Ser	Asp	Leu
385						390					395		400		
Gly	Thr	Thr	Asp	Val	Gln	Lys	Lys	Lys	Leu	Val	Asp	Ala	Ile	Val	Ser
405						410							415		
Gly	Asp	Thr	Ser	Lys	Leu	Met	Lys	Ile	Leu	Gln	Pro	Gln	Asp	Val	Asp
420						425							430		
Leu	Ala	Leu	Asp	Ser	Gly	Ala	Ser	Leu	Leu	His	Leu	Ala	Val	Glu	Ala
435						440					445				
Gly	Gln	Glu	Glu	Cys	Ala	Lys	Trp	Leu	Leu	Leu	Asn	Asn	Ala	Asn	Pro
450						455					460				
Asn	Leu	Ser	Asn	Arg	Arg	Gly	Ser	Thr	Pro	Leu	His	Met	Ala	Val	Glu
465						470					475		480		
Arg	Arg	Val	Arg	Gly	Val	Val	Glu	Leu	Leu	Leu	Ala	Arg	Lys	Ile	Ser
485						490							495		
Val	Asn	Ala	Lys	Asp	Glu	Asp	Gln	Trp	Thr	Ala	Leu	His	Phe	Ala	Ala
500						505					510				

-continued

Gln Asn Gly Asp Glu Ser Ser Thr Arg Leu Leu Leu Glu Lys Asn Ala
 515 520 525
 Ser Val Asn Glu Val Asp Phe Glu Gly Arg Thr Pro Met His Val Ala
 530 535 540
 Cys Gln His Gly Gln Glu Asn Ile Val Arg Ile Leu Leu Arg Arg Gly
 545 550 555 560
 Val Asp Val Ser Leu Gln Gly Lys Asp Ala Trp Leu Pro Leu His Tyr
 565 570 575
 Ala Ala Trp Gln Gly His Leu Pro Ile Val Lys Leu Leu Ala Lys Gln
 580 585 590
 Pro Gly Val Ser Val Asn Ala Gln Thr Leu Asp Gly Arg Thr Pro Leu
 595 600 605
 His Leu Ala Ala Gln Arg Gly His Tyr Arg Val Ala Arg Ile Leu Ile
 610 615 620
 Asp Leu Cys Ser Asp Val Asn Val Cys Ser Leu Leu Ala Gln Thr Pro
 625 630 635 640
 Leu His Val Ala Ala Glu Thr Gly His Thr Ser Thr Ala Arg Leu Leu
 645 650 655
 Leu His Arg Gly Ala Gly Lys Glu Ala Met Thr Ser Asp Gly Tyr Thr
 660 665 670
 Ala Leu His Leu Ala Ala Arg Asn Gly His Leu Ala Thr Val Lys Leu
 675 680 685
 Leu Val Glu Glu Lys Ala Asp Val Leu Ala Arg Gly Pro Leu Asn Gln
 690 695 700
 Thr Ala Leu His Leu Ala Ala His Gly His Ser Glu Val Val Glu
 705 710 715 720
 Glu Leu Val Ser Ala Asp Val Ile Asp Leu Phe Asp Glu Gln Gly Leu
 725 730 735
 Ser Ala Leu His Leu Ala Ala Gln Gly Arg His Ala Gln Thr Val Glu
 740 745 750
 Thr Leu Leu Arg His Gly Ala His Ile Asn Leu Gln Ser Leu Lys Phe
 755 760 765
 Gln Gly His Gly Pro Ala Ala Thr Leu Leu Arg Arg Ser Lys Thr
 770 775 780

<210> SEQ ID NO 57

<211> LENGTH: 202

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 57

Met Ser Ala Ser Thr Ser Ser His Arg Pro Ile Lys Gly Ile Leu Lys
 1 5 10 15
 Asn Lys Ser Ser Ser Gly Ser Ser Val Ala Thr Ser Gly Gln Gln Ser
 20 25 30
 Gly Gly Thr Ile Gln Asp Val Lys Arg Lys Lys Ser Gln Lys Trp Asp
 35 40 45
 Glu Ser Ser Ile Leu Ala Ala His Arg Ala Thr Tyr Arg Asp Tyr Asp
 50 55 60
 Leu Met Lys Ala Asn Glu Pro Gly Thr Ser Tyr Met Ser Val Gln Asp
 65 70 75 80
 Asn Gly Glu Asp Ser Val Arg Asp Val Glu Gly Glu Asp Ser Val Arg

-continued

85					90					95					
Gly	Val	Glu	Gly	Lys	Glu	Ala	Thr	Asp	Ala	Ser	Asp	His	Ser	Cys	Glu
			100					105					110		
Val	Asp	Glu	Gln	Glu	Ser	Ser	Glu	Ala	Tyr	Met	Arg	Lys	Ile	Leu	Leu
		115					120					125			
His	Lys	Gln	Glu	Lys	Lys	Arg	Gln	Phe	Glu	Met	Arg	Arg	Arg	Leu	His
	130					135					140				
Tyr	Asn	Glu	Glu	Leu	Asn	Ile	Lys	Leu	Ala	Arg	Gln	Leu	Met	Trp	Lys
145					150					155					160
Glu	Leu	Gln	Ser	Glu	Asp	Asn	Glu	Asn	Glu	Glu	Thr	Pro	Gln	Gly	Thr
				165					170					175	
Asn	Glu	Glu	Lys	Thr	Ala	Ala	Glu	Glu	Ser	Glu	Glu	Ala	Pro	Leu	Thr
			180					185					190		
Gly	Gly	Leu	Gln	Thr	Gln	Ser	Cys	Asp	Pro						
		195					200								

<210> SEQ ID NO 58

<211> LENGTH: 201

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 58

Met	Ala	Asn	Lys	Gly	Pro	Ser	Tyr	Gly	Met	Ser	Arg	Glu	Val	Gln	Ser
1			5						10					15	
Lys	Ile	Glu	Lys	Lys	Tyr	Asp	Glu	Glu	Leu	Glu	Glu	Arg	Leu	Val	Glu
		20					25						30		
Trp	Ile	Ile	Val	Gln	Cys	Gly	Pro	Asp	Val	Gly	Arg	Pro	Asp	Arg	Gly
	35					40					45				
Arg	Leu	Gly	Phe	Gln	Val	Trp	Leu	Lys	Asn	Gly	Val	Ile	Leu	Ser	Lys
	50					55				60					
Leu	Val	Asn	Ser	Leu	Tyr	Pro	Asp	Gly	Ser	Lys	Pro	Val	Lys	Val	Pro
65				70					75					80	
Glu	Asn	Pro	Pro	Ser	Met	Val	Phe	Lys	Gln	Met	Glu	Gln	Val	Ala	Gln
			85						90					95	
Phe	Leu	Lys	Ala	Ala	Glu	Asp	Tyr	Gly	Val	Ile	Lys	Thr	Asp	Met	Phe
		100					105					110			
Gln	Thr	Val	Asp	Leu	Phe	Glu	Gly	Lys	Asp	Met	Ala	Ala	Val	Gln	Arg
	115					120					125				
Thr	Leu	Met	Ala	Leu	Gly	Ser	Leu	Ala	Val	Thr	Lys	Asn	Asp	Gly	His
	130				135						140				
Tyr	Arg	Gly	Asp	Pro	Asn	Trp	Phe	Met	Lys	Lys	Ala	Gln	Glu	His	Lys
145				150					155					160	
Arg	Glu	Phe	Thr	Glu	Ser	Gln	Leu	Gln	Glu	Gly	Lys	His	Val	Ile	Gly
			165					170						175	
Leu	Gln	Met	Gly	Ser	Asn	Arg	Gly	Ala	Ser	Gln	Ala	Gly	Met	Thr	Gly
		180					185						190		
Tyr	Gly	Arg	Pro	Arg	Gln	Ile	Ile	Ser							
	195					200									

<210> SEQ ID NO 59

<211> LENGTH: 798

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

-continued

<400> SEQUENCE: 59

Met	Asn	Leu	Gln	Pro	Ile	Phe	Trp	Ile	Gly	Leu	Ile	Ser	Ser	Val	Cys	1	5	10	15
Cys	Val	Phe	Ala	Gln	Thr	Asp	Glu	Asn	Arg	Cys	Leu	Lys	Ala	Asn	Ala	20	25	30	
Lys	Ser	Cys	Gly	Glu	Cys	Ile	Gln	Ala	Gly	Pro	Asn	Cys	Gly	Trp	Cys	35	40	45	
Thr	Asn	Ser	Thr	Phe	Leu	Gln	Glu	Gly	Met	Pro	Thr	Ser	Ala	Arg	Cys	50	55	60	
Asp	Asp	Leu	Glu	Ala	Leu	Lys	Lys	Lys	Gly	Cys	Pro	Pro	Asp	Asp	Ile	65	70	75	80
Glu	Asn	Pro	Arg	Gly	Ser	Lys	Asp	Ile	Lys	Lys	Asn	Lys	Asn	Val	Thr	85	90	95	
Asn	Arg	Ser	Lys	Gly	Thr	Ala	Glu	Lys	Leu	Lys	Pro	Glu	Asp	Ile	Thr	100	105	110	
Gln	Ile	Gln	Pro	Gln	Gln	Leu	Val	Leu	Arg	Leu	Arg	Ser	Gly	Glu	Pro	115	120	125	
Gln	Thr	Phe	Thr	Leu	Lys	Phe	Lys	Arg	Ala	Glu	Asp	Tyr	Pro	Ile	Asp	130	135	140	
Leu	Tyr	Tyr	Leu	Met	Asp	Leu	Ser	Tyr	Ser	Met	Lys	Asp	Asp	Leu	Glu	145	150	155	160
Asn	Val	Lys	Ser	Leu	Gly	Thr	Asp	Leu	Met	Asn	Glu	Met	Arg	Arg	Ile	165	170	175	
Thr	Ser	Asp	Phe	Arg	Ile	Gly	Phe	Gly	Ser	Phe	Val	Glu	Lys	Thr	Val	180	185	190	
Met	Pro	Tyr	Ile	Ser	Thr	Thr	Pro	Ala	Lys	Leu	Arg	Asn	Pro	Cys	Thr	195	200	205	
Ser	Glu	Gln	Asn	Cys	Thr	Ser	Pro	Phe	Ser	Tyr	Lys	Asn	Val	Leu	Ser	210	215	220	
Leu	Thr	Asn	Lys	Gly	Glu	Val	Phe	Asn	Glu	Leu	Val	Gly	Lys	Gln	Arg	225	230	235	240
Ile	Ser	Gly	Asn	Leu	Asp	Ser	Pro	Glu	Gly	Gly	Phe	Asp	Ala	Ile	Met	245	250	255	
Gln	Val	Ala	Val	Cys	Gly	Ser	Leu	Ile	Gly	Trp	Arg	Asn	Val	Thr	Arg	260	265	270	
Leu	Leu	Val	Phe	Ser	Thr	Asp	Ala	Gly	Phe	His	Phe	Ala	Gly	Asp	Gly	275	280	285	
Lys	Leu	Gly	Gly	Ile	Val	Leu	Pro	Asn	Asp	Gly	Gln	Cys	His	Leu	Glu	290	295	300	
Asn	Asn	Met	Tyr	Thr	Met	Ser	His	Tyr	Tyr	Asp	Tyr	Pro	Ser	Ile	Ala	305	310	315	320
His	Leu	Val	Gln	Lys	Leu	Ser	Glu	Asn	Asn	Ile	Gln	Thr	Ile	Phe	Ala	325	330	335	
Val	Thr	Glu	Glu	Phe	Gln	Pro	Val	Tyr	Lys	Glu	Leu	Lys	Asn	Leu	Ile	340	345	350	
Pro	Lys	Ser	Ala	Val	Gly	Thr	Leu	Ser	Ala	Asn	Ser	Ser	Asn	Val	Ile	355	360	365	
Gln	Leu	Ile	Ile	Asp	Ala	Tyr	Asn	Ser	Leu	Ser	Ser	Glu	Val	Ile	Leu	370	375	380	
Glu	Asn	Gly	Lys	Leu	Ser	Glu	Gly	Val	Thr	Ile	Ser	Tyr	Lys	Ser	Tyr	385	390	395	400

-continued

Cys	Lys	Asn	Gly	Val	Asn	Gly	Thr	Gly	Glu	Asn	Gly	Arg	Lys	Cys	Ser	405	410	415
Asn	Ile	Ser	Ile	Gly	Asp	Glu	Val	Gln	Phe	Glu	Ile	Ser	Ile	Thr	Ser	420	425	430
Asn	Lys	Cys	Pro	Lys	Lys	Asp	Ser	Asp	Ser	Phe	Lys	Ile	Arg	Pro	Leu	435	440	445
Gly	Phe	Thr	Glu	Glu	Val	Glu	Val	Ile	Leu	Gln	Tyr	Ile	Cys	Glu	Cys	450	455	460
Glu	Cys	Gln	Ser	Glu	Gly	Ile	Pro	Glu	Ser	Pro	Lys	Cys	His	Glu	Gly	465	470	475
Asn	Gly	Thr	Phe	Glu	Cys	Gly	Ala	Cys	Arg	Cys	Asn	Glu	Gly	Arg	Val	485	490	495
Gly	Arg	His	Cys	Glu	Cys	Ser	Thr	Asp	Glu	Val	Asn	Ser	Glu	Asp	Met	500	505	510
Asp	Ala	Tyr	Cys	Arg	Lys	Glu	Asn	Ser	Ser	Glu	Ile	Cys	Ser	Asn	Asn	515	520	525
Gly	Glu	Cys	Val	Cys	Gly	Gln	Cys	Val	Cys	Arg	Lys	Arg	Asp	Asn	Thr	530	535	540
Asn	Glu	Ile	Tyr	Ser	Gly	Lys	Phe	Cys	Glu	Cys	Asp	Asn	Phe	Asn	Cys	545	550	555
Asp	Arg	Ser	Asn	Gly	Leu	Ile	Cys	Gly	Gly	Asn	Gly	Val	Cys	Lys	Cys	565	570	575
Arg	Val	Cys	Glu	Cys	Asn	Pro	Asn	Tyr	Thr	Gly	Ser	Ala	Cys	Asp	Cys	580	585	590
Ser	Leu	Asp	Thr	Ser	Thr	Cys	Glu	Ala	Ser	Asn	Gly	Gln	Ile	Cys	Asn	595	600	605
Gly	Arg	Gly	Ile	Cys	Glu	Cys	Gly	Val	Cys	Lys	Cys	Thr	Asp	Pro	Lys	610	615	620
Phe	Gln	Gly	Gln	Thr	Cys	Glu	Met	Cys	Gln	Thr	Cys	Leu	Gly	Val	Cys	625	630	635
Ala	Glu	His	Lys	Glu	Cys	Val	Gln	Cys	Arg	Ala	Phe	Asn	Lys	Gly	Glu	645	650	655
Lys	Lys	Asp	Thr	Cys	Thr	Gln	Glu	Cys	Ser	Tyr	Phe	Asn	Ile	Thr	Lys	660	665	670
Val	Glu	Ser	Arg	Asp	Lys	Leu	Pro	Gln	Pro	Val	Gln	Pro	Asp	Pro	Val	675	680	685
Ser	His	Cys	Lys	Glu	Lys	Asp	Val	Asp	Asp	Cys	Trp	Phe	Tyr	Phe	Thr	690	695	700
Tyr	Ser	Val	Asn	Gly	Asn	Asn	Glu	Val	Met	Val	His	Val	Val	Glu	Asn	705	710	715
Pro	Glu	Cys	Pro	Thr	Gly	Pro	Asp	Ile	Ile	Pro	Ile	Val	Ala	Gly	Val	725	730	735
Val	Ala	Gly	Ile	Val	Leu	Ile	Gly	Leu	Ala	Leu	Leu	Leu	Ile	Trp	Lys	740	745	750
Leu	Leu	Met	Ile	Ile	His	Asp	Arg	Arg	Glu	Phe	Ala	Lys	Phe	Glu	Lys	755	760	765
Glu	Lys	Met	Asn	Ala	Lys	Trp	Asp	Thr	Gly	Glu	Asn	Pro	Ile	Tyr	Lys	770	775	780
Ser	Ala	Val	Thr	Thr	Val	Val	Asn	Pro	Lys	Tyr	Glu	Gly	Lys			785	790	795

-continued

```

<210> SEQ ID NO 60
<211> LENGTH: 1253
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 60

Met Leu Ser Leu Arg Leu Gln Thr Gly Pro Glu Lys Ala Glu Leu Gln
1          5          10          15

Glu Leu Asn Ala Arg Leu Tyr Asp Tyr Val Cys Arg Val Arg Glu Leu
20          25          30

Glu Arg Glu Asn Leu Leu Leu Glu Glu Glu Leu Arg Gly Arg Arg Gly
35          40          45

Arg Glu Gly Leu Trp Ala Glu Gly Gln Ala Arg Cys Ala Glu Glu Ala
50          55          60

Arg Ser Leu Arg Gln Gln Leu Asp Glu Leu Ser Trp Ala Thr Ala Leu
65          70          75          80

Ala Glu Gly Glu Arg Asp Ala Leu Arg Arg Glu Leu Arg Glu Leu Gln
85          90          95

Arg Leu Asp Ala Glu Glu Arg Ala Ala Arg Gly Arg Leu Asp Ala Glu
100         105         110

Leu Gly Ala Gln Gln Arg Glu Leu Gln Glu Ala Leu Gly Ala Arg Ala
115         120         125

Ala Leu Glu Ala Leu Leu Gly Arg Leu Gln Ala Glu Arg Arg Gly Leu
130         135         140

Asp Ala Ala His Glu Arg Asp Val Arg Glu Leu Arg Ala Arg Ala Ala
145         150         155         160

Ser Leu Thr Met His Phe Arg Ala Arg Ala Thr Gly Pro Ala Ala Pro
165         170         175

Pro Pro Arg Leu Arg Glu Val His Asp Ser Tyr Ala Leu Leu Val Ala
180         185         190

Glu Ser Trp Arg Glu Thr Val Gln Leu Tyr Glu Asp Glu Val Arg Glu
195         200         205

Leu Glu Glu Ala Leu Arg Arg Gly Gln Glu Ser Arg Leu Gln Ala Glu
210         215         220

Glu Glu Thr Arg Leu Cys Ala Gln Glu Ala Glu Ala Leu Arg Arg Glu
225         230         235         240

Ala Leu Gly Leu Glu Gln Leu Arg Ala Arg Leu Glu Asp Ala Leu Leu
245         250         255

Arg Met Arg Glu Glu Tyr Gly Ile Gln Ala Glu Glu Arg Gln Arg Val
260         265         270

Ile Asp Cys Leu Glu Asp Glu Lys Ala Thr Leu Thr Leu Ala Met Ala
275         280         285

Asp Trp Leu Arg Asp Tyr Gln Asp Leu Leu Gln Val Lys Thr Gly Leu
290         295         300

Ser Leu Glu Val Ala Thr Tyr Arg Ala Leu Leu Glu Gly Glu Ser Asn
305         310         315         320

Pro Glu Ile Val Ile Trp Ala Glu His Val Glu Asn Met Pro Ser Glu
325         330         335

Phe Arg Asn Lys Ser Tyr His Tyr Thr Asp Ser Leu Leu Gln Arg Glu
340         345         350

Asn Glu Arg Asn Leu Phe Ser Arg Gln Lys Ala Pro Leu Ala Ser Phe
355         360         365

```

-continued

Asn	His	Ser	Ser	Ala	Leu	Tyr	Ser	Asn	Leu	Ser	Gly	His	Arg	Gly	Ser	370	375	380	
Gln	Thr	Gly	Thr	Ser	Ile	Gly	Gly	Asp	Ala	Arg	Arg	Gly	Phe	Leu	Gly	385	390	395	400
Ser	Gly	Tyr	Ser	Ser	Ser	Ala	Thr	Thr	Gln	Gln	Glu	Asn	Ser	Tyr	Gly	405	410	415	
Lys	Ala	Val	Ser	Ser	Gln	Thr	Asn	Val	Arg	Thr	Phe	Ser	Pro	Thr	Tyr	420	425	430	
Gly	Leu	Leu	Arg	Asn	Thr	Glu	Ala	Gln	Val	Lys	Thr	Phe	Pro	Asp	Arg	435	440	445	
Pro	Lys	Ala	Gly	Asp	Thr	Arg	Glu	Val	Pro	Val	Tyr	Ile	Gly	Glu	Asp	450	455	460	
Ser	Thr	Ile	Ala	Arg	Glu	Ser	Tyr	Arg	Asp	Arg	Arg	Asp	Lys	Val	Ala	465	470	475	480
Ala	Gly	Ala	Ser	Glu	Ser	Thr	Arg	Ser	Asn	Glu	Arg	Thr	Val	Ile	Leu	485	490	495	
Gly	Lys	Lys	Thr	Glu	Val	Lys	Ala	Thr	Arg	Glu	Gln	Glu	Arg	Asn	Arg	500	505	510	
Pro	Glu	Thr	Ile	Arg	Thr	Lys	Pro	Glu	Glu	Lys	Met	Phe	Asp	Ser	Lys	515	520	525	
Glu	Lys	Ala	Ser	Glu	Glu	Arg	Asn	Leu	Arg	Trp	Glu	Glu	Leu	Thr	Lys	530	535	540	
Leu	Asp	Lys	Glu	Ala	Arg	Gln	Arg	Glu	Ser	Gln	Gln	Met	Lys	Glu	Lys	545	550	555	560
Ala	Lys	Glu	Lys	Asp	Ser	Leu	Lys	Glu	Lys	Ser	Val	Arg	Glu	Arg	Glu	565	570	575	
Val	Pro	Ile	Ser	Leu	Glu	Val	Ser	Gln	Asp	Arg	Arg	Ala	Glu	Val	Ser	580	585	590	
Pro	Lys	Gly	Leu	Gln	Thr	Pro	Val	Lys	Asp	Ala	Gly	Gly	Gly	Thr	Gly	595	600	605	
Arg	Glu	Ala	Glu	Ala	Arg	Glu	Leu	Arg	Phe	Arg	Leu	Gly	Thr	Ser	Asp	610	615	620	
Ala	Thr	Gly	Ser	Leu	Gln	Gly	Asp	Ser	Met	Thr	Glu	Thr	Val	Ala	Glu	625	630	635	640
Asn	Ile	Val	Thr	Ser	Ile	Leu	Lys	Gln	Phe	Thr	Gln	Ser	Pro	Glu	Thr	645	650	655	
Glu	Ala	Ser	Ala	Asp	Ser	Phe	Pro	Asp	Thr	Lys	Val	Thr	Tyr	Val	Asp	660	665	670	
Arg	Lys	Glu	Leu	Pro	Gly	Glu	Arg	Lys	Thr	Lys	Thr	Glu	Ile	Leu	Val	675	680	685	
Glu	Ser	Lys	Leu	Thr	Glu	Asp	Val	Asp	Val	Ser	Asp	Glu	Ala	Gly	Leu	690	695	700	
Asp	Tyr	Leu	Leu	Ser	Lys	Asp	Ile	Lys	Glu	Val	Gly	Leu	Lys	Gly	Lys	705	710	715	720
Ser	Ala	Glu	Gln	Met	Ile	Gly	Asp	Ile	Ile	Asn	Leu	Gly	Leu	Lys	Gly	725	730	735	
Arg	Glu	Gly	Arg	Ala	Lys	Val	Val	Asn	Val	Glu	Ile	Val	Glu	Glu	Pro	740	745	750	
Val	Ser	Tyr	Val	Ser	Gly	Glu	Lys	Pro	Glu	Glu	Phe	Ser	Val	Pro	Phe	755	760	765	

-continued

Lys	Val	Glu	Glu	Val	Glu	Asp	Val	Ser	Pro	Gly	Pro	Trp	Gly	Leu	Val	770	775	780
Lys	Glu	Glu	Glu	Gly	Tyr	Gly	Glu	Ser	Asp	Val	Thr	Phe	Ser	Val	Asn	785	790	795
Gln	His	Arg	Arg	Thr	Lys	Gln	Pro	Gln	Glu	Asn	Thr	Thr	His	Val	Glu	805	810	815
Glu	Val	Thr	Glu	Ala	Gly	Asp	Ser	Glu	Gly	Glu	Gln	Ser	Tyr	Phe	Val	820	825	830
Ser	Thr	Pro	Asp	Glu	His	Pro	Gly	Gly	His	Asp	Arg	Asp	Asp	Gly	Ser	835	840	845
Val	Tyr	Gly	Gln	Ile	His	Ile	Glu	Glu	Glu	Ser	Thr	Ile	Arg	Tyr	Ser	850	855	860
Trp	Gln	Asp	Glu	Ile	Val	Gln	Gly	Thr	Arg	Arg	Arg	Thr	Gln	Lys	Asp	865	870	875
Gly	Ala	Val	Gly	Glu	Lys	Val	Val	Lys	Pro	Leu	Asp	Val	Pro	Ala	Pro	885	890	895
Ser	Leu	Glu	Gly	Asp	Leu	Gly	Ser	Thr	His	Trp	Lys	Glu	Gln	Ala	Arg	900	905	910
Ser	Gly	Glu	Phe	His	Ala	Glu	Pro	Thr	Val	Ile	Glu	Lys	Glu	Ile	Lys	915	920	925
Ile	Pro	His	Glu	Phe	His	Thr	Ser	Met	Lys	Gly	Ile	Ser	Ser	Lys	Glu	930	935	940
Pro	Arg	Gln	Gln	Leu	Val	Glu	Val	Ile	Gly	Gln	Leu	Glu	Glu	Thr	Leu	945	950	955
Pro	Glu	Arg	Met	Arg	Glu	Glu	Leu	Ser	Ala	Leu	Thr	Arg	Glu	Gly	Gln	965	970	975
Gly	Gly	Pro	Gly	Ser	Val	Ser	Val	Asp	Val	Lys	Lys	Val	Gln	Gly	Ala	980	985	990
Gly	Gly	Ser	Ser	Val	Thr	Leu	Val	Ala	Glu	Val	Asn	Val	Ser	Gln	Thr	995	1000	1005
Val	Asp	Ala	Asp	Arg	Leu	Asp	Leu	Glu	Glu	Val	Ser	Lys	Asp	Glu		1010	1015	1020
Ala	Ser	Glu	Met	Glu	Lys	Ala	Val	Glu	Ser	Val	Val	Arg	Glu	Ser		1025	1030	1035
Leu	Ser	Arg	Gln	Arg	Ser	Pro	Ala	Pro	Gly	Ser	Pro	Asp	Glu	Glu		1040	1045	1050
Gly	Gly	Ala	Glu	Ala	Pro	Ala	Ala	Gly	Ile	Arg	Phe	Arg	Arg	Trp		1055	1060	1065
Ala	Thr	Arg	Glu	Leu	Tyr	Ile	Pro	Ser	Gly	Glu	Ser	Glu	Val	Ala		1070	1075	1080
Gly	Gly	Ala	Ser	His	Ser	Ser	Gly	Gln	Arg	Thr	Pro	Gln	Gly	Pro		1085	1090	1095
Val	Ser	Ala	Thr	Val	Glu	Val	Ser	Ser	Pro	Thr	Gly	Phe	Ala	Gln		1100	1105	1110
Ser	Gln	Val	Leu	Glu	Asp	Val	Ser	Gln	Ala	Ala	Arg	His	Ile	Lys		1115	1120	1125
Leu	Gly	Pro	Ser	Glu	Val	Trp	Arg	Thr	Glu	Arg	Met	Ser	Tyr	Glu		1130	1135	1140
Gly	Pro	Thr	Ala	Glu	Val	Val	Glu	Met	Asp	Val	Ser	Asn	Val	Glu		1145	1150	1155
Ala	Ile	Arg	Ser	Arg	Thr	Gln	Glu	Ala	Gly	Ala	Leu	Gly	Val	Ser				

-continued

1160	1165	1170
Asp Arg Gly Ser Trp Arg	Asp Ala Asp Ser Arg Asn	Asp Gln Ala
1175	1180	1185
Val Gly Val Ser Phe Lys	Ala Ser Ala Gly Glu Gly	Asp Gln Ala
1190	1195	1200
His Arg Glu Gln Gly Lys	Glu Gln Ala Met Phe Asp	Lys Lys Val
1205	1210	1215
Gln Leu Gln Arg Met Val	Asp Gln Arg Ser Val Ile	Ser Asp Glu
1220	1225	1230
Lys Lys Val Ala Leu Leu	Tyr Leu Asp Asn Glu Glu	Glu Glu Asn
1235	1240	1245
Asp Gly His Trp Phe		
1250		

<210> SEQ ID NO 61

<211> LENGTH: 269

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 61

Met Ser Ala Ala Leu Phe Ser Leu Asp Gly Pro Ala Arg Gly Ala Pro		
1	5	10 15
Trp Pro Ala Glu Pro Ala Pro Phe Tyr Glu Pro Gly Arg Ala Gly Lys		
	20	25 30
Pro Gly Arg Gly Ala Glu Pro Gly Ala Leu Gly Glu Pro Gly Ala Ala		
	35	40 45
Ala Pro Ala Met Tyr Asp Asp Glu Ser Ala Ile Asp Phe Ser Ala Tyr		
	50	55 60
Ile Asp Ser Met Ala Ala Val Pro Thr Leu Glu Leu Cys His Asp Glu		
65	70	75 80
Leu Phe Ala Asp Leu Phe Asn Ser Asn His Lys Ala Gly Gly Ala Gly		
	85	90 95
Pro Leu Glu Leu Leu Pro Gly Gly Pro Ala Arg Pro Leu Gly Pro Gly		
	100	105 110
Pro Ala Ala Pro Arg Leu Leu Lys Arg Glu Pro Asp Trp Gly Asp Gly		
	115	120 125
Asp Ala Pro Gly Ser Leu Leu Pro Ala Gln Val Ala Ala Cys Ala Gln		
	130	135 140
Thr Val Val Ser Leu Ala Ala Ala Gly Gln Pro Thr Pro Thr Ser		
145	150	155 160
Pro Glu Pro Pro Arg Ser Ser Pro Arg Gln Thr Pro Ala Pro Gly Pro		
	165	170 175
Ala Arg Glu Lys Ser Ala Gly Lys Arg Gly Pro Asp Arg Gly Ser Pro		
	180	185 190
Glu Tyr Arg Gln Arg Arg Glu Arg Asn Asn Ile Ala Val Arg Lys Ser		
	195	200 205
Arg Asp Lys Ala Lys Arg Arg Asn Gln Glu Met Gln Gln Lys Leu Val		
	210	215 220
Glu Leu Ser Ala Glu Asn Glu Lys Leu His Gln Arg Val Glu Gln Leu		
225	230	235 240
Thr Arg Asp Leu Ala Gly Leu Arg Gln Phe Phe Lys Gln Leu Pro Ser		
	245	250 255

-continued

Pro Pro Phe Leu Pro Ala Ala Gly Thr Ala Asp Cys Arg
260 265

<210> SEQ ID NO 62

<211> LENGTH: 241

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 62

Met His Ile Thr Gln Leu Asn Arg Glu Cys Leu Leu His Leu Phe Ser
1 5 10 15

Phe Leu Asp Lys Asp Ser Arg Lys Ser Leu Ala Arg Thr Cys Ser Gln
20 25 30

Leu His Asp Val Phe Glu Asp Pro Ala Leu Trp Ser Leu Leu His Phe
35 40 45

Arg Ser Leu Thr Glu Leu Gln Lys Asp Asn Phe Leu Leu Gly Pro Ala
50 55 60

Leu Arg Ser Leu Ser Ile Cys Trp His Ser Ser Arg Val Gln Val Cys
65 70 75 80

Ser Ile Glu Asp Trp Leu Lys Ser Ala Phe Gln Arg Ser Ile Cys Ser
85 90 95

Arg His Glu Ser Leu Val Asn Asp Phe Leu Leu Arg Val Cys Asp Arg
100 105 110

Leu Ser Ala Val Arg Ser Pro Arg Arg Arg Glu Ala Pro Ala Pro Ser
115 120 125

Ser Gly Thr Pro Ile Ala Val Gly Pro Lys Ser Pro Arg Trp Gly Gly
130 135 140

Pro Asp His Ser Glu Phe Ala Asp Leu Arg Ser Gly Val Thr Gly Ala
145 150 155 160

Arg Ala Ala Ala Arg Arg Gly Leu Gly Ser Leu Arg Ala Glu Arg Pro
165 170 175

Ser Glu Thr Pro Pro Ala Pro Gly Val Ser Trp Gly Pro Pro Pro Pro
180 185 190

Gly Ala Pro Val Val Ile Ser Val Lys Gln Glu Glu Gly Lys Gln Gly
195 200 205

Arg Thr Gly Arg Arg Ser His Arg Ala Ala Pro Pro Cys Gly Phe Ala
210 215 220

Arg Thr Arg Val Cys Pro Pro Thr Phe Pro Gly Ala Asp Ala Phe Pro
225 230 235 240

Gln

<210> SEQ ID NO 63

<211> LENGTH: 450

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 63

Met Arg Glu Ile Val His Ile Gln Ala Gly Gln Cys Gly Asn Gln Ile
1 5 10 15

Gly Ala Lys Phe Trp Glu Val Ile Ser Asp Glu His Gly Ile Asp Pro
20 25 30

Ser Gly Asn Tyr Val Gly Asp Ser Asp Leu Gln Leu Glu Arg Ile Ser
35 40 45

Val Tyr Tyr Asn Glu Ala Ser Ser His Lys Tyr Val Pro Arg Ala Ile

-continued

50	55	60
Leu Val Asp Leu Glu Pro Gly Thr Met Asp Ser Val Arg Ser Gly Ala 65 70 75 80		
Phe Gly His Leu Phe Arg Pro Asp Asn Phe Ile Phe Gly Gln Ser Gly 85 90 95		
Ala Gly Asn Asn Trp Ala Lys Gly His Tyr Thr Glu Gly Ala Glu Leu 100 105 110		
Val Asp Ser Val Leu Asp Val Val Arg Lys Glu Cys Glu Asn Cys Asp 115 120 125		
Cys Leu Gln Gly Phe Gln Leu Thr His Ser Leu Gly Gly Gly Thr Gly 130 135 140		
Ser Gly Met Gly Thr Leu Leu Ile Ser Lys Val Arg Glu Glu Tyr Pro 145 150 155 160		
Asp Arg Ile Met Asn Thr Phe Ser Val Val Pro Ser Pro Lys Val Ser 165 170 175		
Asp Thr Val Val Glu Pro Tyr Asn Ala Thr Leu Ser Ile His Gln Leu 180 185 190		
Val Glu Asn Thr Asp Glu Thr Tyr Cys Ile Asp Asn Glu Ala Leu Tyr 195 200 205		
Asp Ile Cys Phe Arg Thr Leu Lys Leu Ala Thr Pro Thr Tyr Gly Asp 210 215 220		
Leu Asn His Leu Val Ser Ala Thr Met Ser Gly Val Thr Thr Ser Leu 225 230 235 240		
Arg Phe Pro Gly Gln Leu Asn Ala Asp Leu Arg Lys Leu Ala Val Asn 245 250 255		
Met Val Pro Phe Pro Arg Leu His Phe Phe Met Pro Gly Phe Ala Pro 260 265 270		
Leu Thr Ala Arg Gly Ser Gln Gln Tyr Arg Ala Leu Thr Val Pro Glu 275 280 285		
Leu Thr Gln Gln Met Phe Asp Ala Lys Asn Met Met Ala Ala Cys Asp 290 295 300		
Pro Arg His Gly Arg Tyr Leu Thr Val Ala Thr Val Phe Arg Gly Arg 305 310 315 320		
Met Ser Met Lys Glu Val Asp Glu Gln Met Leu Ala Ile Gln Ser Lys 325 330 335		
Asn Ser Ser Tyr Phe Val Glu Trp Ile Pro Asn Asn Val Lys Val Ala 340 345 350		
Val Cys Asp Ile Pro Pro Arg Gly Leu Lys Met Ser Ser Thr Phe Ile 355 360 365		
Gly Asn Ser Thr Ala Ile Gln Glu Leu Phe Lys Arg Ile Ser Glu Gln 370 375 380		
Phe Thr Ala Met Phe Arg Arg Lys Ala Phe Leu His Trp Tyr Thr Gly 385 390 395 400		
Glu Gly Met Asp Glu Met Glu Phe Thr Glu Ala Glu Ser Asn Met Asn 405 410 415		
Asp Leu Val Ser Glu Tyr Gln Gln Tyr Gln Asp Ala Thr Ala Glu Glu 420 425 430		
Glu Gly Glu Met Tyr Glu Asp Asp Glu Glu Glu Ser Glu Ala Gln Gly 435 440 445		
Pro Lys 450		

-continued

```

<210> SEQ ID NO 64
<211> LENGTH: 361
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 64

Met Trp Val Leu Thr Pro Ala Ala Phe Ala Gly Lys Leu Leu Ser Val
 1             5             10             15

Phe Arg Gln Pro Leu Ser Ser Leu Trp Arg Ser Leu Val Pro Leu Phe
          20             25             30

Cys Trp Leu Arg Ala Thr Phe Trp Leu Leu Ala Thr Lys Arg Arg Lys
          35             40             45

Gln Gln Leu Val Leu Arg Gly Pro Asp Glu Thr Lys Glu Glu Glu Glu
          50             55             60

Asp Pro Pro Leu Pro Thr Thr Pro Thr Ser Val Asn Tyr His Phe Thr
65             70             75             80

Arg Gln Cys Asn Tyr Lys Cys Gly Phe Cys Phe His Thr Ala Lys Thr
          85             90             95

Ser Phe Val Leu Pro Leu Glu Glu Ala Lys Arg Gly Leu Leu Leu Leu
          100            105            110

Lys Glu Ala Gly Met Glu Lys Ile Asn Phe Ser Gly Gly Glu Pro Phe
          115            120            125

Leu Gln Asp Arg Gly Glu Tyr Leu Gly Lys Leu Val Arg Phe Cys Lys
          130            135            140

Val Glu Leu Arg Leu Pro Ser Val Ser Ile Val Ser Asn Gly Ser Leu
          145            150            155            160

Ile Arg Glu Arg Trp Phe Gln Asn Tyr Gly Glu Tyr Leu Asp Ile Leu
          165            170            175

Ala Ile Ser Cys Asp Ser Phe Asp Glu Glu Val Asn Val Leu Ile Gly
          180            185            190

Arg Gly Gln Gly Lys Lys Asn His Val Glu Asn Leu Gln Lys Leu Arg
          195            200            205

Arg Trp Cys Arg Asp Tyr Arg Val Ala Phe Lys Ile Asn Ser Val Ile
          210            215            220

Asn Arg Phe Asn Val Glu Glu Asp Met Thr Glu Gln Ile Lys Ala Leu
          225            230            235            240

Asn Pro Val Arg Trp Lys Val Phe Gln Cys Leu Leu Ile Glu Gly Glu
          245            250            255

Asn Cys Gly Glu Asp Ala Leu Arg Glu Ala Glu Arg Phe Val Ile Gly
          260            265            270

Asp Glu Glu Phe Glu Arg Phe Leu Glu Arg His Lys Glu Val Ser Cys
          275            280            285

Leu Val Pro Glu Ser Asn Gln Lys Met Lys Asp Ser Tyr Leu Ile Leu
          290            295            300

Asp Glu Tyr Met Arg Phe Leu Asn Cys Arg Lys Gly Arg Lys Asp Pro
          305            310            315            320

Ser Lys Ser Ile Leu Asp Val Gly Val Glu Glu Ala Ile Lys Phe Ser
          325            330            335

Gly Phe Asp Glu Lys Met Phe Leu Lys Arg Gly Gly Lys Tyr Ile Trp
          340            345            350

Ser Lys Ala Asp Leu Lys Leu Asp Trp

```

<210> SEQ ID NO 65																	
<211> LENGTH: 1589																	
<212> TYPE: PRT																	
<213> ORGANISM: Homo sapiens																	
<400> SEQUENCE: 65																	
Met	Ala	Lys	Gln	Leu	Asn	Leu	Pro	Glu	Asn	Thr	Asp	Asp	Trp	Thr	Lys		
1				5					10					15			
Glu	Asp	Val	Asn	Gln	Trp	Leu	Glu	Ser	His	Lys	Ile	Asp	Gln	Lys	His		
			20					25					30				
Arg	Glu	Ile	Leu	Thr	Glu	Gln	Asp	Val	Asn	Gly	Ala	Val	Leu	Lys	Trp		
			35				40					45					
Leu	Lys	Lys	Glu	His	Leu	Val	Asp	Met	Gly	Ile	Thr	His	Gly	Pro	Ala		
	50					55					60						
Ile	Gln	Ile	Glu	Glu	Leu	Phe	Lys	Glu	Leu	Arg	Lys	Thr	Ala	Ile	Glu		
65					70					75				80			
Asp	Ser	Ile	Gln	Thr	Ser	Lys	Met	Gly	Lys	Pro	Ser	Lys	Asn	Ala	Pro		
				85					90					95			
Lys	Asp	Gln	Thr	Val	Ser	Gln	Lys	Glu	Arg	Arg	Glu	Thr	Ser	Lys	Gln		
			100					105					110				
Lys	Gln	Lys	Gly	Lys	Glu	Asn	Pro	Asp	Met	Ala	Asn	Pro	Ser	Ala	Met		
			115				120					125					
Ser	Thr	Thr	Ala	Lys	Gly	Ser	Lys	Ser	Leu	Lys	Val	Glu	Leu	Ile	Glu		
	130					135					140						
Asp	Lys	Ile	Asp	Tyr	Thr	Lys	Glu	Arg	Gln	Pro	Ser	Ile	Asp	Leu	Thr		
145					150				155					160			
Cys	Val	Ser	Tyr	Pro	Phe	Asp	Glu	Phe	Ser	Asn	Pro	Tyr	Arg	Tyr	Lys		
				165					170					175			
Leu	Asp	Phe	Ser	Leu	Gln	Pro	Glu	Thr	Gly	Pro	Gly	Asn	Leu	Ile	Asp		
			180					185				190					
Pro	Ile	His	Glu	Phe	Lys	Ala	Phe	Thr	Asn	Thr	Ala	Thr	Ala	Thr	Glu		
			195				200					205					
Glu	Asp	Val	Lys	Met	Lys	Phe	Ser	Asn	Glu	Val	Phe	Arg	Phe	Ala	Ser		
	210					215					220						
Ala	Cys	Met	Asn	Ser	Arg	Thr	Asn	Gly	Thr	Ile	His	Phe	Gly	Val	Lys		
225				230						235				240			
Asp	Lys	Pro	His	Gly	Lys	Ile	Val	Gly	Ile	Lys	Val	Thr	Asn	Asp	Thr		
				245					250					255			
Lys	Glu	Ala	Leu	Ile	Asn	His	Phe	Asn	Leu	Met	Ile	Asn	Lys	Tyr	Phe		
			260					265				270					
Glu	Asp	His	Gln	Val	Gln	Gln	Ala	Lys	Lys	Cys	Ile	Arg	Glu	Pro	Arg		
		275					280					285					
Phe	Val	Glu	Val	Leu	Leu	Pro	Asn	Ser	Thr	Leu	Ser	Asp	Arg	Phe	Val		
	290					295					300						
Ile	Glu	Val	Asp	Ile	Ile	Pro	Gln	Phe	Ser	Glu	Cys	Gln	Tyr	Asp	Tyr		
305					310					315							

-continued

Thr	Lys	Asn	Lys	Val	Asp	Phe	Arg	Ala	Phe	Lys	Ala	Asp	Phe	Lys	Thr
	355						360					365			
Leu	Ala	Glu	Ser	Arg	Lys	Ala	Ala	Glu	Glu	Lys	Phe	Arg	Ala	Lys	Thr
	370					375					380				
Asn	Lys	Lys	Glu	Arg	Glu	Gly	Pro	Lys	Leu	Val	Lys	Leu	Leu	Thr	Gly
385					390					395					400
Asn	Gln	Asp	Leu	Leu	Asp	Asn	Ser	Tyr	Tyr	Glu	Gln	Tyr	Ile	Leu	Val
			405						410					415	
Thr	Asn	Lys	Cys	His	Pro	Asp	Gln	Thr	Lys	His	Leu	Asp	Phe	Leu	Lys
		420					425						430		
Glu	Ile	Lys	Trp	Phe	Ala	Val	Leu	Glu	Phe	Asp	Pro	Glu	Ser	Asn	Ile
		435					440					445			
Asn	Gly	Val	Val	Lys	Ala	Tyr	Lys	Glu	Ser	Arg	Val	Ala	Asn	Leu	His
	450					455					460				
Phe	Pro	Ser	Val	Tyr	Val	Glu	Gln	Lys	Thr	Thr	Pro	Asn	Glu	Thr	Ile
465					470					475					480
Ser	Thr	Leu	Asn	Leu	Tyr	His	Gln	Pro	Ser	Trp	Ile	Phe	Cys	Asn	Gly
			485						490					495	
Arg	Leu	Asp	Leu	Asp	Ser	Glu	Lys	Tyr	Lys	Pro	Phe	Asp	Pro	Ser	Ser
		500						505					510		
Trp	Gln	Arg	Glu	Arg	Ala	Ser	Asp	Val	Arg	Lys	Leu	Ile	Ser	Phe	Leu
		515					520					525			
Thr	His	Glu	Asp	Ile	Met	Pro	Arg	Gly	Lys	Phe	Leu	Val	Val	Phe	Leu
	530					535					540				
Leu	Leu	Ser	Ser	Val	Asp	Asp	Pro	Arg	Asp	Pro	Leu	Ile	Glu	Thr	Phe
545					550					555					560
Cys	Ala	Phe	Tyr	Gln	Asp	Leu	Lys	Gly	Met	Glu	Asn	Ile	Leu	Cys	Ile
				565					570					575	
Cys	Val	His	Pro	His	Ile	Phe	Gln	Gly	Trp	Lys	Asp	Leu	Leu	Glu	Ala
			580					585					590		
Arg	Leu	Ile	Lys	His	Gln	Asp	Glu	Ile	Ser	Ser	Gln	Cys	Ile	Ser	Ala
	595						600					605			
Leu	Ser	Leu	Glu	Glu	Ile	Asn	Gly	Thr	Ile	Leu	Lys	Leu	Lys	Ser	Val
	610					615					620				
Thr	Gln	Ser	Ser	Lys	Arg	Leu	Leu	Pro	Ser	Ile	Gly	Leu	Ser	Thr	Val
625					630					635					640
Leu	Leu	Lys	Lys	Glu	Glu	Asp	Ile	Met	Thr	Ala	Leu	Glu	Ile	Ile	Cys
				645					650					655	
Glu	Asn	Glu	Cys	Glu	Gly	Thr	Leu	Leu	Glu	Lys	Asp	Lys	Asn	Lys	Phe
		660						665					670		
Leu	Glu	Phe	Lys	Ala	Ser	Lys	Glu	Glu	Asp	Phe	Tyr	Arg	Gly	Gly	Lys
	675						680					685			
Val	Ser	Trp	Trp	Asn	Phe	Tyr	Phe	Ser	Ser	Glu	Ser	Tyr	Ser	Ser	Pro
	690					695					700				
Phe	Val	Lys	Arg	Asp	Lys	Tyr	Glu	Arg	Leu	Glu	Ala	Met	Ile	Gln	Asn
705					710					715					720
Cys	Ala	Asp	Ser	Ser	Lys	Pro	Thr	Ser	Thr	Lys	Ile	Ile	His	Leu	Tyr
				725					730					735	
His	His	Pro	Gly	Cys	Gly	Gly	Thr	Thr	Leu	Ala	Met	His	Ile	Leu	Trp
		740					745						750		
Glu	Leu	Arg	Lys	Lys	Phe	Arg	Cys	Ala	Val	Leu	Lys	Asn	Lys	Thr	Val

-continued

755	760	765
Asp Phe Ser Glu Ile Gly 770	Glu Gln Val Thr Ser 775	Leu Ile Thr Tyr Gly 780
Ala Met Asn Arg Gln Glu 785	Tyr Val Pro Val Leu 790	Leu Leu Val Asp Asp 795 800
Phe Glu Glu Gln Asp 805	Asn Val Tyr Leu Leu 810	Gln Tyr Ser Ile Gln Thr 815
Ala Ile Ala Lys Lys Tyr 820	Ile Arg Tyr Glu Lys 825	Pro Leu Val Ile Ile 830
Leu Asn Cys Met Arg Ser 835	Gln Asn Pro Glu Lys 840	Ser Ala Arg Ile Pro 845
Asp Ser Ile Ala Val Ile 850	Gln Gln Leu Ser Pro 855	Lys Glu Gln Arg Ala 860
Phe Glu Leu Lys Leu Lys 865	Glu Ile Lys Glu Gln 870	His Lys Asn Phe Glu 875 880
Asp Phe Tyr Ser Phe 885	Met Ile Met Lys Thr 890	Asn Phe Asn Lys Glu Tyr 895
Ile Glu Asn Val Val Arg 900	Asn Ile Leu Lys Gly 905	Gln Asn Ile Phe Thr 910
Lys Glu Ala Lys Leu Phe 915	Ser Phe Leu Ala Leu 920	Leu Asn Ser Tyr Val 925
Pro Asp Thr Thr Ile Ser 930	Leu Ser Gln Cys Glu 935	Lys Phe Leu Gly Ile 940
Gly Asn Lys Lys Ala Phe 945	Trp Gly Thr Glu Lys 950	Phe Glu Asp Lys Met 955 960
Gly Thr Tyr Ser Thr 965	Ile Leu Ile Lys Thr 970	Glu Val Ile Glu Cys Gly 975
Asn Tyr Cys Gly Val Arg 980	Ile Ile His Ser Leu 985	Ile Ala Glu Phe Ser 990
Leu Glu Glu Leu Lys Lys 995	Ser Tyr His Leu Asn 1000	Lys Ser Gln Ile Met 1005
Leu Asp Met Leu Thr Glu 1010	Asn Leu Phe Phe Asp 1015	Thr Gly Met Gly 1020
Lys Ser Lys Phe Leu Gln 1025	Asp Met His Thr Leu 1030	Leu Leu Thr Arg 1035
His Arg Asp Glu His Glu 1040	Gly Glu Thr Gly Asn 1045	Trp Phe Ser Pro 1050
Phe Ile Glu Ala Leu His 1055	Lys Asp Glu Gly Asn 1060	Glu Ala Val Glu 1065
Ala Val Leu Leu Glu Ser 1070	Ile His Arg Phe Asn 1075	Pro Asn Ala Phe 1080
Ile Cys Gln Ala Leu Ala 1085	Arg His Phe Tyr Ile 1090	Lys Lys Lys Asp 1095
Phe Gly Asn Ala Leu Asn 1100	Trp Ala Lys Gln Ala 1105	Lys Ile Ile Glu 1110
Pro Asp Asn Ser Tyr Ile 1115	Ser Asp Thr Leu Gly 1120	Gln Val Tyr Lys 1125
Ser Lys Ile Arg Trp Trp 1130	Ile Glu Glu Asn Gly 1135	Gly Asn Gly Asn 1140
Ile Ser Val Asp Asp Leu 1145	Ile Ala Leu Leu Asp 1150	Leu Ala Glu His 1155

-continued

Ala Ser Ser Ala Phe Lys Glu Ser Gln Gln Gln Ser Glu Asp Arg	1160	1165	1170
Glu Tyr Glu Val Lys Glu Arg Leu Tyr Pro Lys Ser Lys Arg Arg	1175	1180	1185
Tyr Asp Thr Tyr Asn Ile Ala Gly Tyr Gln Gly Glu Ile Glu Val	1190	1195	1200
Gly Leu Tyr Thr Ile Gln Ile Leu Gln Leu Ile Pro Phe Phe Asp	1205	1210	1215
Asn Lys Asn Glu Leu Ser Lys Arg Tyr Met Val Asn Phe Val Ser	1220	1225	1230
Gly Ser Ser Asp Ile Pro Gly Asp Pro Asn Asn Glu Tyr Lys Leu	1235	1240	1245
Ala Leu Lys Asn Tyr Ile Pro Tyr Leu Thr Lys Leu Lys Phe Ser	1250	1255	1260
Leu Lys Lys Ser Phe Asp Phe Phe Asp Glu Tyr Phe Val Leu Leu	1265	1270	1275
Lys Pro Arg Asn Asn Ile Lys Gln Asn Glu Glu Ala Lys Thr Arg	1280	1285	1290
Arg Lys Val Ala Gly Tyr Phe Lys Lys Tyr Val Asp Ile Phe Cys	1295	1300	1305
Leu Leu Glu Glu Ser Gln Asn Asn Thr Gly Leu Gly Ser Lys Phe	1310	1315	1320
Ser Glu Pro Leu Gln Val Glu Arg Cys Arg Arg Asn Leu Val Ala	1325	1330	1335
Leu Lys Ala Asp Lys Phe Ser Gly Leu Leu Glu Tyr Leu Ile Lys	1340	1345	1350
Ser Gln Glu Asp Ala Ile Ser Thr Met Lys Cys Ile Val Asn Glu	1355	1360	1365
Tyr Thr Phe Leu Leu Glu Gln Cys Thr Val Lys Ile Gln Ser Lys	1370	1375	1380
Glu Lys Leu Asn Phe Ile Leu Ala Asn Ile Ile Leu Ser Cys Ile	1385	1390	1395
Gln Pro Thr Ser Arg Leu Val Lys Pro Val Glu Lys Leu Lys Asp	1400	1405	1410
Gln Leu Arg Glu Val Leu Gln Pro Ile Gly Leu Thr Tyr Gln Phe	1415	1420	1425
Ser Glu Pro Tyr Phe Leu Ala Ser Leu Leu Phe Trp Pro Glu Asn	1430	1435	1440
Gln Gln Leu Asp Gln His Ser Glu Gln Met Lys Glu Tyr Ala Gln	1445	1450	1455
Ala Leu Lys Asn Ser Phe Lys Gly Gln Tyr Lys His Met His Arg	1460	1465	1470
Thr Lys Gln Pro Ile Ala Tyr Phe Phe Leu Gly Lys Gly Lys Arg	1475	1480	1485
Leu Glu Arg Leu Val His Lys Gly Lys Ile Asp Gln Cys Phe Lys	1490	1495	1500
Lys Thr Pro Asp Ile Asn Ser Leu Trp Gln Ser Gly Asp Val Trp	1505	1510	1515
Lys Glu Glu Lys Val Gln Glu Leu Leu Leu Arg Leu Gln Gly Arg	1520	1525	1530

-continued

```

Ala Glu Asn Asn Cys Leu Tyr Ile Glu Tyr Gly Ile Asn Glu Lys
 1535                               1540                1545

Ile Thr Ile Pro Ile Thr Pro Ala Phe Leu Gly Gln Leu Arg Ser
 1550                               1555                1560

Gly Arg Ser Ile Glu Lys Val Ser Phe Tyr Leu Gly Phe Ser Ile
 1565                               1570                1575

Gly Gly Pro Leu Ala Tyr Asp Ile Glu Ile Val
 1580                               1585

```

<210> SEQ ID NO 66

<211> LENGTH: 122

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 66

```

Met Glu Ala Ser Ala Leu Thr Ser Ser Ala Val Thr Ser Val Ala Lys
 1      5      10      15

Val Val Arg Val Ala Ser Gly Ser Ala Val Val Leu Pro Leu Ala Arg
      20      25      30

Ile Ala Thr Val Val Ile Gly Gly Val Val Ala Met Ala Ala Val Pro
      35      40      45

Met Val Leu Ser Ala Met Gly Phe Thr Ala Ala Gly Ile Ala Ser Ser
      50      55      60

Ser Ile Ala Ala Lys Met Met Ser Ala Ala Ala Ile Ala Asn Gly Gly
      65      70      75      80

Gly Val Ala Ser Gly Ser Leu Val Ala Thr Leu Gln Ser Leu Gly Ala
      85      90      95

Thr Gly Leu Ser Gly Leu Thr Lys Phe Ile Leu Gly Ser Ile Gly Ser
      100     105     110

Ala Ile Ala Ala Val Ile Ala Arg Phe Tyr
      115     120

```

1. A method for detecting CVH in a subject, said method comprising:

- (a) contacting a biological sample with an agent that specifically binds to a polypeptide encoded by a gene listed in Tables 3-8 or a homolog thereof;
- (b) determining a level of binding of the agent to the polypeptide;
- (c) comparing the level of binding of the agent in the biological sample to a level of binding of the agent in a normal control sample; and
- (d) producing a diagnosis based on a result from step (c).

2. The method of claim 1, wherein said polypeptide comprises an amino acid sequence recited in any one of SEQ ID NOS:34-66.

3. The method of claim 1, wherein the agent is an antibody directed against the polypeptide.

4. A method for detecting CVH in a subject, said method comprising the steps of:

- (a) determining a level of a transcribed polynucleotide in a biological sample obtained from the subject, wherein the transcribed polynucleotide is transcribed from a gene listed in Tables 3-8 or homolog thereof;

- (b) comparing the level of the transcribed polynucleotide in the biological sample to a normal level of the transcribed polynucleotide; and

- (c) producing a diagnosis based on a result from step (b).

5. The method of claim 4, wherein said transcribed polynucleotide comprises a nucleic acid sequence recited in any one of SEQ ID NOS:1-33, or a complement of any of the foregoing nucleic acid sequences.

6. The method of claim 4, wherein the transcribed polynucleotide is an mRNA.

7. A method for detecting CVH in a subject, said method comprising the steps of:

- (a) determining an expression pattern of polypeptides in a biological sample, said polypeptides are encoded by the genes listed in Tables 3-8 or homologs thereof;

- (b) comparing the expression pattern of polypeptides obtained in (a) to a normal expression pattern of polypeptides; and

- (c) producing a diagnosis based on a result from step (b).

8. The method of claim 7, wherein the polypeptides comprise polypeptide sequences recited in SEQ ID NOS:34-66.

9. The method of claim 7, wherein the expression pattern of polypeptides in the biological sample is determined using antibodies directed against the polypeptides.

10. The method of claim **7**, wherein the expression pattern of polypeptides is determined by measuring expression levels of at least three polypeptides.

11. A method for detecting CVH in a subject, said method comprising the steps of:

(a) determining an expression pattern of mRNAs in a biological sample, said mRNAs are transcribed from the genes listed in Tables 3-8 or homologs thereof;

(b) comparing the expression pattern of mRNAs obtained in (a) to a normal expression pattern of mRNAs; and

(c) producing a diagnosis based on a result from step (b).

12. The method of claim **11**, wherein said mRNAs comprise polynucleotide sequences recited in SEQ ID NOS:1-33.

13. The method of claim **11**, wherein the expression pattern of mRNAs is determined by measuring expression levels of at least three mRNAs.

14.-27. (canceled)

24. A biochip comprising at least one of:

(a) a polynucleotide comprising a sequence that hybridizes to a gene listed in Tables 3-8 or a homolog thereof;

(b) a polypeptide comprising at least a portion of a sequence encoded by a gene listed in Tables 3-8.

25. The biochip of claim **24**, wherein said polynucleotide comprises a sequence that hybridizes to any one of SEQ ID NOS: 1-33, and wherein said polypeptide comprising any one of SEQ ID NOS:34-66.

26. A diagnostic kit for CVH, said kit comprising at least one of:

a polynucleotide probe, wherein the probe specifically binds to a polynucleotide transcribed from a gene listed in Tables 3-8 or a homolog thereof; and an antibody capable of immunospecific binding to a polypeptide encoded by a gene listed in tables 3-8.

27. The diagnostic kit of claim **26**, wherein the probe specifically binds to a transcribed polynucleotide comprising any one of SEQ ID NOS:1-33.

28. The diagnostic kit of claim **26**, wherein the antibody specifically binds to a polypeptide comprising any one of SEQ ID NOS:34-66.

29.-31. (canceled)

* * * * *